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Background 
Mood problems in people with rheumatoid arthritis (RA) are under-recognised and 
treated, contributing to increased mortality. Comorbid depression is associated with 
increased disease activity and reduced quality of life (QoL), though the impact of anxiety 
is unclear. Understanding patients͛ preferences regarding case-finding for mood 
problems and determining the impact of anxiety in RA, could support the development 
of an intervention to improve the management of comorbid mood problems. There is a 
lack of literature reporting the prevalence of mood problems in other inflammatory 
rheumatological conditions (IRCs).  
Methods 
Using mixed methods, I have conducted a qualitative study, to explore RA patients͛ 
perspectives of comorbid mood problems and a systematic review, to determine the 
impact of anxiety in RA. Through a cohort study, using Read codes from primary care 
data, I have established the incidence and prevalence of mood problems in different 
IRCs. I have also analysed patients͛ responses to case-finding questions for mood 
problems within questionnaires, to determine the proportion with IRCs who self-report 
mood symptoms. 
Results 
People with RA feel able to disclose mood symptoms within a nurse-led review. Anxiety 
is associated with worse QoL and increased disease activity in RA. Self-reported 
symptoms of mood problems are common in different IRCs, though they are less 
 xx 
frequently recorded in primary care records, suggesting potential under-recognition of 
mood problems in people with IRCs. 
Conclusions 
Comorbid mood problems in people with IRCs are common, yet under-recognised, and 
can negatively impact on outcomes, supporting the requirement for case-finding within 
a nurse-led review.   
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1.0 INTRODUCTION 
1.1 Overview                                                                                                            .    
 
 Within my thesis I have investigated comorbid mood problems in people with 
inflammatory rheumatological conditions (IRCs). Through four interconnected studies, I 
have aimed to improve our understanding of the identification, incidence, prevalence 
and potential impact of mood problems in different IRCs. In the following section, I will 
discuss my rationale for performing these studies and outline the content of each 
chapter. 
 
1.2 Rationale for Studies                                                                                       .    
 
The relationship between the mind and body has been debated by philosophers 
for centuries. In 400 BC, the ancient Greek physician Hippocrates developed the concept 
that the life of the whole patient should be considered as part of any disease process 
(Kleisiaris, Sfakianakis & Papathanasiou, 2014). Hippocrates advocated treatments to 
improve both physical and mental health, believing them to be intrinsically connected. 
Six hundred years later, Galen built on the early theories of Hippocrates, hypothesising 
that bodily fluids such as yellow and black bile, blood and phlegm were linked to 
different moods, including feeling melancholy, listless, angry or optimistic (Kagan, 
1998). Hippocrates and Galen were amongst the earliest physicians to recognise the 
interactions that occur between biological and psychological factors, which led them to 
develop a holistic approach to care, taking account of a persons͛ physical, mental and 
emotional health. 
Over 2,000 years later, the benefits of holistic care are now being rediscovered. 
However, many of the complex interactions between physical and mental health 
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problems are still poorly understood and frequently care is fragmented (Kvamme, 
Olesen & Samuelsson, 2001). Understanding the interactions of long-term physical 
health problems with common mental disorders, such as anxiety and depression, could 
support the development of interventions to improve patient outcomes. Therefore, 
within this thesis I have aimed to improve the understanding of comorbid mood 
problems in people with long-term physical health problems, specifically, IRCs. 
IRCs encompass a range of conditions which can cause joint pain, swelling and 
stiffness. Rheumatoid arthritis (RA), one of the commonest IRCs, is frequently associated 
with anxiety and depression (Covic et al., 2012; Matcham et al., 2013). However, these 
mood problems are often not recognised or treated (Cepoiu et al., 2007), which can lead 
to increased morbidity and mortality (Ang et al., 2005). Therefore, improved recognition 
and management of mood problems in RA should be a healthcare priority. 
As past research into IRCs and mood problems has focussed on RA and 
depression, there is a lack of understanding of the impact of anxiety in people with RA. 
Anxiety frequently exists in isolation from depression (Kaufman & Charney, 2000) and 
can be managed differently (NICE, 2011; NICE, 2009a). Anxiety can also be associated 
with altered help-seeking behaviour (Fine et al., 2008). Therefore, it is important that 
the impact of anxiety is understood, to facilitate appropriate treatment. Meanwhile, the 
burden of mood problems in other IRCs, including ankylosing spondylitis (AS), psoriatic 
arthritis (PsA), polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), is poorly 
understood. Consequently, there is a potential health need which is not being addressed 
in people living with AS, PsA, PMR and GCA, that needs to be characterised. 
In chapter 2, I will discuss our current understanding of mood problems in 
different IRCs, including their incidence and prevalence, potential interactions with 
 4 
physical health problems and impact on quality of life (QoL) and disease activity. In 
addition, I will summarise current recommendations for the identification and 
management of comorbid mood problems in people with IRCs. As I will outline in 
chapter 3, my overall aim has been to improve the recognition and management of 
anxiety and depression in people with different IRCs. In chapter 4 I will discuss my 
rationale for taking a pragmatic approach, using a mixed methods multiphase design.  
Through chapters 5-8, I will discuss the four main studies I have conducted. For 
each, I will describe my methods, present my results, consider the implications of my 
findings and reflect on the contributions of patient and public involvement and 
engagement (PPIE). The four study chapters will comprise of a qualitative study (chapter 
5) exploring the perspectives of people with RA on comorbid mood problems, a 
systematic review (chapter 6), to determine the impact of anxiety on QoL and disease 
activity in people with RA, and a cohort study (chapter 7) to determine the incidence 
and prevalence of anxiety and depression in different IRCs. Lastly, in chapter 8, I will 
discuss INCLUDE (INtegrating and improving Care for patients with infLammatory 
rheUmatological DisordErs in the community), a pilot feasibility trial, for which I am a 
co-investigator. Within my thesis, I will present my analysis of baseline questionnaire 
data collected as part of the INCLUDE study, with a focus on comorbid mood problems 
in people with IRCs. 
In chapter 9 I will review the overall findings of my PhD, drawing comparisons 
between the results of different studies in the context of the existing background 
literature. After concluding my investigation of comorbid mood problems in people with 
IRCs, I will consider the wider implications of my results for patients and practitioners, 
and will make recommendations for future research.  
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I will also reflect on my own personal journey, a process that has highlighted to 
me the many challenges and rewards of being an academic general practitioner (GP). 
Completing a PhD has opened my understanding to the world of academia and 
strengthened my resolve to be the best possible GP, who acknowledges the whole 
person and keeps alive the founding principles of medicine, established by the great 
physicians of ancient Greece. 
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2.0 BACKGROUND 
2.1 The National Health Service                                                                           .    
 The National Health Service (NHS) was founded in 1948 on the ideal that good 
healthcare should be available to all. Remaining free at the point of delivery, the NHS 
delivers care for more than 64 million people in the United Kingdom (UK), treating over 
1 million patients every 36 hours (NHS Confederation, 2017).  
 Health care services can be defined as primary, secondary or tertiary. Primary 
care services are often the first point of contact in the healthcare system and include 
general practice, community pharmacy, optometry and dental services. Primary care 
professionals focus on preventing illness, whilst also diagnosing and managing a broad 
range of physical and mental health problems. Patients may be referred by a primary 
care professional, such as a general practitioner (GP), to secondary care for review by a 
specialist, with expertise in a particular health problem. Secondary care delivers planned 
and emergency care and is often hospital based, though some clinics are based within 
the community. Tertiary care is provided in specialist regional centres, where there may 
be access to more specialised equipment or expertise, for the investigation and 
management of particular health problems. 
Following the 70th anniversary of the NHS, the NHS Long Term Plan was 
published (NHS, 2019). This plan has outlined changes to support staff, relieve 
workforce pressures, enhance the quality of care provided, prevent illnesses, upgrade 
technology, improve sustainability and join together care for patients. The long-term 
plan aims to create more integrated teams of GPs, community health and social care 
staff. Primary Care Networks, which were announced as part of the 2019 GP contract, 
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serve communities of 30,000 to 50,000 people. Since the 1st July 2019, these networks 
have been funded to employ a clinical pharmacist and social prescribing link worker, 
who can take a holistic approach to peoples͛ health and wellbeing and connect them to 
community groups and services for practical and emotional support (NHS England, 
2019a) Over the next few years, further funding will be provided to employ 
physiotherapists, physician associates and paramedics. 
Within the 2019 GP contract, changes to the Quality and Outcomes Framework 
(QOF) were also announced. The QOF is an annual reward and incentive programme 
based on the achievement of certain targets by GP practices (NHS England, 2019b). 
These targets have been amended to support more individualised, patient-centred, 
evidence-based care.  
 
2.2 Inflammatory rheumatological conditions                                                 .    
 
Rheumatological conditions affect the joints, bones, cartilage, ligaments and 
muscles. Inflammation of these areas can cause swelling, stiffness, pain and a reduced 
movement range, which can impact on an individual͛s ability to function in their work, 
family and social lives. The presence of inflammation can also contribute to debilitating 
systemic symptoms, such as fatigue (Abhishek et al., 2017). 
The inflammatory rheumatological conditions (IRCs) discussed within this thesis 
include rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), 
polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). My initial two studies have 
focused on people with RA, due to this being one of the most common and frequently 
researched IRCs in the literature. Consequently, this initial focus has enabled me to build 
on a foundation of existing research. Following on from the suggestions of a patient and 
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public involvement and engagement (PPIE) group and due to the relative lack of 
literature reporting the burden of mood problems in other inflammatory conditions, I 
have subsequently widened my focus to other IRCs. 
These other IRCs (AS, PsA, PMR and GCA) were chosen due to them being 
amongst the most frequent IRCs (section 2.1.1- 2.1.5). In addition, from the small 
amount of literature available, some of these conditions were reported to potentially 
be associated with mood problems (section 2.9). Later in this chapter, I will discuss the 
limited evidence reported on comorbid mood problems in people with IRCs, though 
firstly, I have provided an overview of each IRC.  
 
2.2.1 Rheumatoid arthritis 
RA is a long-term condition (LTC) characterised by synovial joint inflammation, 
that affects 0.67% of the adult population (Abhishek et al., 2017). It is multifactorial, 
with a genetic susceptibility linked to human leukocyte antigen (HLA) DR1 and DR4 
(Silman and Pearson, 2002). Women are approximately 3 times more likely to develop 
RA than men, with the commonest age of onset being between 70 to 80 years (Abhishek 
et al., 2017).  
Typically, people with RA present with a symmetrical polyarthritis affecting the 
small joints of the hands and feet. They often describe persistent joint pain, swelling, 
heat and early morning stiffness lasting more than 30 minutes, sometimes associated 
with systemic symptoms of fever, sweats, malaise, and weight loss.  In more advanced 
disease, people can present with loss of function due to joint damage. The American 
College of Rheumatology (ACR) European League Against Rheumatism (EULAR) have 
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produced diagnostic criteria for RA, which are based on the degree of joint involvement, 
serological test results, acute phase reactants and symptom duration (appendix 4).  
RA can have a variety of extra-articular features, involving the eyes, lungs and 
cardiovascular system (Gullick and Scott, 2011), and can contribute to increased 
morbidity and mortality (Ang et al., 2005; Dadoun et al., 2013; Abhishek et al., 2018). 
Therefore, prompt referral of patients with suspected RA is recommended to enable 
early treatment with drugs to prevent inflammation, improving long-term outcomes 
(NICE, 2018). 
In people with newly diagnosed RA, first line treatment is with a conventional 
disease-modifying anti-rheumatic drug (cDMARD), with the option of short-term 
bridging treatment with glucocorticoids. RA activity is subsequently monitored using 
composite scores, such as the Disease Activity Score in 28 joints (DAS28), until the 
disease is controlled. If remission or low disease activity are not achieved despite 
escalation of the cDMARD dose, an additional cDMARD can be commenced. For 
individuals with severe disease that doesn͛t respond to a combination of cDMARDs, 
biological (b)DMARDs can be used. These genetically engineered drugs target proteins 
within the immune system, to help reduce inflammation. 
In the longer term, RA can have major implications on peoples͛ relationships, 
work, self-image and social roles (Coventry et al., 2011). People who sustain joint 
damage or develop extra-articular complications may require the input of multiple 
professionals to support their daily functioning, hence guidelines by the National 
Institute for Health and Care Excellence (NICE) recommend that people with RA should 
be supported by a multidisciplinary team (MDT) (NICE, 2018). Alongside 
rheumatologists and nurse specialists, physiotherapists, occupational therapists, 
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podiatrists and orthotics can provide support with non-pharmacological treatments, 
with one person taking responsibility for coordination of care. Referral to other 
specialities can be arranged, for example, to help manage comorbid mood problems or 
offer advice about potential joint replacements.  
GPs also have an integral role in the management of people with RA. They are 
required to promptly refer patients with suspected RA to secondary care to enable early 
treatment, whilst also assessing for comorbidities (NICE, 2018). However, in a 
qualitative study exploring barriers to integrated care for people with RA, only a 
minority of GPs reported regularly reviewing their patients with RA. After arranging a 
patients͛ initial referral, they felt only marginally involved in ongoing care (Pollard et al., 
2011). Some GPs felt the priority given to RA patients in primary care had fallen due to 
a lack of QOF incentives (Pollard et al., 2011).  
QOF incentives to perform an annual review for people with RA, including an 
assessment of fracture and cardiovascular disease (CVD) risk, were introduced in 2013. 
However, the incentives to assess fracture and CVD risk were retired only a year later 
(NHS Employers, 2015). Since then, the incentive has been to perform an annual review 
for people with RA (NHS England, 2019b), though the content of this has not been 
specified, hence important aspects of comorbidity assessment could be missed. 
In 2015, a national GP survey was performed to determine the content of 
primary care RA annual reviews. Despite NICE advocating a holistic annual review for 
people with RA, primary care reviews were often found to focus on previous QOF 
domains, such as CVD and fracture risk screening (Hider et al., 2015), whilst assessments 
of disease activity and questions to identify potential mood problems were neglected. 
Therefore, possible opportunities for intervention were missed. 
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People with RA also have an important role to play in the management of their 
condition, with NICE Quality standards for the management of RA (QS33), 
recommending that people are offered support to self-manage their condition and 
encouraged to participate in treatment decisions (NICE, 2018). Self-management of LTCs 
is a type of self care. The Department of Health (2005, p1), defines self-care as ͞the 
actions people take to...maintain good physical and mental health; prevent illness or 
accidents; care for minor ailments and LTCs; and maintain health or wellbeing after an 
acute illness or discharge from hospital.͟ Educational, behavioural and cognitive 
strategies to support self-management of LTCs have been developed (Iversen, 
Hammond & Betteridge, 2010).  
A self-management programme developed for people with RA, has been found 
to improve mood and QoL. Participants attended six weekly meetings, during which they 
were educated about how to manage pain, fatigue and the psychological impact of their 
condition (Vermaak et al., 2015). Cognitive behavioural therapy (CBT) techniques were 
used to help people to understand how their thoughts and feelings affected their 
behaviour and to teach them coping skills, whilst goal setting techniques were also used 
to assist with behavioural change. Improvements in fatigue, depression and mental 
quality of life (QoL) were noted immediately after the intervention, with improvements 
in mood and QoL maintained at 12-months follow-up. As this study used a single group 
repeated measures design, there was no control group for comparison. Consequently, 
ongoing medical management was an important confounding factor that was not 
controlled for. In addition, as follow-up was only for a year, the longer term effects are 
also unclear. Therefore, to further assess the effectiveness of the self-management 
programme, a randomised control trial (RCT) would be needed. 
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Online support tools have also been found to improve the ability of people with 
RA to manage everyday stresses linked to their condition, though qualitative interviews 
with people who used the tool found that long-term engagement depended on the 
personality traits of participants and their existing social networks (Kostova, Caiata-
Zufferey & Schulz, 2015). Consequently, the tool may be most useful if targeted towards 
people with RA who lack social support. However, as participants volunteered to be 
interviewed, it is possible there was a selection bias, with people who were more willing 
to discuss their experiences coming forward, leaving less opportunities to explore the 
views of more reticent patients.  
Social support can strengthen self-esteem and improve self-management, whilst 
also buffering the negative impact of low health literacy (Lee, Arozullah & Cho, 2004). A 
cross-sectional study involving Greek patients with RA, found that the social support, 
assessed using the quality of social support scale, predicted QoL far beyond disease 
activity and demographic factors (Pitsilka, Kafetsios & Niakas, 2015). However, as this 
study was conducted in a region of Greece, it may not be generalisable to other 
populations, where cultural differences could impact on the extent to which people rely 
on social support networks to manage their LTCs. 
 
2.2.2 Ankylosing spondylitis 
  AS is an IRC with a prevalence of between 0.1% and 2% (Gran & Husby, 1993). A 
principal symptom of AS is low back pain. Persistent inflammation at the junction of the 
intervertebral spinal ligaments and vertebrae, can eventually lead to fusion from fibrosis 
and calcification (ankylosis). Inflammation can also occur where tendons and ligaments 
attach to bone (enthesitis), where cartilage joins the ribs (costochondritis) and at the 
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sacroiliac joints, causing buttock pain (Elyan & Khan, 2006). Over time, progressive 
involvement of the lumbar, thoracic and cervical spine can lead to a fixed, flexed 
posture. 
  AS is 3 times more common in men than women, and usually begins between 20 
to 30 years of age (Sieper, 2012). AS is thought to be caused by a combination of genetic 
and environmental factors, being more common in people with the HLA-B27 gene 
(Khan, 2002).  
  When suspected, a prompt referral of the patient by their GP to rheumatology 
is advised (NICE, 2013a). On review, a rheumatologist may consider blood tests for HLA-
B27 to support their diagnosis, x-rays of the sacroiliac joints and spine which can be 
diagnostic in well established AS, or Magnetic Resonance Imaging (MRI) which can 
detect early changes in the sacroiliac joints (Elyan & Khan, 2006).  
  Alongside regular physiotherapy, non-steroidal anti-inflammatory drugs 
(NSAIDs) can reduce joint pain and stiffness, whilst glucocoritcoid injections may also be 
used to manage inflamed joints, enthesitis or sacroiliitis (NICE, 2013a). Inadequately 
controlled disease can be managed with biologics such as anti-tumour necrosis factor 
(TNF) agents (Zochling, 2006). 
 
 
2.2.3  Psoriatic arthritis 
 Psoriasis is an autoimmune-mediated chronic, inflammatory disease 
characterised by scaly skin lesions (Menter et al., 2008). The prevalence of psoriasis in 
the general population is estimated at 2-3%. Approximately 5-25% of patients with 
psoriasis develop PsA (Gladman, 2005). PsA affects men and women equally and is most 
common between the ages of 30 and 55 years (NICE, 2012).  
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 Symptoms of PsA include joint pain, swelling and stiffness, swollen fingers or 
toes (dactylitis), enthesitis, nail pitting, discolouration, or onycholysis (detachment) and 
fatigue (Gladman et al., 2005). Some people present with a symmetrical polyarthritis 
predominantly affecting their wrists, hands, ankles and feet, whilst others may develop 
lone distal interphalangeal (DIP) disease, involving only the terminal phalanx (finger 
bone) and nail. Arthritis mutilans is a rare variation of DIP disease, involving resorption 
of the terminal phalanx (Gladman et al., 2005).  
 Due to the variable presentation of psoriatic arthritis, an individualised 
treatment approach is recommended (Gossec et al., 2015). Initial management options 
include physiotherapy, NSAIDs and DMARDs, progressing to biological agents such as 
TNF-alpha or interleukin (IL)-17 inhibitors (Coates et al., 2014; Van den Bosch & Coates, 
2018), whilst in advanced disease, joint surgery may be indicated (Michet et al., 2005). 
 
 
2.2.4  Polymyalgia rheumatica 
PMR is an inflammatory condition of unknown cause, with an average age at 
onset of 70 years (Mitchet & Matteson, 2008). PMR is characterised by pain and morning 
stiffness in the neck, shoulders, and pelvic girdle (Salvarani et al., 2002). The annual 
incidence of PMR is 84 per 100,000 (Smeeth et al., 2006), with a lifetime risk of 1.7% for 
men and 2.4% for women (Crowson et al., 2011). 
PMR should be suspected in a person over 50 years of age, presenting with at 
least 2 weeks of bilateral shoulder and/or pelvic girdle pain and stiffness lasting for at 
least 45 minutes after waking or periods of rest (Dasgupta et al., 2009). Additional 
features include a low-grade fever, fatigue, anorexia, weight loss, and depression. GCA 
(described in section 2.1.5), is an associated condition which can be complicated by a 
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loss of sight. Therefore, this should always be excluded on the assessment of a patient 
with suspected PMR.  
When PMR is suspected, blood tests should be performed to check for raised 
inflammatory markers, which can support the diagnosis. Differential diagnoses such as 
infection or cancer should be excluded. People with atypical features of PMR, such as 
weight loss, night pain, chronic symptom onset or low/ very high inflammatory markers 
should be referred for further investigations. 
  If PMR is the most likely diagnosis, a trial of treatment with oral prednisolone 
should be prescribed, and follow-up arranged after one week to assess the clinical 
response. If the patient reports a global improvement in their symptoms of 70% or more 
within a week, a working diagnosis of PMR can be made. If there is a lesser response, 
the diagnosis should be reconsidered and a referral made to a specialist (Dasgupta et 
al., 2009; NICE, 2013b). 
  For those with a working diagnosis of PMR, the dose of prednisolone should be 
reduced slowly once symptoms are fully controlled. Patients should be reviewed 
regularly for side-effects of treatment and signs of relapse. Treatment is usually required 
for 1 to 3 years (Dasgupta et al., 2009; NICE, 2013b). 
 
2.2.5  Giant cell arteritis 
  GCA is a type of chronic vasculitis characterised by inflammation in the walls of 
medium and large arteries. The extracranial branches of the carotid artery and branches 
of the ophthalmic artery are preferentially involved, although the aorta and its͛ major 
branches may also be affected (Warrington & Matteson, 2007; Dasgupta et al., 2010). 
  GCA often occurs in association with PMR, though its͛ cause is unknown 
(Dasgupta et al., 2010). The annual incidence of GCA in the UK is 20 per 100,000 people 
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(Smeeth et al., 2006). It is three times more common in women than in men (Dasgupta 
et al., 2010) and the average age of onset is 70 years (Gonzalez-Gay, 2004). 
GCA should be suspected if a person aged over 50 years presents with a temporal 
headache, with or without temporal tenderness. Almost half of people with GCA report 
jaw claudication (Hunder et al., 1990), whilst up to 40% may also present with symptoms 
of PMR (Dasgupta et al., 2010). Patients should be asked about visual symptoms, due to 
a risk of partial or complete visual loss. High inflammatory markers support a diagnosis 
of GCA, though they may be normal (Dasgupta et al., 2010). 
All people with suspected GCA should be referred for an urgent rheumatology 
review and consideration of investigations such as temporal artery ultrasound and/or 
biopsy (Dasgupta et al, 2010). Same day ophthalmology review should be requested for 
any patient with visual symptoms (Dasgupta & Hassan, 2007), as intravenous 
glucocorticoids may be required. Otherwise, treatment is with oral prednisolone. 
Treatment response should be reviewed after 48 hours, and if this is poor, differential 
diagnoses should be considered, such as herpes zoster, migraine, glaucoma, sinus 
disease, ear problems, cervical spondylosis and temporomandibular joint pain 
(Dasgupta et al., 2010; NICE, 2014).  
 A good response to treatment within the first two days supports a diagnosis 
of GCA. A specialist can confirm the diagnosis, after which shared care between GPs and 
specialists is recommended. The dose of prednisolone is reduced slowly over several 
months and treatment is often required for 1 to 2 years, though some people may 
require low doses of prednisolone for several years (Dasgupta et al., 2010). Regular 
follow-up is required to monitor for relapses and adverse treatment effects. 
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2.2.6 Burden of inflammatory rheumatological conditions 
IRCs, including RA, AS, PsA, PMR and GCA have wide-ranging impacts. 
Comorbidities such as anxiety and depression are common in people with RA (Gullick 
and Scott, 2011; Matcham et al, 2013; Covic et al., 2012), but are often under-recognised 
and under-treated (Cepoiu et al., 2007), which can contribute to increased morbidity 
and mortality (Marrie et al., 2018a; Ang et al., 2005). However, less data exists to define 
the burden of mood problems in people with other IRCs. 
Therefore, in my thesis I aim to determine the incidence, prevalence and impact 
of anxiety and depression in different IRCs, whilst through interviews I have explored 
patients͛ preferences for the identification and management of comorbid mood 
problems. In the following sections I will define anxiety and depression, discuss current 
evidence for how these mood problems should be identified and treated and more 
specifically, the management of comorbid anxiety and depression in people with LTCs. 
Finally, I will discuss the limited literature that reports on the prevalence, identification 
and management of mood problems in IRCs, highlighting the lack of data available for 
certain conditions.  
 
2.3 Mental Health Problems in Primary Care                                                    .    
 
It is estimated that 300 million consultations are undertaken each year in general 
practice (NHS England, 2017a). A significant proportion of these consultations relate to 
psychological problems, with up to 30% of people presenting to their GP having a mental 
health component to their illness (Royal College of General Practitioners, 2016). 90% of 
all mental health problems are managed entirely within primary care, with the most 
common psychiatric presentations including generalised anxiety disorder (GAD), 
 19 
depression, panic disorder and alcohol or drug dependence (Royal College of General 
Practitioners, 2016).  
Mood can be defined as a persons͛ emotional state of mind ;American 
Psychiatric Association, 2000). In people with mood problems, their emotional state can 
interfere with their ability to function. Within this thesis I have focussed on the two 
commonest mood problems; anxiety and depression. 
 
 
 
2.4 Anxiety and Depression                                                                                  .    
 
 The 2014 Adult Psychiatric Morbidity Survey reported a 7.8% prevalence of 
mixed anxiety and depression amongst the English adult population over the preceding 
week. 5.9% had a GAD, whilst 3.3% reported suffering from a depressive disorder 
(NatCen Social Research, 2016).  
  GAD is characterised by persistent tension and excessive worry about a range of 
events (NICE, 2011a). To meet the diagnostic criteria for GAD, which are listed in figure 
2.1 (p 20), there must be 3 or more associated symptoms of anxiety that have been 
present for at least 6 months and contribute to impaired functioning. GAD is one of 
range of anxiety disorders which include post-traumatic stress disorder, obsessive-
compulsive disorder and specific phobias. Such anxiety disorders can exist in isolation, 
but are commonly associated with other anxiety or depressive disorders (NICE, 2011a). 
 Central to the diagnosis of depression is a persistent low mood and a loss of 
interest or pleasure in most activities persisting for more than two weeks. Associated 
symptoms include a change in weight of more than 5% or an altered appetite, a change 
in sleep or activity, fatigue, poor concentration and suicidal thoughts. The degree of 
depression is determined by the number and severity of associated symptoms, in 
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addition to any associated functional impairment (NICE, 2009a). The diagnostic criteria 
for depression are listed in figure 2.2 (p 21). 
Figure 2.1- Diagnostic criteria for Generalised Anxiety Disorder (American Psychiatric 
Association, 2000) 
 
Generalised Anxiety Disorder- Diagnostic Criteria 
A Excessive anxiety and worry, occurring frequently for at least 6 months, about a number of events or activities (such as work or school performance) 
B The person finds it difficult to control the worry 
C 
The anxiety and worry are associated with three (or more) of the following 
six symptoms (with at least some symptoms present for more days than not 
over the past 6 months); 
 
1. restlessness or feeling on edge 
2. being easily fatigued 
3. difficulty concentrating 
4. irritability 
5. muscle tension 
6. sleep disturbance 
D 
The focus of anxiety is not about; 
 
- having a panic attack (panic disorder) 
- being embarrassed in public (social phobia) 
- being contaminated (obsessive-compulsive disorder) 
- being away from home or close relatives (separation anxiety disorder) 
- gaining weight (anorexia nervosa) 
- having multiple physical complaints (somatisation disorder) 
- having a serious illness (hypochondriasis) 
 
In addition, the anxiety does not occur exclusively in association with 
post-traumatic stress disorder. 
E 
The anxiety, worry, or physical symptoms cause clinically significant distress 
or impairment in social, occupational, or other important areas of 
functioning.  
F 
The disturbance is not due to the direct physiological effects of a substance 
or general medical condition, and does not occur exclusively during a mood 
disorder, psychotic disorder or pervasive developmental disorder. 
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Figure 2.2- Diagnostic criteria for depression (American Psychiatric Association, 2000). 
 
 
Depressive Episode Criteria 
 
A 
 
x Depressed mood 
x Loss of interest in usual activities 
x Reduced energy and decreased 
activity 
 
B 
 
x Reduced self-esteem and 
confidence 
x Ideas of guilt and unworthiness 
x Pessimistic thoughts 
x Disturbed sleep 
x Diminished appetite 
x Ideas of self-harm 
 
 
Severity of Depressive Episode; 
 
x Mild: > 1 from column A plus 1-2 from column B, or 5-6 total symptoms,   
but mild in severity and functional impairment. 
 
x Moderate: > 1 from column A plus 2-3 from column B, or 7 ʹ 8 total 
symptoms, but moderate functional impairment. 
 
x Severe: All 3 from column A plus > 3 from column B. Or fewer symptoms   
but any of these including severe functional impairment, psychotic 
symptoms, a recent suicide attempt, or active suicidal ideation.  
 
 
The literature suggests that depressive symptoms are not recognised in 
approximately half of patients attending general practice with these disorders (Gilbody, 
2003). In addition, the rates of diagnosis and treatment of anxiety are much lower than 
expected, given their high prevalence within the general population (Lecrubier, 2007). 
Multiple barriers to the recognition of anxiety and depression in primary care patients 
have been identified. Mood problems may be normalised as an understandable 
response to the losses associated with a LTC, or patients may struggle to describe how 
they are feeling (Coventry et al., 2011). Some may fear the stigma associated with a 
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diagnosis of mental illness, or may present with associated somatic symptoms, possibly 
believing them to be more medically legitimate (Alderson, Foy & House, 2015). 
Doctors may lack appropriate training to recognise symptoms, or may be 
reluctant to openly inquire about depression (Richards et al., 2004). Some could 
attribute symptoms to physical illness requiring further investigation, whilst other 
health problems such as alcohol dependence could obscure the diagnosis (Buszewicz & 
Chew-Graham, 2011). Further potential barriers include financial constraints, a lack of 
time and poor continuity of care (Docherty, 1997). 
 
2.5 Management of people with anxiety and depression                              .    
 
NICE has produced clinical guidelines (CG) for the management of GAD (CG 113), 
depression (CG 90) and depression in people with chronic physical health problems (CG 
91). Guidelines for GAD and depression outline a stepped-care model to guide 
practitioners to identify the most effective and least intrusive interventions (NICE, 
2011a; NICE, 2009a). If a person declines or does not benefit from a treatment they are 
offered an appropriate intervention from the next step. The stepped care models are 
summarised in figures 2.3 (p23) and 2.4 (p24). 
 GPs can help to diagnose and educate patients, signposting to online and self-
help resources, or referring onto social prescribing services (discussed in section 2.1). 
Social prescribing has been suggested to work for a range of people, including those 
living with LTCs, people who are lonely or have complex social needs and those who 
require mental health support (NHS England, 2017b). GPs can refer people to 
psychological therapies or specialist care for more intensive management. People can 
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also self-refer to Improving Access to Psychological Therapies (IAPT) services (NHS 
England, 2018a), who will communicate the outcome of psychological treatments with 
GPs. 
 
Figure 2.3- The stepped-care model for Generalised Anxiety Disorder (NICE, 2011a). 
 
Step Focus of the intervention Nature of the intervention 
STEP 1 All known and suspected presentations of GAD. 
Identification and assessment; 
education about GAD and treatment 
options; active monitoring. 
STEP 2 
Diagnosed GAD that has not 
improved after education and 
active monitoring in primary 
care. 
Low-intensity psychological 
interventions: individual non-
facilitated self-help, individual guided 
self-help and psychoeducational 
groups. 
STEP 3 
GAD with an inadequate 
response to step 2 
interventions or marked 
functional impairment. 
Choice of a high-intensity 
psychological intervention (cognitive 
behavioural therapy/ applied 
relaxation) or a drug treatment. 
STEP 4 
Complex treatment-
refractory GAD and very 
marked functional 
impairment, such as self-
neglect or a high risk of self-
harm. 
Highly specialist treatment, such as 
complex drug and/or psychological 
treatment regimens; input from 
multi-agency teams, crisis services, 
day hospitals or inpatient care. 
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Figure 2.4- The stepped-care model for depression (NICE, 2009a). 
 
Step Focus of the intervention Nature of the intervention 
STEP 1 All known and suspected presentations of depression. 
Assessment, support, psychoeducation, 
active monitoring and referral for 
further assessment and interventions. 
STEP 2 
Persistent subthreshold depressive 
symptoms; mild to moderate 
depression. 
Low-intensity psychosocial 
interventions, psychological 
interventions, medication and referral 
for further assessment and 
interventions. 
STEP 3 
Persistent subthreshold depressive 
symptoms or mild to moderate 
depression with inadequate 
response to initial interventions; 
moderate and severe depression. 
Medication, high-intensity 
psychological interventions, combined 
treatments, collaborative care and 
referral for further assessment and 
interventions. 
STEP 4 Severe and complex
 depression; 
risk to life; severe self-neglect. 
Medication, high-intensity 
psychological interventions, 
electroconvulsive therapy, crisis 
service, combined treatments, 
multiprofessional and inpatient care. 
 
For step 1 of the stepped care model, GPs have a role in providing information 
and educating people about anxiety or depression and ensuring they are closely 
followed up to assess for any deterioration in their mood. For people who are 
persistently symptomatic, step 2 consists of low intensity interventions. For anxiety, 
these include self-help and educational groups, whilst people with depression can be 
offered guided self-help or CBT, which aims to explore and change how people think 
about their lives, to help free them from unhelpful patterns of behaviour (NHS England, 
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2018b). For depression that persists despite these measures, further management 
options include medication or group CBT. 
 If these treatments prove ineffective, people can be offered high-intensity 
interventions, as part of step three of the care model. For anxiety, these include 
medication prescribed by a persons͛ GP, applied relaxation or CBT through IAPT services. 
People with depression can be offered antidepressants by their GP, or psychological 
therapies, including CBT, interpersonal therapy or behavioural activation. Interpersonal 
therapy is a talking treatment that helps people with depression to identify and address 
problems in their relationships with family, friends and partners, whilst behavioural 
activation helps depressed people take practical steps towards enjoying life again (NHS 
England, 2018b). If these treatments prove ineffective, patients can be stepped up to a 
specialist step 4 service, where they may be offered more intensive psychological 
therapy, combinations of medication or inpatient support. 
 In the following sections, I will discuss the burden of mood problems in LTCs 
(section 2.6), evidence for how anxiety and depression should be identified and 
managed in LTCs (section 2.7) and patient and practitioner perspectives of mood 
problems in LTCs (section 2.8). Afterwards, I will specifically focus on anxiety and 
depression in people with IRCs. 
 
2.6 Anxiety and depression in people with long-term conditions                .    
 
 
An estimated 15 million people in the UK suffer from LTCs (Naylor et al., 2012). 
These encompass a range of illnesses that can be managed, but not cured. Examples 
include diabetes mellitus (DM), asthma, chronic obstructive pulmonary disease (COPD), 
coronary heart disease (CHD) and RA. Mood problems are more prevalent in people 
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with LTCs compared to those without. Approximately 20% of have depression, whilst 
anxiety is 2 to 3 times more common (Naylor et al., 2012). In comparison, the adult 
psychiatric morbidity survey of UK adults, conducted in 2014, reported 5.9% of the 
general population to have symptoms of a GAD, and 3.3% to have symptoms of a 
depressive disorder, in the preceding week (NatCen Social Research, 2016) 
Considering specific LTCs, 14% of people with DM have been reported to have 
anxiety (Grigsby et al., 2002), whilst approximately 20% have depression (Salinero-Fort 
et al., 2018). Depression is also 2 to 3 times more common amongst people with CHD, 
whilst 24% are estimated to suffer from anxiety (Bankier, Januzzi & Littman, 2004). 
People with COPD are three times more likely to have a mental health problem (Naylor 
et al., 2012), with panic disorders being ten times more prevalent in people with COPD 
when compared to the general population (Livermore et al., 2010).  
 Whilst physical illness can lead people to be at high risk of depression or anxiety, 
mood disorders may also lead to physical illness, amplify physical symptoms or 
potentially increase the chance of complications from physical illness (Chew-Graham et 
al., 2014). For instance, depression has been linked to an increase in the production of 
pro-inflammatory cytokines (Dowlati et al., 2010), influencing the pathogenesis of a 
range of LTCs including CHD, type 2 DM and IRCs (Kiecolt & Glaser, 2002). 
 For example, depression has been found to be a risk factor for incident CHD in 
women ;O͛Neil et al., ϮϬϭϲͿ. A prospective longitudinal study involving ϴϲϬ Australian 
women randomly selected from electoral rolls, found that depression predicted the 18-
year incidence of CHD following adjustment for typical risk factors (odds ratio (OR)= 
3.22, 95% CI, 1.45-6.93). However, as baseline depression diagnosis was determined 
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using retrospective reports by participants during structured clinical interviews, recall 
bias could have affected the associations observed ;O͛Neil et al., ϮϬϭϲͿ. 
Comorbid mood disorders have been linked to higher morbidity and mortality 
rates in people with different LTCs (Lin et al., 2009). A large prospective study involving 
over 4,000 people with type 2 DM, recruited from primary care, examined the 
association between depression (baseline Patient Health Questionnaire (PHQ)-9ш 10) 
and mortality. After adjustment for baseline demographic and clinical characteristics, 
depression in people with DM was significantly associated with all cause mortality 
(hazard ratio (HR) 1.52, 95% confidence interval (CI), 1.19- 1.95) (Lin et al., 2009). 
 Comorbid depression has also been found to be associated with increased 
cardiac morbidity and mortality in people CHD (Carney et al., 2002). The question of 
whether there is a direct causal link between depression and poor CHD outcomes has 
proven more difficult to answer, with several theories having been proposed. For 
instance, adverse cardiac outcomes in depression could relate to behavioural factors 
such as inactivity, smoking and poorer compliance with medications (Carney & 
Freedland, 2017). However, biological factors could also mediate the relationship 
between depression and poor cardiac outcomes through autonomic dysregulation and 
inflammation (Carney & Freedland, 2017). Alternatively, as those with the most severe 
CHD generally have the worst physical health and functional ability, they could be more 
likely to develop depression. Due to the severity of their underlying CHD, this subset of 
patients would inherently have higher morbidity and mortality rates (Katon, 2011).  
Anxiety has also been found to be associated with increased mortality in people 
with LTCs, including CHD (Watkins et al., 2013). A cohort of 934 people with CHD who 
were enrolled at a UK medical centre for cardiac catheterisation, were followed up for 
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3 years. Anxiety, defined as a Hospital anxiety and depression score for anxiety (HADS-
A) ш8, was associated with significantly increased mortality (HR (95% CI) = 2.18 (1.47, 
3.22) (Watkins et al., 2013). However, attending hospital for an emergency procedure, 
may have increased baseline anxiety, whilst the association between anxiety and 
mortality may have been affected by an increased number of deaths from the 
catheterisation procedure.  
Depression in DM negatively impacts on QoL (Goldney et al., 2004), can lead to 
poorer concordance with medical management and may adversely affect diet, exercise 
and smoking behaviour (de Groot et al., 2001). Poor concentration, social isolation and 
feelings of hopelessness related to depression can also reduce a patients͛ motivation to 
self-manage, contributing to higher morbidity and mortality in people with DM (Mut-
Vitcu et al., 2016). In addition, an association has been found between depressive 
symptoms in people with DM and higher cholesterol levels, potentially contributing to 
worse physical health outcomes (Gary et al., 2000). However, as this was a cross-
sectional study, inferences about causality must be made cautiously. Although 
depression could worsen metabolic control, poor diabetic control could also lead to 
depression. In addition, patients self-reported a diagnosis of depression, so results could 
have been biased by individuals under-reporting symptoms or incorrectly assigning 
themselves a diagnosis of depression. In addition, three times as many women, 
compared to men, participated in the study, meaning potential selection bias could have 
influenced the cross-sectional associations observed.  
An association between depression and increased use of emergency care has 
also been identified in people with LTCs. A prospective study involving 355 patients from 
6 GP practices, examined the association between COPD and emergency hospital 
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admissions over a 12-month follow-up period (Blakemore et al., 2019). Depression was 
assessed by questionnaire using the HADS Score for depression (HADS-D). Validated cut 
off scores for anxiety and depression on the HADS are as follows; 8-10 mild, 11-14 
moderate, 15-21 severe symptoms (Zigmond & Snaith, 1983; Bjelland et al., 2002). In 
this study, depression, defined as a HADS-D score ш8, was independently associated with 
4.8 times increased odds of emergency hospital attendance and admission, whilst even 
subthreshold depressive symptoms (HADS-D score 4-7) were associated with a 2.8 times 
increased odds of emergency hospital admission (Blakemore et al., 2019). Only 50% 
responded to questionnaires, introducing potential bias, though the authors found no 
significant differences between the rates of mental health problems in the group who 
returned their questionnaires, to overall rates recorded using the QOF database.  
 Mood problems in people with LTCs have also been linked to the length of 
hospitaI admissions (Ng et al., 2017). In a prospective cohort study, 376 people with 
COPD who were hospitalised for an acute exacerbation, were followed up for a year. 
After adjustment, comorbid anxiety and depression were found to be associated with 
increased mortality, length of hospital stay and reduced QoL. However, data on 
hospitalisation and length of stay were based on self-report, hence associations could 
have been affected by recall bias (Ng et al., 2017). 
 
2.7 Identification and management of anxiety and depression in people 
with long-term conditions    
 
Depression is often under-recognised and under-treated in people with LTCs 
(Memel et al., 2000; Cepoiu et al., 2007). A systematic literature review and meta-
analysis found the accuracy of depression recognition by non-psychiatric physicians to 
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be low (Cepoiu et al., 2007). However, potentially relevant literature could have been 
missed, as only articles written in French and English were included. In addition, many 
studies classed patients with sub-threshold symptoms as missed depression diagnoses. 
Sub-threshold depression is often transient and in this category of depression (Jackson 
et al., 1998), treatment and placebo have similarly high rates of remission (Barrett et al., 
2001), hence recognition and treatment may not have offered any benefit in these 
cases. 
GPs have been found to under-recognise anxiety and depression in people with 
osteoarthritis (OA) (Memel et al., 2000). At two UK practices, where patients had a good 
continuity of care with the same GP, 200 people with OA, who had seen their usual GP 
in the previous week, were identified using electronic records. These patients were sent 
a questionnaire to complete, which included the HADS, whilst their GP was also asked 
to complete a questionnaire, which included a three-point scale to assess for anxiety or 
depression. There was a moderate prevalence of depression and anxiety identified, 
though these mood problems, particularly anxiety, were often not recognised by the 
GP. For example, 8.3% of patients reported symptoms of depression, though GPs only 
identified symptoms of low mood in 6% of participants. Meanwhile, 24.4% of patients 
reported anxiety symptoms, which were only recognised by 11.9% of GPs (Memel et al., 
2000). However, this study was dependent on the frequency of consultation by 
participants and the familiarity of different GPs with their patients. 
 In recognition of the links between mood disorders and higher morbidity and 
mortality in LTCs, guidelines have been written on how depression should be identified 
and treated in adults with chronic physical health problems (NICE, 2009b). However, no 
similar guideline has been published to assist the recognition and management of 
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anxiety in LTCs. This is despite anxiety being under-recognised and associated with 
increased morbidity and mortality in people with LTCs (Watkins et al., 2013). 
The General Health Questionnaire (GHQ)-28, PHQ-9 and PHQ-2 (also referred to 
as the two stem questions), have been found to be most sensitive at detecting 
depression in people with a chronic physical illness (Meader et al., 2011). The PHQ-2 
questions ask about the frequency of depressed mood and anhedonia over the past 2 
weeks, scoring each as 0 ("not at all") to 3 ("nearly every day") (Kroenke, Spitzer and 
Williams, 2003). The PHQ-2 questions overlap with the two-question instrument 
(Whooley et al., 1997), which asks about depression symptoms over the preceding 
month, rather than the past 2 weeks, and has the option of a ͞yes͟ or ͞no͟ response, 
rather than 4 potential responses, numbered 0-3 (Whooley et al., 1997). The PHQ-2 
questions are often favoured due to their ease of application and efficiency (Meader et 
al., 2011), though the two-question instrument also has a high sensitivity and moderate 
specificity for the detection of depression (Bosanquet et al., 2015). The PHQ-2 questions 
and two-question instrument are outlined in figure 2.5 (p 32). 
A meta-analysis examining the utility of PHQ-9 and the PHQ-2 for screening and 
case finding revealed that both tools had high negative predictive values of 98.6% and 
94.1% respectively. This would imply that the PHQ-2 or PHQ-9 could be used to rule out 
those without depression, with few false negatives. Although the PHQ-2 was found to 
be useful as a screening test, lower positive predictive values for case-finding on 
comparison to the PHQ-9, suggested it would not be optimal for the confirmation of a 
diagnosis of depression. Therefore, the PHQ-2 has been suggested to be most useful as 
an initial screening tool for depression, to be followed by the PHQ-9 in those scoring 
positively (Mitchell et al., 2016).  
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Figure 2.5- The PHQ-2 (Kroenke, Spitzer & Williams, 2003) and the two-question 
instrument (Whooley et al., 1997) 
 
Tool PHQ-2  (Two-stem questions) 
Two-question instrument 
(Whooley questions) 
Prompt 
Over the last 2 weeks, how often 
have you been bothered by any 
of the following problems: 
During the past month, have you 
been bothered by: 
Symptoms 1. Feeling down, depressed or hopeless? 2. Having little interest or pleasure in doing things? 
Responses 
0= Not at all 
1= Several days 
2= More than half the days 
3= Nearly every day 
0= No 
1= Yes 
Score Range 0 to 6 0 to 2 
 
A more recent meta-analysis analysed the accuracy of the PHQ-9 using individual 
data from 17,357 people, who participated in 58 studies (Levis et al., 2019). Again the 
PHQ-9 was found to be sensitive at detecting depression. Participants without a prior 
diagnosis of depression completed the PHQ-9, then underwent diagnostic interviews 
after 2 weeks. A PHQ-9 score of ш10 maximised combined sensitivity (0.88 (95% CI= 
0.82-0.88) and specificity (0.85 (95% CI= 0.82-0.88) in the 29 studies using semi-structed 
interviews as a reference. However, there was significant heterogeneity across studies. 
Some subgroup analysis on the age and gender of participants was performed, though 
a lack of data on comorbidities meant this couldn͛t be analysed.  
Although the literature suggests that the PHQ-2 questions are sensitive to 
depression, the way in which the questions are posed could lead to systematic under-
detection of depression (Maxwell et al., 2013). In a qualitative study exploring the 
experiences of primary care practitioners involved in the identification of depression in 
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patients with DM and CHD, Maxwell and colleagues reported that practitioners 
struggled to incorporate the PHQ-2 questions into a consultation. Some nurses 
described lacking the skills required to provide patients with adequate support at the 
point of use (Maxwell et al., 2013), suggesting an unmet training need. In addition, 
several practitioners described the assessment as too mechanistic or reported finding 
the process uncomfortable. Consequently, a more individualised approach has been 
recommended, with less time pressures to facilitate the development of rapport. 
However, due to increasing demands on their time, practitioners may struggle to 
achieve this (Maxwell et al., 2013). As study participants were self-selecting, people with 
an interest in research or depression management could have been more likely to 
volunteer, potentially reducing the diversity of perspectives gained. In addition, data for 
this study was gathered through focus groups, some of which were small or did not 
include a mix of different professionals. This could have reduced the diversity in 
perspectives shared, particularly if there were more dominant participants who could 
have discouraged others from disclosing opposing views.  
A qualitative study explored the experiences of nurses in recognising depression, 
in older people with multimorbidity (Waterworth et al., 2015). Overall, nurses reported 
a lack of confidence in discussing low mood with patients, with many believing this was 
not their responsibility, further supporting a requirement for training to improve the 
recognition and management of mood problems in people with LTCs. However, as this 
study involved nurses working in New Zealand, the results may not be generalisable to 
other countries, where nurses could have received different training.  
A qualitative study involving interviews with patients and their GPs, revealed 
different perceptions of depression assessment using tools, incentivised by the QOF. 
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GPs considered their clinical judgement to be more important than objective 
assessments, and felt the use of structured questions could compromise the doctor-
patient relationship by interfering with the consultation process. However, patients 
perceived the use of incentivised tools as an efficient way to supplement medical 
decisions and as evidence of their GP taking their problems seriously (Leydon et al., 
2011). Interviews were conducted until data saturation was reached, to help ensure a 
full diversity of perspectives were considered. However, as participants volunteered, 
those who agreed to be interviewed could have had more negative views of depression 
assessment tools, compared to the norm. Patients were recruited to the study by their 
GP, who may have selected people to be interviewed who would be likely to share more 
positive views of their experiences consulting their GP (Leydon et al., 2011). 
Consequently, self-reported measures to identify mood problems can be easy to 
apply, whilst facilitating comparisons between studies. However, some practitioners can 
struggle to integrate structured questions within consultations, prefering an 
individualized approach that facilitates the development of rapport to encourage 
disclosure of concerns, rather than socially desirable responses. 
The GAD-7 scale is used to assess the severity of anxiety (Spitzer et al., 2006). A 
systematic review of the accuracy of the GAD-7 tool, involving 5223 participants from 
12 studies, found an acceptable pooled sensitivity (0.83 (95% CI 0.71, 0.91) and 
specificity (0.84 (95% CI 0.70, 0.92) of the GAD-7 tool for identifying anxiety (Plummer 
et al., 2016). An abbreviated version, GAD-2, which includes the first two questions of 
GAD-7, has been recommended as a case-finding tool for anxiety in primary care, having 
90% sensitivity for GAD (Ballenger et al., 2001). The GAD-2 questions are listed in figure 
2.6 (p35). 
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Figure 2.6- GAD-2 (Spitzer et al., 2006). 
 
GAD-2  
Prompt Over the last 2 weeks, how often have you been bothered by any of the following problems: 
Symptoms 1. Feeling nervous, anxious or on edge? 2. Being unable to stop or control worrying? 
Responses 
0= Not at all 
1= Several days 
2= More than half the days 
3= Nearly every day 
Score Range 0 to 6 
 
 QOF incentives to ask case-finding questions for depression in CHD and DM were 
retired in 2013 (NHS Employers, 2015). A study exploring the impact of these incentives 
found that whilst these QOF indicators were in place there was a significant increase in 
new depression-related diagnoses. However, as there were no control practices the 
influence of emerging national and local guidelines on this outcome could not be 
excluded (McLintock et al., 2014). It is possible that the use of structured tools could 
have led to some screening bias, with positive responses to questions being more likely 
to be recorded. 
A systematic review aimed to determine the impact of routinely assessing 
depression severity using structured tools in primary care, as incentivised by the QOF 
(Shaw et al., 2013). From 8 studies that met the eligibility criteria, no evidence was found 
on whether a structured assessment of depression severity and subsequent treatment 
based on the assessment, led to improved QoL or depression remission. Increased 
depression severity at diagnosis, determined by GP judgement or use of a structured 
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tool, was associated with higher treatment and referral rates, though this was based on 
low quality evidence, hence further research would be required to determine the impact 
of using structured case-finding questions for depression on outcomes.   
It is possible that the retirement of the QOF indicators for use of tools to identify 
depression, could have led to fewer patients with LTCs being asked the case-finding 
questions, hence reduced recognition of comorbid mood problems. However, QOF 
targets could also have contributed to a performance managed and time-limited 
primary care environment, which could have led to less patient-centred discussions 
about mood. In fact, a qualitative study of barriers to managing depression in people 
with LTCs found evidence to suggest that consultations under the terms of the QOF 
could encourage reductionist approaches to case-finding for depression in people with 
CHD and DM, with discussion of depression being pushed into the margins of annual 
physical health check-ups, creating barriers to a patient-centered approach to the 
recognition and management of mood problems (Coventry et al., 2011). 
To improve the management of comorbid mental health problems in people 
with LTCs, an expansion of IAPT services focusing on people with LTCs has been planned, 
as outlined within the Five Year Forward View for Mental Health (NHS England, 2016). 
Psychological therapy will be integrated into existing services, either within primary or 
secondary care, meaning physical and mental health care provision will be co-located.  
Older people could particularly benefit from this expansion of IAPT services, as 
multimorbidity, the presence of 2 or more LTCs, is more prevalent in people aged over 
65 years (Barnett et al., 2012). Multimorbidity is associated with an increased risk of 
developing comorbid anxiety (Vancampfort et al., 2017) and depression (Read et al., 
2017). Evidence suggests that older people are under-represented in those accessing 
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IAPT services (Pettit et al., 2017), with fewer referred, despite a greater proportion of 
older adults completing their treatment and sometimes having better outcomes, 
compared to those of working age. 
NICE CG91 on the management of depression in adults with a chronic physical 
health problem, highlights the role of collaborative care (CC) as a model to improve the 
liaison between physical and mental health services, in addition to primary and 
specialist care (NICE, 2009b). NICE CG123 on the identification of common mental 
health disorders and pathways to care, also outlines how clinicians, managers and 
commissioners should work together to design local care pathways that provide an 
integrated programme of care across primary and secondary care services (NICE, 
2011b). 
Key components of CC include a MDT approach to care, structured management 
plans, scheduled follow-ups and enhanced inter-professional communication (Gunn et 
al., 2006). CC is particularly advocated for people with moderate to severe depression 
associated with a LTC that has failed to respond to high-intensity psychological 
interventions and pharmacological treatment (NICE, 2009b). The foundations of CC 
were set by the Chronic Care Model (CCM), which aimed to transform the care of people 
with chronic illnesses from acute and reactive to proactive, and planned. In people with 
LTCs, team-based delivery of care, improved use of information symptoms and patient 
education and support, as advocated by the CCM, have been found to improve overall 
outcomes (Coleman et al., 2009).  
A Cochrane systematic review published in 2012 aimed to assess the 
effectiveness of CC for people with anxiety and depression (Archer et al., 2012). 
Following review of 79 RCTs involving 24,308 participants, a significant improvement in 
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mood outcomes for adults treated with the CCM was found for up to two years, though 
not beyond this time. Heterogeneity in terms of participants, interventions, 
comparisons and outcome measures was noted. Some limitations, such as the blinding 
of participants and clinicians, reflected the reality of conducting intervention trials in 
practice. 
 The Collaborative Interventions for Circulation and Depression (COINCIDE) trial 
was designed to test whether depression in LTCs could be improved by integrating low-
intensity psychological interventions within the routine primary care management of 
LTCs (Coventry et al., 2015). CC delivered in partnership with practice nurses was found 
to reduce mood problems and improve self management of chronic disease in people 
with mental and physical multimorbidity. Again, a lack of blinding of participants and 
researchers could have introduced bias. In addition, the treatment effects were only 
small, though the population studied were deprived with high levels of multimorbidity 
(Coventry et al., 2015).  
A nested qualitative study within the COINCIDE trial found that CC between 
physical and mental health specialists facilitated access to depression care for patients 
with LTCs (Knowles et al., 2015). However, some participants reported preferring their 
mental and physical health to be managed by recognised ͚experts͛, not their primary 
care nurse, whilst several felt that having a separate space to review their mental health 
liberated discussion of concerns (Knowles et al., 2015). Therefore, models of integrated 
care would need to be flexible to the needs of patients who may view their depression 
and LTC as separate problems (Knowles et al., 2015). The majority interviewed were 
older patients, so although this would represent the population most likely to be seeking 
help, it may not reflect the views of younger patients.  
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Building on the requirement for integrated treatment of LTCs and mood 
problems, the ENHANCE (Healey et al., 2015) study, evaluated the feasibility and 
acceptability of a nurse-led LTC review for identifying and managing osteoarthritis (OA)-
related joint pain and mood problems within primary care LTC reviews. Preliminary 
results showed that some of the practice nurses had difficulty managing a combination 
of joint pain alongside mood problems within one consultation. However, there was 
some evidence of good integration, and the consultation was reported to be acceptable 
to patients (Jinks et al., 2015). Therefore, incorporating case-finding for anxiety and 
depression within primary care nurse-led LTC reviews could potentially improve the 
recognition and management of mood problems in people with LTCs. 
Having discussed the burden of mood problems in people with LTCs and 
evidence for how comorbid anxiety and depression should be managed in this 
population, in the next section, I will discuss the perspectives of patients and 
practitioners on mood problems in people with LTCs.  
 
2.8 Patient and practitioner perspectives of mood problems in people with 
long-term conditions   
 
In a systematic review of the beliefs held by people with depressive symptoms, 
particularly in the presence of a LTC, multiple causes for low mood were reported, from 
negative life events to stress and physical illness (Alderson et al., 2012). Whilst some 
perceived their symptoms to be part of normal life, hence preferred to not be told they 
had depression, others gleaned comfort from their diagnosis by knowing that treatment 
would be available (Alderson et al., 2012). Several felt that a diagnosis of depression 
gave them a new identity, which for the majority was unwelcome, with some fearing 
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that they would be perceived as unable to cope or that their judgement would not be 
trusted, jeopardising potential friendships or employment prospects (Alderson et al., 
2012). Limiting this review to primary care-based studies written in the English 
language, could have led to potentially relevant studies being excluded, though this did 
increase the relevance of the review to the management of depression in primary care, 
particularly to inform case-finding for depression.  
A qualitative meta-synthesis of the experiences of patients with a LTC and 
comorbid mood problems, found that most perceived their LTC to have caused their 
anxiety or depression (DeJean, 2013). Alternatively, some perceived their mood 
problems to have caused their LTC, attributing high blood sugars to constant worry, or 
heart disease to depression having caused a "heavy heart". Others perceived their LTC 
and mood to be inter-related, with the two conditions exacerbating each other, whist 
some perceived no connection between their LTC and mood. A greater range of 
perspectives may have been captured if the review had focused on broader 
psychological responses to living with a chronic disease, rather than the experiences of 
people with LTCs of being diagnosed with comorbid anxiety or depression. However, 
the focus of this review ensured that the authors͛ objectives were met, whilst a second 
stage of analysis involving a comparison of findings across studies, helped to highlight 
exceptions for development into new themes, facilitating a greater depth of 
understanding. 
 As part of a study aiming to develop a community-based intervention for older 
people living with anxiety and depression, older adults were interviewed to determine 
their perspectives of mood problems (Kingstone et al., 2017). Participants reported 
multiple forms of loss after developing a LTC, which they perceived to have caused 
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mood problems.  For example, participants reported reduced mobility, the loss of 
significant relationships, changes in their ability to participate in hobbies and a loss of 
independence as a consequence of ageing with a LTC, to negatively impact on their 
mood. Despite the researchers attempting to recruit a broad range of people to 
interview, a lack of male or housebound people participated, meaning some 
perspectives may have been missed. 
A mixed methods study aimed to determine whether people with heart disease 
and comorbid depression had different causal beliefs about their depression, when 
compared to people in routine care for depression (Magaard et al., 2018). Beliefs about 
depression were measured using the Brief-Illness Perception Questionnaire and 
categorised using qualitative methods. Compared to people in routine care for 
depression, those with heart disease and comorbid depression more often attributed 
their depression to physical illness (48% vs. 16%), and less often to problems at work 
(25% vs. 35%) or negative life events (19% vs. 25%). However, a significant limitation of 
this study was that the presence of other LTCs was not accounted for. The group with 
cardiac diseases were older, hence were more likely to have other LTCs, which could 
have affected their causal beliefs, whilst the characteristics of the depression group 
were not described, hence they could have had other LTCs that influenced their beliefs. 
A study exploring the views of older people on the relationship between 
depression and CHD, found that treatment for depression could be more acceptable if 
discussed in terms of its' effects on overall CVD risk. Therefore, highlighting the negative 
impact of poorly managed mental health problems on physical comorbidities, could 
make patients more willing to acknowledge and treat their mood disorders (Bogner et 
al., 2008). As this study focused on the views of people over 65 years, who were all from 
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the same geographical area, alternative perspectives may have been gained from a 
more diverse or younger population. 
In a qualitative study exploring patients͛ experiences of living with depression 
and CHD, participants perceived strong links between their LTC and depression, with 
some men feeling emasculated by their CHD and others feeling depressed by the 
͞medicalization͟ of their lives ;Simmonds et al., 2013). Participants were ambivalent 
about accessing primary care interventions for depression, due to feeling their GP would 
not be able to help with their complex health and social needs. Most cited a preference 
for talking therapies and interventions providing opportunities for social interaction 
rather than medication. After 30 interviews, data saturation was reached, though as 
participants were mainly from deprived areas, alternative perspectives may have been 
gained from a more diverse population.  
A further qualitative study exploring the perspectives of people with depression 
and CHD or DM, found that participants feared stigmatization for having depression or 
taking medication, whilst some felt responsible for independently overcoming their 
depression (Alderson et al., 2014). More diverse perspectives may have been gained if 
the interviewer had not disclosed their identity as a GP and if the sample had included 
more females and ethnic minorities. Overall, results suggest that to engage patients in 
the detection and management of depression, their beliefs about comorbid mental 
illness and treatment need to be explored. 
A related Q-methodology study aimed to identify patients͛ views about 
depression in CHD or DM and understand how these could influence clinical practice 
(Alderson, Foy & House, 2015). Participants were asked to rank 57 statements about 
their understanding of depression in chronic physical illness from +5 (strongly agree), to 
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-5 (strongly disagree) on a grid. A researcher was present who interviewed participants 
afterwards, to explore their reasons for the placing of statements. Five different 
accounts about depression in LTCs were identified, which varied in terms of the role 
chronic illness had in depression, the role of medical interventions and the importance 
given to supportive networks. Based on these accounts, different management 
approaches were recommended, highlighting the need for clinicians to explore patients͛ 
perspectives of mood problems and develop an individualised approach to the 
detection and treatment of comorbid depression. Although participants varied in age, 
they were mainly white British and from the same geographical area, potentially limiting 
generalisability. When using Q-methodology, participants may not have understood the 
meaning of some statements hence they could have randomly placed some cards. 
However, a researcher was present who explored the reasons behind the ranking of 
statements. It is still possible that some perspectives on mood problems could have 
been missed, though the statements used were informed by a systematic review and 
qualitative interview study. Identifying socially shared viewpoints through Q-
methodology enabled different management approaches to be suggested, to improve 
provision of individualised care and concordance with treatment. 
A further qualitative study explored the perceptions of patients and practice 
nurses (PNs) of depression in people with DM and CHD screened for subthreshold 
depression (Pols et al., 2018). Interviewing both PNs and patients facilitated deeper 
insights. In particular, PNs often perceived patients to not be depressed and to have a 
minimal need for specific care, whilst most patients interviewed perceived themselves 
to be at least mildly depressed (Pols et al., 2018). This could have been due to an overlap 
between the symptoms of a patients͛ LTC and mood problems, making it difficult for the 
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PN or patient to recognise anxiety or depression as separate problems (DeJean, 2013). 
This could also have reflected normalisation of mood problems by patients and their 
practitioners, who could have conceptualised depression as a frequent and 
understandable response to the losses associated with a LTC (Coventry et al., 2011). 
Furthermore, practitioners may have lacked certainty on how to negotiate labels for 
depression in people with LTCs, in a way that facilitated shared understanding and 
management (Coventry et al., 2011).  
As identified in other qualitative studies (Simmonds et al., 2013), patients 
expressed a preference for self-help advice and talking therapies to manage their 
depression (Pols et al., 2018). An individuals͛ perceived need for care did not always 
match their help-seeking behavior, often due to a lack of awareness of depression and 
its͛ management, suggesting an educational need (Pols et al., 2018). Stigmatization was 
a further barrier to help-seeking (Pols et al., 2018), as identified in other studies 
(Alderson et al., 2014). A limitation was that six of the nine PNs interviewed were 
psychosocial PNs, who may have had different perspectives from PNs without specialist 
training, limiting the generalisability of findings.  
 In another qualitative study, GPs were interviewed regarding their role in the 
detection and management of comorbid mood problems in people with chronic physical 
illnesses. GPs cited time constraints, a lack of confidence in diagnostic acumen and a 
perception that patients don't wish to discuss emotional problems as barriers to the 
identification of anxiety and depression in LTCs (Chew-Graham & Hogg, 2002). To enable 
the implications for GP training to be discussed, all GPs interviewed were involved in 
undergraduate teaching. It is possible that different perspectives may have been gained 
from a wider sample of GPs. However, interviewing this subset of GPs helped to 
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highlight potential training requirements, to facilitate the empowerment of patients to 
disclose mood problems and engage with management plans. Findings would support 
the need for collaborative management strategies for depression in people with LTCs, 
as discussed in section 2.6 (Gunn et al., 2006). 
A nested qualitative evaluation within a service development pilot aimed to 
determine the feasibility of training PNs to deliver a psychosocial intervention within a 
CC framework for people with depression and LTCs (Webster et al., 2016). Patients and 
a purposive sample of professionals taking part in the intervention were interviewed. 
Patients valued a PN being available to listen to their mood concerns. However, a 
perceived scarcity of time and resources, in addition to a lack engagement by the whole 
practice team in a model of CC, exacerbated pressures perceived by PNs. A need for 
formal supervision of PNs was identified, to support them in undertaking the role of a 
case manager for people with depression and LTCs. Only three patients participated in 
interviews, despite the offer of reimbursement for participation, hence alternative 
perspectives could have been missed, though the study findings were strengthened by 
the analysis of clinicians͛ and patients͛ perspectives.  
A mixed methods study aimed to determine patients͛ readiness to receive 
psychosocial care during nurse-led DM consultations in primary care (van Dijk-de Vries 
et al., 2016). In depth patient interviews were followed by questionnaires designed to 
explore findings within a larger group of patients. Although patients supported an 
integrated approach, they often did not expect a discussion about psychosocial 
problems within their DM consultation. Younger patients were generally more open to 
discussing psychosocial problems with the PN compared to people aged over 65 years. 
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This would suggest a requirement for patients to be informed about the changing role 
of PNs. 
Having discussed the prevalence, impact, identification and management of 
anxiety and depression in people with LTCs, in addition to the perspectives of patients 
and practitioners on comorbid mood problems in this population, I will now focus on 
mood problems in people with IRCs. 
 
2.9 Anxiety and depression in people with IRCs                                              .    
 
  The majority of literature on comorbid mood problems in IRCs is focused on RA. 
Therefore, the first two parts of this section are about anxiety and depression in people 
with RA (section 2.9.1), in addition to patients͛ and practitioners͛ perspectives on the 
identification and management of mood problems in people with RA (section 2.9.2). The 
final section summarises the relative lack of literature on anxiety and depression in 
other IRCs (2.9.3). 
 
2.9.1 Anxiety and depression in people with rheumatoid arthritis 
In common with other physical LTCs, there is an increased prevalence of both 
depression and anxiety in people with RA. A meta-analysis reported the prevalence of 
depression in RA to be 38.8%, with 16.8% suffering from a major depressive disorder 
(Matcham et al., 2013). However, a limited number of studies within the review used a 
psychiatric assessment supported by diagnostic criteria to confirm a depression 
diagnosis, meaning the reported prevalence could have been overestimated. The high 
prevalence of depression could also have been affected by an overlap between 
symptoms of RA and somatic symptoms of depression, such as poor sleep or fatigue. 
One study estimated that up to 20% of people with RA have anxiety (VanDyke et 
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al., 2004), though anxiety was identified using screening questionnaires without any 
diagnostic evaluation, hence this prevalence could have been overestimated. A study 
using potentially more accurate psychiatric assessments to diagnose anxiety in people 
with RA, reported a lower prevalence of 13% (Isik et al., 2006), whilst a later study using 
questionnaires to assess for anxiety reported a prevalence of 14% (Covic et al., 2012). 
This still suggests that the prevalence of anxiety in RA is much higher than the general 
population of England, where a survey an estimated 5.9% to have had symptoms of a 
GAD in the preceding week (NatCen Social Research, 2016).  
The literature also suggests that the incidence of mood problems in people with 
RA is increased (Marrie et al., 2018b). A Canadian cohort study estimated the incidence 
of depression and anxiety in people with RA, using population-based administrative 
health data. 10,206 incident cases of RA identified between 1989 and 2012, were 
matched to 50,960 controls. The incidence of depression (incidence rate ratio (IRR) (95% 
CI) 1.46 (1.35, 1.58)) and anxiety (IRR (95%CI) 1.24 (1.15, 1.34)) was significantly higher 
in the RA cohort, when compared to the control group over the study period. However, 
medical comorbidities were not evaluated or controlled for, which could have 
confounded the associations observed. The use of administrative data may also have 
limited the accuracy of diagnostic codes reported. Conversely, strengths of the study 
included its͛ size and general population approach. 
A recent quantitative meta-analysis aimed to evaluate the relationship between 
RA and incident anxiety. This included 10 studies, involving 139,875 participants, with 
follow-up varying between 1 to 9.2 years (Qui et al., 2019). The incidence of anxiety was 
significantly increased in people with, compared to those without RA (OR 1.20, 95% CI 
1.03-1.39). There were high levels of heterogeneity between studies, potentially 
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attributable to study design, geographical area and follow-up duration. However, 
studies included were of high quality and individual studies were found to have little 
influence on the overall results in the sensitivity analysis.  
Comorbid depression in people with RA has been found to be associated with 
increased RA-related hospitalization and overall healthcare costs (Joyce et al., 2009). 
However, as this study was conducted in the United States of America (USA), the cost of 
a potential admission could have been a deterrant to attending hospital when ill. 
Consequently, it is possible that a stronger association would be seen in a UK population, 
where there are no financial barriers to accessing care.  
The literature also suggests that depression in people with RA is a risk factor for 
increased mortality (Ang et al., 2005). A cohort of people with RA were followed-up at 
clinic appointments over 18 years. The primary independent variable was the mean 
Arthritis Impact Measurement Scale (AIMS) depression score during the first 4 years of 
entry into the clinic cohort. After adjusting for covariates, the hazard ratio for each unit 
increase in the average 4-year AIMS depression score on mortality, was 1.14 (p<0.0001), 
suggesting that depression in RA was associated with increased mortality. The 
generalisability of this data could be questioned as it all originated from a single arthritis 
centre, though the prevalence of depression and mortality rate in this sample were 
similar to other settings. As the relationship between depression and mortality in the 
RA cohort may have been confounded by comorbid medical disorders, sensitivity 
analyses were performed, and deaths within the first two years of the study were 
excluded. In addition, a combination of the Health Assessment Questionnaire (HAQ) 
score, erythrocyte sedimentation rate (ESR) and grip strength were used to help control 
for the confounding effect of higher disease activity.  
 49 
It has been suggested that the causal pathways between RA and depression are 
bidirectional, with possible explanations including biological, psychological and 
behavioural processes (Rathbun, Reed & Harrold., 2013). In terms of biological 
processes, depression has been linked to a rise in pro-inflammatory cytokines (Maes et 
al., 1995). A small study has also suggested that anti-TNF could interact with serotonin 
transmission, potentially affecting mood, though further research would be needed to 
confirm this association (Cavanagh et al., 2010). As cytokine dysregulation is pivotal in 
the pathogenesis of RA, pro-inflammatory cytokines produced in RA could potentially 
precipitate or exacerbate depression and vice-versa. 
In terms of psychological processes, negative thoughts in people with depression 
could influence how symptoms of RA are perceived, whilst depression could also affect 
behaviour, potentially causing a decrease in exercise, deconditioning, reduced 
endorphin release and increased pain (Covic et al., 2003). When clinical and 
psychological measures were collected from 157 patients with RA over a 12-month 
period, helplessness and passive coping were found to significantly mediate the 
relationship between physical disability in people with RA, and future depression and 
pain. When specific passive coping strategies were identified, catastrophising was a 
particularly detrimental factor associated with increased pain and low mood (Covic et 
al., 2003). Consequently, interventions that focus on improving coping strategies, such 
as CBT, could potentially reduce future depression and pain severity in people with RA. 
A recent cohort study found evidence supporting a bidirectional association 
between RA and depression (Lu et al., 2016). The incidence of depression was higher in 
the RA cohort, when compared to those without RA (15.69 vs. 8.95 per 1,000 person-
years). However, the incidence of RA was also found to be higher amongst those with 
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depression compared to those without (2.07 vs. 1.21 per 1,000 person years), athough 
there may have been some residual confounding as there was no data on educational 
level and social networks to enable adjustments to be made.  
A large cohort study aimed to determine predictors of psychological health 
(using the mental component summary (MCS) score of the short form (SF)-36) in people 
with RA. A total of 15,282 participants were recruited from a Swiss and an American 
cohort. Pain was found to be the most important predictor of psychosocial health in 
people with RA, followed by disease activity and functional disability (Courvoisier et al., 
2012). As participants had to complete at least two SF-36 scores, they may have been 
more compliant with treatment and had a higher QoL than the general RA population. 
However, the use of large cohorts from different geographical areas enhanced the 
generalisability of findings. 
The interactions between mental health and RA have been conceptualised in 
model by Sturgeon et al. (2016), which I have adapted, as shown in figure 2.7 (p51). The 
figure highlights the bidirectional association between disease activity and mental 
health. Increased disease activity in people with RA, associated with inflammation, pain 
and fatigue, can lead to functional impairment, which can negatively influence mental 
health. Changes in cognitive appraisal ;a patients͛ interpretation of their disease 
activity), behavioural response (eg. catastrophising) and mood, can affect a persons͛ 
mental health, which is further mediated by psychological or pharmacological 
treatments and active coping, again impacting on disease activity. I have added a 
dimension, a central circle, to highlight the influence of other comorbidities, MDT 
support and social networks on mental health and disease activity in people with RA. 
Beyond this are general socio-economic, cultural and environmental conditions that can 
 51 
affect the complex relationship between physical and mental health, as summarised in 
Dahlgren and Whitehead͛s Rainbow model ;ϭϵϵϭͿ. In particular, poor living and working 
conditions, which may relate to lack of employment opportunities, poor housing, or lack 
of basic requirements such as food, water or sanitation, can negatively impact on mental 
health and disease activity. 
Figure 2.7- Interactions between RA disease activity and mood, adapted from Sturgeon 
et al., 2016. 
 
Most literature examining the impact of mood problems in RA has focused on 
depression, not anxiety. Several studies have found a significant association between 
depression in people with RA and a reduced QoL. For example, an Italian study involving 
92 RA patients examined the impact of comorbid depression on QoL (Bazzichi et al., 
2005). Depressive symptoms contributed to a significant reduction in QoL, even after 
controlling for functional status, duration of illness and demographic characteristics, 
though other potential confounding factors such as comorbidities were not controlled 
for, which could also have affected this association. A further study based in Colombia 
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examined the relationship between depression and QoL in 103 RA patients compared 
to 73 controls. RA patients had much higher rates of depression and a lower QoL than 
controls and a significant negative correlation was found between depression and all 
QoL subscales, assessed using SF-36 (Senra et al., 2017). However, the small size of this 
study, limited to a specific geographical area, would limit generalisability.  
Several studies have also found depression in people with RA to impact on 
treatment response. A systematic review examined the relationship between 
depression, disease activity and treatment response in RA (Rathbun, Reed & Harrold, 
2013). Depression was found to decrease the efficacy of pharmacological and some non-
pharmacological treatments, such as CBT. Overall results suggested that depression may 
increase disease activity in RA. However, only English-language articles were included 
and a search of the grey literature was not performed, meaning the review only included 
7 studies. These were of variable quality, with several using convenience sampling which 
could have led to selection bias, reducing generalisability. Sample sizes were often small, 
hence when no association was observed this may have been due to a lack of statistical 
power. In addition, there was a lack of adjustment for potential confounders, hence the 
observed results could have been due to factors other than depression. 
A UK study investigated how mood changed when people with RA were exposed 
to anti-TNF drugs (Hider et al., 2009). People starting an anti-TNF drug were assessed 
for depression using the HADS-D, then changes in mood and disease activity (using 
DAS28) were reviewed at interval over the following year. People with depression had 
higher DAS28 scores at all time points. In people with persistent depression, smaller 
reductions in DAS28 scores were also noted in response to anti-TNF therapy. Data were 
collected at a time when anti-TNF drugs were first introduced to the UK, hence a 
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severely affected group of historical non-responders to DMARDs were included. Due to 
having more severe RA and a higher burden of depression, they may not have 
responded as well, due to having irreversible joint damage from their RA, influencing 
their mood. However, results suggest that improved identification and management of 
comorbid depression in people with RA could potentially improve their response to anti-
TNF drugs.  
A further study examined the relationship between depression and treatment 
response in 18,421 people with RA receiving biologic treatment, using data from the 
British Society for Rheumatology Biologics Register (Matcham et al., 2018). Patients who 
were experiencing symptoms of depression when started on biologic treatment had a 
20-40% reduced odds of achieving a good treatment response at 1 year. This poorer 
response to treatment was maintained beyond 1 year of follow-up. However, this study 
was limited by the lack of validated tools or diagnostic interviews used to ascertain the 
diagnosis of depression. Within the database used for this study, three measures of 
depression were available; any self-reported history of depression upon enrolment to 
the database; a threshold of чϰϬ on the normed mental health subscale of the SF-36; 
one item specific to mental health on the EuroQol 5-Dimension Scale (EQ-5D). 
Therefore, there may have been some misclassification of depression, athough the size 
of the study adds to the likely precision of the estimates. 
Another study explored factors influencing disease remission in people with 
inflammatory polyarthritis. Depression was found to predict a lower disease remission 
(OR (95% CI) 0.74 (0.55, 1.00)) (Cook et al., 2016). As comorbidities including depression 
were self-reported, patients could have incorrectly self-diagnosed depression, which 
could have reduced the observed effect of depression on remission rates.  
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When the impact of anxiety in people with RA has been examined, this has often 
been in combination with depression. However, at least 40% of people with anxiety in 
the general population do not have comorbid depression (Kaufman and Charney, 2000). 
A study involving a secondary analysis of clinical trial data aimed to determine whether 
depression and anxiety would predict physical disability, disease activity and treatment 
response in 379 people with RA (Matcham et al., 2016b). Baseline depression and 
anxiety symptoms were associated with increased DAS28 and tender joint counts (TJC), 
whilst persistent mood symptoms were associated with a higher DAS28, TJC, patient 
global assessment (PtGA) and HAQ scores, indicating increased disease activity and 
worse physical functioning. Baseline depression and anxiety were also associated with 
reduced odds of clinical remission and a 50% reduction in response to prednisolone 
treatment. However, adjustments were not made for the socioeconomic status of 
participants, which was not recorded, hence it is not possible to establish the extent to 
which these results reflect patients of low socioeconomic status, or the wider RA 
population. Therefore, future studies would benefit from taking account of the 
socioeconomic status of participants and controlling for this within any analysis. In 
addition, the EQ-5D was used to identify people with RA who had comorbid anxiety and 
depression. Validated tools containing more detailed questions, such as GAD-7 and 
PHQ-9, could have more accurately identified people with anxiety and depression, 
though the proportion of people reporting mood problems within this study was similar 
to prevalence estimates, improving confidence in the results.  
A study in China considered the impact of anxiety and depression on QoL in 
people with RA (Mok et al., 2012). 200 people with RA were interviewed by a physician, 
who determined a diagnosis of anxiety and depression. After adjustment for covariates, 
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anxiety and depression were found to be associated with reduced QoL, measured using 
the SF-36. Study participants did not include those on biological drugs, who often have 
more severe RA. Therefore, the QoL of the overall RA population with comorbid mood 
problems may be worse than reported in this study.  
Mental health problems in people with RA have also been found to affect how 
disease activity is self-reported. For example, a cross-sectional study involving 101 
people with RA recruited from a tertiary rheumatology department, evaluated the 
difference between patient and physician reported global assessments of disease 
activity (Duarte et al., 2015). People with RA were found to rate their disease activity 
higher than their physicians. This difference was strongly correlated with increased 
patient anxiety (r=0.551, p<0.001) and depression (r=0.464, p<0.001). In another study, 
195 people with RA completed a global assessment of disease activity, which was 
compared to an assessment by a physician. Anxiety and depression were associated 
with greater discordance between the patient and physician global assessments of 
disease activity (Liu, Bathon & Giles, 2015). Both studies used validated tools to diagnose 
a mood disorder, had moderate sample sizes and considered other potential covariates 
such as fatigue, functional status and QoL, though almost half of the disconcordance 
between physician and patient global assessments remained unexplained. This suggests 
that there are other covariates that have not been considered, that are influencing the 
differences observed between patient and physician global assessments of disease 
activity. 
A cross-sectional study involving 322 people with RA awaiting biologic 
treatment, found that when assessing disease activity using DAS28, patient-reported 
measures such as the visual analogue scale (VAS), which forms part of the DAS28 score, 
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were more strongly influenced by psychological variables (Cordingley et al., 2014). 
Therefore, separate reporting of the different components of DAS28 alongside an 
assessment of mood could help to guide patient management. 
Acknowledging the links between mental and physical health in people with RA, 
a recent systematic review and meta-analysis of 57 trials aimed to determine the impact 
of RA treatment on mental health problems (Matcham et al., 2019). Following 
treatment with biologic DMARDs, a small but significant improvement in the mental 
health of people with RA was noted, when assessed using the SF-36. However, the 
impact of RA treatment on the MCS score of the SF-36 was approximately half the effect 
seen on the SF-36 physical component summary (PCS) score. This suggests that mental 
health problems are unlikely to resolve by just controlling disease activity in people with 
RA, supporting the need for integrated mental health care within routine practice. 
In recognition of the links between mood problems in people with RA, reduced 
QoL and treatment response, and increased morbidity and mortality, NICE has created 
Quality Standards for the management of RA (QS33), to facilitate early recognition of 
comorbid mood problems (NICE, 2013c). Within this Quality Standard, NICE 
recommends that clinicians should regularly reassess mood within the context of an 
annual review clinic (NICE, 2013c). This recommendation is also supported by NICE 
guidelines for the management RA in adults, which recommend that people with RA are 
offered psychological interventions as part of multidisciplinary care (NICE, 2018). 
Recognition and treatment of depression in people with RA can have multiple 
benefits. For instance, a meta-analysis of 27 RCTs, testing the efficacy of psychological 
interventions to manage pain, found that people with RA receiving a psychological 
treatment, reported significantly less pain compared to control groups. Improvements 
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in secondary outcomes, such as anxiety, depression and self-efficacy were also noted in 
response to psychological interventions (Dixon et al., 2007). The review was limited by 
heterogeneity between studies due to the use of different psychological interventions, 
including CBT, hypnosis and stress management, whilst outcome measures for pain also 
varied. However, the large number of RCTs included in the meta-analysis increased the 
overall strength of evidence. 
In addition to CBT, affective interventions such as mindfulness meditation have 
been found to reduce depression in people with RA (Zautra et al, 2008). In a study 
involving 144 people with RA, participants were randomly assigned to one of three 
treatments; CBT for pain, mindfulness meditation or an education only group. People 
with RA who had recurrent depression benefited most from mindfulness meditation, 
which led to improvements in mood and a reduced TJC. However, the diagnosis of 
depression was determined using 6 yes/ no questions about mood, not a validated tool, 
reducing the reliability of results. In addition, although NICE guidelines recommend 
mindfulness as a way to prevent depression, in people who have had 3 or more episodes 
of low mood in the past, they do not recommend mindfulness for treatment of active 
depression, due to a lack of evidence. 
An RCT aiming to determine the impact of a self-help intervention on mood 
problems, involved 82 people with rheumatic disease being allocated to an intervention 
group, who received an internet-based cognitive behavioural self-help programme, or a 
control group (Garnefski et al., 2013). When participants were followed up after 2 
months, the self-help programme had significantly reduced anxiety and depression 
symptoms, measured using the HADS. However, participants were recruited online and 
only included a small number of men, limiting generalisability. In addition, differences 
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seen between the intervention and control groups could have been due to the 
additional attention given to the intervention group, rather than the actual self-help 
programme delivered. 
A systematic review and meta-analysis of interventions for depression and 
anxiety in people with RA, found no RCTs reporting on interventions for anxiety, and 
eight reporting on interventions for depression (Fiest et al., 2017). From six 
pharmacological interventions, three were found to improve depression in people with 
RA. A further RCT reporting the proportion who achieved a 50% reduction in RA 
symptoms, in response to two different pharmacological treatments, found no 
significant treatment effect (Bird & Broggini, 2000), whilst one reported psychological 
intervention did not lead to any significant improvement in depression (Evers et al., 
2002). Due to the small number of trials available and the risk of bias within these trials, 
the level of evidence was only low to moderate, hence further studies would be required 
to make more definitive conclusions about the most effective treatments to 
recommend for anxiety and depression in people with RA.  
A more recent pilot study aimed to determine whether treatment with 
antidepressants altered how 128 people with RA and comorbid anxiety and depression 
responded to DMARD or biologic drug treatment (Abramkin et al., 2018). Over five 
years, people treated with DMARDs and antidepressants achieved remission 
significantly more often than those taking DMARDs alone (p=0.02), highlighting the 
potential benefits of integrated treatment of RA and comorbid mood problems, which 
could improve overall outcomes. 
A further study explored the efficacy of a combined pharmacologic and 
cognitive-behavioural approach to the management of major depression in RA (Parker 
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et al., 2003). The use of antidepressant medication alone was found to be as effective 
as a combination of medication and psychological treatment. In addition to improving 
depression, antidepressants were found to improve the self-efficacy, social interaction 
and coping skills of participants, whilst reducing anxiety, stress and fatigue. 
Antidepressant treatment did not impact on pain or disease activity measures, though 
the small sample size in this study could have led to minor differences between the 
treatment groups not being recognised. In addition, as the study was only focussed on 
those with severe depression, different responses to psychological therapies may have 
been observed in those with mild or moderate depression.  
Three hours of low impact aerobic exercise per week, has also been found to 
positively impact on depression in people with RA. In an RCT involving 220 people with 
RA, participants were randomised to class or home exercises, or a control group. 
Exercises did not involve any running or jumping movements and one foot always had 
to remain on the ground (Neuberger et al., 2007). After 12 weeks of exercise, there had 
been a significant reduction in pain, fatigue and depression symptoms in the class 
exercise compared to the control group. This trend was not observed in the home 
exercise group, potentially due to participants exercising less intensively at home. 
Through use of a convenience sample, potential selection bias could have affected 
results, whilst a large number dropped out the study before baseline measures were 
taken, meaning the remaining participants may have been more motivated to engage 
with an exercise programme than the general population living with RA.  
Despite the benefits of treating comorbid anxiety and depression in people with 
RA, a national GP survey performed in 2015 found that primary care reviews for people 
with RA frequently focus on previous QOF domains such as CVD and fracture risk 
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screening (Hider et al., 2015), whilst questions to identify potential mood problems are 
often not included. The literature also suggests that most rheumatologists do not 
routinely screen for depression in people with RA, due to time constraints, a lack of 
confidence in dealing with mental health issues, or a belief that it is not their 
responsibility (Nicassio, 2008; Sleath et al., 2008).  
A secondary analysis of baseline data from an RCT aimed to determine how 
rheumatologists and people with RA who had symptoms of depression communicated 
about their low mood during appointments (Sleath et al., 2008). Audio-recorded 
consultations of rheumatologists with people with RA were reviewed. From 21 patients 
who were scored as having moderately severe to severe symptoms of depression (PHQ-
9 score >15), only 4 discussed depression during their medical visits, and each time the 
discussion was initiated by the patient. During 200 audio-recorded consultations, none 
of the rheumatologists raised the topic of mood problems.  The small sample size was a 
potential limitation of this study, though the study findings highlight the need to 
improve case-finding for comorbid anxiety and depression in people with RA. No data 
was obtained on the barriers and facilitators to the discussion of depression during the 
clinic appointments, which would have provided greater insights as to how care could 
be improved. 
 
2.9.2 Patient and practitioner perspectives on the identification and 
management of anxiety and depression in people with rheumatoid arthritis 
 
There is a lack of literature reporting patient and practitioner perspectives on 
the identification and management of mood problems in people with RA. A study 
exploring the perspectives of Hispanic patients with RA and depression, reported that 
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antidepressants were often perceived as unnecessary, or associated with side-effects. 
Many believed depression was linked to a weakness of character, so perceived that a 
positive attitude and personal strength would be most important in overcoming 
depression. However, 80% reported they would be open to seeing a therapist if 
necessary. The majority felt that support groups providing information about 
depression and facilitating dialogue between patients would be beneficial (Withers et 
al., 2015).  
The potential stigma associated with a diagnosis of depression could have been 
a barrier to disclosure or discussion of depression in interviews. Study participants also 
reported seeing rheumatology clinics as an opportunity to discuss physical, not mental 
health. The applicability of these results to people with RA, living in the UK, could be 
questioned, as the majority of Hispanic patients interviewed were of low socioeconomic 
status, with many being uninsured hence unable to afford treatment. Therefore, they 
could have expressed a preference for self-management due to the potential expense 
of psychological therapies or antidepressants. They may also have lacked awareness of 
alternative management options. Outcomes could also have been influenced by 
selection bias, as those invited to take part had to be in regular attendance at a 
rheumatology clinic in Los Angeles. This would have excluded those unable to afford 
hospital care, newly diagnosed patients or those not motivated to regularly attend the 
clinic. As a more motivated subset may have been interviewed, the propensity to self-
manage depression may have been over-represented. As 89% of participants were 
female, male views could also have been under-represented. 
A survey sent to rheumatology units at 143 acute trusts in England explored the 
provision of psychological support for people with inflammatory arthritis (Dures et al., 
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2014). Nurses from 73 rheumatology units (51%) responded. From these, 73% rated 
their units͛ psychological support provision as inadequate, despite most acknowledging 
that it was within their remit to offer support. Up to 42% reported that they had referred 
patients requiring psychological support to other services, whilst 26% cited using CBT 
approaches as part of their consultations. Barriers to the provision of psychological 
support included a lack of training and sufficient time, difficulty obtaining funding, an 
emphasis on addressing physical rather than mental health problems and a concern that 
there was no-one to refer the patient to if problems were identified. Recommendations 
to improve provision included to address clinicians' training needs and to integrate 
psychological support into care pathways. Of note, almost half of surveys were not 
returned in this study. It is possible that the units who didn͛t respond were 
systematically different from those who did complete the survey. Some may not have 
responded due to a lack of knowledge about local services or due to a fear of disclosing 
negative views about their rheumatology unit, leading to potential under-estimation of 
the gap in service provision. Alternatively, some may have been motivated to respond 
by poor local services, to publicise their need for support. It is also possible that some 
questionnaire responses were influenced by discussion with colleagues, rather than 
reflecting participants͛ own perceptions. Respondents may also have lacked sufficient 
knowledge about local psychological support provision to provide accurate responses.  
To explore patients͛ preferences for psychological support in inflammatory 
arthritis, a questionnaire was mailed to 1,200 randomly selected people with RA from 
an arthritis charity database, whilst questionnaires were also consecutively handed out 
to 1,080 patients attending 6 regional hospitals (Dures et al., 2016a). From these, 53% 
of patients completed the questionnaire. Overall, demand for psychotherapy was high. 
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Whilst 66% of patients reported that they would use a self-management clinic, 48% felt 
they would also benefit from peer support groups. Whilst 46% expressed a desire for 
counselling, 34% wanted support with managing the impact of their depression. Three 
quarters identified the rheumatology nurse as one of their ideal sources of support, 
whilst 50% selected their GP. Less than a third also named a psychologist or counsellor, 
suggesting fewer patients perceived a need to access specialist psychological support 
(Dures et al., 2016a). This would mirror a stepped care approach in which patients start 
with the lowest appropriate treatment and step up to more intensive services as needed 
(NICE, 2011a; NICE, 2009a). Further preferred sources of support included family and 
friends, patient support groups and occupational therapists. 
 It could be argued that the preferences expressed in this study would depend on 
the individual experiences of patients and their perceptions of different care providers' 
roles and accessibility (Dures et al., 2016a). With improved access and exposure patients 
could come to prefer individualised psychological interventions. In addition, the 
preference of patients in this study to have psychological support delivered by their LTC 
team contrasts with a nested interview study in the COINCIDE trial, in which patients 
expressed a preference for a separate space to discuss their mental health concerns 
(Knowles et al., 2015). Nevertheless, the questionnaire's findings support other research 
that has found rheumatology team involvement can help patients to improve their 
sense of disease control and psychological wellbeing (Avidsson et al., 2006). Self-
management advice from clinical teams often focusses on biomedical aspects of 
rheumatic disease. Exploring biopsychosocial factors and empowering patients with CBT 
techniques could potentially enhance self-management (Dures and Hewlett, 2012). 
However, this would be dependent on patients taking some responsibility for self-
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management and having a degree of cognitive and emotional self-awareness. In 
addition, clinicians would require training to teach basic CBT techniques and in a time-
pressured environment, they could struggle to deliver such interventions effectively. 
Responses to the open-ended questions from the study questionnaires provided 
further insights into the perceptions of patients about the psychological impact of 
inflammatory arthritis (Dures et al., 2016b). Psychological distress was often attributed 
to pain and fatigue. Patients reflected on the challenges of an altered life course, 
including strained relationships, loneliness and fears about the future. Many recounted 
experiences of feeling unheard or struggling to ask for help and a need to be understood 
and supported by others, from family and friends, to clinicians. Participants also 
commented on how they had developed ways to cope with the impact of their arthritis. 
Strengths of this study included the large and diverse sample size. However, the 
closed questions which preceded subsequent open ended questions might have 
influenced responses and imposed constraints on what participants perceived to be 
relevant. Compared with qualitative data collected through face-to-face semi-
structured interviews, there was no opportunity to encourage participants to clarify 
responses. However, questionnaire data might have been less affected by social 
desirability, leading participants to be more open in their responses.  
 
2.9.3 Anxiety and depression in people with ankylosing spondylitis, psoriatic 
arthritis, polymyalgia rheumatica and giant cell arteritis 
 
As past research exploring mood problems in people with IRCs has mainly 
focused on one of the commonest conditions, RA, the scale and burden of anxiety and 
depression in other IRCs, particularly PMR and GCA, has not been studied as extensively. 
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The main reported literature for AS, PsA, PMR and GCA is summarised in sections 2.9.3.1 
to 2.9.3.4. 
 
2.9.3.1    Ankylosing Spondylitis 
In AS, estimates of the prevalence of depression vary. A systematic review to 
determine the prevalence of depression in AS included 17 studies, involving 3187 
participants (Hopkins & Moulton, 2016). Within these studies, 6 different diagnostic 
tools were reported, with prevalence estimates for depression ranging between 4.9-
55.5%. In studies using HADS-D to screen for depression, 37.7% had mild depression, 
(HADS-D шϴ) and 8.2% had moderate depression (HADS-D шϭϭ). Significant correlations 
were noted between depression, disease activity and CRP. However, the review was 
limited by heterogeneity between studies due to the use of different diagnostic tools 
and thresholds for a diagnosis of depression. Consequently, the prevalence of 
depression could have been over-estimated due to the lower thresholds required for a 
depression diagnosis in some studies. 
 A more recent systematic review aiming to determine the prevalence of 
depression in AS included 14 studies (Zhao et al., 2018). The pooled prevalence of 
depression, according to a HADS-D score of шϭϭ, was 18% (95% CI 3-36%). Almost all of 
the studies included in the review involved hospital cohorts, who would potentially have 
had more severe disease than a primary care cohort. However, the included studies 
were generally of high quality with a low risk of publication bias. 
A population-based cohort study based in Sweden aimed to determine the risk 
of depression in people with AS, relying on depression diagnoses made by a doctor 
(Meesters et al., 2014). The prevalence of depression in the AS cohort of 1,738 patients 
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was 10%. Compared to the general population seeking care, there was an 80% increase 
in depression diagnosed by a doctor in women with AS, and a 50% increase in men. 
Although adjustments were made for the age and gender of participants, adjustments 
were not made for other potential confounders. In addition, data was only obtained 
from individuals who consulted their doctor. Therefore, it is possible the prevalence of 
depression was under-estimated as some individuals with depression may not have 
consulted their doctor, due normalising mood symptoms, attributing them to a physical 
health problem, or potentially lacking motivation to seek help. However, relying on 
depression diagnoses made by a doctor helped to ensure the validity of diagnoses made. 
A population-based cohort study using data from 2 large healthcare 
organisations in the USA examined the risk of depression in people with AS (Wu et al., 
2017). Patients with AS were frequency matched (1:4) with a general population cohort. 
The adjusted IRR of depression was 1.34 (95% CI 1.23, 1.47). However, patients with a 
prior diagnosis of depression were not excluded, which could have biased results.  
Nonetheless, a retrospective cohort study examining the risk of psychiatric 
disorders following a diagnosis of AS supported an association between AS and mood 
problems (Shen et al, 2016). Using the Taiwan National Health Insurance Research 
Database, the records of 2331 patients with AS were compared to an age and gender 
matched cohort of 9324 patients without AS. The overall adjusted HR for depressive 
disorders was 1.72 (95% CI 1.30, 2.27) and for anxiety, 1.85 (95% CI 1.37, 2.50), 
suggesting that AS is associated with an increased risk of both depression and anxiety. 
The risk of depression was significantly elevated within a year of diagnosis, though the 
risk of anxiety only increased beyond a year after diagnosis with AS. The risk of anxiety 
and depression remained significantly increased over 5 years after diagnosis. Certain 
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confounding factors could not be controlled for due to a lack of information in the 
research database, including excessive alcohol consumption, tobacco use and a high 
body mass index (BMI), all potential risk factors for anxiety or depression. However, it is 
possible that the prevalence of mood problems was underestimated in this study, as all 
those included had to have sought medical review. It is possible that individuals with 
mild symptoms may not have mentioned them, lacking candidacy for care, whilst more 
severe mood symptoms could have been a barrier to help-seeking. However, AS and 
psychiatric diagnoses were validated by specialists, whilst a further strength of this study 
was the large sample size.  
Another study aimed to describe the association between disease activity and 
psychological status in AS. Participants were recruited from an AS review group based 
at a regional UK hospital and assessed at 6 monthly intervals, up to 4 times (Martindale 
et al., 2006). From 110 participants, 89 completed all 4 assessments, which included the 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and HADS.  The estimated 
prevalence of anxiety in AS was 25%, and depression, 10%.  Increased BASDAI scores 
had a significant positive correlation with anxiety and depression. However, it is possible 
that the characteristics of people attending the AS review group were different from the 
general population living with AS, reducing the generalisability of findings. 
A qualitative study aimed to explore the impact of AS on the daily lives of young 
men (Primholdt et al., 2017). Semi-structured interviews were conducted with 5 men 
recruited from a rheumatology hospital in Denmark. For analysis, the natural meaning 
units in interview texts were identified, then summarised into short statements, before 
being developed into themes, following discussion by the research team. A main theme 
was daily living and psychological reactions. Within this theme, one participant reflected 
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on their experience of being diagnosed with depression after developing AS. They 
reported being offered antidepressant medication, which they declined in favour of 
psychological therapy due to already taking several medications. Another participant 
reported having rarely opened up about their feelings, though the reasons for this were 
not explored further. Several described how they perceived stress to trigger periods of 
inflammation and pain. A significant limitation of this study was the small sample size, 
only consisting of young men. Further patient perspectives could have been gained from 
a more diverse sample. However, it does suggest that comorbid depression has a 
significant impact on young men with AS. There is a preference for psychological therapy 
to manage mood problems, rather than pharmacological treatment, which supports 
findings in people with RA (Withers et al., 2015; Pols et al., 2018). There are potential 
barriers to the disclosure of mood problems in this population, which require further 
exploration. 
 
2.9.3.2    Psoriatic Arthritis 
In a systematic review aiming to determine the point prevalence of anxiety and 
depression in people with PsA, and the impact of PsA treatment on mood, 3 studies met 
the inclusion criteria (Kamalaraj et al., 2019). The prevalence of depression in people 
with PsA ranged between 9-22%, whilst the prevalence of anxiety was between 15-30%. 
One study found that treatment for PsA with etanercept for 24 weeks, led to a reduction 
in the prevalence of depression and anxiety (Gniadecki et al., 2012), though insufficient 
reporting of sampling, response rates and methods of analysis increased the risk of bias. 
The search was kept broad to ensure eligible studies were included, though due to the 
systematic review only including 3 studies, heterogeneity was high, with variation in 
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sample populations and the method of anxiety or depression assessment, limiting the 
strength of findings (Kamakaraj et al., 2019).  
A systematic review assessing the incidence and prevalence of anxiety and 
depression in people with PsA, found 10 studies meeting the inclusion criteria (Zusman 
et al., 2018). Mood problems were assessed using the HADS, PHQ-9 and the 
International Classification of Diseases 9th Revision Codes. The pooled prevalence of 
anxiety, based on 4 studies involving 15,878 people with PsA, was 27% (95% CI=12%, 
43%) whilst the pooled prevalence of depression from 6 studies, involving 22,163 people 
with PsA, was 20% (95% CI= 15%, 25%). The incidence of depression was reported in 3 
studies, with meta-analysis yielding a pooled IRR of 1.34 (95% CI= 1.20, 1.49), though 
the incidence of anxiety was not reported. The quality of included studies varied, 
increasing the risk of potential bias. In particular, the cut off scores for diagnosis of 
anxiety or depression within individual studies varied, with some including mild mood 
symptoms, potentially leading to the pooled prevalences of anxiety and depression 
being overestimated within this review. 
A Canadian study involving 611 people with PsA reported the prevalence of 
anxiety and depression to be 20.7%. However, as participants were asked to self-report 
their diagnosis, the accuracy of this estimate would be limited. For instance, some 
participants may not have recognised they had symptoms of a mood disorder, whilst 
others may have misdiagnosed themselves with anxiety or depression (Husted et al., 
2011).  
A cross-sectional study involving 495 patients with PsA determined the 
prevalence of comorbid anxiety and depression, either by attributing a diagnosis to 
individuals receiving pharmacological treatment for a mood disorder or by using a score 
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of шϭϭ on the HADS. Whilst 29.7% had symptoms of anxiety, 17.6% were found to have 
depression (Freire et al., 2011). The study was strengthened by the use of a validated 
outcome measure, and by being conducted across 75 Spanish hospitals to help ensure 
a more diverse and representative sample of people with PsA. The higher prevalence of 
anxiety compared to depression in PsA was supported in a more recent study, where 
603 consecutive patients attending a rheumatology outpatient appointment were 
assessed for anxiety and depression using the HADS (McDonough et al., 2014). However, 
in this study the threshold for diagnosis was lower, with a HADS score of шϴ indicating 
anxiety and depression. Therefore, the overall prevalence of mood disorders was higher 
in the second study, due to the inclusion of individuals with mild symptoms (HADS score 
of 8-10), with 36.6% suffering from anxiety and 22.2% depression (McDonough et al., 
2014).  
A US population-based cohort study examined the risk of depression in 5138 
people with PsA, who were frequency matched with a general population cohort (Wu 
et al., 2017). There was an increased risk of depression in the PsA cohort compared to 
the general population, with an adjusted IRR of 1.22 (95% CI 1.16, 1.29). However, as 
patients with a preceding history of depression were not excluded the incidence rate 
could have been overestimated. 
Data from the Clinical Practice Research Datalink (CPRD) was used to examine 
the incidence rate of treated depression in 7,643 patients with PsA (Hagberg et al., 
2016). People with PsA had higher rates of treated depression compared to people 
without PsA (IRR (95% CI) = 1.38 (1.27, 1.49). The incidence rate of treated depression 
was even higher in people with PsA who were on systemic therapy, such as a DMARD, 
to treat their arthritis (IRR (95% CI) = 1.59 (1.35, 1.86). It is possible that the people with 
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PsA on systemic therapy had more severe PsA, hence potentially more joint pain and 
functional limitation, which could have impacted negatively on their mood.  
A study in Greece aimed to determine the association between psychological 
factors and Health-Related QoL (HRQoL) in people with PsA and RA (Kotsis et al., 2012). 
Consecutive patients with PsA attending a follow-up clinic at a rheumatology hospital 
were recruited (n=83), and compared to patients with RA (n=199) attending the same 
department. Patients were reviewed by a rheumatologist and asked to complete self-
reported questionnaires, which included the PHQ-9 questions and the World Health 
Organisation QoL instrument (WHOQoL-BREF). In addition, the validated Greek version 
of the Symptom Checklist-90-Revised (SC-90-R) was used to assess for psychological 
problems, including anxiety and depression. From 83 patients with PsA, 21.7% had 
moderate or severe depression, compared to 25.1% with RA, determined by a PHQ-9 
score of шϭϬ. Although the proportions with anxiety were not reported, multiple 
regression analysis found anxiety and depression, when assessed using the SC-90-R, to 
be associated with reduced physical HRQoL. However, this association was only 
statistically significant for anxiety (standardized (ß) regression coefficient= -0.28, 
p<0.01). Due to the small sample size of patients with PsA, the generalisability of these 
findings would be limited. It is possible that the association between PsA and depression 
could also have reached statistical significance with a larger sample size.  
A systematic review and thematic synthesis of patients͛ experiences of psoriasis 
and PsA included 56 studies involving 337 individuals with PsA (Sumpton et al., 2019). 
The majority of data related to people with psoriasis. However, people with PsA 
reported a sense of life disruption and fear of deterioration, with anxiety provoked by 
the unpredictability of joint flares. Some reported poor recognition of their distress by 
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medical professionals or expressed hopelessness and suicidal thoughts due to the 
burden of their symptoms. Preliminary findings suggest that through validation of the 
burden of PsA and a holistic approach to care, the recognition of mood symptoms in this 
population could be improved. Initially though, further research is required to 
determine the prevalence of anxiety in people with PsA.   
2.9.3.3    Polymyalgia Rheumatica 
A study exploring the clinical characteristics of people with PMR found the 
prevalence of depression to be 2% (Kimura et al., 2009). However, this study only 
involved 123 patients who were all treated at one community hospital, limiting 
generalisability. In addition, the diagnosis of depression was determined by medical 
record review, without using a validated measurement tool, hence it is likely that some 
people with depression were missed.  
A study using the MCS of the SF-36 to ascertain depression, found that people 
with PMR had significantly lower mean MCS scores at presentation, than population 
norms within the same age range (65-74 years) (MCS scores 38.9 versus 53.2) (Hutchings 
et al., 2007). This would indicate that the emotional QoL or mental health of people with 
PMR, was worse than in people without PMR. However, the MCS had improved 
significantly after 12 months, suggesting that depression improved following treatment 
for PMR. 
A recent cross-sectional study aimed to determine the prevalence of depression 
in PMR (Vivekanatham et al., 2018). Questionnaires were sent to older adults from 150 
general practices with a first Read code for PMR in their medical records within the 
preceding 3 years. Depression was measured using the PHQ-8, with current depression 
defined as a PHQ-ϴ score of шϭϬ. From 550 respondents, 15% reported symptoms of 
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depression. Depression was significantly associated with female gender and PMR 
symptoms. People aged over 80 years were less likely to report depressive symptoms 
than younger people aged 50-59 years. Due to the complexity of diagnosing PMR, it is 
possible that some diagnoses made by GPs were inaccurate. However, the majority of 
PMR diagnoses are made in primary care and rheumatologists are likely to see 
individuals with a different disease spectrum, who are unlikely to represent the general 
population living with PMR, hence using a primary care population increased 
generalisability. 
For a cohort study aiming to characterise people with incident PMR in primary 
care, people with newly diagnosed PMR were mailed baseline questionnaires to 
complete (Muller et al., 2016). These included the GAD-7 and PHQ-8 questions for 
anxiety and depression, with a score of шϭϬ indicating moderate to severe mood 
problems. From 739 individuals mailed a questionnaire, 654 responded, of whom 13% 
had moderate to severe anxiety and 22% had moderate to severe depression. This study 
was strengthened by a large sample size including participants from across the UK, 
increasing generalisability.  
A qualitative study explored peoples͛ experiences of living with PMR (Twohig et 
al., 2015). A total of 22 semi-structured interviews were analysed thematically using 
constant comparison, with 5 key themes emerging, including the psychological impact 
of PMR. Participants described the impact of disability on their mood and reported 
feeling fearful about their future prognosis. Many reported feeling relieved after being 
diagnosed with PMR, as they had both a label to validate their experiences and knew 
they could have an effective treatment to relieve their symptoms. Following diagnosis, 
several reported feeling anxious about potential medication side-effects and their 
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future disease trajectory. Results suggest PMR has a profound psychological impact, 
particularly prior to a diagnosis being made, hence acknowledging and helping patients 
to manage their anxiety could lead to improved outcomes. Of note, GPs conducted 
interviews, which could have affected the way participants discussed their experiences. 
However, the setting of interviews which were conducted in a naturalistic style helped 
to mitigate against this. The study was strengthened by the recruitment of participants 
from primary care, where the majority of PMR is managed, to help ensure transferability 
of findings. 
 
2.9.3.4    Giant Cell Arteritis 
A UK cohort study examined the association between GCA, vascular disease and 
other comorbidities in people with GCA compared to non-vasculitis patients (Li, Neogi 
and Jick, 2017). Within the CPRD database, 9,778 people with GCA were identified. Each 
individual was matched by age, gender and practice, to 10 people without vasculitis. 
Individuals with GCA were more likely to have a history of depression (17.6% Vs 13.8%, 
p<0.0001), whilst the risk of developing depression in people with GCA was also 
significantly increased (HR (95% CI) = 1.32 (1.25, 1.39). Limitations included the potential 
misclassification of GCA cases and a risk of detection bias, whereby people with GCA 
may have had more clinical contacts leading to an increased number of comorbidities 
being recognised and coded in the clinical record. However, a strength of this study was 
the large national database utilised, which increased the generalisability of results. 
A qualitative study explored the perspectives of individuals with GCA on the 
impact of their condition (Liddle et al., 2017). A total of 24 patients with GCA 
participated in semi-structured telephone interviews and an inductive thematic analysis 
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of transcripts was performed. GCA was noted to have a substantial impact on patients͛ 
bodies and minds, with themes including fear and anxiety, loss of confidence, and 
changes in mood and sleep. Body changes secondary to glucocorticoid therapy and fear 
of potential visual loss contributed to the psychological symptoms reported by patients. 
It is possible that face-to-face interviews could have facilitated further development of 
rapport and subsequent disclosure of more thoughts and experiences by participants, 
enabling deeper insights. In addition, the sample included a lack of individuals from 
ethnic minorities. However, analysis was supported by brief field notes, and interviews 
were conducted until data saturation was reached. 
There is a lack of literature on the incidence and prevalence of anxiety in GCA, 
though comorbid mood problems are likely to be a significant burden in this condition 
which require further investigation. 
 
2.10 Summary                                                                                                          .    
 
 RA is an inflammatory joint disease that affects 0.67% of the population 
(Ahbishek et al., 2017). In common with other LTCs, the prevalence of mood disorders 
in people with RA is high, with approximately 20% having anxiety and 38.8% depression 
(VanDyke et al., 2004; Matcham et al., 2013). Links have been identified between 
anxiety and depression in LTCs such as RA, and increased morbidity and mortality (Ang 
et al., 2005; Abhishek et al., 2018). Therefore, recognition and treatment of mood 
disorders in LTC's should be a health care priority. Despite this, QOF incentives to ask 
case-finding questions in CHD and diabetes have recently been retired, and although 
the QOF incentivises an annual review of RA this doesn't specify mood assessment (NHS 
Employers, 2015). NICE does recommend a regular reassessment of mood within an RA 
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annual review clinic (NICE, 2013cͿ though this guidance doesn͛t extend to patients with 
other IRCs such as AS, PsA, PMR and GCA. 
 There is some evidence to suggest that comorbid mood problems are also 
common in other IRCs, though further research is required, particularly to determine 
the prevalence of anxiety and depression in people with PMR and GCA. 
 NICE has created guidelines on the identification and mangement of depression 
in adults with chronic physical health problems (NICE, 2009b), though guidelines for 
anxiety have been relatively neglected. The literature suggests that the two stem 
questions are sensitive at detecting depression and also preferred due to their ease of 
application (Meader et al., 2011; Whooley et al., 1997), though the way in which these 
questions are posed could lead to systematic under-detection of depression (Maxwell 
et al., 2013).  
 SMIs to support people with RA to self-manage their condition (Vermaak et al., 
2015), in addition to psychological interventions (Dixon et al., 2007), can reduce anxiety, 
depression and pain. Antidepressants can also reduce low mood and fatigue, whilst 
helping to improve the self-efficacy of people with RA (Parker et al., 2003). Despite a 
high demand for psychological therapies in people with RA (Dures et al., 2016a), a recent 
survey suggested that provision of support in UK rheumatology units is largely 
inadequate (Dures et al., 2014). There is a lack of evidence about how comorbid mood 
problems in other IRCs should be managed.  
 
2.11 Rationale for studies reported in this thesis                                            .    
 
In people with RA, comorbid mood problems are often not recognised or treated 
and can lead to increased morbidity and mortality. Understanding patients͛ preferences 
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regarding case-finding for anxiety and depression in RA could inform the development 
of an intervention to improve the recognition and management of comorbid mood 
problems, potentially improving overall outcomes. 
Past research into comorbid mood problems in IRCs has mainly focused on the 
prevalence and impact of depression in RA. When the impact of anxiety in RA has been 
examined, this has often been in combination with depression, despite at least 40% of 
individuals with anxiety in the general population not having associated depression. 
Anxiety has also been linked to different help-seeking behaviour and can be managed 
differently from depression. Understanding the impact of anxiety on the QoL and 
disease activity of people with RA could provide evidence to support the recognition 
and appropriate management of this frequent comorbidity, and suggest areas for future 
implementation studies to improve outcomes. 
As prior research has focused on RA, there is a lack of literature reporting the 
prevalence of mood problems in people with other IRCs, such as AS, PsA, PMR and GCA. 
Determining the proportion of people living with IRCs who have recognised mood 
problems and comparing this to the number who self-report mood symptoms when 
asked to respond to case-finding questions, could help to determine whether many 
people with IRCs have unrecognised mood problems. 
Although NICE recommends that people with RA should have a holistic annual 
review including an assessment of mood, there is no similar guideline for people with 
other IRCs. Improving our understanding of comorbid mood problems in different IRCs 
could help to inform the development of a primary care nurse-led annual review for 
people with IRCs, to improve the recognition and management of anxiety and 
depression, which could potentially reduce associated morbidity and mortality. 
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3.0 AIMS AND OBJECTIVES 
 
 
3.1 Research questions                                                                                          .    
 
1. What are the preferences of people with rheumatoid arthritis (RA) for the 
identification and management of comorbid anxiety and depression? 
2. What is the association between anxiety in people with RA, and disease activity and 
quality of life (QoL)? 
3. What is the incidence and prevalence of anxiety alone, in addition to anxiety and/ or 
depression, in people with different inflammatory rheumatological conditions (IRCs), 
including RA, ankylosing spondylitis (AS), psoriatic arthritis (PsA), polymyalgia 
rheumatica (PMR) and giant cell arteritis (GCA)?  
4. What is the prevalence of anxiety and depression, when determined using the case-
finding questions for mood problems, in people with different IRCs (RA, AS, PsA, PMR 
and GCA)? 
 
3.2 Aims and objectives                                                                                         .    
 
My overall aim within this thesis, has been to investigate comorbid mood disorders in 
people with IRCs.  
 
My specific aims have been as follows; 
1. To explore the experiences of people with RA of help-seeking for comorbid anxiety 
and depression and to understand their preferences for the identification and 
management of comorbid mood problems. 
2. To understand the impact of anxiety on the QoL and disease activity of people with 
 80 
RA. 
3. (a) To determine the proportion of people with different IRCs who have mood 
problems which have been recognised and treated. 
(b) To establish whether the risk of a person developing a mood problem is increased 
after they are diagnosed with an IRC. 
4. To determine the proportion of people with IRCs who have active mood problems, 
which may not have been recognised or recorded using Read codes in their primary care 
records. 
 
My specific objectives have been as follows; 
1. Interview people with RA to explore their perspectives of comorbid anxiety and 
depression and their preferences for the identification and management of comorbid 
mood problems. 
2. Review the literature reporting the association between anxiety in people with RA, 
and disease activity and QoL. 
3. (a) Determine the proportion of people with IRCs who have a current mood problem 
that has been identified and recorded in their primary care records. 
(b) Retrospectively examine the number of people who have developed a mood 
problem after being diagnosed with an IRC, which has been identified and recorded in 
their primary care records. 
4. Send people with IRCs a questionnaire to complete which includes case-finding 
questions to identify potential anxiety and depression, then analyse their responses to 
determine the prevalence of self-reported mood symptoms. 
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3.3 Studies performed to respond to the research questions                      .    
 
In order to respond to my specific research questions, I have used mixed 
methods to complete four main studies, as outlined below. These include a qualitative 
study, a systematic review, a cohort study and an analysis of baseline questionnaire data 
collected as part of the INCLUDE (INtegrating and improving Care for patients with 
infLammatory rheUmatological DisordErs in the community: A pilot randomised 
controlled trial) study (Hider et al., 2018). INCLUDE is a pilot trial, aiming to determine 
the feasibility and acceptability of a nurse-led annual review based in primary care, for 
people with IRCs. 
 
1. Qualitative Study (Chapter 5)  
To explore the perspectives of people with RA of comorbid mood problems, I have 
interviewed people with RA who attended a nurse-led integrated review at a community 
rheumatology hospital. 
2. Systematic Review and meta-analysis (Chapter 6) 
To determine the association between anxiety in people with RA, and QoL and disease 
activity, I have performed a narrative synthesis, then meta-analysis of primary outcome 
measures for QoL and disease activity.  
3. Cohort Study (Chapter 7) 
Using primary care data, I have investigated the prevalence of, and factors associated 
with (a) anxiety alone and (b) anxiety and/ or depression, in people with IRCs and have 
investigated whether there is an association between the diagnosis of an IRC (RA, PsA, 
 82 
AS, PMR, GCA) and subsequent consultation for (a) anxiety alone or (b) anxiety and/ or 
depression. 
4. INCLUDE Study (Chapter 8):  
I have analysed responses to baseline patient questionnaires, completed by INCLUDE 
study participants, to determine the prevalence of anxiety and depression in people 
with IRCs (RA, AS, PsA, PMR, GCA) and covariates associated with mood problems. 
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4.0 METHODOLOGIES 
4.1 Overview                                                                                                            .    
 
Within this chapter I will review my overall aims which have guided my research 
methodologies. Considering my ontology and epistemology, I will justify my decision to 
take a pragmatic approach (section 4.3), using mixed methods (section 4.4). In 
particular, I will discuss my use of a multiphase mixed methods design (section 4.5), 
which has enabled me to address a broad range of sequential research questions. 
Finally, in response to each research question, I will justify my methodological approach 
to data collection and analysis (section 4.6). I have described my methods in further 
detail within each study chapter (5-8). 
 
4.2 Overall study aims                                                                                            .    
 
Overall, I aim to investigate comorbid mood problems in people with 
inflammatory rheumatological conditions (IRCs). As discussed in chapter 3, my specific 
aims are as follows;  
1. To explore the experiences of people with rheumatoid arthritis (RA) of help-
seeking for comorbid anxiety and depression and to understand their 
preferences for the identification and management of comorbid mood 
problems. 
2. To understand the impact of anxiety on the quality of life (QoL) and disease 
activity of people with RA. 
3. To determine the proportion of people with different IRCs who have mood 
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problems which have been recognised and treated, and to establish whether the 
risk of a person developing a mood problem is increased after they are diagnosed 
with an IRC. 
4. To determine the proportion of people with IRCs who have active mood 
problems, which may not have been recognised or recorded in their primary care 
records. 
 
4.3 Theoretical Approach                                                                                      .    
 
Ontology is a word derived from the Greek, ontos (means) and logos (reason), 
meaning the study of being.  Ontology is concerned with understanding existence and 
what constitutes reality. Epistemology, from the Greek, episteme (knowledge) and logos 
(reason), means the theory of knowledge (Grix, 2010). Epistemology builds on the desire 
to know about being and reality, by determining how we understand the world, what 
constitutes valid knowledge and how it can be obtained (Grix, 2010).  
My first research question aimed to explore the perspectives of people with RA 
on case-finding for comorbid mood problems. Therefore, my understanding of what it 
meant to be human and what constituted human experience was essential. I needed to 
gain insight to the meaning people drew from their interactions with the world. I did not 
want to merely explain how people behaved when seeking help for mood problems, but 
to understand the reasons why they behaved in a certain way, so that I could suggest 
ways in which the recognition of mood problems in people with RA could be improved.  
Consequently, when approaching my first research question, my ontology, or 
understanding of what constituted reality, was a world in which existence became 
meaningful in the minds of humans through their interactions with the world. 
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Therefore, when approaching my first study I referred to a method of inquiry in 
philosophy known as phenomenology, which is based on the premise that reality 
consists of objects and events (phenomena) as they are perceived in the human 
consciousness (Kaufer & Chemero, 2015). In particular, I was influenced by 
phenomenologists such as Edmund Husserl (1859-1938) and Maurice Merleau-Ponty 
(1908-1961), who studied the meaning of human consciousness and awareness. Husserl 
(1970) argued that people and objects in the world were interdependent, hence could 
not be described in isolation, whilst Merleau-Ponty (1945) suggested that all human 
experiences were formed by an interaction between the body, mind and world. 
Therefore, in order to obtain deep insights, I needed to explore peoples͛ 
interactions with the world and how they interpreted their experiences of seeking help 
for mood problems. From my review of the background literature, I understood that 
mood problems in people with RA had complex biological, behavioural and psychosocial 
interactions, hence could not be considered in isolation of the world. Peoples͛ 
perspectives would differ based on their experiences and interpretations, hence I was 
not seeking an objective truth, rather an understanding of multiple truths observed 
through the eyes of individuals. In depth insight into these perspectives would not have 
been possible through structured questionnaires, but rather through exploratory 
questioning.  
Building on this understanding of what constitutes reality, my epistemology, or 
theory of knowledge, was based on constructing meaning from peoples͛ interactions 
with the world. This is known as a constructivist epistemology (Crotty, 1998). 
Constructivists believe that individuals develop varied subjective views of their 
experiences, formed through interactions with others, but also, through historical and 
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social norms that operate in individuals͛ lives. Constructivist researchers aim to interpret 
the views others have about the world to generate theories. I determined that an 
inductive approach, constructing theories from the data, would enable me to 
incorporate different perspectives and be open to new insights, to facilitate 
understanding about mood problems in people with RA. 
This approach contrasts with positivism, a theoretical perspective drawn from 
an objectivist epistemology. Positivists believe knowledge is based on natural 
phenomena and assume there is a stable reality where phenomena exist whether we 
observe or understand them. They believe knowledge is based on natural phenomena, 
which researchers derive information about through sensory experiences, then 
interpret using reason and logic (Green & Thorogood, 2009). A positivist approach would 
have been too inflexible to address my initial research question and would not have 
facilitated the depth of understanding of social processes that I aimed to achieve. Whilst 
a positivist approach would have helped me to explain the behaviour of participants, a 
constructivist approach enabled me to understand it, through exploration of peoples͛ 
perspectives of their experiences. 
Positivists advocate ͞value-free͟ enquiry. To enable scientific enquiry to be true 
for all places and times, positivists believe research should not be influenced by a 
researchers͛ political or emotional views ;Green & Thorogood, 2009). However, it could 
be argued that truth varies according to the time and place. Throughout history our 
understanding of the world has developed and widely held truths have evolved. In order 
to obtain deep insights into phenomena, we also need to acknowledge their context in 
peoples͛ lives and in the wider political environment. With depth of understanding then 
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comes the ability to suggest outcomes that can be applied in the real world to have a 
meaningful impact. 
A ͞value-free͟ approach to understanding patients͛ perspectives of mood 
problems in RA would not have been possible. In order to obtain deep insights, I had to 
closely interact with participants, during which time my role as an interviewer and 
furthermore, a general practitioner (GP), potentially influenced patients͛ perspectives. 
Denscombe described the Ηinterviewer effectΗ, whereby an individuals͛ perception of 
their interviewer influences their response to questions (Sim & Wright, 2000, p109), 
with social differences such as nationality, race, class, age, gender and socioeconomic 
status all potentially affecting the establishment of rapport. When GPs participating in 
qualitative studies were interviewed by a peer, rather than a researcher from another 
discipline, richer and more personal accounts of attitudes and behaviour were obtained 
from participants, when they knew their interviewer was a clinican (Chew-Graham, May 
& Perry, 2002). However, the GP interviewer was also identified as an expert and judge 
of clinical decision making and moral judgements. This could have led participants to be 
reluctant to disclose negative views of clinicians, or to be afraid of saying something 
clinically inaccurate, possibly making interviews less insightful.  
Therefore, I determined a ͞value-bound͟ approach to my first research question 
would be most appropriate. This acknowledges the researcher as part of what is being 
studied that cannot be separated (Sim & Wright, 2000). However, if a researcher is not 
open about their preconceptions and how these influence their research, this could 
affect the reliability of a study. Consequently, Lincoln and Guba (1985), have described 
the importance of reflexivity, which entails a researcher being aware of their influence 
on the process and outcomes of research. Through reflexivity, researchers acknowledge 
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how the research process has bought about changes in themselves, but also how these 
changes have affected the research process.  
Lincoln and Guba (1985), have suggested that researchers could make regular 
diary entries during a research project, to facilitate reflexivity. However, researchers 
could keep these diary entries private and not critically reflect on their content or openly 
acknowledge their own influence on the interpretation of results. Alternatively, 
researchers could discuss their interpretations of phenomena with colleagues, to help 
acknowledge their personal impact on a study. However, the success of this approach 
would depend upon colleagues feeling able to challenge each others͛ beliefs and would 
be less effective if researchers were selective about who they discussed their research 
with, for example, if they approached people with similar world viewpoints. 
Consequently, having multiple investigators contributing to a study could help to 
promote dialogue and reveal hidden beliefs or perspectives, which could lead to the 
development of complementary as well as divergent understandings of a study (Barry 
et al., 1999). Reporting the influence of preconceptions and values on a research project 
within publications could also help individuals to more accurately interpret research 
outcomes, through awareness of a researchers͛ viewpoint.  
Alternatively, postpositivism represents the thinking after positivism, 
recognising that all observation has error, and theories are revisable (Philips & Burbules, 
2000). Whilst positivists emphasize independence between the researcher and the 
object of research, postpositivists accept that the values of the researcher can influence 
what is observed. In addition, whilst positivists believe science aims to uncover the 
truth, postpositivists believe an absolute truth can never be found, hence they indicate 
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a failure to reject a hypothesis, rather than stating they have proven a hypothesis to be 
correct or incorrect (Creswell, 2014).  
Whilst postpositivists acknowledge that researchers and the object of their 
research (eg. a person being interviewed) are not independent, a postpostivisit 
approach would still have required me to test a hypothesis, be objective and examine 
my methods and conclusions for bias (Creswell, 2014). Drawing on my experiences as a 
GP and the background literature on comorbid mood problems in long-term conditions 
(LTCs), I had some pre-existing ideas which I could have used to develop a hypothesis. 
However, in response to my first research question, I wanted to maintain an open and 
exploratory approach, to ensure that I considered all potential perspectives. Therefore, 
I determined a constructivist approach would be most appropriate, to enable me to 
discover the meaning participants attached to their experiences and also to react to 
unexpected findings and broaden my enquiry when necessary.  
Although my initial study was underpinned by a constructivist epistemology, my 
approach had to change in response to my subsequent research questions. To provide 
further insight into mood problems in people with IRCs, I had to utilise quantitative 
methods, guided by an objectivist epistemology.  
For example, by performing a cohort study, and through analysis of baseline 
questionnaire data within the INCLUDE study, I aimed to test a hypothesis, that mood 
problems were more common in people with IRCs. I aimed to uncover objective truths, 
not to understand patients͛ perspectives or to generate theories. Taking a ͞value-
bound͟ approach underpinned by a constructivist epistemology could have biased my 
results, as I aimed to conduct a ͞value-free͟ enquiry, avoiding any potential emotional, 
subjective or political influence on my results.  
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In addition, to determine the impact of anxiety in people with RA, I aimed to test 
a theory that anxiety was associated with increased disease activity and a reduced QoL. 
Consequently, I again needed to undertake value-free enquiry, underpinned by an 
objectivist epistemology. However, I was also open to identifying any patterns in the 
data and generating new potential theories when analysing data found through the 
review.  
Systematic reviews can be described as aggregative or configurative in nature. 
Whilst aggregative reviews have a positivist foundation, aiming to test a theory using a 
priori methods to draw together all available evidence, configurative reviews have an 
idealist philosophy, aiming to generate theories by exploring available evidence (Gough 
et al., 2012). Therefore, although my review had a realist foundation, underpinned by 
an objectivist epistemology, I was open to generating new theories on performing my 
analysis, taking a constructivist approach. Therefore, my theoretical foundation for this 
review included different philosophical viewpoints.  Consequently, in order to respond 
to all of my research questions, I decided that I needed to take a more pragmatic 
approach.  
A pragmatic worldview emphasizes using all approaches available to understand 
a research problem (Creswell, 2014). Charles Pierce (1839-1914) developed the 
pragmatic maxim, which functions to guide the conduct of thought toward its͛ purpose. 
Pierce sought to clarify the meaning of different intellectual concepts by tracing their 
practical consequences, whilst later twentieth century contributors, William James 
(1845-1910) and John Dewey (1839-1914), emphasized the importance of the 
consequences of actions based upon particular conceptions (Cherryholmes, 1992). 
Therefore, Pierce, along with James and Dewy, sought to move the focus of research 
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from theories and descriptions to future practical applications, with research being 
driven by anticipated consequences (Haack & Lane, 2006: p.18-26). This suggests that 
they were keen for research to have a practical application, rather than being performed 
to build on existing theories and descriptions, without any meaningful change being 
implemented. Morgan (2007) later highlighted the importance of a pragmatic approach, 
to focus attention on a research problem and enable the use of a combination of 
approaches to derive further knowledge about a problem. The use of different 
philosophical approaches with a combination of methods, was recognised to enable 
more complex research questions to be answered, with the focus being maintained on 
problem solving to reach a practical application or meaningful consequence. 
Pragmatism is not committed to one system of philosophy. Truth is not based on 
a duality between reality within the mind or independent of the mind. Instead, 
pragmatists see truth as what works at the time. Therefore, rather than subscribing to 
a single approach (eg. qualitative or quantitative), pragmatists use different methods to 
collect and analyse data, to gain the best possible understanding of the research 
problem (Creswell, 2014). Taking a pragmatic approach, enabled me to conduct a 
qualitative study underpinned by a constructivist epistemology, then subsequently take 
an objectivist approach to my quantitative research on the incidence and prevalence of 
mood problems. A pragmatic approach also enabled me to conduct a systematic review 
underpinned by positivist foundations, but to consider a theory generating approach 
when analysing the overall evidence found, to help explain patterns in the results. 
Consequently, a pragmatic approach enabled me to use a range methods underpinned 
by different epistemologies, in order to gain a greater understanding of my overall 
research question. 
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4.4 Mixed Methods Design                                                                                 .    
 
In this section I will provide a background to mixed methods designs and how 
they can be classified. Subsequently, in section 4.5, I will discuss my methodological 
approach to each of my studies, before justifying my use of a multiphase mixed methods 
design (section 4.6), to address my research questions. 
 
4.4.1 Overview 
Methodology refers to the principles underlying the research approach taken 
and applies to data collection and analysis (Britten, 2011). I have taken a mixed methods 
approach to maximise my potential to understand the detection, incidence, prevalence 
and impact of mood problems in people with IRCs. 
Mixed methods research involves the generation, analysis and mixing of both 
quantitative and qualitative data in response to research questions or hypotheses 
(Johnson, Onwuegbuzie & Turner, 2007). Data can be collected in a single study or a 
series of studies, concurrently, whereby different sets of data are obtained 
simultaneously and are independent of each other, or sequentially, whereby data are 
collected in different phases, through which the data are connected (Creswell & Plano 
Clark, 2007).  
Mixed methods research emerged as a concept during the 1950s, and has since 
gone through several stages of development which include the Formative Period, 
Paradigm Debate Period, Procedural Development Period, Advocacy and Expansion 
Period and the Reflective Period (Creswell, 2011).  
During the Formative Period, researchers first began using more than one 
method within a study. For example, Campbell and Fiske (1959), introduced the use of 
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multiple quantitative methods within a single study, to enable better validation of 
diagnostic measures. Later, Cook and Reichardt (1979) discussed ways to combine both 
qualitative and quantitative data, arguing that both of these approaches would be 
required to enable a comprehensive evaluation. For example, a medical screening test 
could have a high sensitivity and specificity on quantitative evaluation, though would 
need to be acceptable to patients on qualitative evaluation, to make it viable for use in 
screening.  
Despite the benefits of comprehensive evaluation being recognised during the 
Formative Period of mixed methods development, researchers began to question 
whether it would be appropriate to integrate different philosophical perspectives within 
a mixed methods study, which led to the Paradigm Debate Period (Rossman & Wilson, 
1985). Whilst people known as ͞purists͟ viewed qualitative and quantitative methods 
as mutually exclusive, others, known as ͞situationalists͟, argued that both methods 
were of equal value and that their use should be adapted to different circumstances. 
Meanwhile, ͞pragmatists͟ argued that different methods could be integrated together 
to provide a more workable solution to research questions (Rossman & Wilson, 1985).  
A pragmatic approach, using mixed methods, aims to combine the strengths and 
offset the weaknesses of qualitative and quantitative studies. Qualitative studies can 
provide deep insights into peoples͛ lives and enable voices to be directly heard, though 
sample sizes are often small and lack generalisability. Meanwhile, although quantitative 
studies don͛t provide the same depth of understanding about individuals͛ lives, through 
the use of large, randomised samples, they can provide data which is more generalisable 
at a population level. Therefore, using a combination of methods can help to answer 
more complex questions and provide a more complete understanding of phenomena 
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(Gelo, Braakmann, & Benetka, 2008).  Although the skills, time and resources required 
for mixed methods research can be challenging, particularly for a single researcher, 
taking this approach can provide useful opportunities for collaboration between 
qualitative and quantitative researchers, who can learn from each others͛ expertise, 
corroborate or elaborate on findings (Creswell, 2011). 
Over time, quantitative and qualitative researchers began to reach agreement 
on some points of philosophical disagreement, acknowledging that observation was not 
a direct window into reality, but that observations were affected by peoples͛ prior 
experiences and knowledge (Tashakkori & Teddlie, 1998). However, some researchers 
continued to debate whether pragmatism could be embraced as a philosophical 
foundation for mixed methods research. For example, in 2004, Howe argued that mixed 
methods approaches could lead to the marginalisation of qualitative research. 
Subsequently, in 2006, Giddings argued that mixed methods would not necessarily 
produce the ͞best of both worlds͟ ;p. ϭϵϱͿ and could lead to reduced methodological 
diversity within qualitative and quantitative research. However, others argued that a 
team-based approach, involving both qualitative and quantitative researchers, would 
ensure equal representation of different methods and help to maintain methodological 
diversity within studies (Creswell, 2011).  
Despite continued debate, researchers did begin to seek a greater understanding 
of how to conduct a mixed methods study. This led to the third phase of mixed methods 
development, known as the Procedural Development Period. Designs were developed 
that varied in terms of the priority given to qualitative and quantitative data and the 
sequence in which data were collected (Morgan, 1998). However, these designs did not 
consider different stages of data integration. Therefore, Tashakkori and Teddlie (1998) 
 96 
proposed further mixed methods designs which included integration of methods at the 
data collection, analysis or interpretation stages. Another consideration raised during 
the Procedural Development Period was the need to take account of a researchers͛ 
perspective when commencing a study.  All researchers have pre-existing assumptions 
based on their gender, culture and experiences that may influence their research, whilst 
social scientists can also view their enquiries through a formal lens, for example, from a 
feminist perspective. Therefore, researchers also suggested that a transformational 
value or action-orientated perspective would need to be considered within mixed 
methods designs (Greene & Caracelli, 1997).  
During the Advocacy and Expansion Period, mixed methods became recognised 
as a distinct discipline (Johnson & Onwugebuzie, 2004). Methodological pluralism 
facilitated the triangulation of data, using different methods or data sources to develop 
a comprehensive understanding of phenomena and to test the validity of results 
(Patton, 1999). Publications also highlighted the rationale and potential for mixing 
methods within research (Creswell, 2009). The final period of mixed methods 
development, the Reflective Period, has continued until the present day. Researchers 
are still discussing the priorities, issues and controversies surrounding mixed methods 
research (Creswell, 2011). A growing body of evidence suggests that merging different 
approaches to answer a specific research problem does not compromise 
methodological purity, but can enhance the rigour of a study. It is important that this 
debate continues, as more regular use and discussion of mixed methods will facilitate 
advancement of its͛ concepts. The multitude of mixed methods designs that were 
proposed during the Paradigm Debate Period have since been distilled into three basic 
and several advanced designs. These designs take account of the main factors that help 
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researchers to determine which mixed methods design to use, and are described in 
detail in section 4.4.2 (Creswell, 2014). 
 
4.4.2 Classification of mixed methods designs 
Creswell (2014) identified three basic mixed methods study designs, as outlined 
in figure 4.1 (p98). First, a convergent parallel approach involves the researcher 
collecting and analysing qualitative and quantitative data separately, for example 
through qualitative interviews and questionnaires on the same subject, then comparing 
the results to see if the findings confirm or refute each other. Secondly, an explanatory 
sequential design involves a first phase in which the researcher collects and analyses 
quantitative data. The results are then used to plan a second qualitative phase, which 
helps to explain the initial quantitative data in more detail. An example would be to 
collect and analyse survey data, then conduct qualitative interviews to help explain the 
survey findings. Thirdly, an exploratory sequential design involves a first phase during 
which qualitative data is collected and analysed, with the results informing the design 
of a second quantitative phase. For example, this could involve an initial focus group 
which informs the development of an instrument which can be tested on a sample of 
the population. These different designs help to highlight the benefits of mixed methods 
research, which can be used to gain deeper insights by comparing outcomes of different 
methods or to plan and inform different stages of research, helping to ensure plans are 
evidence-based and relevant to patients. 
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Figure 4.1- Basic mixed methods designs. Figure adapted from Creswell, 2014, p220. 
 
 
 
As outlined in figure 4.2 (p99), Creswell (2014) also developed several advanced 
mixed methods designs, incorporating elements of the convergent, explanatory 
sequential and exploratory sequential approaches. Firstly, the embedded mixed 
methods design nests one or more forms of data (qualitative, quantitative or both) 
within a larger design (eg. a narrative study). Secondly, in transformative mixed 
methods, the researcher uses a social justice theory (eg. feminist) as a framework for a 
mixed methods study, with the theory framing aspects of the study from the research 
question to data collection, analysis and interpretation. Thirdly, in multiphase mixed 
methods, researchers conduct several projects in a longitudinal study, with each stage 
building on the last to address a common issue. This can include convergent and 
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sequential mixed methods approaches, or sometimes only qualitative or quantitative 
studies. 
 
Figure 4.2- Advanced mixed methods designs. Figure adapted from Creswell, 2014, p221. 
 
 
 
 
4.5 Methodological Approaches to Individual Studies                                   .    
 
In the following sections, I will provide an overview of my main research 
questions, before justifying my methodological approach to each. Subsequently, in 
section 4.6, I will describe how these studies were linked within a multiphase mixed 
methods design and explain my reasons for this overall approach, referring back to my 
justifications for the methodological approach taken in each study. 
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4.5.1 Exploring the perspectives of people with RA of comorbid mood problems 
 
4.5.1.1 Research question and overview of methodological approach 
To address this first question, I conducted a qualitative study, aiming to explore the 
perspectives of people with RA of comorbid mood problems. 
4.5.1.2 Justification for qualitative methods 
Qualitative methods involve a process of enquiry to understand a social or 
human problem (Creswell, 2003). Qualitative methods aim to answer ͚what͛, ͚how͛ and 
͚why͛ questions ;Green & Thorogood, 2009), to help us understand the meaning people 
draw from situations, to identify unknown phenomena, to gain insight into processes 
underlying social life and to develop an explanation for human activity and interaction 
(Sim & Wright, 2000). Therefore, I determined that a qualitative approach would be best 
to enable me to explore, understand and evaluate the impact of anxiety and depression 
in RA.  
Exploratory research is flexible, allowing a change in the research process based 
on new insights. It is often used to approach problems on which little prior research has 
been performed, and can form the foundation of more conclusive research (Sim & 
Wright, 2000). Although I had read literature on comorbid mood problems in other LTCs, 
which could have enabled me to make a tentative hypothesis, I wanted to ensure I used 
a flexible design, to enable me to respond to any unexpected cues within interviews. 
Consequently, I took an exploratory approach.  
 
What are the preferences of people with RA for the identification and 
management of comorbid anxiety and depression? 
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Alternatively, I could have used a descriptive design. Descriptive designs are used 
to describe the characteristics of a population or phenomenon, and can be used as a 
basis for further research (Sim & Wright, 2000). For example, a survey of people with 
RA about comorbid mood problems, could identify a preference for talking treatments, 
after which exploratory interviews could be performed to understand the reasons 
behind this. However, descriptive designs do not answer questions about how, when or 
why certain characteristics are found or phenomena occur (Sim & Wright, 2000). 
Consequently, a descriptive design would have enabled me to describe the 
phenomenon surrounding anxiety and depression, but would not have facilitated the 
depth of insight potentially gained from an exploratory approach, to understand the 
reasons underlying a persons͛ preferences or behaviours.  
Explanatory research is frequently used to test a hypothesis and to explain rather 
than describe phenomena being studied (Sim & Wright, 2000). An explanatory approach 
can be used to identify the extent and nature of cause and effect relationships. 
However, due to the potential impact of a range of factors on a relationship between 
two variables, causality can often be inferred, though not proven with a high level of 
certainty. Drawing on the findings of research into comorbid mood problems in other 
LTCs, I could have generated a hypothesis, and used an explanatory approach to test 
this, though this approach would not have been flexible enough to address my research 
question and explore emerging ideas, as supported by an exploratory approach. 
Qualitative studies have already been used to explore patient perspectives of 
mood problems in LTCs (Coventry et al., 2011; Alderson et al., 2012; Simmonds et al., 
2013; Alderson et al., 2014; Bogner et al., 2008). Therefore, I felt that a qualitative study 
design would be appropriate to add to the existing literature.  
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4.5.1.3 Qualitative methods  
On deciding to conduct a qualitative study, I considered several methods to 
generate data, including semi-structured or unstructured interviews, focus groups, 
observation, content analysis of written materials and video or audio-recorded 
consultations (Bryman, 2016).  
I chose to conduct semi-structured interviews. This method enabled me to pose 
specific questions to fulfil my research aims, whilst also leaving an opportunity for 
discussions to be extended into unexpected areas, helping to increase the depth and 
breadth of data (Green & Thorogood, 2009).  
 I could have analysed video or audio-recorded consultations of patients with a 
practitioner, where they were asked the case-finding questions for anxiety or 
depression. However, this approach would not have enabled as detailed insights into 
patient perspectives as a face-to-face interview. Although a video-recorded consultation 
would have enabled me to observe patients͛ responses to questions through their body 
language, I would not have been able to respond to cues or directly question patients 
to explore their personal perspectives more deeply. It is possible that the behaviour of 
participants would have been influenced by the knowledge that they were being 
recorded. In addition, this approach could have generated a lot of irrelevant data that 
would have been time consuming to process.  
Ethnographic research, which involves observing society from the point of view 
of participants could have enabled the exploration of certain cultural phenomena 
surrounding anxiety and depression in RA (Green & Thorogood, 2009). However, this 
process would have been time consuming and generated a significant amount of data 
irrelevant to my research aims. Due to this method involving no direct communication 
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with participants, it would also have been difficult to obtain the required depth of insight 
into the specific topic of interest. 
 A focus group would have been an alternative method to explore a range of 
views. A focus group involves a small group of people meeting to discuss a particular 
topic under the direction of a facilitator, who has a list of topics to discuss (Krueger & 
Casey, 2000). Within a group, participants may have felt more confident to express 
negative opinions. However, some could have preferred to share personal accounts 
within the privacy of their home environment in a semi-structured interview, rather 
than in a public focus group. The breadth of data obtained through a focus group could 
also have been limited by the influence of dominant personalities, who may have 
prevented more reserved participants from expressing opposing views. In addition, a 
focus group could have been difficult to arrange when participants were geographically 
isolated.  
Unstructured interviews, without any predetermined questions or answer 
categories, could have provided interesting insights (Minichiello, Aroni & Timewell, 
1992). Participants could have directed the conversation further, potentially leading 
them to discuss new phenomena not previously considered. In addition, participants 
could have felt more at ease and able to open up about their true feelings leading to the 
generation of more valid data. However, with a lack of direction, participants could 
easily have diverged from the topic of interest, leading to a proportion of the data being 
irrelevant to the research aims, making the interview and subsequent analysis more 
time consuming. In addition, without questions to prompt particular discussion areas, 
certain topics could have been left unexplored. 
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4.5.1.4 Analysis 
There were a broad range of potential approaches to qualitative research 
analysis that I considered. I discounted discourse and conversation analysis, as these 
would have been used to analyse the linguistic characteristics of data and I was not 
concerned with how language was used by participants to communicate, but rather the 
ideas and beliefs contained within responses (Bryman, 2016). 
 I aimed to explore and identify new patient perspectives on case-finding for 
mood problems, to inform future health care policies and guidelines for the optimal care 
of people with RA. Consequently, I decided to perform a thematic analysis, which 
involves examining and recording patterns of meaning ;or ͞ themes͟Ϳ within data. Stages 
of thematic analysis include initial familiarisation with the data, then identification of 
codes, which are often words or short phrases. Coding of the data is a way of indexing 
or categorising the text, to help establish a framework of ideas about it. Codes can be 
organised and linked together to develop themes, which are recurrent concepts used to 
summarise the range of beliefs voiced by participants (Braun & Clarke, 2006). 
To help ensure recognition of the full range of perspectives, I used a cyclical 
process of data collection, analysis and provisional coding, followed by the use of codes 
to guide further sampling and analysis (Glaser & Strauss, 1967). This cyclical process was 
continued until a point of data saturation was met, when no new ideas emerged 
(Saunders et al., 2018). The constant movement between data and emerging theories 
meant that analysis was both inductive and deductive, with emerging data and analysis 
guiding further cases to investigate by ͚ theoretical sampling͛ (Charmaz, 2012). A process 
of constant comparison, through which cases within the same data set were compared, 
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helped the recognition of recurring ideas, whilst also highlighting exceptions, which 
could then be developed into new themes (Dye et al., 2000).  
Thematic analysis was flexible, as I was able to adopt an inductive approach, in 
which the coding and theme development were directed by the content of the data, or 
a deductive approach, in which codes and theme development were directed by existing 
concepts. However, a thematic approach did not promote deeper analysis of the data 
to link the descriptions of participants' key beliefs to theories, for example, to explain 
why patients may prefer certain care settings or providers for assessment of their mood 
disorders in RA. Nonetheless, my main aim was not to develop theories to explain the 
data, but to understand and give meaning to the data (Braun & Clarke, 2006).  
By using inductive analysis, I enabled my research to be grounded in the data, 
and for new emerging concepts to be recognised. In addition, I was able to use the 
background knowledge I had acquired through my review of the literature to enhance 
my analysis, by taking a deductive approach to test emerging ideas derived from the 
literature.  
Data collection and analysis were performed simultaneously. This iterative 
process ensured I would have the opportunity to adapt my hypotheses and 
methodology in response to new emerging data (Bryman, 2016). However, recognising 
that this approach could lead to a loss of focus, I regularly consulted with my supervisors 
to discuss new data and maintain my focus on the research question through the 
process of analysis (Britten et al., 1995). In addition, these regular meetings with 
research colleagues provided an opportunity to develop my topic guide and themes 
within my analysis.  
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I also used 'memos', which can be defined as the written forms of our abstract 
thinking about data (Strauss, Corbin, & Corin, 2008), to assist my transition between 
coding and analysis of the data. Memos can include operational notes about data 
collection, whilst theoretical memos can also contain ideas about emerging hypotheses 
and the development of codes and themes. These can act as an intermediate step 
between coding and writing, helping researchers to categorise codes for analysis, 
identify gaps in the data and note where comparisons can be made (Charmaz, 2006). 
 Several concepts within a grounded theory approach overlap with thematic 
analysis. Grounded theory involves the generation of theory, grounded in the data, that 
has been systematically collected and analysed (Noble & Mitchell, 2016). Data collection 
and analysis occur simultaneously, with codes developed from the data, categories 
constructed inductively and memos used to assist the transition between coding and 
writing. However, I did not take a pure grounded theory approach, as this would have 
required me to possess no prior knowledge which could have influenced my research, 
which was not possible (Green & Thorogood, 2009). As a clinician, I was aware of the 
connections between LTCs and mood problems and had personal experiences of case-
finding for mood problems. I had also developed my research question after reviewing 
existing literature. Therefore, some background knowledge was integral to my study, to 
ensure that my research enabled new insights and added to the literature on RA. 
Alongside my thematic analysis, I applied a framework to improve my depth of 
understanding of the data obtained. Framework analysis was originally developed for 
use in healthcare research. It involves "summarising and classifying data within a 
thematic framework", to enable deep analysis of data, with a final stage of mapping and 
interpreting codes to promote the development of practical strategies as an endpoint 
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(Green & Thorogood, 2009, p218). As my study was exploratory, the use of a pre-
determined framework for analysis could have led to unexpected themes and anomalies 
being overlooked within the analysis. However, I applied a framework later in my 
analysis when access to care had emerged as a predominant theme. I felt that this 
secondary analysis would lead to greater depth of insight into patients͛ perceptions, 
helping me to recognise patterns in the data, whilst also drawing attention to new 
potential themes (Gale et al., 2013). 
For my analysis, I adapted an existing framework, which was developed to 
analyse potential barriers to accessing primary mental health care for people from hard 
to reach groups, including people with advanced cancer, medically unexplained 
symptoms and the elderly (Kovandžić et al., ϮϬϭϭͿ. The original framework was reported 
to be fruitful in highlighting ͞fine grain͟ insights, increasing the impact of participants͛ 
and researchers͛ efforts ;Kovandžić et al., 2011, p1). I adapted the framework to help 
analyse potential barriers to accessing mental health support within primary and 
secondary care for people with RA and comorbid anxiety or depression.  
The original framework, and my adapted version, were informed by the work of 
Dixon-Woods (2006), who drew together key processes occurring before and at the 
point of entry into systems of care. In particular, three useful concepts relating to access 
to care were considered. The first concept, candidacy, refers to the process by which a 
person͛s eligibility to use a service is formulated through their interactions with health 
services. The second, concordance, indicates the importance of a match between a 
users͛ and practitioners͛ narrative and successful access to an intervention (Stevenson 
& Scambler, 2005). The third, recursivity refers to the influence of a users͛ previous 
 108 
experiences of health services on their future help-seeking (Rogers, Hassell & Nicolaas, 
1999).  
Figure 4.3- A framework for researching access to mental health care for individuals 
with RA and comorbid mood problems (adapƚed from Koǀandǎić eƚ al͕͘ ϮϬϭϭ: p5). 
 
This framework helped to draw together data at particular points where 
individuals with RA might have encountered barriers to accessing care for comorbid 
mood problems. However, I recognised that by using a framework for analysis, there 
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was a risk of data losing its͛ context, hence when I analysed interview extracts using the 
framework, I repeatedly referred back to the original context of the data. 
 
4.5.1.5 Integration of qualitative and quantitative data 
To understand the perspectives of people with RA about mood problems, I could 
have used quantitative methods. Quantitative research explains phenomena by 
collecting numerical data that are analysed using mathematically based methods, to 
answer ͚how many͛ or ͚how much͛ type questions (Sim & Wright, 2000). I could have 
used survey methods to ask a larger number of patients about how approachable they 
found their GP when help-seeking for mood problems, for example, using the General 
Practice Assessment Questionnaire, a patient survey used by GPs and their practices, 
which includes questions about the approachability of practitioners (Roland et al., 
2013).  
However, a purely quantitative approach would not have enabled me to fulfil my 
aim, to gain insight into patients͛ experiences by exploring their attitudes and beliefs in 
detail. I could have utilised open questions within a questionnaire, but patients may 
have not completed these due to a lack of understanding or time, or they may have 
been too embarrassed to record their mood concerns. In addition, a questionnaire 
would not have been able to record and respond to participants͛ body language, whilst 
patients may have misunderstood questions, or lacked the necessary hand dexterity or 
health literacy to answer questions. In addition, due to a lack of literature, I would not 
have known what questions would be important to ask, highlighting the importance of 
an open and exploratory approach. 
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However, I felt that by utilising some quantitative data I could enhance my 
research findings by providing a context to the patient population from which I drew my 
sample of patients to interview. Within chapter 5, I have described my methods in detail. 
In brief, interview participants were sampled from people who had attended an RA 
annual review clinic (section 5.6). Before the clinic, they had been asked to complete 
questionnaires that included the case-finding questions for mood problems. By 
analysing patients͛ responses to these case-finding questions within the annual review 
clinic questionnaire, I was able to provide a background to the prevalence of mood 
disorders in the local population with RA, helping to demonstrate the proportion who 
could benefit from case-finding for anxiety and depression and subsequent signposting 
for management. Performing a qualitative study that was linked to a pilot nurse-led 
annual review facilitated the sampling of patients for interviews, as questionnaire 
responses were used to identify patients who had potential anxiety or depression. This 
meant I was able to invite a sample of patients to be interviewed who had experience 
of living with a mood problem, increasing the potential breadth of experiences I was 
able to explore.   
By integrating qualitative and quantitative data, I was able to triangulate findings 
to develop a comprehensive understanding of phenomena and to test the validity of 
results (Bryman, 2006). Patton described four forms of triangulation, including 
investigator triangulation, where multiple researchers are involved in an investigation, 
theory triangulation, where more than one theoretical scheme is used to interpret 
phenomena, data source triangulation, where data is collected at different times, places 
or by different people, and method triangulation, which involves more than one method 
being used to gather data. By using a form of method triangulation, using data from 
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interviews and questionnaires, I was able to use patient perspectives to help illustrate 
and explain findings generated from the case-finding questions within questionnaires. 
By exploring patient perspectives of the annual review consultation within my 
interviews, I also built on the quantitative data generated, improving the relevance and 
validity of my results (Bryman, 2006). 
 
4.5.2 Determining the impact of anxiety in people with rheumatoid arthritis 
4.5.2.1 Research question and overview of methodological approach 
In response to this question, I have conducted a systematic review and meta-analysis. 
4.5.2.2 Justification for performing a systematic review and meta-analysis 
To determine the impact of anxiety in people with RA, I aimed to test a theory 
that anxiety was associated with increased disease activity and a reduced QoL, by 
aggregating all available evidence. To fulfil this aim, I performed a systematic review and 
meta-analysis. Performing a meticulous search of the literature and subsequent quality 
assessment of relevant articles enabled me to minimise bias and determine the 
magnitude of the association between anxiety and different outcomes in people with 
RA.  
A systematic review involves the collation of evidence fitting pre-specified 
eligibility criteria to answer a specific research question. Systematic reviews have a 
reproducible methodology, involve a systematic search to identify all studies meeting 
the eligibility criteria, include an assessment of the validity of findings to reduce the risk 
 
What is the association between anxiety in people with RA, and disease 
activity and QoL? 
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of bias and a synthesis of all relevant findings. Subsequent meta-analysis involves the 
use of statistical methods to combine the data from several studies into a single 
quantitative measure or summary effect size (Higgins and Green, 2011). 
Alternatively, I could have performed a narrative review, though this would not 
have involved a systematic search of the literature, hence could have led to selection 
bias. In my review of the literature, I had identified that a systematic review had 
previously been performed to determine the impact of comorbid depression in people 
with RA (Rathbun, Reed & Harrold, 2013), so I felt this would be an appropriate design 
to help me to review and collate existing research evidence. 
An exploratory design would not have been appropriate as I had a hypothesis 
about the impact of mood problems in people with IRCs. I knew that research had been 
performed on my topic of interest, though no systematic review had been performed 
to collate this evidence. Therefore, a descriptive approach enabled me to review and 
describe existing evidence.  
 
4.5.3 Determining the incidence and prevalence of mood problems in different 
inflammatory rheumatological conditions 
4.5.3.1 Research question and overview of methodological approach 
I have conducted a cohort study using a regional primary care database to determine 
the incidence and prevalence of mood problems, in people with different IRCs.  
 
 
What is the incidence and prevalence of anxiety alone, in addition to anxiety 
and/ or depression, in people with different IRCs? 
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4.5.3.2 Justification for performing a cohort study 
To establish the incidence and prevalence of anxiety and depression in different 
IRCs, I aimed to test a hypothesis, that mood problems were more common in people 
with IRCs. I aimed to uncover objective truths, not to understand patients͛ perspectives 
or to generate theories. An exploratory design would not have been appropriate as I 
had a hypothesis about the relationship between IRCs and mood problems. Therefore, 
I wanted to have a predetermined design to keep my study focused on my research 
question and to minimise any potential bias. Alternatively, a descriptive design would 
have enabled me to describe the prevalence of mood problems cross-sectionally, 
though I would not have been able to analyse the association between IRCs and mood 
problems over time. Therefore, to enable me to determine the both the incidence and 
prevalence of anxiety and depression, I used an explanatory design. Specifically, I 
conducted a cohort study.  
Performing a cohort study enabled me to retrospectively match a group of 
individuals with IRCs, to a group without IRCs, and compare how many developed mood 
problems over time. An alternative would have been a case-control study, though this 
would have required me to group participants based on the presence or absence of 
anxiety and/ or depression, then to make a retrospective comparison of variables that 
were possible causative factors. However, I just wanted to focus on the association 
between IRCs and mood problems. My primary objective was not want to determine 
the association between mood problems and other variables, so if I had used this design, 
a large proportion of individuals would not have been relevant to my analysis. 
My study design was quasi-experimental. This design lacks the full control of an 
experimental design, either due to there not being a separate control group, or due to 
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subjects not being randomly assigned to the control group. For this study, I did have a 
control group, though group membership was determined by the presence or absence 
of an IRC, rather than individuals being randomised from a single pool of subjects. 
 
4.5.4 Determining the prevalence of mood problems in people with IRCs using 
the case-finding questions for anxiety and depression 
4.5.4.1 Research question and overview of methodological approach 
 
 
I have analysed baseline questionnaire data from a pilot feasibility study called 
INCLUDE (Hider et al., 2018), in which individuals with different IRCs were invited to a 
nurse-led review based in primary care. This review focused on identifying comorbidities 
including cardiovascular disease (CVD), osteoporosis and mood problems, and 
signposting patients for management of these.  
Within the baseline questionnaire, people with different IRCs were asked to self-
report known anxiety or depression and to answer the case-finding questions for mood 
problems. I was then able to analyse participants͛ responses.  
 
4.5.4.2 Justification for analysing questionnaire data 
 
As outlined in section 4.5.3.2, I had planned a cohort study to establish the 
incidence and prevalence of anxiety and depression in different IRCs, using a primary 
care dataset. However, knowing that mood problems were under-recognised and 
 
What is the prevalence of anxiety and depression in people with different IRCs, 
when determined using the case-finding questions? 
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under-treated in people with RA (Cepoiu et al., 2007), I hypothesised that mood 
problems in people with other IRCs were also likely to be under-recognised, hence not 
recorded within primary care records.  Therefore, as a co-investigator on the INCLUDE 
study, I aimed to re-test the same hypothesis, that mood problems were more common 
in people with IRCs, but to do this by analysing patients͛ responses to the case-finding 
questions for anxiety and/ or depression.  
By comparing the proportion of people with IRCs found to have anxiety and 
depression through the use of the case-finding questions, to the proportion with mood 
problems already coded in their primary care records, I determined I would be able to 
characterise the potential burden of unrecognised comorbid mood problems in people 
with IRCs. 
I aimed to uncover objective truths, not to understand patients͛ perspectives or 
to generate theories. Therefore, an exploratory design would not have been appropriate 
as I had a predetermined hypothesis about a potential relationship between IRCs and 
mood problems that I wanted to test using different methods. Instead, I determined 
that a descriptive study would be more appropriate, to enable me to collect information 
on the psychological characteristics of individuals. However, my approach could also be 
described as explanatory, as I planned to analyse differences in the associations 
between variables.  
The INCLUDE study team, guided by the suggestions of a patient and public 
involvement and engagement (PPIE) group and stakeholder group, attended by GPs, 
nurse practitioners and practice nurses (PNs), collaboratively decided on the content of 
the study questionnaires (section 8.6). To collect data on psychological characteristics, 
the INCLUDE questionnaires included the EuroQol 5-Dimension Scale (EQ-5D), the 
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Patient Health Questionnaire (PHQ)-8 and Generalised Anxiety Disorder (GAD)-7 
questions. These closed-ended questions, with predetermined response options, 
provided me with quantitative data to analyse.  
Alternatively, I could have performed structured interviews to collect responses 
to these questions. Structured interviews would have enabled individuals lacking the 
appropriate literacy to complete a questionnaire to respond. There could have been less 
omissions or errors in responses to questions, as through interviews, I could have 
probed for answers and provided people who I interviewed, the opportunity to clarify 
questions if needed. However, interviews would have been more time consuming, 
whilst responses could have been influenced by my body language or communication 
skills. A lack of anonymity, compared to a postal questionnaire, could also have 
influenced responses, as some people could have been reluctant to disclose symptoms 
of mood problems due to fear of stigmatisation. In addition, people of a working age 
may have been less likely to agree to participate in a structured interview compared to 
retired individuals who could have had more time available to participate. Using a 
questionnaire meant that data could be gathered from a large number of individuals, 
representative of the general population, over a shorter period of time (Sim and Wright, 
2000).  
 
4.6 A Multiphase Mixed Methods Design                                                          . 
 
In this section, I will discuss how I used an embedded mixed methods design in 
response to my first research question, and how this study was sequentially linked to 
subsequent studies within a multiphase mixed methods design. 
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4.6.1 Embedded mixed methods design in response to my first research question 
In section 4.5.1.5, I have discussed how I integrated qualitative and quantitative 
data for my qualitative study, and how triangulation of data helped to improve the 
validity of my results. Data yielded from interviews was integrated with quantitative 
data (PHQ-2 and GAD-2 scores) reported in questionnaires completed by people with 
RA attending a pilot nurse-led annual review. PHQ-2 and GAD-2 scores were used to 
provide a background to the prevalence of mood disorders in the local population with 
RA, whilst questionnaire responses also facilitated the sampling of people with RA and 
potential mood problems for interviews.  
This approach of having concurrent qualitative and quantitative data collection, 
using quantitative data from questionnaires to sample patients, then using data from 
qualitative interviews to add meaning to findings from the clinic questionnaires, could 
be described as an embedded mixed methods design (Creswell, 2014). 
 
4.6.2 Connection to a multiphase mixed methods design 
 My mixed methods design developed further as I progressed to answer my other 
research questions through a systematic review, cohort study and questionnaire data 
analysis. Therefore, the embedded mixed methods design became the first stage of a 
multiphase design, aiming to further understand the scale and impact of mood 
problems in people with IRCs. A multiphase mixed methods design involves a researcher 
or team examining a problem through a series of qualitative and quantitative studies, 
with each new approach building on what was learned previously to address an overall 
objective (Creswell, 2014). My final multiphase mixed methods design is outlined in 
figure 4.4, with a summary of each stage written below.
  Figure 4.4- A m
ultiphase m
ixed m
ethods design for m
y thesis. Adapted from
 Cresw
ell, 2014, p221 
 
Study 1: M
ixed M
ethods (Qualitative interview
 data supported by quantitative data from
 RA annual review
 questionnaires). 
Study 2: M
ixed M
ethods (System
atic review
 using an aggregative and configurative approach to determ
ine the association betw
een anxiety in people w
ith RA, and 
disease activity and Q
oL). 
Study 3: Q
uantitative (Cohort study to determ
ine the incidence and prevalence of anxiety and depression in people w
ith IRCs, recorded in prim
ary care data). 
Study 4: Q
uantitative (Analysis of baseline questionnaire data w
ithin the INCLUDE Study, to determ
ine the proportion of people w
ith IRCs and self-reported 
sym
ptom
s of anxiety and/ or depression, determ
ined through use of the case-finding questions).
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4.6.3 Justification for a multiphase mixed methods design 
Prior to planning a multiphase study, I considered other mixed methods designs 
(Creswell, 2014). A convergent parallel mixed methods design would have required me 
to collect qualitative and quantitative data concurrently, then integrate this data when 
interpreting my results. However, my research was sequential, with my focus expanding 
from RA to other types of IRCs, following analysis of my initial qualitative data. 
Alternatively, an explanatory design would have required me to begin with a 
quantitative project, before conducting a qualitative study to provide greater meaning 
to the data. However, the initial focus of my study was to understand patient 
perspectives through a qualitative study, hence this approach would not have been 
suitable. With an exploratory sequential design, I could have built on my initial 
qualitative study findings by conducting a quantitative study. However, my qualitative 
study provided inspiration for further multi-staged work expanding on the original 
research focus, hence a two stage design process would not have been suitable.  
Using a multiphase mixed methods design required more time, support and 
experience using qualitative and quantitative methods to implement, due to the 
expertise required in a variety of methods. However, this approach enabled me to 
address a broader range of research questions in which studies built on each other, 
providing a greater depth of understanding about mood problems in people with IRCs. 
 A multiphase mixed methods design is flexible enough to incorporate different 
design elements to address connected research questions as they arise through a study. 
Concurrent and sequential strands can be included over a period of time. For example, 
a team used this study design to develop evidence-based mental health practices for 
the school-aged population in Sri-Lanka (Nastasi et al., 2007). Whilst some qualitative 
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and quantitative studies were conducted independently, then data merged to obtain a 
greater understanding, at other times the methods were sequentially connected, with 
qualitative data being used to develop a psychological measure, then quantitative data 
being used to validate it (Natasi et al., 2007).  
In contrast to this design (Natasi et al., 2007), my research has not aimed to 
develop or validate an intervention or measure, rather to improve our understanding of 
comorbid mood disorders in people with IRCs. However, there are similarities between 
my thesis design (figure 4.4) and Natasi͛s mixed methods design ;ϮϬϬϳͿ, which have both 
included sequentially connected studies. For example, within my qualitative study, 
patient perspectives shared during interviews (discussed in chapter 5), led me to 
systematically review the literature on the impact of anxiety in people with RA, which I 
noted was under-reported in comparison to depression. Perspectives shared by PPIE 
participants within my qualitative study also informed my cohort study, by prompting 
me to analyse the impact of anxiety alone and widen the focus of my research to mood 
problems in other IRCs. Systematic review findings highlighted the impact of anxiety 
alone (discussed in chapter 6), whilst my cohort study demonstrated a variable burden 
of mood problems in different IRCs, with some potentially not being recognised or 
recorded in primary care records (chapter 7). These findings, along with perspectives 
shared by PPIE participants, all informed the INCLUDE study questionnaire analysis, by 
prompting a focus on case-finding for anxiety and/or depression in people with different 
IRCs (chapter 8). At the end of each individual chapter, I have described how data 
obtained has informed subsequent steps in my thesis (sections 5.12, 6.7 and 7.8). 
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5.0 QUALITATIVE STUDY 
 
5.1 Overview                                                                                                           .    
 
 As part of the evaluation of a nurse-led rheumatoid arthritis (RA) annual review 
service at a community rheumatology hospital, I conducted a nested qualitative study 
to explore the perspectives of people with RA about comorbid mood problems. Within 
this chapter I have first explained the role of the annual review service, use of clinic 
questionnaires and how patients were recruited to be interviewed. Alongside my 
analysis, I have discussed the impact of patient and public involvement and engagement 
(PPIE) and how this study informed subsequent work within my thesis. 
 
5.2 Rheumatoid Arthritis Annual Review Clinic                                                .    
 
The National Institute for Health and Care Excellence (NICE) quality standards 
(2013c), suggest that people with RA should have an annual review of their condition, 
although guidelines do not specify where this should occur. The Haywood Foundation, 
a local charity supported a pilot annual annual review service for patients with RA in 
North Staffordshire.  
Patients with RA attending two consultant rheumatology clinics, were invited by 
letter (appendix 5), to attend a nurse led annual review service instead of their usual 
consultant follow-up appointment. The service was delivered by a rheumatology nurse 
specialist who reviewed disease activity, quality of life (QoL), physical functioning and 
comorbidities such as hypertension (HTN), ischaemic heart disease (IHD), osteoporosis 
The perspectives of people with rheumatoid arthritis about 
comorbid anxiety and depression 
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and depression. The aim of the annual review clinic was to offer a holistic approach to 
disease management and to facilitate better exploration of the wider impact of RA, 
including on mental health.  
 
 
5.3 Patient Completed Questionnaire                                                                .    
 
Prior to their appointment, patients were sent a short questionnaire to complete 
(appendix 6). The content and layout of the questionnaire was informed and refined 
with input from the Haywood User Group, comprising of patients and carers who met 
regularly at the local rheumatology hospital. The questionnaire captured patient 
demographics, RA disease activity (Visual Analogue Scale (VAS)), disease damage 
(Health Assessment Questionnaire (HAQ)), anxiety (Generalised Anxiety Disorder (GAD)-
2) and depression (Patient Health Questionnaire (PHQ)-2), pain control, work status and 
self reported comorbidities. The questionnaire also assessed the requirement for 
patients to be informed and educated about their RA drug treatment. Further domains 
highlighted as good practice by NICE, such as a review of cardiovascular risk (QRisk2), 
bone health (with FRAX if appropriate), disease complications and the impact of RA on 
QoL and functioning were also assessed (NICE, 2018). 
 
 
5.4 Two Phase Study                                                                                              .    
 
Phase 1: Data on patient demographics and responses to GAD-2 and PHQ-2 questions 
was extracted from the patient questionnaires. 
Phase 2: A purposive sample of patients from phase 1 were invited to participate in a 
semi-structured interview to explore their views of the annual review clinic and their 
perspectives on comorbid mood problems in people with RA. 
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5.5 Ethical Considerations                                                                                    .    
 
 Ethical approval was granted by the West of Scotland Research Ethics Service 
Committee (WoSRES/15/WS/0063), Project ID 170210 (appendix 7). Data for the study 
was handled in accordance with the 1ϵϵϴ Data Protection Act and its͛ amendment in 
ϮϬϬϯ ;Information Commissioner͛s Office, ϮϬϭϭͿ. Indentifiable patient data, including 
addresses, audio recordings of the interviews and transcripts were stored on a single 
computer protected with a firewall, up-to-date antivirus software and password access. 
All interviews and transcripts were anonymised.  
 
5.6 Identification and Study Processes                                                               .    
 
5.6.1 Phase 1- Cross sectional patient questionnaire at annual review clinic 
 Questionnaires were reviewed and if necessary, completed during the nurse-led 
consultation. Following the nurse consultation, if required, patients were signposted for 
specialist advice from different multidisciplinary team (MDT) members, including 
podiatry, orthotics, physiotherapy, occupational therapy and orthopaedics. Through use 
of the GAD-2 and PHQ-2 case-finding questions, the clinic nurse was also able to identify 
and signpost patients with symptoms of anxiety and depression to appropriate 
community services, such as MIND, a mental health charity, or Improving Access to 
Psychological Therapies (IAPT) services, facilitating access to counselling or cognitive 
behavioural therapy (CBT). If required, General Practitioner (GP) review was also 
suggested for consideration of medication or secondary care involvement for the 
management of anxiety and depression. 
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 During the clinic, the nurse was able to consult an overseeing rheumatology 
consultant for advice. GPs were informed of the clinic outcomes by letter, preventing 
unnecessary duplication of work.  
Patients were asked to consent to their anonymised data being used for research 
purposes. To support later qualitative analysis of interviews, data was extracted on 
patient demographics and responses to the GAD-2 and PHQ-2 questions for anxiety and 
depression.  
 
5.6.2 Phase 2- Interviews 
 A score of 3 or more out of a possible score of 6, on the PHQ-2 (Kroenke, Spitzer 
& Williams, 2003) or GAD-2 (Spitzer et al., 2006) questions (detailed in figures 2.5 and 
2.6), indicated that a patient could have symptoms of anxiety or depression. 
Consequently, these individuals were given a patient information sheet (PIS) at the end 
of their annual review appointment by the clinic nurse (appendix 8), inviting them to 
take part in the qualitative interview phase of the study. Patients providing consent to 
future contact had their details securely emailed (via nhs.net) to the interviewer. 
 Patients were then invited to take part in a single face to face interview at a 
convenient time and place, such as their home, the local community rheumatology 
hospital or university. Consent to participate in the study and digitally record the 
interview was re-checked with each participant prior to their interview, and a consent 
form signed (appendix 9). Two copies of the consent form were completed, one for the 
patient and the other for the interviewer. Participants were given the opportunity to 
withdraw their consent at any point.  
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Each interview was digitally recorded. A topic guide was utilised (appendix 10), 
which had been developed from existing literature, and informed by discussion within 
the research team. After enquiring about participants͛ general health problems, the 
interviewer explored the perspectives of people with RA of comorbid anxiety and 
depression and their preferences for the management of mood problems. In addition, 
peoples͛ views of the annual review service were explored, including whether they felt 
it was an appropriate place to discuss their mood. Relevant areas were explored in 
depth until data saturation was achieved. The topic guide was refined during the course 
of the study, with the information that emerged in early interviews used to develop 
further questions for exploration in subsequent interviews.  
The first interview was treated as a pilot, but as data collection was successful, 
it was included in the final dataset. All interviews were audio-recorded and lasted 
between 12-73 minutes, with an average length of 34 minutes. A total of 14 interviews 
were conducted until data saturation was reached. 
Digital recordings and transcripts were stored on a password protected 
computer. In addition, two password protected excel documents were used to store 
data (appendices 11 and 12). The first of these contained the patients' name, ID number, 
telephone number, address and GP. A further column within this document was used to 
record circumstances when an interview was declined or cancelled. The second 
document contained the patients' ID number, gender, ethnicity, the first part of their 
postcode, employment status, GAD-2 and PHQ-2 scores. After the completion of each 
interview, the patients' name was removed from the first excel document and replaced 
by initials.  
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5.7 Data Analysis                                                                                                     .    
 
5.7.1 Quantitative Analysis 
 A total of 179 questionnaires completed at the nurse-led review clinic were 
reviewed. An excel document was used to record patients͛ demographics (age and 
gender), in addition to their PHQ-2 and GAD-2 scores. The document was stored 
securely on a password protected computer. The proportion of patients responding 
positively to the case-finding questions for anxiety and depression was calculated, in 
addition to the number with low, moderate and high GAD-2 and PHQ-2 scores. Simple 
statistics were used to describe the data, including frequencies and percentages, in 
addition to the mean and range of data obtained (Stark, 2018). 
 
5.7.2 Qualitative Analysis 
The first 7 interviews were transcribed verbatim by the interviewer to increase 
familiarity with the data. An independent transcription company was subsequently 
used. Prior to analysis all transcripts were checked and anonymised by the interviewer. 
Analysis began as soon as the first transcript was available. Therefore, data collection 
and analysis were conducted concurrently, enabling modification of the topic guide to 
reflect emerging themes (appendix 10). 
The researcher performing the interviews led analysis. Data were analysed using 
principles of constant comparison (Creswell, 2003). To generate conceptual themes, 
inductive coding of text segments, followed by re-coding and memo writing was used. 
Regular meetings took place between the study team members to agree overarching 
thematic interpretations. 
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Following analysis of the first 7 transcripts, access to care was noted to be a key 
emerging theme. Therefore, further analysis was conducted using a framework, as 
discussed in my methodology (section 4.5.1.4), and displayed in figure 4.3 (p108). This 
was adapted from an existing framework developed to analyse potential barriers to 
accessing primary mental health care for people from hard to reach groups (Kovandžić 
et al., 2011). On adapting the framework for my study, I was informed by the work of 
Dixon-Woods (2006a, 2006b), drawing together processes that occur before and at the 
point of entry into systems of care.  
 
5.8 Quantitative Results                                                                                        .    
 
5.8.1 The annual review clinic 
Once ethical and Human Research Authority approvals had been obtained, the 
annual review clinic was established in July 2015. Over the following 12 months until 
August 2016, 179 patients attending the nurse-led annual review clinic consented to be 
part of the research study and completed the clinic questionnaire. From these, 120 
(67%) were female, reflecting the known higher prevalence of RA in women (Abhishek 
e al., 2017). The average age of patients attending the clinic was 67 years, with a range 
of 29-92 years. From the 179 people who attended the clinic, 38 (21%) scored ш ϯ on the 
PHQ-2 questions, whilst 43 (24%) scored ш ϯ on the GAD-2 questions, suggesting they 
might have anxiety or depression.  
 
5.8.2 Interview participants 
Between September ϮϬϭϱ and August ϮϬϭϲ, Ϯϵ patients scoring ш ϯ on the PHQ-
2 and/or GAD-2 were invited to take part in a single face to face interview at a venue 
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convenient to them. Interviews lasted between 12-73 minutes, with an average length 
of 34 minutes.  From the 29 patients invited to be interviewed, 14 agreed to participate. 
As detailed in appendix 11, from the 15 who did not participate, 5 were unable to be 
contacted, 2 declined, citing to poor physical health and 1 reported they were too busy. 
The remaining patients who declined to participate did not give a reason.  
Table 5.1 (p130), summarises the characteristics of the 14 participants, who 
were all white British, reflecting the demographics of the local area. More females 
participated, reflecting both the higher prevalence of RA in women (Abhishek et al., 
2017) and the proportion of females attending the clinic (67%). The majority of people 
interviewed were retired, with an average age of 63 years.  
For each interview participant, an index of multiple deprivation (IMD) score was 
calculated. This is a measure of relative deprivation for neighbourhoods in England, 
expressed in deciles from 1 (most deprived) to 10 (least deprived). The score is based 
on a person͛s postcode ;Department for Communities and Local Government, ϮϬϭϱͿ. 
For my interview participants, the mean IMD was 5.9, with a range of 1-9, demonstrating 
that a range of socioeconomic statuses were represented within those patients I 
interviewed.  
From the 14 individuals who consented to be interviewed, the burden of anxiety 
symptoms (mean GAD-2= 4.9, standard deviation (SD)= 1.1), was slightly higher than 
depression symptoms (mean PHQ-2= 4.6, SD=1.1). Whilst 5 people predominantly 
reported symptoms of anxiety, 2 mainly described symptoms of depression. The 
remaining 7 individuals had equal scores on both the PHQ-2 and GAD-2 questions. 
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Table 5.1- Demographic Characteristics of participants (n=14). 
Gender Female = 12 Male = 2 
Ethnicity White British = 14 
Age 
 
40-50 years = 1 
50-60 years = 4 
60-70 years = 7 
>70 years = 2 
Employment status 
Employed = 3 
Retired = 4         
Retired through ill health = 6  
Unemployed = 1 
Index of Multiple Deprivation 
(IMD) 1 
Mean= 5.4 
Standard Deviation= 2.8 
Range= 1-9 
PHQ-2 Score Mean= 4.6 Standard Deviation= 1.1 
GAD-2 Score Mean= 4.9 Standard Deviation 1.1 
 
1 Measure of relative deprivation for neighborhoods in England, expressed in deciles from 1 (most 
deprived) to 10 (least deprived) 
 
 
 
5.9 Qualitative Results                                                                                           .   
 
I have presented my qualitative data as a series of four connected themes, some 
with several sub-themes, as outlined in figure 5.1 (p131), For each theme, I will give 
illustrative data with participant identifiers, and discuss my interpretation. 
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Figure 5. 1- Themes discussed within qualitative results 
 
 
5.9.1 Recognition of psychological problems 
Participants described the processes through which they came to recognise that 
they were suffering from a mood problem. Some noted a change in their sense of self, 
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whilst others required time to reflect on their feelings before they recognised that they 
were anxious and/ or depressed.  
Η…the way I͛m feeling now I could just cry at the drop of a hat. That͛s not me.Η 
(Participant 8, female, 62 years). 
 ͞… deep down I have noticed my mood change whilst I͛ve been off, you know, and 
I think that͛s when you͛ve got more time to think… I think those worries are always 
there but because you͛re so busy and your life͛s busy you haven͛t got time to think 
about them.͟ ;Participant ϭϭ, female, ϱϯ yearsͿ. 
Several participants only recognised that they were suffering from anxiety or 
depression when a relative commented on their mood. 
"I know I've been moody, I mean like I say, I think I've been alright, but until 
somebody tells you you've not been alright you don't know." (Participant 4, female, 
58 years). 
"I like joking. So for me to be like this is very unusual. It͛s getting worse, I suppose. 
I͛ve actually got to the stage where my husband said to the kids, ͚DonΖt tell mum 
anything that͛d stress her out.͛Η ;Participant ϴ, female, ϲϮ yearsͿ. 
Some participants described how discussing their mood with the annual review 
clinic nurse helped them to recognise that they were suffering from anxiety or 
depression. 
ΗShe said, ͚Do you get depressed?͛ and I said, ͚Not a lot, no, not really,͛ but it͛s only 
until afterwards when you think about it and you think, ͚Yes, you do really,͛ and it is 
connected to the arthritis.͟ ;Participant ϴ, female, ϲϮ yearsͿ. 
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 ͞When she was saying it I was thinking, god, I feel like that, you know, it͛s so, it͛s so, 
like when somebody else said it, I thought, well I͛m not on my own, somebody else 
must feel like that.͟ ;Participant ϭϰ, female, ϳϭ yearsͿ. 
In summary, the recognition of anxiety and depression was facilitated by the 
personal reflections of participants and comments made by relatives. For some, direct 
questioning by the annual review clinic nurse also provided a forum for the 
acknowledgement of mood problems and encouraged participants to reflect on 
whether they had anxiety and/or depression.  
 
5.9.2 Perceived causes of anxiety and/ or depression in people with RA 
Participants variably perceived the interaction between their mood problems 
and RA. Most felt that joint pains, fatigue and loss of mobility related to their RA had led 
them to suffer from anxiety and/or depression.  
"I felt I had a very low mood, because, well because it was really about the worst I'd 
ever felt, last time I went, because I'd had shoulder pain for weeks." (Participant 2, 
female, 56 years). 
͞It wears you down, it wears you down and you͛re fatigued at times quite badly and 
that can make you worn out, mentally and physically worn out, it has a physical side, 
has a mental effect on you…͟ ;Participant ϭϭ, female, ϱϯ yearsͿ. 
Several participants reported that their mood could vary in relation to flares of RA.  
͞Yeah, it does make you really miserable and grumpy and then some days can be 
okay.͟ ;Participant ϭϯ, female, ϰϱ yearsͿ. 
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"I mean when you have a flare, that's miserable, but it isn't just the flares, it͛s how I 
feel in myself as well...the depression, the anxiety, I get ever so anxious." (Participant 
7, female, 61 years). 
             Other participants perceived their mood problems to have been provoked by a 
loss of independence and social isolation as a result of their RA. Some described the 
impact of reduced mobility on their personal relationships and how they had been 
forced to give up hobbies that they used to enjoy. 
 ͞…I get very, very frustrated. Because I used to love walking, and I͛d do a lot of keep 
fit, and all of it, I can͛t do nothing like that. No… But it͛s like things like, I can͛t play 
with me grandson. You know what I mean, it͛s like, his other nanna takes him to the 
park and chases him around, whereas I can͛t do that, no.͟ ;Participant ϭϰ, female, 
71 years). 
Η … I can't do what I want to do. It͛s nice having somebody here just to talk to, you 
know. I mean my daughter stops now and then, but she's working all day you know, 
and she comes round every night." (Participant 3, female, 64 years). 
             Several participants reported work-related stress and financial pressures due to 
their RA leading them to feel anxious and/ or depressed. For some, this was exacerbated 
by the loss of social connections at work. 
Η… I donΖt think the arthritis is helping at all, but without it IΖd still be working, IΖd still 
be at X (work), and I'd have all my friends, and I'd be doing what I enjoyed doing." 
(Participant 7, female, 61 years). 
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͞It͛s depressing at times because you͛re thinking what would happen you know, how 
would I get money if I hadn͛t got a job, who would employ me with health problems 
and at ϱϰ, I͛m nearly ϱϰ would they like they͛d probably put you under the pile.͟ 
(Participant 11, female, 53 years). 
              One participant thought that their low mood had been precipitated by anaemia, 
which they had developed secondary to their RA. 
 ͞Some of it I think is linked to my arthritis because I tend to be anaemic quite a lot 
and I have to keep an eye on that and it͛s surprising how that affects you, if you don͛t 
sort it out really…You are more tired, but I think it also makes you feel low in yourself 
as well…͟ ;Participant ϭϮ, female, ϳϬ yearsͿ. 
 Rather than RA triggering mental health problems, some participants perceived 
the reverse to be true, with stress, anxiety or low mood triggering flares of RA. 
͞Every time I͛ve had severe stress come my way and I͛ve not been feeling good that 
seems to have an effect on the rheumatoid…͟ ;Participant ϭϭ, female, ϱϯ yearsͿ. 
"I had my forms through from the DLA is it? And I'd got to fill them in, and for a 
couple of weeks of trying to do it, everything's churning, I made an appointment at 
the citizen's advice, to go and get them to sit and help me with it. So it͛s coming to 
the appointment, got a flare, can't go." (Participant 7, female, 61 years) 
 Several participants perceived other chronic physical health problems to have 
caused their mood symptoms, such as hypothyroidism, whilst one participant reported 
recurrent hospital admissions for the treatment of abscesses to have negatively 
impacted on their mental health.  
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"I had a bit of a weep, and she looked at my records and said that my thyroid was 
too low. So she upped my thyroid... I do feel a little better with my thyroxine being 
upped a bit." (Participant 4, female, 58 years). 
"I always seem to be in hospital for one thing or another, you know. I had a bout last 
year. I went in hospital as many as four times and had operations, with the abscesses 
that I used to get, and that used to get me down, you know." (Participant 1, female, 
54 years). 
Some participants couldn͛t understand why they had developed mood 
problems. One suggested that their propensity to become anxious and depressed was 
related to their personality.  
ΗI can always remember saying, ͚but why am I depressed, I've got nothing to be 
depressed about!͛ You know, IΖd got a fantastic husband, fantastic kids...Η pϳ, line 
30-31. "But that's down to, that's down to personality, you know what I mean? It͛s 
nothing to do with the arthritis that's just how I am." (Participant 7, female, 61 
years). 
"I get a bit grumpy maybe. I just can͛t help it. I go down a bit. I can͛t think of the 
reason why. I haven͛t actually got a reason to be down. Everything͛s fine, money-
wise and everything, and yet I go down, and then I come out of it again." (Participant 
10, female, 61 years). 
Another participant perceived their low mood to be multifactorial, with their RA 
and chronic obstructive pulmonary disease (COPD) contributing. 
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"It͛s a combination of my arthritis and my lung condition, COPD, you know. The lung 
condition is percentage wise 70:30" (Participant 6, male, 70 years). 
Others accounted their mood problems to social issues, such as domestic 
violence or bereavement.  
͞Nobody bothers. You feel worthless. It just all gets you down. I͛ve had quite a rocky 
marriage. He used to be violent. That didn͛t help none. That was very bad.͟ 
(Participant 9, female, 68 years). 
͞… I did feel quite low but I thought it was more to do with my mum passing away 
than so much with my arthritis, you know, because it was traumatic, because she͛d 
been with me a long time as well, she was more like a partner really than my mum.͟ 
(Participant 12, female, 70 years). 
One participant also felt that their family history of depression and suicide 
strongly influenced their mental health. 
͞I had a brother what committed suicide, gassed himself in his car. My nephew tried 
hanging himself with a belt round his neck and he nearly died. It͛s one family 
problem after another.͟ ;Participant ϵ, female, ϲϴ years). 
 Another participant perceived their anxiety and/ or depression to have 
developed before their RA, but to be negatively influenced by their arthritis. 
"I suffer anxiety and depression, which I think have got worse, having the arthritis 
as well.͟ (Participant 7, female, 61 years). 
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In summary, some participants perceived their RA and mood problems to be 
linked, though the direction of this link varied. Whereas several reported RA-related 
pain, loss of mobility and social isolation to precipitate their anxiety and depression, 
others described RA flares being triggered by low mood or anxiety. Others perceived 
their mood problems to be separate from their RA, related to other chronic physical 
health problems or social circumstances, whilst some acknowledged that their anxiety 
and depression were multifactorial. 
 
5.9.3 Barriers to help-seeking  
 Candidacy is the process by which a person͛s eligibility to use a service is 
formulated through their local interactions with health services (Stevenson and 
Scambler, 2005). Participants perceived various barriers to help-seeking for anxiety and 
depression in RA, which led some to perceive they lacked candidacy for care.  
Fear of stigmatisation and normalisation of mood problems prevented some 
participants from seeking help, whilst others described how past negative experiences 
of consulting their GP or rheumatologist had recursively affected their future help-
seeking behaviours.  
 
5.9.3.1     Stigma and shame 
Several participants reported having felt too embarrassed to disclose their mental 
health concerns to their GP, with some perceiving their low mood as a sign of weakness.  
 ͞It was particularly at first because I had been active and I suppose periodically, you 
might anyway, feel a bit low you know, when things get on top of you a bit…but 
certainly I did at first, I felt a bit inadequate and don͛t like to admit weakness and 
stuff like that…͟ ;Participant ϭϮ, female, ϳϬ yearsͿ. 
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͞…it͛s only in the last few weeks that I have mentioned about my anxiety and 
depression to my GP, because I find it very embarrassing. I feel ashamed of having 
it really, because I've got no reason to, well I have now, I've got the arthritis, but 
somehow it excuses it, it allows it.͟ (Participant 7, female, 61 years). 
One participant described their fear of appearing ͚ stupid͛ if they were to disclose 
their mood concerns to their rheumatology consultant, whilst another reported 
problems opening up to their GP due to medical students often being present during 
consultations, which further limited disclosure of mood problems. 
 
"I never mentioned it to Dr X (consultant rheumatologist), because I think they'd 
think I'm being stupid." (Participant 5, female, 78 years). 
͞…there are students in there and when you try and tell him personal stuff and you 
look at the fellow sitting there and you think, ͚My son is as old as you͛.  It͛s sort of 
embarrassing… that sort of stops me dead in my tracks…͟ ;Participant ϭϯ, female, 
45 years). 
 Thus, the perception of mental health problems as a sign of weakness and fear 
of stigmatization were significant barriers to help-seeking for mood problems. The 
presence of other witnesses, such as medical students, during consultations was 
perceived as a further source of potential embarrassment. 
 
5.9.3.2   Normalisation of mood problems 
 Several participants did not formulate their experience of suffering into a mental 
health problem. Instead, they perceived their symptoms to be stress-related or part of 
a ͚grumpy͛ personality.  
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"I'm always worried. I think a lot of it͛s stress. I worry about anything and nothing. I 
know it͛s nothing to worry about but I can't help myself. Everyday things I worry 
about.͟ ;Participant ϱ, female, ϳϴ yearsͿ. 
͞I have been dubbed grumpy by my family sometimes.Η ;Participant ϲ, male, ϳϬ 
years). 
Others normalised mood problems as an expected ͞ side-effect͟ of any long-term 
condition (LTC), which prevented them from seeking help for their mood problems. 
"I think low mood is just a side-effect of any illness." (Participant 2, female, 56 years). 
 
5.9.3.3   Candidacy for care of mood problems 
Several participants perceived other people to have greater health needs, which 
led them to lack candidacy for care. This was a barrier to them them seeking help for 
their anxiety and depression. 
"I tend to keep it to myself I think. I don͛t want to bother. I͛d just rather be left alone 
and get on with it. I try not to be too much trouble, really.͟ ;Participant ϭϬ, male, ϲϭ 
years). 
͞I mean I always think, some people are so much worse off so you just have to get 
on with it, that͛s my mother͛s adage as well.͟ ;Participant ϭϮ, female, ϳϬ yearsͿ. 
 Some participants described how their relatives influenced their perceived 
candidacy for care. For instance, several reported their relatives to be dismissive of their 
mental health concerns, which prevented them from seeking help. 
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Η…they ;relativesͿ keep saying donΖt be silly, you're alright. But it͛s ok for people 
saying donΖt worry if I can help it. Well I canΖt and IΖm sure a lot of people canΖt.͟ 
(Participant 5, female, 78 years). 
However, others reported their relatives to prompt them to seek help for 
psychological concerns. 
"I know I've been moody, I mean like I say, I think I've been alright, but until 
somebody (husband) tells you you've not been alright you don't know...͟ 
(Participant 4, female, 58 years). 
In summary, several participants did not formulate their symptoms into a mental 
health problem, or normalised them as an expected consequence of any illness, which 
was a barrier to help-seeking for mood concerns. Some participants perceived others to 
have greater health needs, hence lacked candidacy for care. Several participants 
described how their feelings of candidacy were influenced by their relatives, which was 
often a barrier to accessing care, but could also facilitate help-seeking for anxiety and 
depression. 
 
5.9.3.4   Physical, not mental health treatment required 
          Further barriers to help-seeking for anxiety and depression related to patients͛ 
perceptions of the interaction between their RA and mood problems. Some participants 
didn͛t raise their mood concerns during RA review appointments as they perceived that 
better physical, not mental health treatment would be required to improve their mood. 
For example, one participant perceived their low mood to be caused by joint pains, and 
another, anaemia, secondary to their RA.  
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͞Some of it I think is linked to my arthritis because I tend to be anaemic quite a lot 
and I have to keep an eye on that and it͛s surprising how that affects you, if you don͛t 
sort it out really…͟ ;Participant ϭϮ, female, ϳϬ yearsͿ. 
͞It͛s one (an injection) I went onto ʹ a research one which was about 400 around 
the world from what I can gather…That͛s what I͛m waiting for…as I͛m sick of my arms 
and that aching and it͛ll take a bit away so I don͛t feel as depressed then...͟ 
(Participant 9, female, 68 years). 
Consequently, perceptions of the treatment required for anxiety and depression 
in RA, influenced participants͛ help-seeking behaviour. As some felt that their mood 
problems were a consequence of a physical health problem, they focussed on seeking 
physical, not mental health treatment. 
 
5.9.3.5    Experiences of appointments 
Participants reported a lack of continuity of care and problems accessing 
appointments with their GP as barriers to the disclosure of mood problems.  
͞I phoned up. No, she wasnΖt available. She said weΖd got two other doctors and I 
said no, I'd rather see the same doctor." (Participant 7, female, 61 years). 
͞I͛ve been there years and years. I just find them a waste of time. You never get to 
see a doctor. You get palmed off with anybody. You͛re lucky if you see a doctor 
there, anybody. I don͛t feel they are bothered.͟ ;Participant ϵ, female, ϲϴ yearsͿ. 
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Participants recognised the pressure of restricted appointment times on GPs, 
but felt that provision of time during individual appointments and encouragement to 
attend follow-up would be integral to disclosure of psychological concerns. 
͞I suppose it͛s because they are so busy and as I͛ve said, I do understand where 
they͛re coming from, they have so many people to deal with…and they͛ve only got 
a certain length of time, you know, they͛re not, whilst there͛s some brilliant doctors 
about and there undoubtedly is, GPs I mean, they do have a really tough job…͟ 
(Participant 12, female, 70 years). 
ΗHe͛s just very approachable. You just can talk to him about anything. I did go a few 
times and he said I must come back." (Participant 8, female, 62 years). 
Consequently, system-level problems related to access to GPs, restricted time 
during appointments and a lack of continuity of care or adequate follow-up 
appointments were further barriers to help-seeking for anxiety and depression. 
 
5.9.3.6    Perceptions of GP 
 Several participants described appointments with their GP as anxiety-provoking 
which recursively affected future help-seeking for mental health problems. Some 
admitted telling their doctor they were fine in order to finish their consultation quickly, 
meaning any underlying problems were not addressed. 
"I get ever so anxious. I'm not good with, when I have doctor's appointments or 
medical appointments. I tend to go in and say yeah I'm fine, just so I can get out 
again." (Participant 7, female, 61 years). 
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 ͞I get all, I donΖt know, when I see the doctor. Although they are very good, donΖt 
get me wrong, they're marvellous. I forget half of it, then I come away and I don't 
know anything then…͟ (Participant 5, female, 78 years). 
Some participants perceived their GP to prioritise physical above mental health 
concerns.  
Η…doctors are busy enough with physical complaints.Η ;Participant Ϯ, female, ϱϲ 
years). 
Several participants reported past negative experiences of help-seeking, when 
their GP had lacked time or been dismissive, which had prevented them from disclosing 
their mental health concerns.  
͞…they haven͛t got the time really. I think that͛s the only thing.͟ ;Participant ϭϰ, 
female, 71 years). 
͞There are a lot of people in that surgery and you go in, you sit down and you͛ve got 
five or ten minutes and then you͛re coming back out again and you forget half the 
stuff you want to really talk about because I͛ve only gone, usually, for my 
medication.  It͛s just when he does actually say, ͚How do you feel?͛  I just say, ͚I feel 
really down͛ and he briefly asks me why and I don͛t feel like I have time to tell him 
before he͛s giving me the leaflet.͟ ;Participant ϭϯ, female, ϰϱ yearsͿ. 
Other participants described their GP as intimidating, which had recursively 
affected their future help-seeking for psychological problems. 
͞And you go in and he just looks at you, you know, and I think to myself, well I͛m not 
telling you how I feel, you know……God, well he just sits there and he͛s very stern 
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looking, and you go in, and he͛ll say ͚what can I do for you?͛, and you think nothing, 
I͛m out the door!͟ ;Participant ϭϰ, female, ϳϭ yearsͿ. 
Other participants described establishing positive relationships with their GP 
influenced by body language and rapport which helped to facilitate the disclosure of 
mental health concerns. 
͞I just think he͛d got a really big heart and I think he was very, very understanding 
of how you might be feeling and very, very supportive indeed.͟ ;Participant ϭϭ, 
female, 53 years). 
In summary, some participants perceived their GP prioritised physical above 
mental health concerns and reported their appointments to be anxiety-provoking, 
recursively affecting help-seeking. Lack of time and poor continuity of care were 
perceived to be further barriers to disclosure of mood problems. However, participants 
suggested that good communication and encouragement to attend follow-up would 
facilitate discussion of psychological concerns. 
 
5.9.3.7     Perceptions of Rheumatologist  
          Participants perceived their rheumatologist to only be responsible for physical, not 
mental health care, which was a barrier to the disclosure of mood concerns during RA 
review appointments.  
͞I donΖt talk about mood and anxiety when I go for a consultant, no I don't. The only 
thing when I go, I just think about my body, my neck, my skeleton, my body 
basically." (Participant 7, female, 61 years). 
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Often participants perceived their consultant to lack the time required to discuss 
mood problems, which was a further barrier to disclosure. Several reported never being 
asked about their mood during review appointments.  
͞I saw one once and he was very nice, but the others, they sort of want you in and 
out.͟ ;Participant 14, female, 71 years). 
͞They͛re more concerned about the pain and if I was in any pain and what 
medication I was taking and, I suppose, if they could add another tablet.  I don͛t 
recall being asked how my mood was at the time, no.͟ ;Participant 13, female, 45 
years). 
  Some participants described appointments with their rheumatologist to be 
anxiety-provoking, which prevented disclosure of mental health concerns and detracted 
from an effective discussion of how well their RA was controlled. 
͞I knew I've got to get this anxiety sorted, because it͛s stopping me actually telling 
the medical profession, ie. the consultants just what's going on, because the 
moment I get in there, my stomach starts churning…͟ (Participant 7, female, 61 
years). 
One participant described their fear of appearing ͚ stupid͛ if they were to disclose 
their mood concerns to their rheumatology consultant, whilst another reported having 
sufficient rapport to disclose psychological concerns. 
͞I never mentioned it to Dr X (consultant rheumatologist), because I think they'd 
think I'm being stupid." (Participant 5, female, 78 years). 
͞…Dr X ;consultant rheumatologistͿ and everybody I͛ve seen there to be honest with 
you, you feel comfortable with yeah, very, very laid back indeed, they͛ve no, how 
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can I put it, I͛m the doctor, there͛s none of that, I think they don͛t make you feel like 
that at all, they͛re amazing, absolutely.͟ ;Participant ϭϭ, female, ϱϯ yearsͿ. 
In summary, participants generally perceived their rheumatologist to be 
responsible for physical, not mental health care, which was a barrier to the disclosure 
of mood concerns. Further barriers included a lack of time, fear of stigmatization and 
anxiety-provoking appointments. However, one participant reported feeling 
comfortable to discuss their anxiety and depression with their rheumatologist. 
 
5.9.4 Perceptions of the annual review clinic 
5.9.4.1     The appointment 
The majority of patients perceived the annual review appointment to be more 
detailed than their usual consultant review, which was facilitated by the provision of 
time.  
͞…she covered everything. Yes, she really did, it͛s like me leg just sticks out. And, err, 
and she examined me and everything, whereas the doctors, they haven͛t got the 
time.͟ ;Participant ϭϰ, female, ϳϭ yearsͿ. 
͞I went for an interview with the nurse, into a separate room, and she went through, 
many things really, how things were, and how I was being affected by certain things, 
and it was quite useful…͟ ;Participant Ϯ, female, ϱϲ yearsͿ. 
Some participants found it helpful to consult someone different, as it enabled 
them to retrace their history and amend any factors that had changed. 
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"It was a different person. Talking to her was like a fresh start, when you speak to 
somebody new. I could go over it again and add things or take things away or 
what͛s gone better, what͛s gone worse.Η ;Participant ϭϬ, male, ϲϭ yearsͿ. 
Participants recognised an emphasis on understanding the wider psychosocial 
impact of their RA within the clinic, which they often perceived to be poorly explored by 
their rheumatologist (as described above), who they felt, focused on joint swelling and 
pain. 
͞Well she wanted to know how it affected me like you͛ve asked me, which the doctor 
doesn͛t go into that, it͛s more, how much pain, he looks at your joints you know, if 
they͛re more swollen, all those sort of things...͟ ;Participant ϭϮ, female, ϳϬ yearsͿ. 
Some participants expressed initial concerns about seeing a nurse instead of 
͚their doctor͛, though the majority reported their problems to have been addressed and 
consultant advice sought if required, for instance, regarding a change in RA medication.   
So how did that make you feel, that you didn't see Dr X? "Initially relieved, and 
disappointed, because I know the flares are coming more. But X (clinic nurse) was 
very good. She spoke to, I think it was Dr X she spoke to and they have increased my 
medication.  Which at the end of the day is what I was going to ask them to do." 
(Participant 7, female, 61 years). 
Participants reported feeling involved in treatment decisions made at the RA 
annual review clinic. 
"...there was two options with this new medication, and also they'd asked me to 
read both leaflets and decide which I thought was the better, and I don't know if it 
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was fortunate because I picked the right one, and that was the one they thought." 
(Participant 6, male, 70 years). 
͞She was on about injecting into me knees at first, and I said I͛d got like, is it a 
titanium knee? So she said she wouldn͛t, she thought that wouldn͛t do. She said, ͚so 
what do you think about a steroid injection͛. I said, ͚do you think that would help?͛, 
and she said ͚yes, I think it would.͛ ͟ ;Participant 14, female, 71 years). 
            Participants perceived the case-finding questions, used to identify anxiety and 
depression during the clinic, to be acceptable. Some reported feeling better after being 
given the opportunity to discuss their mood. 
So how did it make you feel when they asked you about your mood?   
͞Well, in a way better, because I could explain to them how I was feeling, you 
know. IΖm not the sort of person to get down, but I have been just lately͟ 
(Participant 5, female, 78 years). 
Were you asked about your mood whilst you were at the clinic?  
͞Yes, yes…͟ 
And how did you feel about that? 
͞Alright, and I don't mind saying it because, you know, I felt I had a very low 
mood, because, well because it was really about the worst I'd ever felt, last 
time I went, because I'd had shoulder pain for weeks and I hadn't really 
been able to do anything at all.͟ ;Participant Ϯ, female, ϱϲ yearsͿ. 
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 Recently diagnosed patients described the annual review clinic as a learning 
process about potential complications of RA, including anxiety and depression. For one 
participant, learning that others with RA were affected by mood problems led them to 
realise they were not on their own, facilitating discussion of mood concerns. 
͞…if you donΖt get prompted ʹ if it͛s new to you, you wouldn͛t know to ask that 
question. Anything that͛s relative to arthritis needs to be put down and say, ͚Have 
you got this, that, or the other?͛ And they can say, ͚ Ooh yes. I͛ve got that.͛ Otherwise 
you wouldn't perhaps think about it. So it is helpful, yes͟ ;Participant ϭϬ, male, ϲϭ 
years). 
 ͞Yes, and when she was saying it I was thinking, god, I feel like that, you know, it͛s 
so, it͛s so, like when somebody else said it, I thought, well I͛m not on my own, 
somebody else must feel like that!͟ ;Participant ϭϰ, female, ϳϭ yearsͿ. 
              In summary, participants perceived the annual review clinic to be useful and 
recognised the focus on the wider impact of their RA. Participants reported feeling 
involved in treatment decisions made and although some reported initial concerns 
about seeing a nurse instead of their doctor, the majority felt that their concerns were 
addressed. Participants perceived the case-finding questions to be acceptable, with 
several describing the clinic as a learning process, during which they were provided with 
a forum for the disclosure of mood concerns. 
5.9.4.2    The nurse 
One participant reported that they would need more time to build a rapport with 
the annual review nurse before disclosing their mood concerns, highlighting the 
importance of continuity of care. 
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 ͞…I think with your health you͛ve got to know somebody to, I don͛t know, to tell 
them how you͛re feeling...͟ ;Participant ϭϭ, female, ϱϯ yearsͿ. 
Some participants had previously seen the annual review nurse at their local 
rheumatology hospital, hence felt that their familiarity would facilitate disclosure of 
mood concerns. One participant also reported that the review nurses͛ experience in 
treating joint problems would enable her to understand their RA-related problems, such 
as low mood, better. 
"I think I opened up to that nurse because I knew her. Whereas a counsellor, I don't 
know them." (Participant 4, female, 58 years). 
"I think they understand more, the women at the X (rheumatology hospital), they 
know everything. I feel they're listening to me and trying to explain everything." 
(Participant 5, female, 78 years). 
Another participant felt their rapport with the annual review nurse was affected 
by an unwelcome comment she made about her being obese. 
͞Yes, till she said I was obese! And I͛m sat in there, I͛m sitting there, and, and I͛m 
thinking, oh my god…͟ ;Participant ϭϰ, female, ϳϭ yearsͿ. 
 However, the annual review clinic nurse was largely perceived to facilitate 
disclosure of mood concerns. Participants described her as approachable, caring and 
understanding.  
͞…she seemed to understand. Again, I think it͛s probably a personality thing. It 
sounds snobbish to say it͛s because she wasn't a consultant, because that's my age 
coming into play. Doctors, they're up there. I don't know, she was just really nice, 
and really easy to talk to...͟ ;Participant ϳ, female, ϲϭ yearsͿ. 
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͞Yes, she was warm, she was friendly, you know, she was very approachable I would 
say.͟ ;Participant ϭϮ, female, ϳϬ years). 
In addition, participants perceived the clinic nurse to listen well to their 
concerns, a process which was facilitated by the adequate provision of time to talk about 
their mood.  
͞I did prefer talking to the nurse about everything… talking to the nurse I was one to 
one and could tell her a little bit more. She'd got the time to do it." (Participant 5, 
female, 78 years). 
͞Yeah, she was relaxed.  She wasn͛t trying to shove me through the door.  She͛d just 
got time to listen.͟ ;Participant ϭϯ, female, 45 years). 
Participants described feeling more relaxed during their nurse-led review than 
their consultant appointment, which facilitated disclosure of concerns they said that 
they might have forgotten on seeing their doctor.  
͞You always come out thinking, ͚I should have said this.  I should have said that͛.  
That͛s why, sometimes, I do make an appointment and go and speak to the 
Rheumatology Nurse where she͛ll just answer the questions I have but it͛s nice.͟ 
(Participant 13, female, 45 years). 
͞I suppose I did open up more to the nurse, because I get all, I don't know, when I 
see the doctor. Although they are very good, don't get me wrong, they're 
marvellous. I forget half of it, then I come away and I don't know anything then, 
whereas with the nurse, whether it͛s more time with them, and I can get back to 
them more if you know what I mean.͟ (Participant 5, female, 78 years). 
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Therefore, although some participants felt they would need more time to build 
a rapport, the majority reported the clinic nurse to be approachable, caring and to listen 
well, all of which facilitated the disclosure of mood concerns. 
 
5.10 Discussion                                                                                                        .    
 
5.10.1 Summary of findings 
The proportion of people with RA who reported symptoms suggestive of possible 
anxiety (24% scoring ш 3 on the GAD-2 questions) and depression (21% scoring ш 3 on 
the PHQ-2 questions) within the annual review questionnaires, exceeded one-week 
prevalence rates for GAD (5.9%) and depression (3.3%), determined by a survey of the 
general population of England (NatCen Social Research, 2016).  
Whilst the proportion of people with RA who reported symptoms of possible 
depression was slightly lower than the prevalence of depression reported in the 
literature (Matcham et al., 2013), the proportion with symptoms of anxiety was higher 
than previously reported (Covic et al., 2012). The impact of anxiety, particularly on help-
seeking for care of mood problems, emerged on analysis of the interview data. 
The recognition of anxiety and depression was facilitated by the personal 
reflections of participants and comments made by their concerned relatives. For some, 
direct questioning by the annual review clinic nurse also provided a forum for the 
acknowledgement of mood problems. Some participants perceived their RA and mood 
problems to be linked, though the direction of this link varied. Whereas several reported 
RA-related pain, loss of mobility and social isolation to precipitate their anxiety and 
depression, others described RA flares being triggered by low mood or anxiety. Others 
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perceived their mood problems to be separate from their RA, often due to social 
circumstances. 
 Overall, there were multiple barriers to help-seeking for anxiety and depression 
in RA. Fear of stigmatization prevented some participants from discussing their mental 
health problems, whilst others normalised their symptoms of distress. Several 
participants lacked candidacy for care, perceiving others to have greater health needs, 
whilst others sought better management of their physical health, to improve their 
mental health. 
 Participants generally perceived their rheumatologist to be responsible for 
physical, not mental health care, which was a barrier to the discussion of mood 
concerns. Poor access to GP appointments was described as a barrier to the disclosure 
of mental health concerns and was perceived to negatively impact on continuity of care. 
GPs were perceived to lack time, whilst several participants described appointments as 
anxiety-provoking, recursively affecting help-seeking. Good communication and 
encouragement to attend follow-up were suggested as methods to facilitate disclosure 
of mood problems. 
 The case-finding questions were perceived to be acceptable, when asked in the 
context of the annual review clinic. Participants reported the annual review clinic to be 
useful and recognised a focus on the wider impact of their RA. Several described the 
clinic as a learning process, during which they were provided with a forum for the 
disclosure of mood concerns. Although some participants felt they would need more 
time to build a rapport, the majority reported the clinic nurse to be approachable, caring 
and to listen well, all of which facilitated the disclosure of mood concerns. 
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5.10.2 Strengths and limitations 
Use of exploratory methods, followed by further analysis using a framework, 
enabled deeper insights into the barriers and facilitators to patients with RA accessing 
care for psychological problems. To help participants to feel at ease and not see the 
interview as an encounter with a stranger, telephone conversations with participants 
prior to the face-to-face interviews were used to establish rapport. Participants were 
not informed that their interviewer was a GP, as this could have been a barrier to them 
sharing negative opinions of clinicians. To facilitate reflexivity memo notes were kept 
and regular team meetings were held where the interpretation of data was discussed.  
As only patients with a high PHQ-2 or GAD-2 score were interviewed, different 
views could have been articulated by individuals without mood problems. In addition, 
participants were predominantly white British and female, hence a greater range of 
perspectives may have been gained from a more diverse population. However, a range 
of different socioeconomic statuses were represented within the sample interviewed 
and attempts were made to purposively sample participants of different ages. 
 
5.10.3 Patient and public involvement and engagement 
The content and layout of the patient questionnaire was informed and refined 
with input from the local Haywood User Group, who offered anonymous feedback on 
its͛ layout and content. I gained funding from Royal College of General Practitioner͛s 
(RCGP) Scientific Foundation Board (SFB) to conduct a further PPIE meeting, to discuss 
the potential interpretation of ambiguous data extracts, in addition to strategies for 
dissemination of findings.  
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Initially, attempts were made to recruit PPIE group members from the Haywood 
User Group. A simple presentation of the research aims and the reasons for patient 
involvement was made to the group at one of their regular meetings, and although 9 
volunteered to participate, only 2 had RA. Following discussion between research team 
members, it was agreed that as the research would impact on patients with RA, it would 
be best to just include this subset of patients, who would potentially benefit the most 
from their involvement and have personal experiences of living with inflammatory 
arthritis to draw upon. Therefore, to supplement the 2 patients with RA recruited from 
the Haywood User Group, a further 6 patients were invited from the Keele Research 
User Group (RUG). The Keele RUG includes over 130 members who have experience of 
living with a LTC, or are a carer or close relative of someone with a LTC (Keele University, 
2019). One of the PPIE group participants had previously attended the annual review 
clinic.  
During the PPIE meeting, various interview extracts were presented to the 
group. Although participants agreed with the interpretation of the majority, some 
offered alternative perspectives, enriching analysis. Participants agreed that anxiety and 
depression were common in people with chronic illness, but suggested that sometimes 
people don͛t recognise this, or feel that nothing can be done. In addition, participants 
suggested that people may feel more comfortable disclosing mood problems to a nurse 
rather than a consultant. 
The PPIE group suggested that there was a need for patients with RA to be 
educated about mood problems and potential treatments. On discussing ways to 
publicise findings, patients suggested that leaflets could be given out at pharmacies or 
GP surgeries. The role of the patient information and educational resource (PIER) at the 
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local rheumatology hospital, as an information resource was also discussed. Participants 
suggested that disease-specific support groups and Arthritis Research United Kingdom 
(ARUK) would also be interested in the findings. 
Feedback from the group was used to support future decisions regarding 
continuation of the pilot clinic. A leaflet was collaboratively produced with patients 
(appendix 13) to outline the links between RA and anxiety and depression, which 
included information on where patients could seek further help. The leaflet, which was 
approved by the RCGP SFB, was left for patients to access at the PIER. In addition, overall 
findings of the qualitative study were presented to the Haywood User Group.  
 
5.11 Conclusion                                                                                                       .    
 
A nurse-led annual review clinic provides a suitable forum for the discussion of 
comorbid anxiety and depression in patients with RA. There is need for education of 
people with RA about comorbid mood problems, hence patients have helped to 
collaboratively develop a leaflet, endorsed by the SFB, which is available for the public 
to access at a local rheumatology hospital educational resource.  
The annual review clinic has been commissioned to continue in the longer-term, 
with the aim of improving the recognition and management of comorbidities such as 
anxiety and depression in RA. 
 
5.12 Connection to subsequent studies                                                             .    
 
 
Within the next chapter I have aimed to build on the findings of my qualitative 
study, by determining the impact of anxiety in RA. I was led to focus on comorbid anxiety 
after hearing patients describe the multiple ways this had impacted on their help-
  158 
seeking behaviour, access to care and perceived response to RA treatments. From a 
review of the background literature, I had identified a lack of studies focusing on the 
impact of anxiety, with the majority reporting on the impact of depression in RA, hence 
I felt this would be an important area to investigate further. 
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6.0 SYSTEMATIC REVIEW 
 
6.1 Introduction                                                                                                       .    
 
As discussed in the background chapter (section 2.9.1), the link between 
rheumatoid arthritis (RA) and mental health problems is well established. The estimated 
prevalence of anxiety in people with RA is 13-20% (VanDyke et al., 2004; Isik et al., 2006; 
Covic et al., 2012), whilst prevalence estimates for depression vary from 16.8% when 
assessed by diagnostic interview, to 38.8% when determined using the Patient Health 
Questionnaire (PHQ)-9 (Matcham et al., 2013). These estimates are substantially higher 
than in the general adult population of England, in which the one-week prevalence of 
generalised anxiety disorder (GAD) and depression determined by screening questions, 
is 5.9% and 3.3% respectively (NatCen Social Research, 2014). Despite their frequency, 
comorbid anxiety and depression in people with RA are often under-recognised and 
under-treated (Cepoiu et al., 2007), contributing to increased morbidity and mortality 
(Ang et al., 2005).  
To date, most literature examining the impact of mood problems on quality of 
life (QoL) and disease activity in RA has focused on depression. As discussed in section 
2.9.1, several studies have shown depressive symptoms in people with RA to be 
associated with a significant reduction in QoL (Bazzichi et al., 2005; Senra et al., 2017), 
whilst a systematic review examining the impact of mood problems on disease activity, 
found that depression may be associated with increased disease activity in RA (Rathbun, 
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Reed & Harrold, 2013). Baseline depressive symptoms have also been associated with a 
reduced response to RA treatment over time (Matcham et al., 2018; Hider et al., 2009) 
and a lower disease remission rate (Cook et al., 2016). 
When the impact of anxiety in RA has been examined, this has often been in 
combination with depression (Matcham et al., 2016b). However, at least 40% of 
individuals with anxiety in the general population do not have comorbid depression 
(Kaufman & Charney, 2000). Anxiety has been linked to different help-seeking behavior 
when not associated with comorbid depression. A recent study found the severity of 
mood symptoms, determined using Becks͛ Anxiety Inventory ;BAIͿ and Becks 
Depression Inventory (BDI), to predict help-seeking behavior in individuals with anxiety 
alone, but not in those with a combination of anxiety and depression (Fine et al., 2018). 
In addition, evidence suggests the direct effect of anxiety on pain, is higher than that of 
depression (Smith & Zautra, 2008). It is possible that anxiety leads to increased physical 
arousal, increasing pain sensitivity or the interpretation of sensations as painful (Clark 
& Watson, 1991). Meanwhile, depression, through the absence of pleasure, may 
increase vulnerability to pain at times of stress (Smith & Zautra, 2008). Therefore, it can 
not be assumed that anxiety interacts the same as depression with QoL and disease 
activity in people with RA.  
In addition, although some options for the management of anxiety (Clinical 
Guideline (CG) 113) and depression (CG90) overlap, there are several key differences 
(NICE, 2011; NICE, 2009a). For example, the stepped care model for anxiety includes 
treatment options such as applied relaxation, and suggests a higher threshold for 
medication use than for depression. Consequently, it is important that anxiety is 
recognised, especially when it exists in isolation, to facilitate the provision of 
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appropriate treatment. Despite this, few studies have examined the impact of anxiety 
alone in people with RA. 
 
6.2 Aims and Objectives                                                                                        .    
 
The aim of this study was to understand the impact of anxiety on the QoL and 
disease activity of people with RA.  My objective was to perform a systematic review 
and meta-analysis, to determine the association between anxiety, and QoL and disease 
activity, in people with RA. 
6.3 Methods                                                                                                             .    
 
6.3.1 Systematic Review Protocol (PROSPERO) 
A systematic review protocol was established a priori for this review and 
registered with the international prospective register of systematic reviews, PROSPERO 
(number CRD42017062580) (Machin, 2018). The protocol is detailed in appendix 14. 
This contains a background to the review, specific objectives, eligibility and exclusion 
criteria for studies, the search strategy and review methods utilised. 
 
6.3.2 Search strategy and study eligibility 
A search strategy was developed using comprehensive text word searching of 
the title, abstract or keywords and database Subject Headings, combining terms for 
anxiety ;͞anxiety͟, ͞anxiolytic agent͟, ͞anxietΎ or anxious͟Ϳ and RA ;͞arthritis, 
rheumatoid͟ or ͞rheumatΎ adjϯ ;arthritiΎ or diseasΎ or conditionΎ or noduleΎͿ͟Ϳ.  
As it was anticipated that there would be a lack of eligible studies examining the 
primary outcome measures (section 6.3.3), the search was kept broad to capture as 
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many alternative descriptive terms for the outcomes of interest as possible, to be 
considered as additional outcome measures.  
Systematic searches were conducted in five electronic databases (Web of 
Science, PsycINFO (EBSCO), CINAHL (EBSCO), Embase (Ovid), Medline (Ovid)) from 
inception to February 2019, using customised search terms for each database (appendix 
15). In addition, a search for grey literature from across Europe was conducted using 
͞www.opengrey.eu͟.  
Grey literature is research that is either unpublished or has been published in a 
non-commercial form. Examples can include government reports, theses, dissertations, 
newsletters, policy statements and conference proceedings (Winters and Weir, 2017). 
Some grey literature sources such as doctoral theses can be more detailed than 
published articles, and often these can be available in advance of academic publications 
(Winters and Weir, 2017). Searching for grey literature helped to minimise potential 
publication bias. Publication bias occurs when the decision to publish or distribute 
research findings is based on the outcome of a study (Winters and Weir, 2017). 
Consequently, a grey literature search was included to facilitate a less biased, real world 
view of the interaction between anxiety and QoL or disease activity in RA. 
After completion of the database searches and removal of duplicate articles in 
refworks, unique citations were imported into Covidence, a review management 
software. Titles, abstracts and full texts were screened by paired independent reviewers 
(Dr Annabelle Machin and either Dr Ian Scott or Dr Randula Haththotuwa (see 
acknowledgements)) using pre-specified selection criteria. Inter-rater disagreement 
was minimal, with any disagreements resolved through discussion, re-examination of 
the article, or by the independent vote of a third reviewer (Dr Opeyemi Babatunde).  
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The reference lists of key papers were hand-searched to identify other relevant 
studies that hadn͛t been found during the initial database searches. Citation tracking of 
index papers was also used to identify any relevant related studies.  
All articles including adults (>18 years) with RA, which reported anxiety 
(separately from depression) and either QoL or disease activity outcome measures were 
included. Any study setting or design was included. The full inclusion and exclusion 
criteria are detailed in table 6.1. 
Table 6.1- Inclusion and Exclusion Criteria 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
x Population aged ш ϭϴ years with   
RA. 
 
x Exposure of anxiety. 
 
x People in the comparator/       
control group ;if anyͿ aged ш ϭϴ 
years with RA. 
 
x Primary outcome of short form   
(SF)-36 and/ or disease activity  
score in 28 joints (DAS28) and/        
or additional validated outcome 
measures for QoL or disease  
activity. 
x Any participants < 18 years. 
 
x Data not specific to anxiety and RA. 
 
x An interpreter could not be found 
for an article not written in the 
English Language. 
 
x Efforts to retrieve a full text were 
unsuccessful and the abstract 
contained insufficient data. 
 
6.3.3 Outcome measures 
6.3.3.1 Disease activity  
The Disease Activity Score in 28 joints (DAS28) (Prevoo et al., 1995) was the 
primary outcome measure for disease activity, though other validated measures of 
disease activity were also included. DAS28 is a composite score comprising of 
biochemical measures (erythrocyte sedimentation rate (ESR) or C-reactive protein 
(CRP), clinician assessment of disease activity via a 28 swollen joint count (SJC) and 
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tender joint count (TJC), and self-report via a visual analog scale (VAS), to determine a 
patients͛ perceived disease activity). The DAS28 score is used to monitor RA activity, 
gauge response to therapy and determine treatment pathways; particularly access to 
biologic treatment in the United Kingdom (UK). On commencing treatment with a 
disease modifying anti-rheumatic drug (DMARD), clinicians monitor DAS28 scores over 
time, aiming for remission (a DAS28 score <2.6), or low disease activity if remission is 
not possible despite appropriate escalation of treatment (DAS28 <3.2) (NICE, 2018). 
DAS28 was chosen as the primary outcome as it is the most widely used and 
reported outcome measure for disease activity in RA. However, DAS28 has several 
disadvantages. For example, the 28 joint counts used as part of the DAS28 do not include 
the feet, meaning those with significant foot synovitis may have falsely low scores. 
However, individuals with significant foot involvement often have hand symptoms 
which are included in the score, whilst exclusion of the feet makes the score more 
efficient to complete. In addition, joint damage in the feet can often be a chronic 
problem, hence not indicative of ongoing disease activity, meaning examination of the 
feet is a less accurate way of assessing treatment response. A further potential 
disadvantage of DAS28 is that scores could be misleadingly low if an individuals͛ 
inflammatory markers don͛t rise significantly during a disease flare. Also, when it is 
unclear to a clinician whether a joint is swollen or tender, this could lead to significant 
variation in the score (Fransen & van Riel, 2009). 
 
6.3.3.2 Quality of life  
QoL is a multi-dimensional concept used to describe an individual͛s perceptions, 
satisfaction, and evaluation of different aspects of their lives, such as physical health, 
functioning, emotional wellbeing, social life and relationships. Health-related (HR)QoL 
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is important for measuring the impact of disease and subjective wellbeing (Carr et al., 
2015).  
The short form (SF)-36 was the primary outcome measure used for QoL in this 
review, though additional validated QoL outcome measures were included. SF-36 is a 
set of patient self-reported QoL measures (Ware & Sherbourne, 1992). The SF-36 
assesses eight health concepts: 1) limitations in physical activities; 2) limitations in social 
activities; 3) limitations in usual role activities because of physical health problems; 4) 
bodily pain; 5) general mental health; 6) limitations in usual role activities because of 
emotional problems; 7) vitality; and 8) general health perceptions. These eight scales 
can be aggregated into two summary measures, the Physical Component Summary 
(PCS) and Mental Component Summary (MCS) scores. 
The PCS and MCS scores are calculated by weighting, then summing the 8 
original health domains. Weights are gained from factor analysis of datasets gained from 
general population surveys (Ware, Kosinski & Keller, 1994). Domain scores are weighted 
due to the 8 health domains being significantly intercorrelated, with changes to physical 
dimensions impacting on dimensions measuring mental health, and vice versa (Ware et 
al., 1995). Therefore, weighting the 8 health domains, helps to take account of how 
changes in a primarily physical domain impact on mental health, whilst conversely 
accounting for the impact of changes in a predominantly mental health domain on 
physical health. 
The SF-36 was chosen due to it being acceptable to patients, having high internal 
validity and being more precise than the SF-12 and SF-8 health surveys (Brazier et al., 
1992). However, as a consequence of being more detailed, SF-36 can take longer to 
complete, whilst it also contains no variable for sleep. An alternative would have been 
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the Nottingham Health Profile, though this can be less sensitive to lower levels of 
dysfunction (Jenkinson, Coulter and Wright, 1993), whilst EuroQol (EQ)-5D can be less 
sensitive to variations in health status, when compared to the SF-36 (Liao, Tan and Yang, 
2016).  
One study assessed the reliability and responsiveness of different QoL 
instruments used in people with RA. When the reliability of different QoL instruments 
was evaluated, by agreement and internal consistency, the RA-QoL scale was found to 
be more reliable than the SF-36 in people with RA. However, components of the SF-36 
were more responsive to change (Linde et al., 2008). The SF-36 is widely used and 
reported in the literature as a measure of QoL, enabling comparison with different 
conditions, hence this was used as the primary outcome measure for QoL. 
 
6.3.4 Data extraction  
A customised and piloted data extraction tool was used to extract relevant data 
from the included articles. Extracted data included country of origin, study design, 
methodology, sample characteristics, main findings and relevant statistical measures. 
Data extraction was completed independently by AM and RH, and any disagreements 
resolved through discussion. Where only abstracts were available, or insufficient 
information was reported, authors were contacted via email for further details.  
 
6.3.5 Study quality assessment 
For this systematic review, a quality assessment tool for non-randomised studies 
was required, as eligible studies were anticipated to be either cohort or cross-sectional 
studies. 
Deeks et al. (2003), systematically reviewed 182 tools for assessing the 
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methodological quality of non-randomised studies. From this, six tools were identified 
as potentially useful for systematic reviews. However, not all of these tools adequately 
reviewed how study participants were allocated into groups, hence did not assess the 
risk of selection bias. In addition, several of the tools were not suitable to use for 
different study designs. The two most useful tools identified were the Downs and Black 
instrument (Downs and Black, 1998) and the Newcastle Ottawa Scale (NOS) (Wells et 
al., 2019). 
The Downs and Black checklist includes 27 questions and enables articles to be 
assigned a numeric score for study quality out of 30. Whilst detailed, when used, 
reviewers have reported it to be difficult to apply and time consuming to use 
(MacLehose et al., 2000). 
The NOS comprises an eight-item scale, with versions for cohort, case-control 
and cross-sectional studies (Wells et al., 2019). Domains of selection, comparability and 
outcome or exposure are evaluated, with stars allocated for features of quality, up to a 
maximum of nine. Higher scores indicate an article has better methodological aspects. 
However, the ability of the NOS to distinguish between high and low quality studies has 
been questioned (Stang, 2010), whilst it has also been found to have low reliability 
between individual reviewers, meaning scores can vary considerably dependent on the 
reviewer (Hartling et al, 2013). However, it has been found to be simple to use and 
interpret, hence has been recommended by the Cochrane Collaboration (Higgins & 
Green, 2011).  
An alternative would have been the RTI Item Bank on Risk of Bias and Precision 
of Observational Studies. Consisting of 29 multiple choice items within 11 domains, the 
RTI Item Bank can be applied to multiple study designs (Viswanathan & Berkman, 2012). 
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Although it can be useful at detecting variation in study quality, it has been described as 
more burdensome to use than the NOS (Margulis, 2014), whilst many aspects of the RTI 
item bank also overlap with the NOS.  
Another option would have been the Critical Appraisal Skills Programme 
checklist, a set of eight tools designed to assess the quality of different study types 
(CASP, 2018). The tool for cohort studies includes 12 questions which encourage the 
reviewer to critically appraise the study under review. However, unlike the NOS, there 
is no tool adapted for use in cross-sectional studies.  
Due to the advantages of the NOS above other tools, this was used to assess the 
quality of studies within this review. The quality assessment criteria for both cohort and 
cross-sectional studies are listed in table 6.2. 
 
Table 6.2- NOS cohort and cross-sectional study quality assessment criteria 
 
Newcastle Ottawa Scale Study Criteria 
Cohort study Cross-sectional study 
x Representativeness of the 
exposed cohort 
 
x Selection of the non-exposed 
cohort 
 
x Ascertainment of the exposure 
 
x Comparability of the cohorts 
 
x Assessment of the outcome 
 
x Length of follow-up 
 
x Adequacy of follow-up cohorts 
x Representativeness of the 
sample 
 
x Sample size 
 
x Non-respondents 
 
x Ascertainment of the exposure 
 
x Controlling for confounding 
factors 
 
x Assessment of the outcome 
 
x Statistical analysis 
 
 
  170 
6.3.6 Analysis                                                                                                                        
 
6.3.6.1 Meta-analysis 
Meta-analysis is a method used to combine the results of different trials in order 
to obtain a quantified synthesis. As the size of individual studies can sometimes be too 
small to reliably detect an outcome, meta-analysis can be used to pool the results of 
studies and increase the power of statistical analyses (Borenstein et al. 2009). However, 
when combining the results from a group of studies, the individual studies need to be 
similar enough so that the combined study estimate provides a meaningful description 
of the set of studies. Some variation between studies due to chance is expected, though 
excessive variation, known as statistical heterogeneity needs to be assessed for 
(Borenstein et al., 2009). 
A meta-analysis of quantitative data on the primary outcome measures was 
performed. Due to differences in the reporting of SF-36, for meta-analysis, correlation 
coefficients between anxiety and the PCS or ͞ physical functioning͟ subscale scores were 
pooled to give an overall impression of the association between anxiety and physical 
QoL. Additionally, correlation coefficients between anxiety and the MCS or ͞mental 
health͟ subscale scores were pooled to give an overall value for the association between 
anxiety and mental QoL. 
To pool the estimates of the correlation coefficient values, two methods were 
considered; a fixed effects and random effects model (DerSimonian & Laird, 1989). A 
fixed effects model accounts for within study variability using the inverse variance 
method. This gives more weight to studies that have small variances, using the 
reciprocals of study variances (standard error squared) as study weights. Therefore, the 
fixed effect model is used when there is little evidence of heterogeneity. 
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The random effects model accounts for variance both within and between 
individual studies, hence is used when a large degree of heterogeneity is noted. The 
method used within the random effects model is a variation of the inverse variance 
approach, with weight given to studies according to the reciprocals of the sum of within 
and between study variances. 
As there was evidence of significant heterogeneity between the studies, a 
random effects model was used (DerSimonian & Laird, 1989). The ʖ2 statistic was used 
to assess for the presence of heterogeneity. Due to the sampling distribution of 
correlation coefficients not being normally distributed, Fisher͛s z͛ transformation was 
used to calculate a confidence interval on the population value of Pearson͛s correlation.  
Using atanh command in Stata (version 14.0), correlation coefficients (r) were 
converted to Fisher͛s z scores r;z͛Ϳ and an associated standard error calculated using the 
standard formula SE΀r;z͛Ϳ΁с я;ϭͬ;n-ϯͿͿ. The r;z͛Ϳ values were pooled using the metan 
command in Stata, and subsequently transformed back to obtain a pooled r-value using 
tanh command in Stata, then plotted together with study-specific estimates. The 
Cochran Q statistic was used to assess for the presence of heterogeneity. In addition, 
the I2 statistic (DerSimonian & Laird, 1989; Higgins et al., 2003) was calculated to 
examine the proportion of total variation in study estimates which could be explained 
by heterogeneity. 
As meta-analysis could only be used to synthesise the quantitative results for 
primary outcome measures, a narrative synthesis was utilised to summarise the overall 
study results, including additional outcome measures. 
 
 
 
  172 
6.3.6.2 Narrative Synthesis 
Narrative synthesis is an approach to the review and synthesis of findings from 
multiple studies. Words and text are used to explain the findings of included studies. A 
narrative synthesis approach was chosen as it was anticipated that there would be a 
variety of data including qualitative and quantitative findings to synthesise. In addition, 
this method was chosen as it was felt the search would yield a variety of additional 
outcome measures that could not be synthesised using a purely statistical meta-
analysis.  
A common criticism of narrative synthesis is that it is subject to author 
interpretation. Therefore, guidance funded by the Economic and Social Research 
Council of the UK was followed (Popay et al., 2006). 
Extracted data were synthesised using a narrative synthesis framework in four 
stages: 
1. An idea of how anxiety relates to QoL and disease activity was developed, to 
inform decisions about the review question, the types of studies to include, and 
to contribute to the interpretation of findings.  
2. A preliminary synthesis of the findings of included studies was developed to 
organise findings. After a summary of all studies was tabulated, separate data 
analysis of primary and additional outcome measures for QoL and disease 
activity was performed. 
3. Relationships between the studies were explored. Potential sources of 
heterogeneity were considered, that could explain differences in study findings.  
4. The strength of evidence for drawing conclusions and generalising findings to 
different populations was assessed, considering the methodological quality of 
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included studies and the overall evidence in relation to each of the specified 
outcomes.  
 
6.4 Results                                                                                                                .    
 
A hypothesis that anxiety would be associated with reduced QoL and increased 
disease activity was developed. Due to an anticipated lack of literature, all study types 
were considered, with primary and additional validated outcome measures for each 
outcome analysed separately, as outlined below.  
6.4.1 Summary of included studies 
Figure 6.1 shows the flow of studies within the review (p174). A total of 20 final 
studies were identified for inclusion (Al-Fadl et al., 2014; Kojima et al., 2009b; Nas et al., 
2011; Ozcetin et al., 2007; Alpi et al., 2017; Celiker & Borman, 2001; Grosso et al., 2015; 
Ichikawa et al., 1995; Karahan et al., 2016; Matcham et al., 2016a; Miwa et al., 2002; 
Mok, Lock & Cheung, 2012; Overman et al., 2012; Wan et al., 2015; Zulgerel & 
NandinErdene, 2014; Kuijper et al., 2018; Dyball et al., 2018; Sergeant et al., 2018; 
Ruhaila & Cheng, 2018; Fragoulis et al., 2018).  
The characteristics of the 20 studies included in the final analysis are summarised 
in 3 tables. Table 6.3a (prospective cohort studies) (p175) and 6.3b (cross-sectional 
studies) (p176), contain studies reporting disease activity outcomes, whilst table 6.4 
summarises the studies reporting QoL outcomes (p177-178), which are all cross-
sectional. Significant results are highlighted in bold on the right of each table in the 
͞findings͟ column, with the significance level indicated in the results column, using 1-3 
asterix. In the footnotes below each table, abbreviations are given in full, quality 
assessment scores described and the interpretation of significance levels explained. 
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Figure 6.1- Study Flow 
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Table 6.3a- Sum
m
ary of characteristics of prospective cohort studies reporting disease activity outcom
e m
easures 
 
First Author/ 
Year/Country 
Sam
ple Size 
(m
ale:fem
ale) 
M
ean 
Age 
Ascertainm
ent 
of anxiety 
O
utcom
e 
m
easures 
Results 
Study 
Q
uality
1 
Findings 
Dyball, 2018. 
(Abstract) UK 
2919  
(701: 2218) 
57.3 
HADS-A 
DAS28 
Baseline HADS-A and change in DAS28 at 6 
m
onths.  
Adjusted b=0.01 (n.s.), 95%
 CI, -0.01, 0.04. 
6 
Baseline anxiety associated w
ith sm
aller 
im
provem
ents in DAS28 at 6 m
onths, not 
significant. 
Fragoulis, 2018. 
(Abstract) UK 
848 
(gender not 
reported) 
Not 
reported 
HADS-A 
DAS28 
HADS-A and DAS 28 at: 
    -baseline r=no value given*** 
    -6 m
onths r=0.230*** 
    -12 m
onths r=0.217*** 
4 
Baseline anxiety correlated w
ith disease 
activity at baseline, 6 and 12 m
onths, 
significant. 
Kuijper, 2018. 
Netherlands. 
281  
(91:190) 
53.0 
HADS-A 
DAS28 
HADS-A and DAS28 at:  
3 m
onths, b=0.043**, 95%
CI, 0.013, 0.073 
9 m
onths, b=0.017(n.s.), 95%
CI, 0.010,0.044 
15 m
onths, b=0.012(n.s.), 95%
CI, -0.020, 0.043 
7 
Anxiety associated w
ith increased disease 
activity, significant at 3 m
onths, non-
significant at 9 and 15 m
onths. 
M
atcham
, 
2016a.   
UK
 
56  
(12:44) 
53.6 
HADS-A 
DAS28  
Anxiety and DAS28 
Baseline, r= 0.29 *  
7 
Anxiety correlated w
ith increased disease 
activity at baseline, significant. 
Baseline anxiety and DAS28 at 1 year follow
 up,  
 r= 0.33* 
Baseline anxiety correlated w
ith increased 
disease activity at 1 year, significant. 
unadjusted b= 0.04*. 95%
 CI, 0.00, 0.07. 
Adjusted b = 0.02 (n.s.), 95%
 CI, 0.00, 0.05.  
Anxiety associated w
ith disease activity at 
1 year, non-significant w
hen adjusted. 
Overm
an, 2011.  
Netherlands 
545 (168:377) 
56.0 
10 item
 anxiety 
scale 
Thom
pson 
Articular Index 
Anxiety and Thom
pson Articular Index  
b(SE)=55.1736 (21.0731) ** 
6 
Anxiety is associated w
ith m
ore sw
ollen, 
tender joints, significant. 
ESR 
Anxiety and ESR 
b(SE) =0.2448 (0.0759) ** 
Anxiety is associated w
ith increased 
inflam
m
ation, significant. 
Sergeant, 2018. 
UK 
1050  
(343:707) 
59.0 
HADS-A 
Non-response 
to treatm
ent  
HADS-A and non-response (im
provem
ent in DAS28 
чϬ.ϲͬ stopped due to inefficacyͿ at 6 m
onths 
-M
ultivariable analysis 
OR (95%
CI) =1.07 (1.03, 1.12)** 
7 
Higher baseline anxiety predicts non-
response (reduced im
provem
ent in 
disease activity in response to 
treatm
ent), significant. 
 r = pearsons correlation coefficient, b = m
ultiple regression coefficient, CI= confidence interval, SE= standard error, O
R= odds ratio, SD= standard deviation.  
n.s.= not significant (p>0.05), *(p<0.05), ** (p<0.01), ***(p<0.001) 
DAS28= Disease Activity Score in 28 Joints, ESR= Erythrocyte Sedim
entation Rate, HADS-A= Hospital Anxiety and Depression Score, for anxiety. 
1 Q
uality rated out of 9 using New
castle Ottaw
a Scale: 0ʹ2 = low
 quality, 3ʹ6 = m
edium
 quality and 7ʹ9 = high quality
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Table 6.3b- Sum
m
ary of characteristics of cross-sectional studies reporting disease activity outcom
e m
easures 
   r= pearsons correlation coefficient, SD= standard deviation, n.s.= not significant (p>0.05), *(p<0.05), ** (p<0.01), ***(p<0.001) 
BAIс Beck͛s A
nxiety Inventory, CRP= C-Reactive Protein, DAS28= Disease Activity Score in 28 Joints, DASS= Depression, Anxiety and Stress Scale, LAI= Lansbury͛s Articular Index, HADS-A= 
Hospital Anxiety and Depression Score (for anxiety), HAM
-A
с H
am
ilton͛s A
nxiety Rating Scale, SJC= Sw
ollen Joint Count, TJC= Tender Joint Count, VAS= Visual Analogue Scale 
 
1 Q
uality rated out of 9 using New
castle Ottaw
a Scale: 0ʹ2 = low
 quality, 3ʹ6 = m
edium
 quality and 7ʹ9 = high quality.
First Author/ 
Year/Country 
Sam
ple Size 
(m
ale:fem
ale) 
M
ean 
Age 
Ascertainm
ent 
of anxiety 
O
utcom
e 
m
easures 
Results 
Study 
Q
uality
1 
Findings 
Al-Fadl, 2014.  
Egypt 
26   
(8:18) 
43.4 
HAM
-A 
DAS28 
 
HAM
-A and DAS28  
r= 0.47* 
5 
Anxiety correlated w
ith increased disease activity, 
significant. 
Grosso, 2015. 
(Abstract)  Italy
 
200  
(29:171) 
62.4 
HADS-A 
DAS28  
 
RA and Anxiety vs. RA and no m
ood problem
.  
M
ean DAS28(SD): 3.38(1.18) vs. 2.48(0.78) ** 
5 
Patients w
ith anxiety have increased disease 
activity com
pared to those w
ithout anxiety, 
significant. 
Ichikaw
a, 
1995.  
Japan 
92  
(16:76) 
53.4 
BAI 
Pain VAS 
Anxiety and Pain VAS  
r=0.432 *** 
5 
Anxiety correlated w
ith increased pain, significant. 
LAI 
Anxiety and LAI 
r=0.237 * 
Anxiety correlated w
ith increased disease activity, 
significant. 
Karahan, 2016.  
Turkey
 
148  
(32:116) 
51.1 
Zung͛s self 
rating anxiety 
scale 
DAS28 
BAI and DAS28 
r=0.159, (n.s.) 
5 
Anxiety correlated w
ith increased disease activity, 
non-significant. 
Kojim
a, 2009b.  
Japan 
120  
(22:98) 
57.7 
HADS-A 
SJC, TJC, CRP, 
Physicians͛ 
global 
assessm
ent 
HADS-A and disease activity (com
posite score 
of SJC, TJC, CRP, Physicians͛ global 
assessm
ent) Factor loading -0.10 (n.s.) 
6 
Relationship betw
een anxiety and disease activity 
non-significant. 
M
iw
a, 2002.  
Japan 
82  
(20:62) 
62.0 
HADS-A 
VAS 
Anxiety and VAS 
(a) In group w
ith m
ean activity <0.5, 
r=0.2935*  
(b) In group w
ith m
ean activity >=0.5,  
r=-0.0269 (n.s.) 
4 
Anxiety correlated w
ith increased pain. Significant 
in people w
ith low
er m
ean activity, non-significant 
in people w
ith higher m
ean activity.  
Ruhaila &
 
Cheng, 2018. 
M
alaysia 
192 
(22:167) 
49.6 
DASS 
DAS28 
DASS (21) and DAS28 
r=0.233** 
5 
Anxiety correlated w
ith increased disease activity, 
significant. 
Zulgerel,2014 
(Abstract)  
Russia 
51  
(2:49) 
43.0 
Spielberg 
Chennai Test 
DAS28 
Anxiety and DAS28  
r=0.126 (n.s.) 
1 
Anxiety correlated w
ith increased disease activity, 
non-significant. 
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Table 6.4- Sum
m
ary of characteristics of studies reporting Q
oL outcom
e m
easures (all cross-sectional) 
 
First Author/ 
Year/Country 
Sam
ple 
Size  
(m
ale: 
fem
ale) 
M
ean 
Age 
Ascertainm
ent 
of anxiety 
Outcom
e 
m
easures 
Results 
Study 
Q
uality 
1 
Study findings 
Al-Fadl, 2014.  
Egypt 
26  
(8:18) 
43.4 
HAM
-A 
PCS/ M
CS 
of SF-36 
Anxiety and PCS, r= -0.38 * 
Anxiety and M
CS, r= -0.34 * 
5 
Anxiety correlated w
ith low
er physical 
and m
ental Q
oL, significant. 
Alpi, 2016.  
Colom
bia 
62  
(3:59) 
59.7 
HADS-A 
Q
oL-RA 
scale 
Anxiety and Q
oL-RA scale, r=-0.644 ** 
Anxiety and Q
oL-RA sub-scores; 
-Physical ability, r=-0.492 **  -Support, r=-0.454 ** 
-Pain, r=-0.489 *** -Tension, r=-0.581 ** -Health, r=-0.624 **                 
-Arthritis, r=-0.510 ** -Support, r=-0.593 ** -M
ood, r=-0.674 ** 
5 
Anxiety correlated w
ith reduced Q
oL, 
significant. 
 
Anxiety and Q
OL-RA, 
adjusted b=-0.453 *** 
Anxiety has a negative association w
ith 
Q
oL, significant. 
Celiker, 2001.  
Turkey 
20  
(0:20) 
46.6 
STAI  
LSI 
Anxiety and LSI. 
A- State (current anxiety), r=-0.5005 * 
A-Trait (long-standing anxiety), r=-0.5103 (n.s.) 
3 
Anxiety correlated w
ith reduced life 
satisfaction, significant for current 
anxiety, non-significant in long-
standing anxiety. 
Karahan, 2016.  
Turkey 
148 
(32:116) 
51.1 
BAI 
W
HOQ
oL-
BREF 
 
BAI and W
HOQ
ol-BREF 
-M
ild anxiety - (n.s.) 
-M
oderate/ severe anxiety - * 
5 
Non-significant correlation betw
een 
m
ild anxiety and w
orse Q
oL, significant 
in m
oderate to severe anxiety. 
Kojim
a, 2009b.  
Japan 
120  
(22:98) 
57.7 
HADS-A 
SF36 
(PCS/ 
M
CS)  
HADS-A and PCS of SF-36, r= -0.25 ** 
HADS-A and M
CS of SF-36, r= -0.51 *** 
6 
Anxiety correlated w
ith low
er physical 
and m
ental health Q
oL scores, 
significant. 
M
ok, 2012.  
China 
200 
(42:158) 
51.4 
Chinese Bilingual 
Structured 
Interview
 
SF-36 
Anxiety vs no psychiatric disorders, 
m
ean (SD) SF36= 31.2 (12.9)*** vs. 56.6 (20)** 
 
6 
Anxiety group, reduced Q
oL com
pared 
to group w
ithout psychiatric disorders, 
significant. 
Nas, 2011.  
Turkey 
421 
(72:349) 
50.15 
(at risk 
of 
anxiety 
group) 
HADS-A 
SF-36  
 
Anxiety and SF-36 subscales. 
-Physical function, r=-0.28 *** -Vitality, r=-0.40 *** 
-Social function=-0.36 *** -General health, r=-0.29 *** 
-Physical role, r=-0.24 ***   -M
ental health, r=-0.48 *** 
-Em
otional role, r=-0.23 ***  -Bodily pain, r=-0.32 *** 
 
6 
Anxiety is correlated w
ith reduced Q
oL 
for all SF-36 subscales, significant. 
  
178 
Anxiety (n=166) vs. w
ithout anxiety (n=255).  SF-36 subscales, 
adjusted OR (95%
 CI), significant in bold. 
Physical function, 0.99 (0.98, 1.00), Physical role, 0.99 (0.99, 1.00) 
Bodily pain, 0.99 (0.97, 1.00), General health, 0.99 (0.98, 1.00) 
Vitality, 0.972 (0.961, 0.984), Social functioning, 0.984 (0.975, 0.995) 
M
ental health, 0.97 (0.95, 0.98), Em
otional role, 0.99 (0.99, 1.00) 
 
The Q
oL of RA patients w
ith, com
pared 
to patients w
ithout anxiety, is 
significantly w
orse on m
ost SF-36 
subscales apart from
 physical role and 
bodily pain. 
RA-Q
oL 
Anxiety (n=166) vs. w
ithout anxiety (n=255). 
RA-Q
oL, OR (95%
 CI) = 1.060 (1.032,1.088) 
The Q
oL of RA patients w
ith, com
pared 
to w
ithout anxiety is w
orse, significant. 
NHP 
Anxiety (n=166) vs. w
ithout anxiety (n=255), 
NHP subscales, OR (95%
 CI).  Significant in bold (all). 
Physical m
obility, 1.017 (1.009, 1.025), Energy, 1.015 (1.009, 1.021) 
Social isolation, 1.017 (1.011, 1.023), Pain, 1.011 (1.004,1.018), 
Em
otional reaction, 1.026 (1.019, 1.033),  Sleep, 1.018 (1.011, 1.025) 
The Q
oL of RA patients w
ith, com
pared 
to patients w
ithout anxiety, is w
orse on 
all NHP subscales, significant. 
Ozcetin, 2007
 
Turkey 
34  
(8:26) 
50.4 
BAI 
SF-36 
Beck anxiety scores and SF-36 subscale scores 
Physical role, r= -0.451 **, Bodily pain, r= -0.583 *** 
General health, r= -0.706 ***, Vitality, r= -0.737 *** 
Social functioning, r= -0.718 ***, M
ental health, r=- -0.655 *** 
Em
otional role, r= -0.326 (n.s.) 
6 
Anxiety correlated w
ith reduced Q
oL 
scores. Statistically significant for m
ost 
SF-36 subscales except em
otional role. 
W
an, 2015  
Singapore 
108  
(22:86) 
56.4 
HADS-A 
HRQ
oL 
(EQ
-5D) 
Anxiety and HRQ
oL using EQ
-5D, r=-0.58** 
 
8 
Anxiety is correlated w
ith reduced Q
oL, 
significant. 
 r = Pearsons correlation coefficient, b = m
ultiple regression coefficient, CI= confidence interval, SE= standard error, O
R= odds ratio, SD= standard deviation, n.s.= not significant (p>0.05), 
*(p<0.05), ** (p<0.01), ***(p<0.001) 
 BAIс Beck͛s A
nxiety Inventory, EQ
-5D= EuroQ
ol 5-Dim
ension Scale, HADS-A= Hospital Anxiety and Depression Score (anxiety scale), HAM
-A= Ham
ilton Anxiety Rating Scale, HRQ
oL= Health 
related quality of life, LSI= Life Satisfaction Index, M
CS= M
ental Com
ponent Sum
m
ary Score of SF-36, NHP= Nottingham
 Health Profile, PCS= Physical Com
ponent Sum
m
ary Score of SF-36, 
RA= Rheum
atoid arthritis, STAI= Spielberger State and Trait Anxiety Inventory, SF-36= Short Form
 36, W
HO
Q
oL-BREF= W
orld Health Organisation Q
uality of Life-BREF, Q
oL-RA scale= Q
uality 
of life rheum
atoid arthritis scale. 
 1 Q
uality rated out of 9 using New
castle Ottaw
a Scale: 0ʹ2 = low
 quality, 3ʹ6 = m
edium
 quality and 7ʹ9 = high quality
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Included studies involved a total of 7,455 patients with a mean age of 53.5 years. 
The overall proportion of females was 80%. Sample sizes ranged from 20-2919 with a 
mean of 372. From the 20 studies, 16 were full text articles (Al-Fadl et al., 2014; Kojima 
et al., 2009b; Nas et al., 2011; Ozcetin et al., 2007; Alpi et al., 2017; Celiker & Borman, 
2001; Ichikawa et al., 1995; Karahan et al., 2016; Matcham et al., 2016a; Miwa et al., 
2002; Mok, Lok & Cheung, 2012; Overman et al., 2012; Wan et al., 2015; Kuijper et al., 
2018; Sergeant et al., 2018; Ruhaila & Cheng, 2018), whilst 4 were conference abstracts 
(Grosso et al., 2015; Zulgerel & NandinErdene, 2014; Dyball et al., 2018; Fragoulis et al., 
2018).  
The majority, 14, were cross-sectional in design (Al-Fadl et al., 2014; Kojima et 
al., 2009b; Nas et al., 2011; Ozcetin et al., 2007; Alpi et al., 2017; Celiker & Borman, 
2001; Grosso et al., 2015; Ichikawa et al., 1995; Karahan et al., 2016; Miwa et al., 2002; 
Mok, Lok & Cheung, 2012; Wan et al., 2015; Zulgerel et al., 2014; Ruhaila & Cheng, 
2018), whilst 6 were prospective cohort studies (Matcham et al., 2016a; Overman et al., 
2012; Kuijper et al., 2018; Dyball et al., 2018; Sergeant et al., 2018; Fragoulis et al., 2018).  
In terms of outcomes, 11 of the studies assessed disease activity only (Grosso et 
al., 2015; Ichikawa et al., 1995; Matcham et al., 2016a; Miwa et al, 2002; Overman et 
al., 2012; Zulgerel & NandinErdene, 2014; Kuijper et al., 2018; Dyball et al., 2018; 
Sergeant et al., 2018; Rahaim et al., 2018; Fragoulis et al., 2018), 6 assessed QoL only 
(Nas et al., 2011; Ozcetin et al., 2007; Alpi et al., 2017; Celiker & Borman, 2001; Mok, 
Lok & Cheung, 2012; Wan et al., 2015) and 3 assessed both disease activity and QoL (Al-
Fadl et al., 2014; Kojima et al., 2009b; Karahan et al., 2016). The Hospital Anxiety and 
Depression Scale (HADS) was the most frequently used tool to identify anxiety. 
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The primary outcome measure for disease activity, DAS28, was reported in 9 
studies. Additional outcome measures for disease activity across 4 studies included the 
Lansbury Articular Index (LAI), Thompson Articular Index, Pain VAS and a composite 
score comprising of CRP, SJC, TJC and a Physician͛s global assessment. 
The primary outcome measures for QoL, SF-36 or the PCS, MCS or subscale 
scores of SF-36, were reported in 5 studies. Other outcome measures for QoL reported 
in 5 studies, included Health Related QoL (HRQoL) using the EuroQol 5-Dimension Scale 
(EQ-5D), Life-Satisfaction Index (LSI), Nottingham Health Profile (NHP), QoL-RA scale and 
World Health Organisation QoL- BREF (WHOQoL-BREF). 
 
6.4.2 Methodological Quality Assessment for included studies 
Quality assessment using the NOS is presented in tables 6.3a (p175), 6.3b (p176) 
and 6.4 (p177), whilst additional details are reported in appendix 16.   
 Most articles were of moderate methodological quality. Many lacked detail on 
the representativeness of their RA sample (Al-Fadl et al., 2014; Celiker and Borman, 
2001; Ichikawa et al., 1995; Karahan et al., 2016; Kojima et al., 2009b; Miwa et al., 2002; 
Zulgerel and NandinErdene, 2014), or on non-responders (Al-Fadl et al., 2014; Alpi et al., 
2017; Celiker and Borman, 2001; Dyball et al., 2018; Fragoulis et al., 2018; Grosso et al., 
2015; Ichikawa et al., 1995; Karahan et al., 2016; Kojima et al., 2009b; Kuijper et 
al.,.2018; Miwa et al., 2002; Mok, Lok & Cheung, 2012; Nas et al., 2011; Ozcetin et al., 
2007; Sergeant et al., 2018; Zulgerel and NandinErdene, 2014), whilst several studies 
also had small sample sizes, of 20 (Celiker and Borman, 2001), 26 (Al-Fadl et al., 2014; 
Nas et al., 2011) and 34 participants (Ozcetin et al., 2007), which limited generalisability.  
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Most studies reported using validated tools to ascertain the exposure, anxiety. 
The HADS was most frequently used, whilst other tools used included Beck͛s Anxiety 
Inventory (BAI), the Spielberger State and Trait Anxiety Inventory (STAI), the Hamilton 
Anxiety Rating Scale (HAM-AͿ and Zung͛s self-rating anxiety scale. One study used the 
Speilberg Chennai test (Zulgerel and NandinErdene, 2014). This non-validated tool was 
not described, making it difficult to determine its͛ diagnostic accuracy and whether its͛ 
use could have introduced potential bias. Another study used the Chinese Bilingual 
Studied Interview (Mok, Lok & Cheung, 2012) to ascertain the exposure. Although this 
tool is not widely utilised, it involves an interview being conducted by a psychiatrist, 
hence is likely to have a high diagnostic accuracy. 
Some studies did not report if they controlled for potential confounding factors, 
which could have introduced bias (Alpi et al., 2017; Fragoulis et al., 2018; Miwa et al., 
2002; Zulgerel and NandinErdene, 2014). All cross-sectional studies apart from one, a 
conference abstract (Zulgerel and NandinErdene, 2014), included a description of their 
approach to statistical analysis, reporting confidence intervals and p-values as 
appropriate. Across the 6 included cohort studies, the length of follow-up ranged from 
6 months to 5 years (Dyball et al., 2018; Fragoulis et al., 2018; Kuijper et al., 2018; 
Matcham et al., 2016a; Overman et al., 2012; Sergeant et al., 2018), sufficient time 
periods to determine the association between anxiety and disease activity. 
 
6.4.3 Association between anxiety and disease activity in RA 
6.4.3.1 Anxiety and DAS28 
The overall findings of the 9 studies that reported the association between 
anxiety and DAS28, the primary outcome measure for disease activity, are summarised 
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in table 6.3a (p175) and 6.3b (p176). These included 5 cross-sectional (Al-Fadl et al., 
2014; Grosso et al., 2015; Karahan et al., 2016; Ruhaila & Cheng, 2018; Zulgerel and 
NandinErdene, 2014) and 4 cohort studies (Dyball et al., 2018; Fragoulis et al., 2018; 
Kuijper et al. 2018; Matcham et al., 2016a), involving a total of 7,455 participants.  
All 5 cross-sectional studies found anxiety to be associated with an increased 
DAS28 score, although this was only statistically significant in 3 studies (Al-Fadl et al, 
2014; Grosso et al., 2015; Ruahila & Cheng, 2018). From the 4 cohort studies, 2 found a 
statistically significant association between baseline anxiety and increased DAS28 at 6 
and ϭϮ months͛ follow-up (Matcham et al., 2016a; Fragoulis et al., 2018). One study 
found a statistically significant association between baseline anxiety and increased 
DAS28 at 3 months, but not at 9 and 15 months (Kuijper et al., 2018), whilst another 
study found an association between anxiety and increased DASϮϴ at ϲ month͛s follow-
up, that was not statistically significant (Dyball et al., 2018). 
One further study reported DAS28 in terms of non-response to treatment with 
methotrexate, being indicated as an improvement in DAS28 by чϬ.ϲ or treatment 
discontinuation due to inefficacy (Sergeant et al., 2018). On multivariable analysis, 
higher baseline anxiety was found to significantly predict non-response to treatment 
after 6 months, odds ratio (OR) (95% confidence interval (CI)) = 1.07 (1.03, 1.12). 
In addition, 4 studies also reported the subcomponents of DAS28, including the 
Patient Global Assessment (PtGA) or Pain VAS, TJC, SJC and ESR or CRP (Grosso et al., 
2015; Matcham et al., 2016a; Dyball et al., 2018; Ruhaila & Cheng, 2018). Further 
examination of these results found anxiety to be most significantly associated with the 
more subjective assessments of disease activity, such as the PtGA, Pain VAS and TJC. For 
example, one cohort study found anxiety to be positively correlated at baseline and at 
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1-year follow-up with the PtGA, TJC, SJC and ESR, though this correlation was only 
significant for the PtGA (r=0.31, p<0.05 at baseline, r=0.43, p<0.01 at 1-year follow-up) 
(Matcham et al., 2016a). On multiple regression analysis baseline anxiety was also 
significantly associated with PtGA and TJC at 1-year follow-up (Matcham et al., 2016a). 
In another study, Pain VAS and TJC measurements were significantly higher in people 
with anxiety compared to those without, though there was no significant difference in 
the ESR or SJC between groups (Grosso et al., 2015). A further study found anxiety to be 
significantly correlated with increased VAS pain (r=0.341, p<0.001) and TJC (r=0.197, 
p=0.007), but not SJC (r=0.060, p=0.412) (Ruhaila & Cheng, 2018). In addition, Dyball et 
al. (2018) found baseline anxiety to be associated with smaller improvements in PtGA 
at 6 months (b=0.74, 95% CI 0.32, 1.26, p=0.001). 
 
6.4.3.2 Anxiety and additional disease activity outcomes 
Additional disease activity outcome measures were reported in 4 studies, which 
are detailed in tables 6.3a and 6.3b. These included a cohort study (Overman et al., 
2012) and 3 cross-sectional studies (Ichikawa et al., 1995; Kojima et al., 2009b; Miwa et 
al., 2002). Overall, anxiety was associated with increased pain, inflammatory markers 
and disease activity for the majority of additional outcome measures. 
One study used the Thompson articular index, a weighted score including 
swollen and painful joints (Taal et al., 1998), and ESR, as additional disease activity 
outcome measures. A significant association was found between anxiety and an 
increased Thompson articular index and ESR, suggesting anxiety in people with RA is 
associated with increased disease activity (Overman et al., 2012). Another study 
(Ichikawa et al., 1995), assessed disease activity using Pain VAS and the LAI, which 
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consists of morning stiffness, ESR, grip strength and a painful joint count (Lansbury, 
1956). A significant positive correlation was found between anxiety and Pain VAS, in 
addition to the LAI, suggesting anxiety in people with RA to be associated with increased 
pain and disease activity (Ichikawa et al., 1995). A further study analyzing the correlation 
between anxiety and VAS (reported as a measure of arthralgia) split participants into 
two subgroups with lower and higher mean activity levels (Miwa et al., 2002). In less 
active patients, anxiety was significantly correlated with higher VAS scores, though this 
correlation became non-significant in more active patients, suggesting anxiety only 
increases arthralgia in people with RA who are less active. One study found no 
association between anxiety and disease activity, when assessed using a combination of 
the physician͛s global assessment, TJC, SJC and CRP (Kojima et al., 2009b). This was 
potentially due to the physician completing the global assessment, rather than the 
patient, as with DAS28, since the physician may have reported lower disease activity on 
their global assessment than a patient with anxiety, who may have self-assessed their 
disease activity to be worse. 
 
6.4.4 Association between anxiety and QoL in RA 
6.4.4.1 Anxiety and SF-36 
The findings of the 5 studies reporting SF-36 for QoL (Al-Fadl et al., 2014; Kojima 
et al., 2009b; Mok, Lok and Cheung, 2012; Nas et al., 2011; Ozcetin et al., 2007), are 
summarised in table 6.4 (p177). These were all cross-sectional studies, involving a total 
of 801 patients. Anxiety had a significant negative association with SF-ϯϲ and its͛ 
subscale scores in the majority of studies reporting this outcome, indicating worse QoL. 
In particular, a significant negative correlation was reported between anxiety 
and SF-36 in one study (Mok, Lok and Cheung, 2012), in addition to the PCS and MCS of 
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SF-36 in 2 further studies (Al-Fadl et al., 2014; Kojima et al., 2009b). Another article 
found a significant negative correlation between anxiety and all SF-36 subscale scores 
apart from emotional role (Ozcetin et al., 2007). A further study reported a significant 
negative correlation between high risk anxiety (defined as a score ш10 on the Turkish 
version of the HADS) and all SF-36 subscales (Nas et al., 2011). In addition, when people 
with RA, with and without anxiety were compared, all SF-36 subscale scores apart from 
physical role and bodily pain were significantly worse in the group with anxiety (Nas et 
al., 2011).  
6.4.4.2 Anxiety and additional QoL outcome measures 
Different QoL outcome measures were reported in 5 studies (Alpi et al., 2017; 
Celiker and Borman, 2001; Karahan et al., 2016; Nas et al., 2011; Wan et al., 2015), which 
are summarised in table 6.4 (p177). These were all cross-sectional studies, involving 759 
participants. Anxiety was negatively associated with all additional QoL outcome 
measures. This finding was significant in the majority of studies.  
In particular, a significant negative correlation was found between moderate or 
severe anxiety and the Turkish version of the WHOQoL-BREF score (Karahan et al., 
2016), though this correlation was non-significant in mild anxiety. A significant negative 
correlation was also found between current anxiety and the LSI (Celiker et al., 2001), 
EQ-5D (Wan et al., 2015) and QoL-RA scale (Alpi et al., 2017). In addition, one study 
found a significant negative association between anxiety and the QoL-RA scale on 
multiple regression analysis, supporting a link between anxiety and worse QoL in people 
with RA (Alpi et al., 2017). Another study reported RA-QoL scores and NHP subscale 
scores to be significantly worse in people with RA and anxiety, compared to those 
without anxiety, supporting a link between anxiety and worse QoL (Nas et al., 2011). 
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6.4.5 Meta-analysis 
 
On meta-analysis, anxiety was associated with increased disease activity using 
DAS28 scores. Meta-analysis of mental and physical QoL scores also found anxiety to be 
negatively correlated with QoL, as reported in table 6.5. Pooled r values showed the 
strongest association to be between anxiety and reduced QoL, in particular worse 
mental QoL.  
 
Table 6.5- Meta-analysis of correlation coefficients between anxiety and DAS28, physical 
QoL and mental QoL 
 
Meta-analysis DAS28 Physical QoL Mental QoL 
Pooled r (CI) 0.23 (0.14, 0.31) -0.39 (-0.58, -0.20) -0.50 (-0.57, -0.43) 
Q statistic χ2=3.85 (d.f.=4) p=0.43 χ2=13.95 (d.f.=3)  p<0.01 χ
2=3.35 (d.f.=3) p= 
0.34 
I2 0.0% 78.5% 10.3% 
 
r = pearsons correlation coefficient, CI= confidence interval, p= p value, ʖ2= chi-squared, d.f.= 
degrees of freedom 
 
There was only evidence of significant heterogeneity between studies for 
physical QoL (Q statistic= 13.95, p<0.01; I2=78.5%). This could have been due to one 
study that was used in the physical QoL meta-analysis involving proportionately more 
participants (Nas et al. 2011). Alternatively, another study used in the physical QoL 
meta-analysis had a correlation coefficient value that was much lower, compared to the 
other reported values, which could have contributed to increased heterogeneity 
(Ozcetin et al., 2007).   
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In contrast, heterogeneity was 0% for the DAS28 meta-analysis. This was due to 
the studies reporting DAS28 being more homogeneous. Further, if we consider the 
calculation used to determine I2 (I2= 100% x (Q- degrees of freedom)/Q), as the Q 
statistic was 3.85 and the degrees of freedom 4, the I2 value for DAS28 was negative. I2 
values are automatically set to 0 when the value is negative, so that the value falls 
between 0-100 (Higgins et al., 2003). Figures 6.2, 6.3 and 6.4 (p188), contain forest plots 
of the meta-analysis of DAS28, Physical QoL and Mental QoL outcomes for the original 
scale r. More detailed calculations are listed in appendix 17.  
 
Figure 6.2- Forest Plot displaying meta-analysis of correlation coefficients between 
anxiety and DAS28  
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Figure 6.3- Forest Plot displaying meta-analysis of correlation coefficients between 
anxiety and physical QoL 
 
 
 
 
 
Figure 6.4- Forest Plot displaying meta-analysis of correlation coefficients between 
anxiety and mental QoL 
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6.4.6 Strength of Evidence 
 
The overall strength of evidence for the association between anxiety in people 
with RA, and disease activity and QoL has been reviewed in table 6.6 (p190), using the 
Modified Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) system (Schünemann et al., 2013). Most studies reporting disease activity 
outcomes had consistent effect sizes, moderate sample sizes and controlled for 
confounding factors, with low heterogeneity on meta-analysis of the correlation 
between anxiety and DAS28. Therefore, the strength of evidence for the association 
between anxiety and disease activity was felt to be moderate. Meanwhile, though effect 
sizes were relatively consistent for QoL outcomes, almost half of the studies had small 
sample sizes and there was significant heterogeneity on meta-analysis of mental QoL, 
meaning the overall strength of evidence for the association between anxiety and QoL 
was low. Details of how the GRADE score was calculated are in appendix 18.
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Table 6.6- Strength of evidence for association betw
een anxiety in people w
ith RA, and disease activity and Q
oL.  
 
O
utcom
e 
Evidence Base 
Strength of Association 
Strength of Evidence 
(GRADE)  a.b 
Com
m
ents 
Disease 
Activity 
14 studies 
n=6613 
 6 cohort  
(table 6.3a) 
 8 cross-sectional  
(table 6.3b) 
  
M
eta-analysis 
Anxiety correlation w
ith DAS28 
Pooled r (CI)= 0.23 (0.14, 0.31) 
Narrative synthesis  
Association betw
een anxiety and increased disease activity 
- 
2 studies significant baseline to 12 m
onths 
- 
1 study significant 3 m
onths, non-significant 9 /15 m
onths 
- 
1 study non-significant 6 m
onths 
Correlation betw
een anxiety and increased disease activity  
- 
7 studies significant, 3 studies non-significant 
M
oderate  
⊕⊕⊕ 
 
M
ost studies had 
consistently sm
all/ 
m
oderate effect sizes, a 
reasonable sam
ple size 
and controlled for 
confounding factors. 
There w
as low
 
heterogeneity in the 
m
eta-analysis.  
Q
uality of 
Life 
9 Studies 
n=1139 
 All cross-sectional  
(table 6.4) 
 
M
eta-analysis 
Anxiety correlation w
ith Physical QoL  
Pooled r (CI)= -0.39 (-0.57, -0.20) 
Anxiety correlation w
ith M
ental QoL  
Pooled r (CI)= -0.50 (-0.57, -0.43) 
Narrative synthesis  
Correlation betw
een anxiety and reduced QoL 
- 
6 studies significant negative correlation 
- 
1 study non-significant negative correlation w
ith m
ild anxiety, 
but significant negative correlation w
ith m
oderate/ severe 
anxiety 
- 
1 study non-significant w
ith long-standing anxiety but 
significant w
ith current anxiety 
Low
 
⊕⊕ 
  
M
ost studies had 
consistently sm
all/ 
m
oderate effect sizes, 
though nearly half of the 
studies had sm
all sam
ple 
sizes and there w
as 
significant heterogeneity 
on m
eta-analysis of 
m
ental QoL, lim
iting the 
strength of evidence. 
 a. GRADE assessm
ent included risk of bias, inconsistency, indirectness, im
precision, large effect (strength of association) and dose-response gradient (appendix 18). 
b. Sym
bols for quality of evidence: ⊕⊕⊕⊕ High, further research is unlikely to change our confidence in the estim
ate of effect; ⊕⊕⊕ M
oderate, further research is likely to 
have an im
portant im
pact on our confidence in the estim
ate of effect and m
ay change it; ⊕⊕ Low
, further research is likely to have an im
portant im
pact on our confidence 
in the estim
ate of effect and is likely to change the estim
ate; ⊕Very low
, any estim
ate of effect is very uncertain.
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6.5 Discussion                                                                                                  .    
 
 
6.5.1 Summary of findings 
This is the first systematic review to examine the relationship between anxiety 
in people with RA, and disease activity and QoL. Findings suggest that anxiety is 
associated with increased disease activity and reduced QoL. 
This systematic review demonstrates that anxiety in people with RA is associated 
with increased disease activity, both cross-sectionally and at 3 months (Kuijper et al., 
2018), 6 months (Fragoulis et al., 2018) and 12 months (Matcham et al., 2016a) follow-
up. These findings complement previous research, showing that depression in people 
with RA is associated with increased disease activity (Rathbun, Reed & Harrold, 2013).  
Whilst one study (involving 52 participants) found the impact of baseline anxiety 
on disease activity to increase between 6 and 12-month follow-up (Matcham et al., 
2016a), two larger studies (involving 281 and 848 participants) found the impact of 
baseline anxiety to reduce over time (Kuijper et al., 2018; Fragoulis et al., 2018). The 
reasons for this observation are unclear, with Kuijper et al. (2018), hypothesising that in 
early RA, when treatment has not yet been optimised, anxiety could influence subjective 
components of DAS28, whilst once disease is better controlled, people may adapt to 
living with RA, leading to a reduction in anxiety. 
Alternatively, this review, suggests the association between anxiety and 
increased disease activity may, in part, be due to people with anxiety reporting higher 
PtGA scores and other subjective measures of disease activity (Grosso et al., 2015; 
Matcham et al., 2016a; Dyball et al., 2018; Ruhaila & Cheng, 2018), rather than an 
objective increase in disease activity.  
  192 
The strength of evidence for the association between anxiety and increased 
DAS28 was moderate, as although most studies had good sample sizes and all used 
validated tools to determine the exposure and outcome, there were several potential 
sources of bias and the reported effect sizes were only small to moderate. 
Considering QoL outcomes, this systematic review also demonstrates that 
anxiety in people with RA is cross-sectionally associated with reduced QoL, 
complementing previous research showing that depression in RA is associated with 
poorer QoL (Bazzichi et al., 2005; Senra et al., 2017). On review of the SF-36 subscale 
effect sizes, the largest impact of anxiety was seen on vitality, social functioning and 
mental health scores (Ozcetin et al., 2007; Nas et al., 2011). Effect sizes for reduced 
social functioning and mental health scores could be interpreted as symptoms of anxiety 
as well as components of QoL. Meanwhile, larger effect sizes for the correlation 
between anxiety and vitality, could have been confounded by known associations 
between mood problems and fatigue in RA (Matcham et al., 2015), with fatigue having 
a further negative impact on QoL.  
The strength of evidence for the association between anxiety and reduced QoL 
was low, as although all studies used validated tools to determine the exposure and 
outcome, and the majority controlled for confounding factors, there were several 
potential sources of bias, including small sample sizes and a lack of detail on sampling 
methods. Most effect sizes were only small to moderate, whilst on performing a meta-
analysis, heterogeneity was high for physical QoL. 
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6.5.2 Strengths and limitations 
A number of strengths and limitations need to be considered when interpreting 
the results. The search strategy was kept broad, to ensure that all available evidence on 
this topic was considered. A search for grey literature was also performed, though no 
additional studies meeting the inclusion criteria were found. In addition, there were 
some limitations as to which studies could be included. For example, nine potentially 
relevant studies could not be included as the published conference abstracts lacked 
sufficient data, and the authors did not respond to requests to provide additional data. 
Furthermore, twelve studies had to be excluded as anxiety was not reported separately 
from depression as an outcome. As anxiety frequently exists in isolation, future studies 
should consider reporting anxiety and depression separately, to enable their individual 
effects to be assessed. 
Meta-analysis was limited by the small number of studies which provided 
suitable data to enable statistical pooling of results. Where pooled estimates of 
correlation were obtained, these, as well as the associated measures of the extent of 
heterogeneity, should be interpreted with caution. Potential sources of heterogeneity 
were differences in the source populations, sampling methods and adjustments made 
for confounding factors between studies. In the future, availability of suitable data may 
allow the impact of individual factors on the outcomes to be investigated using meta-
regression analysis. 
All available evidence regardless of the methodological study quality was 
incorporated within this review. Overall, the quality of the included studies was varied. 
Several potential sources of bias were identified in terms of the sampling methods, 
sample sizes, method of outcome measurement and loss of participants to follow-up. 
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Half of the studies had sample sizes of less than 100, suggesting results may be less 
generalisable. Qualitative studies may have provided a greater depth of understanding 
of how anxiety impacts on assessments of disease activity from the perspective of 
patients, whilst a randomised control trial (RCT) would have provided stronger evidence 
on the impact of anxiety on QoL and disease activity in people with RA.  
 
6.5.3 Patient and Public Involvement 
The results were discussed with a patient and public involvement and 
engagement (PPIE) group comprised largely of the members who met to discuss the 
prior qualitative study. On reviewing evidence from the systematic review, some PPIE 
attendees initially asked for clarification about the quality of individual articles and the 
size of the studies, hence the weight that could be applied to study findings. Attendees 
commented that the majority of articles found a strong link between anxiety and 
increased disease activity, particularly those reporting DAS28. Participants also agreed 
that the overall evidence on QoL outcomes, suggested that anxiety had a negative 
impact on QoL in people with RA.  
The PPIE group also contributed to the dissemination plan. Attendees gave 
multiple suggestions, which included the use of social media, practice newsletters or 
summaries sent to patient participation groups at regional GP practices and the 
Haywood Foundation, a local organisation supporting arthritis research. These 
suggestions were used to develop a dissemination plan to help ensure results were 
shared with a wide clinical, academic and public audience. Details of presentations given 
to lay audiences are listed in appendix 27. 
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6.5.4 Implications 
As recommended by the National Institute for Health and Care Excellence (NICE) 
(NG 100) (2018), GPs need to actively seek to identify and treat comorbid anxiety in 
people with RA to improve outcomes. Rheumatologists should consider reviewing the 
subcomponents of DAS28 scores in people who respond poorly to RA treatments, as 
disproportionately high subjective component scores (PtGA, TJC) compared to objective 
scores of disease activity (SJC, ESR), could indicate a deterioration in a patients͛ mental 
health rather than an increase in their disease activity. This would be supported by 
previous studies which have found people with RA and psychological comorbidities to 
rate their disease activity higher than their physicians (Liu, Bathon & Giles, 2015; Duarte 
et al., 2015), with patient-reported measures such as the VAS being more strongly 
influenced by psychological variables (Cordingley et al., 2014). Consequently, in this 
situation, managing any underlying anxiety or depression alongside joint inflammation, 
rather than purely focusing treatment on reducing the physical symptoms of RA, could 
lead to reduced disease activity and an improved QoL. 
 
6.6 Conclusion                                                                                                          .    
 
Anxiety in people with RA is associated with worse QoL and increased disease 
activity. Therefore, optimal management plans could involve pharmacological and/ or 
psychological approaches to manage comorbid anxiety, in addition to anti-inflammatory 
medications to reduce joint pain, swelling and stiffness. Better identification and 
management of comorbid anxiety by both patients and clinicians has the potential to 
improve outcomes for people with RA.  
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6.7 Connection with subsequent studies                                                           .    
 
This systematic review builds on the findings of my qualitative study by providing 
further evidence of the negative impact of anxiety in RA. It highlights the need for a 
focus on the identification and management of comorbid anxiety in addition to 
depression in individuals with RA. 
Following on from the suggestions of my PPIE group detailed in chapter 5 
(section 5.10.3), in chapter 7, I have widened my focus to other inflammatory 
rheumatological conditions (IRCs). This is due to past research mainly focusing on 
comorbid mood problems in RA, but not other IRCs, such as ankylosing spondylitis (AS), 
psoriatic arthritis (PsA), polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Due 
to a lack of prior literature reporting the burden of mood problems, particularly anxiety, 
in this population (section 2.9.3), I aim to determine the incidence and prevalence of 
anxiety and depression in different IRCs. 
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7.0 COHORT STUDY 
 
7.1 Introduction                                                                                                     .    
 
Rheumatoid arthritis (RA) is a common inflammatory rheumatological condition 
(IRC), which is associated with an increased risk of comorbid anxiety and depression 
(section 2.9.1). Most research examining comorbid mood problems in IRCs has focussed 
on depression in people with RA, finding low mood to be associated with a reduced 
quality of life (QoL) and increased disease activity and mortality. Due to a lack of 
literature on the impact of anxiety in people with RA, a systematic review and meta-
analysis were performed, as detailed in chapter 6. Anxiety was found to be correlated 
with both increased disease activity and reduced QoL in people with RA. 
As discussed in chapter 2 (section 2.9.3), there is a lack of literature reporting 
the prevalence of anxiety and depression in people with different IRCs, particularly 
polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Consequently, given the 
known links between RA, mood problems and increased morbidity and mortality, 
further research is needed to determine the incidence and prevalence of mood 
problems in people with different IRCs. 
 
7.2 Aims and Objectives                                                                                        .    
 
Aims: To perform a matched retrospective cohort study to investigate the incidence 
and prevalence of (a) anxiety alone and (b) anxiety and/ or depression, in people with 
The incidence and prevalence of mood problems in IRCs 
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RA, ankylosing spondylitis (AS), psoriatic arthritis (PsA), PMR and GCA. The reasons for 
analysing anxiety, but not depression alone, are discussed in section 7.3.1.1. 
Objectives: 
1. Investigate the prevalence of, and factors associated with, anxiety in addition to 
anxiety and/ or depression among patients with IRCs. 
2. Assess whether there is an association between the diagnosis of an IRC (RA, AS, 
PsA, PMR, GCA) and subsequent consultation for anxiety, in addition to anxiety 
and/ or depression.  
7.3 Methods                                                                                                    .    
7.3.1 Data source: CiPCA Database 
The study was undertaken using the Consultations in Primary Care Archive 
(CiPCA), a well established database of anonymised medical record data from a set of 9 
general practices in North Staffordshire, in the United Kingdom (UK) (Medical Record 
Data Research, 2014), dating from the year 2000. CiPCA is an extensively used on-going 
database of routinely collected primary care information, such as consultations, 
prescriptions, investigations and referrals on approximately 90,000 registered patients. 
General Pracitioners (GPs) enter the data using coding schemes such as Read codes and 
British National Formulary (BNF) codes. Read codes are the standard clinical 
terminology system used within general practice in the UK (Benson, 2011). They support 
electronic coding for patient phenomena, including clinical symptoms and signs, 
laboratory results, diagnoses and procedures.  
The practices that contribute data to CiPCA undergo a regular Keele consultation 
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data training and validation programme, hence coded clinical activity is of a high 
standard (Porcheret et al., 2004). Therefore, the quality of data is comparable to larger 
national databases (Jordan et al., 2007). The application submitted to use data from the 
CiPCA database is in appendix 19. 
7.3.1.1 Required Read codes 
Read code lists were used to identify medical records relating to IRCs (RA, AS, 
PsA, PMR, GCA) and mood problems, as well as a range of comorbidities (chronic 
obstructive pulmonary disease (COPD), asthma, diabetes mellitus (DM), heart failure 
(HF), ischaemic heart disease (IHD), peripheral vascular disease (PVD), stroke and 
cancer) and lifestyle factors (obesity, alcohol consumption and smoking). 
For RA, AS, PsA, PMR, depression, comorbidities and lifestyle factors, permission 
was sought to use established Read code lists derived using a rigorous consensus 
approach from the CiPCA data manager (Morbidity Definitions, 2014). Lists of all such 
codes used may be found in the morbidity section of the medical record data research 
repository at www.keele.ac.uk/mrr. For GCA, a Read code list from a prior CiPCA study 
was used (Petri et al., 2015), whilst for anxiety, a Read code list developed by a 
consensus group, including GPs and electronic health record researchers, was used. 
These Read code lists are in appendix 20. 
Within the established Read code list for depression, is the code ͞anxiety with 
depression͟. This is frequently used by GPs when recording a consultation with an 
individual who has depression and associated anxiety symptoms. To determine the 
association between different IRCs and isolated depression, this Read code for ͞anxiety 
with depression͟ would have had to be removed from the list. However, this potentially 
would have led to a large number of depressed people being excluded from the analysis, 
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making the results inaccurate. Therefore, depression alone was not examined, though 
the established depression and anxiety Read code lists were combined to enable 
analysis of individuals with anxiety and/ or depression. 
Having a second Read code list for anxiety alone was felt to be important, due to 
the lack of literature reporting the prevalence of anxiety in different IRCs, in addition to 
the findings of the systematic review discussed in chapter 7, which suggested that 
anxiety has a significant impact on QoL and disease activity in people with RA. The Read 
code list for anxiety did not include the code ͞anxiety with depression͟, meaning some 
individuals with anxiety could have been missed. However, from my clinical experience, 
when an individual consults their GP with predominantly anxiety symptoms, a Read 
code for anxiety is usually recorded, not ͞anxiety with depression͟. 
 
7.3.2 Prevalence of anxiety and depression (objective 1) 
This section outlines details pertaining to objective 1. 
7.3.2.1 Study population 
The cohort included men and women aged шϭϴ years with a first ever Read code 
diagnosis of one of the IRCs of interest (RA, AS, PsA, AS, GCA) recorded between 
1/1/2001 and 31/12/2015. The date of diagnosis with an IRC was defined as the index 
date.   
A comparison group without any IRCs were drawn by assigning each individual 
with an IRC at their index date with up to 4 age (within 3 years), gender and general 
practice matched individuals. The comparison group had no record of an IRC up until 
the point of their matched case͛s index date and were alive and contributing medical 
record data at the time. Individuals in the comparison group were assigned the same 
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index date as their matched individuals with an IRC. All individuals were required to have 
at least ϭϮ months͛ general practice registration history before the index date. Figure 
7.1 shows how the study population for objective 1 was derived to determine the 
prevalence of mood problems in people with IRCs. The approach to statistical analysis 
is detailed in section 7.3.2.2. 
Figure 7.1- Objective 1: graphical representation 
 
7.3.2.2 Statistical analysis  
The characteristics of individuals were summarised using frequencies and 
percentages, and compared between those with and without an IRC using chi square 
tests. The success of matching was also described.  
Prevalence rates, and corresponding 95% confidence intervals (CIs), of anxiety, 
in addition to anxiety and/ or depression, in the 12 months prior to index date were 
calculated among those with an IRC, and among those without for comparison 
purposes. Logistic regression models were used to obtain estimates of association, in 
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terms of odds ratios (ORs) and associated 95% CIs, between IRCs and anxiety alone, in 
addition to anxiety and/ or depression. Estimates of unadjusted associations were 
obtained first, followed by adjustment for covariates.  
For overall IRCs, logistic regression models were also used to analyse the 
association between covariates (age, gender, deprivation, COPD, asthma, DM, HF, IHD, 
PVD, stroke, cancer, obesity, alcohol consumption, smoking status) and anxiety, in 
addition to anxiety and/ or depression. The association between covariates and mood 
problems was also analysed for people with RA and PMR separately, to determine any 
condition-specific associations. There were too few individuals with AS, PsA or GCA and 
mood problems to enable separate analysis for these conditions. Adjustments were 
made for covariates that had a significant unadjusted association. This was to avoid 
overadjustment. Section 7.3.3.4 contains more details on the covariates and how they 
were established. 
 
7.3.3 Incidence of anxiety and depression (objective 2) 
This section outlines details pertaining to objective 2. 
7.3.3.1 Study population 
Two separate datasets were constructed for incidence analyses, as represented 
graphically in figure 7.2 (p204).  
1. Incidence of anxiety - study population as in section 7.3.2.1, excluding individuals 
with a record of anxiety during the 12-months pre-index date. 
2. Incidence of anxiety and/ or depression - study population as in section 7.3.2.1, 
excluding individuals with a record of anxiety and/ or depression during the 12-
months pre-index date. 
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Figure 7.2- Objective 2: graphical representations. 
 
 
 
 
 
7.3.3.2 Exposure  
The exposure was a Read code for one of the IRCs of interest being investigated 
(RA, AS, PsA, PMR, GCA). 
7.3.3.3 Outcome  
The outcome of interest was the time from the index date to the first diagnosis 
of anxiety, and the time to the first diagnosis of anxiety and/ or depression. Anxiety and/ 
or depression comprised of a combination of the Read code lists for anxiety and 
depression. The depression Read code list included the code ͞anxiety with depression͟, 
hence when the anxiety and depression Read code lists were combined, they included 
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people with anxiety or depression alone, and individuals with a combination of both 
mood problems. 
7.3.3.4 Covariates 
Covariates believed to potentially confound the relationship between IRCs and 
anxiety or depression were selected based on their previously established relationship 
with IRCs and anxiety and depression. These included age and gender (mostly accounted 
for through the matched study design), select comorbidities (COPD, asthma, DM, HF, 
IHD, PVD, stroke, cancer) (Naylor et al., 2012), obesity, smoking status and alcohol 
misuse/ dependence, determined by a clinical record of alcoholism or alcohol 
dependence (Velten et al., 2018). Read codes are listed in appendix 20.  
Deprivation status was considered as a further covariate (Elliot, 2016). This was 
determined using the index of multiple deprivation (IMD), which is based on a persons͛ 
postcode. The IMD is commonly used as a measure of relative deprivation for 
neighbourhoods in England, expressed in deciles from 1 (most deprived) to 10 (least 
deprived) (Department for Communities and Local Government, 2015).  
The total number of primary care contacts over 12-months pre-index, were also 
included as a covariate. This was to enable adjustments to be made for the frequency 
of consultation, to take account of the extra potential opportunities that individuals 
attending more primary care appointments would have for the discussion of mood 
concerns. The average member of the public consults their GP approximately six times 
per year, whilst the frequency of consultation is likely to be higher in people with LTCs, 
such as an IRC, compared to people without any long-term health problems (NHS Digital, 
2009). 
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Multimorbidity (ш2 comorbidities), was considered as an additional covariate, 
due to its͛ known association with LTCs and mood problems ;Vancampfort et al., ϮϬϭϳ; 
Read et al., 2016). However, individuals with IRCs already have one morbidity, whilst 
people with IRCs and mood problems are multimorbid. Therefore, to take account of 
the association between mood problems in people with IRCs and the burden of further 
comorbidities, a variable titled, ͞one of more additional comorbidities͟ was included in 
analyses. 
Potential confounders were identified via Read codes in the record at any time 
prior to the index date. For confounders that could change over time (obesity, alcohol 
misuse/ dependence and smoking), information recorded closest to the index date was 
used. To determine the number of primary care contacts, every entry on the primary 
care computer system, EMIS, counted as a single contact. If several blood test results 
were recorded on a single day, these were counted as a single contact. 
The absence of Read codes for IRCs, anxiety, depression and covariates (with the 
exception of obesity, alcohol dependence and smoking) was assumed to indicate that 
people did not have the condition of interest and consequently that these data were 
not missing. Categories for missing data were defined for obesity, alcohol dependence 
and smoking status. Multiple imputation was not considered for these variables as 
previous studies using the Clinical Practice Research Datalink (CPRD) indicated that 
missing data on these variables was not missing at random (Clarson et al., 2015). 
7.3.3.5 Analysis 
Data were managed and analysed in SPSS (version 24) and STATA (version 14). 
The characteristics of individuals were summarised using frequencies and percentages, 
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and compared between those with and without an IRC using chi square tests. The 
success of matching was also described.  
Cox proportional hazard regression models were used to obtain associations 
between IRCs and the time to occurrence of anxiety, in addition to anxiety and/or 
depression, in terms of Hazard Ratios (HR). Corresponding 95% CIs were based on robust 
standard errors to account for any possible clustering due to matching (Lin & Wei, 1989). 
Unadjusted HRs were obtained first, followed by adjustment for the covariates 
discussed in section 7.3.3.4. Proportionality of hazards assumption, the assumption that 
the effect of covariates is constant over time, was tested graphically and via Schoenfeld 
residuals. Where the assumption failed for any covariate, the interaction of that 
covariate with appropriate function(s) of time was included in the model. Right 
censoring was assumed to be non-informative and was taken as the earliest of date of 
death, end of registration at the practice, or the 31/08/2016.  
The association between IRCs and anxiety alone, in addition to anxiety and/ or 
depression was primarily explored over the whole follow-up, but also specifically at one, 
two and five years post index date; stratified effect sizes were obtained, using the lincom 
command in STATA, which calculates appropriate linear combinations of coefficients 
and associated CIs.  
 
 
7.4 Results                                                                                                        .    
 
 
7.4.1 Prevalence of anxiety and depression (objective 1) 
 
7.4.1.1 Cohort characteristics 
The prevalence cohort comprised of 7425 individuals; 1485 with IRCs and 5940 
without IRCs (exact 1:4 matching was possible). As detailed in table 7.1 (p208), the 
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majority of people with IRCs had RA (n=565) or PMR (n=679), whilst fewer had GCA 
(n=104), PsA (n=85) and AS (n=57). This would fit with population estimates, with the 
prevalence of RA being reported as approximately 0.67% (Abhishek et al., 2017) and 
PMR between 0.91-1.53% (Yates et al., 2016), compared to lower prevalence estimates 
of 0.13% for AS (Dean et al., 2016), 0.22% for PsA (Egeberg et al., 2017) and 0.25% for 
GCA (Yates et al., 2016). From the 1485 individuals with IRCs, 4 had Read codes for both 
PMR and GCA, whilst one had a combination of AS and PsA. 
 
Table 7.1- Individuals with and without IRCs   
 
Individuals with and without IRCs in the prevalence cohort 
Total number of individuals in the cohort= 7425 
1485 with IRCs 
x Rheumatoid Arthritis (RA)= 565 
x Ankylosing Spondylitis (AS)= 57  
x Psoriatic Arthritis (PsA)= 85 
x Polymyalgia Rheumatica (PMR)= 679 
x Giant Cell Arteritis (GCA)= 104 
5940 without IRCs 
 
Table 7.2 summarises the demographics, comorbidities, lifestyle factors and 
numbers of primary care contacts by people with and without IRCs (p209). To calculate 
associations between covariates and IRCs, overall and individual IRCs have been 
compared to people without IRCs. Significant associations between covariates and IRCs 
have been emphasized in bold and between 1 to 3 asterix have been used to indicate p-
values for reported associations. Further details are given in the table footnotes. Anxiety 
and depression have not been included in the comorbidities listed in table 7.2, as they 
are reported separately in table 7.3 (p214), with more detailed analysis. 
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Table 7.2- Dem
ographics, com
orbidities, lifestyle characteristics and prim
ary care contacts by IRC status.  
 Covariate
 b 
Condition
 a 
No IRC(n=5940) 
All IRCs(n=1485) 
RA (n=565) 
AS (n=57) 
PsA (n=85) 
PM
R (n=679) 
GCA (n=104) 
Age M
ean (SD) 
65.7 (15.5) 
65.7 (15.5) 
59.5 (13.1) 
45.3 (14.5) 
47.8 (13.4) 
74.1 (9.5) 
74.1 (10.4) 
Age Group  
Num
ber (%
) 
18-50 1 
1068 (18.0) 
257 (17.3) 
161 (28.5) ** 
36 (63.2) ** 
49 (57.7) ** 
9 (1.3) ** 
2 (1.9) ** 
51-65 2 
1579 (26.6) 
384 (25.8) 
196 (34.7) ** 
17 (29.8) 
27 (31.8) 
122 (17.9) ** 
24 (23.1) 
66-75 3 
1534 (25.8) 
394 (26.5) 
127 (22.5) 
1 (1.7) ** 
8 (9.4) ** 
233 (34.3) ** 
27 (26.0) 
76-95 4 
1759 (29.6) 
451 (30.4) 
81 (14.3) ** 
3 (5.3) ** 
1 (1.1) ** 
316 (46.5) ** 
51 (49.0) ** 
Fem
ale (%
)  5 
3920 (66) 
980 (66) 
379 (67) 
15 (26) *** 
43 (51) *** 
462 (68) 
76 (73) 
Deprivation 
Status   
Num
ber (%
) 
Least 
971 (16.4) 
284 (19.9) 
92 (16.3) 
11 (19.3) 
17 (20.0) 
157 (23.1) 
20 (19.2) 
M
id 
3636 (61.6) 
880 (59.3) 
350 (61.9) 
29 (50.9) 
46 (54.1) 
393 (57.9) 
65 (62.5) 
M
ost 6 
1297 (22.0) 
309 (20.8) 
123 (21.8) 
17 (29.8) 
22 (25.9) 
129 (19.0) 
19 (18.3) 
шϭ addiƚional com
oƌbidiƚǇ N (%
) 7 
2914 (49.1) 
804 (54.1) *** 
290 (51.3) 
17 (29.8) ** 
22 (25.9) *** 
407 (59.7) *** 
69 (66.3) *** 
Com
orbidity 
Num
ber (%
) 
HF 8 
183 (3.1) 
57 (3.8) 
17 (3.0) 
1 (1.8) 
0 (0) 
33 (4.9) ** 
6 (5.8) 
IHD 9  
874 (14.7) 
246 (16.6) 
71 (12.6) 
3 (5.3) * 
4 (4.7) * 
144 (21.2) *** 
24 (23.1) * 
DM
 10 
681 (11.5) 
176 (11.9) 
62 (11.0) 
4 (7.0) 
4 (4.7) 
87 (12.8) 
19 (18.3) * 
PVD 11 
249 (4.2) 
74 (5.0) 
29 (5.1) 
2 (3.5) 
4 (4.7) 
31 (4.6) 
8 (7.7) 
COPD
 12 
1176 (19.8) 
387 (26.1) *** 
157 (22.8) *** 
9 (15.8) 
10 (11.8) * 
181 (26.6) ** 
30 (28.8) 
Asthm
a
 13 
781 (13.1) 
270 (19.2) *** 
119 (21.1) *** 
7 (12.3) 
6 (7.1) 
118 (17.4) * 
20 (19.2) ** 
Stroke 14 
488 (8.2) 
125 (8.4) 
27 (4.8) ** 
0 (0) * 
2 (2.4) * 
77 (11.3) * 
19 (18.3) *** 
Cancer 15 
924 (15.5) 
230 (15.5) 
72 (12.7) 
2 (3.5) * 
6 (7.1) ** 
133 (19.6) ** 
18 (17.3) 
Sm
oking 
Status 
Num
ber (%
) 
Current 16 
1421 (23.9) 
388 (26.1) *** 
184 (32.6) *** 
21 (36.8) 
26(30.6) 
135 (19.4) *** 
22 (21.2) 
Non-sm
oker 
2541 (42.8) 
620 (41.8) 
214 (37.9) 
21 (36.8) 
30 (35.3) 
315 (46.4) 
41 (39.4) 
Ex-sm
oker 
1767 (29.7) 
467 (31.4) 
163 (28.8) 
14 (24.6) 
28 (32.9) 
225 (33.0) 
41 (39.4) 
Not know
n 
211 (3.6) 
10 (0.7) 
4 (0.7) 
1 (1.8) 
1 (1.2) 
4 (0.7) 
0 (0) 
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Table 7.2- ConƚinƵed͙
 
 Covariate 
Condition
 a 
No IRC(n=5940) 
All IRCs(n=1485) 
RA (n=565) 
AS (n=57) 
PsA (n=85) 
PM
R (n=679) 
GCA (n=104) 
O
besity
 Num
ber (%
)  17 
756 (12.7) 
224 (15.1) * 
112 (19.8) *** 
5 (8.8) 
16 (18.8) 
80 (11.8) 
4 (3.8) 
Alcohol dependence
 N (%
) 18 
130 (2.2) 
29 (2.0) 
13 (2.3) 
1 (1.8) * 
5 (5.9) * 
6 (0.9) * 
4 (3.8) 
Num
ber 
of 
prim
ary 
care 
contacts  
 (12M
 pre-
index) 
M
ean (SD) 
13.0 (11.7) 
21.0 (12.8) 
20.9 (12.6) 
14.4 (8.9) 
16.6 (10.0) 
21.8 (12.8) 
23.8 (15.6) 
(n/10,000 
people, 
95%
 CI) 
0-5  
3016  
(2957, 3075)  
445  
(436, 454)  
442  
(433,451) 
1579  
(1548,1610) 
1294 
(1269,1319) 
279  
(274,282) 
192  
(188,196) 
6-20 
4972 
(4875, 5059)  
5186 
(5079,5283) 
5204  
(5102,5306) 
5965  
(5848,6082) 
5294  
(5190,5398) 
5103 
(5003,5203) 
5096 
(4996,5196) 
21-50 
1873  
(1837, 1911) 
3997  
(3919, 4075) 
4000  
(3922,4078) 
2456  
(2408,2504) 
3294  
(3229,3339) 
4221 
(4138,4304) 
3942 
(3865,4019) 
>50 19 
139  
(135, 143) 
377  
(369, 385) ** 
354  
(347,361) ** 
0  
(0,0) 
118  
(116,120) 
397  
(390,404) ** 
769  
(754,784) *** 
 Abbreviations; HF (heart failure), IHD (ischaem
ic heart disease), DM
 (diabetes m
ellitus), peripheral vascular disease (PVD), chronic obstructive pulm
onary disease (COPD), 
RA (rheum
atoid arthritis), AS (ankylosing spondylitis), PsA (psoriatic arthritis), PM
R (polym
yalgia rheum
atica), GCA (giant cell arteritis), SD (standard deviation), n (num
ber). 
a All IRCs and individual IRCs are com
pared to people w
ithout IRCs. P-values for the association betw
een different covariates and overall/ different IRCs are represented as 
*p<0.05, **p<0.01, ***p<0.001. W
here no asterix is given, associations are not statistically significant.  
b Reference categories for each covariate analysed are listed in footnotes 1-20 below
. 
 1 Aged 18-50 years Vs not aged 18-50 years,  2 Aged 51-65 years Vs not aged 51-65 years,  3 Aged 66-75 years Vs not aged 66-75 years,  4Aged 76-95 years Vs not aged 76-95 
years,  5  Fem
ale Vs m
ale gender,  6 M
ost Deprived Vs less deprived,  7 1 or m
ore com
orbidities in addition to IRC Vs no additional com
orbidities,  8 HF Vs no HF, 9 IHD Vs no IHD, 
10 DM
 Vs no DM
, 11 PVD Vs No PVD, 12 COPD Vs no COPD, 13 Asthm
a Vs no asthm
a, 14 Stroke Vs no stroke, 15 Cancer Vs no cancer, 16 Current Sm
oker Vs non-sm
oker, 17 Obese 
Vs not obese, 18 Alcohol dependence Vs no alcohol dependence, 19 Prim
ary Care Contacts >50 Vs Prim
ary Care Contacts ч50. 
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Approximately two thirds of the individuals with IRCs were female. In common 
with population epidemiology, more males had AS (Sieper, 2012) and more females had 
RA (Abhishek et al., 2017), PMR (Crowson et al., 2011) and GCA (Dasgupta et al., 2010). 
There were almost equal proportions of males and females with PsA, reflecting the 
gender ratio observed in general population (Gladman et al., 2005). 
The age of individuals ranged between 18-95 years, with a mean of 66 years 
(standard deviation (SD)= 15.5). More individuals with RA, AS and PsA were aged 18-50 
years, whilst more people with PMR and GCA were aged 76-95 years, compared to those 
without IRCs. These differences were all statistically significant. This would reflect age 
trends observed for these conditions within the general population (Sieper, 2012; 
Gladman, 2005; Michet & Matteson, 2008; Gonzalez-Gay, 2004). There were no 
significant differences between the deprivation status of people with and without IRCs, 
though the proportion of individuals in the ͞ most deprived͟ group was highest in people 
with AS and PsA. 
The proportion with one or more comorbidities (in addition to an IRC) was higher 
in people with IRCs, compared to those without IRCs (54.1% Vs 49.1%, p<0.001). 
Considering different IRCs, the proportion with one of more additional comorbidities 
was higher in people with RA (51.3% Vs 49.1%, p<0.05), PMR (59.9% Vs 49.1%, p<0.001) 
and GCA (66.3% Vs 49.1%, p<0.001), compared to those without IRCs. All of these 
differences were statistically significant.  
All comorbidities apart from cancer were more prevalent in people with IRCs, 
compared to those without IRCs, but this difference was only statistically significant for 
COPD (26.1% Vs 19.8%, p<0.001) and asthma (19.2% Vs 13.1%, p<0.001). IHD and 
strokes were more frequent in people with GCA (IHD: 23.1% Vs 14.7%, p<0.05) (Stroke: 
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18.3% Vs 8.2%, p<0.001) and PMR (IHD: 21.2% Vs 14.7%, p<0.001) (Stroke: 11.3% Vs 
8.2%, p<0.01), compared to those without IRCs. In addition, more individuals with PMR 
had comorbid HF (4.9% Vs 3.1%, p=0.01) and cancer (19.6% Vs 15.5%, p<0.01), whilst 
DM was more frequent in people with GCA (18.3% Vs 11.5%, p<0.05), compared to 
those without IRCs. COPD and asthma were more frequent in RA (COPD: 22.8% Vs 
19.8%, p<0.001) (Asthma: 21.1% Vs 13.1%, p<0.001) and PMR (COPD: 26.6% Vs 19.8%, 
p<0.001) (Asthma: 17.4% Vs 13.1%, p<0.01), whilst more individuals with GCA also had 
asthma (19.2% Vs 13.1%, p=0.01), compared to those without IRCs. All of these 
differences were statistically significant. Meanwhile, less people with AS and PsA had a 
history of IHD and cancer, whilst fewer individuals with RA, AS and PsA had a background 
of stroke, compared to those without IRCs. These differences were all significant. 
Considering lifestyle factors, a higher proportion of people with IRCs were 
current smokers (26.1% Vs 23.9%, p<0.001) or obese (15.1% Vs 12.7%, p<0.05), when 
compared to individuals without IRCs. Considering different IRCs, more people with RA 
were smokers (32.6% Vs 23.9%, p<0.001) and obese (19.8% Vs 12.7%, p<0.001), whilst 
less people with PMR were current smokers (19.4% Vs 23.9%, p<0.001), compared to 
those without IRCs. Although similar proportions of people with and without IRCs had a 
history of alcohol dependence, more people with PsA (5.9% Vs 2.2%, p<0.05), but less 
with AS (1.8% Vs 2.2%, p<0.05) and PMR (0.9% Vs 2.2%, p<0.05), had a history of alcohol 
dependence, compared to those without matched IRCs. These differences were all 
statistically significant. 
The mean number of primary care contacts over 12 months before the index 
date, was higher in individuals with IRCs compared to those without IRCs (mean(SD)= 
21.0 (12.8) Vs 13.0 (11.7)). More individuals with RA, PMR and particularly GCA, had 
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over 50 primary care contacts, compared to individuals without IRCs (RA: 354 Vs 139/ 
10,000 people, p<0.01) (PMR: 397 Vs 139/ 10,000 people, p<0.01) (GCA: 769 Vs 139/ 
10,000 people, p<0.001). These differences were statistically significant, though no 
significant differences were found between the number of primary care contacts by 
people with AS and PsA, compared to those without IRCs. 
 
7.4.1.2 The association of anxiety alone, and anxiety and/ or depression with IRCs 
 
The prevalence of anxiety alone, in addition to anxiety and/ or depression, in 
people with IRCs compared to those without IRCs, is reported in table 7.3 (p214). There 
was no difference in the prevalence of anxiety alone between those with and without 
IRCs (4.2% Vs 4.2%, p=0.98). Anxiety alone was more prevalent in individuals with RA 
(4.6% Vs 4.1%, p=0.61), AS (5.3% Vs 4.1%, p=0.87), PsA (9.4% Vs 4.1%, p=0.07) and GCA 
(7.7% vs 4.1%, p=0.08), compared to people without IRCs, though these differences 
were not statistically significant. In contrast, anxiety alone was less prevalent in 
individuals with PMR, when compared to those without IRCs (2.8% Vs 7.5%, p=0.09). 
Again, this difference was not statistically significant.  
Anxiety and/or depression were more prevalent in people with IRCs compared 
to those without (8.3% Vs 7.5%, p=0.28). However, this difference was not statistically 
significant. Considering individual IRCs, anxiety and/ or depression were more prevalent 
in those with RA (8.7% Vs 7.5%, p=0.29), AS (12.3% Vs 7.5%, p=0.11), PsA (14.1% Vs 
7.5%, p=0.02) and GCA (14.4% vs 7.5%, p<0.01), compared to people without IRCs. This 
difference was statistically significant in people with PsA and GCA. In contrast, anxiety 
and/ or or depression were less prevalent in individuals with PMR, compared to those 
without IRCs (6.0% Vs 7.5%, p=0.18). This difference was not statistically significant.  
  
214 
Table 7.3- The prevalence, unadjusted and adjusted odds of anxiety and anxiety and/or depression in overall and individual IRCs 
 M
ood problem
 
Condition 
No IRCs 
(n=5940) 
O
verall IRCs 
(n=1485) 
RA (n=565) 
AS (n=57) 
PsA (n=85) 
PM
R (n=679) 
GCA (n=104) 
Anxiety 
 
Prevalence  
Num
ber (%
) 
247 (4.2) 
62 (4.2) 
26 (4.6) 
3 (5.3) 
8 (9.4) 
19 (2.8) 
8 (7.7) 
Unadjusted O
R             
(95%
 CI), p-value 1 
 
1.00  
(0.76, 1.34) 
p=0.98 
1.11 
(0.74, 1.88) 
p=0.61 
1.12  
(0.27, 4.67) 
p=0.87 
2.07 
(0.95, 4.53) 
p=0.07 
0.66 
(0.41, 1.07) 
p=0.09 
1.92 
(0.92, 4.00) 
p=0.08 
Adjusted OR                 
(95%
 CI), p-value 1, 2 
 
0.98  
(0.74, 1.30) 
p=0.88 
1.04 
(0.68, 1.58) 
p=0.86 
1.37  
(0.30, 6.20) 
p=0.69 
1.75  
(0.78, 3.93) 
p=0.18 
0.68  
(0.42, 1.09) 
p=0.11 
1.76 
(0.83, 3.70) 
p=0.14 
Anxiety 
and/ or 
Depression 
Prevalence 
Num
ber(%
) 
443 (7.5) 
123 (8.3) 
49 (8.7) 
7 (12.3) 
12 (14.1) 
41 (6.0) 
15 (14.4) 
Unadjusted O
R  
(95%
 CI), p-value 1 
 
1.12  
(0.91, 1.38) 
p=0.28 
1.18 
(0.87, 1.61) 
p=0.29 
2.01  
(0.85, 4.80) 
p=0.11 
2.04  
(1.10, 3.79) 
p=0.02 
0.80  
(0.57, 1.11) 
p=0.18 
2.09  
(1.20, 3.65) 
p<0.01 
Adjusted OR  
(95%
 CI), p-value  1, 2 
 
1.09  
(0.89, 1.35) 
p=0.34 
1.02 
(0.74, 1.40) 
p=0.90 
1.69 
(0.64, 4.47) 
1.90 
(1.01, 3.57) 
p=0.04 
0.88  
(0.63, 1.23) 
p=0.46 
2.15  
(1.21, 3.79) 
p<0.01 
 CI= confidence interval, OR= odds ratio 
1 O
verall and individual IRCs have been com
pared to people w
ithout IRCs. Significant values are in bold. 
2 Adjusted for age, gender, sm
oking status (current sm
oker), obesity, alcohol dependence, com
orbidities (HF, IHD, DM
, PVD, COPD, Asthm
a, Stroke, Cancer) and prim
ary 
care contacts. 
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The odds of anxiety alone, in addition to anxiety and/ or depression are also 
reported in table 7.3 (p214). The odds of anxiety in overall IRCs were marginally reduced 
after adjustment, compared to people without IRCs (odds ratio (OR) (95% confidence 
interval (CI) = 0.98 (0.74, 1.30)). Considering different IRCs, the adjusted odds of anxiety 
were increased in RA (OR (95% CI) = 1.04 (0.68, 1.58)), AS (OR (95% CI) = 1.37 (0.30, 
6.20)), PsA (OR (95% CI) = 1.75 (0.78, 3.93)) and GCA (OR (95% CI) = 1.76 (0.83, 3.70)), 
though they were reduced in PMR (OR (95% CI) = 0.68 (0.42, 1.09)), compared to people 
without IRCs. None of these differences were significant. 
The odds of anxiety and/or depression in overall IRCs were increased, compared 
to people without IRCs, though this increase was not significant, before or after 
adjustment (adjusted OR (95% CI) = 1.09 (0.89, 1.35)). Considering different IRCs, the 
adjusted odds of anxiety and/or depression were increased in RA (OR (95% CI) = 1.02 
(0.74, 1.40)), AS (OR (95% CI) = 1.69 (0.64, 4.47)), PsA (OR (95% CI) = 1.90 (1.01, 3.57)) 
and GCA (OR (95% CI) = 2.15 (1.21, 3.79)), compared to people without IRCs. The 
increased odds of anxiety and /or depression were statistically significant in people with 
PsA and GCA. However, the adjusted odds of anxiety and/ or depression were reduced 
in PMR (OR (95% CI) = 0.88 (0.63, 1.23)), compared to people without IRCs.  
In table 7.4 is an analysis of the association between different covariates and 
anxiety alone, and anxiety and/ or depression, in people with IRCs (p217). The odds of 
having a Read code for a mood problem varied dependent on age. The unadjusted odds 
of anxiety alone (OR (95% CI) = 0.46 (0.22, 0.94)), and anxiety and/ or depression (OR 
(95% CI) = 0.58 (0.36, 0.93)), were reduced in people aged 66-75 years, though statistical 
significance was lost after adjustment. Meanwhile, there was a statistically significant 
increase in the adjusted odds of people aged 18-50 years with IRCs having anxiety alone 
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(adjusted OR (95% CI) = 2.46 (1.33, 4.56)), or anxiety and/ or depression (adjusted OR 
(95% CI) = 2.69 (1.66, 4.36)). 
In people with IRCs, there was also a statistically significant increase in the 
unadjusted odds of being a female and having anxiety alone (OR (95% CI) = 1.68 (1.10, 
2.57)), though this association became non-significant after adjustment. No significant 
associations were found between deprivation status and mood problems. In addition, 
no significant associations were found between the comorbidities analysed and anxiety 
alone. Increased odds of anxiety and/ or depression in people with IRCs and asthma lost 
significance after adjustment, though there was a statistically significant increase in the 
adjusted odds of anxiety and/ or depression in people with IRCs and cancer (OR (95% 
CI) = 1.75 (1.07, 2.87)).  
In people with IRCs and one or more additional comorbidities, the odds of having 
a mood problem were increased, though no statistically significant associations were 
found. However, in people with a high number of primary care contacts, there was a 
statistically significant increase in the adjusted odds of mood problems, particularly with 
over 50 primary care contacts per 10,000 people (over 12-months pre-index date) 
(Anxiety: OR (95% CI) = 18.30 (5.85, 57.28)) (Anxiety and/or depression: OR (95% CI) = 
3.34 (2.21, 5.36)). 
Considering lifestyle factors, a statistically significant association was found 
between alcohol dependence and anxiety and/ or depression in people with IRCs 
(adjusted OR (95% CI) = 4.82 (1.83, 12.73)). An association between obesity and anxiety 
and/ or depression lost significance after adjustment. No significant associations were 
found between smoking and mood problems in people with IRCs.  
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Table 7.4- Association betw
een covariates and anxiety, in addition to anxiety and/or depression, in people w
ith IRCs 
 Covariates 
Anxiety 
Anxiety and/ or depression 
Unadjusted OR (95%
 CI) p value 
Adjusted OR * (95%
 CI) p value 
Unadjusted OR (95%
 CI) p value 
Adjusted OR * (95%
 CI) p value 
Age Group (years) 
18-50 
2.02 (1.15, 3.57) p=0.01 
2.46 (1.37, 4.56) p=0.01 
2.14 (1.41, 3.24) p<0.001 
2.90 (1.66, 4.36) p<0.001 
51-65 
1.09 (0.61, 1.93) p=0.77 
1.37 (0.68, 2.76) p=0.38 
1.16 (0.77, 2.74) p=0.49 
0.74 (0.44, 1.26) p=0.27 
66-75 
0.46 (0.22, 0.94) p=0.03 
0.50 (0.23, 1.09) p=0.08 
0.58 (0.36, 0.93) p=0.03 
0.82 (0.54, 1.18) p=0.14 
76-95 
0.94 (0.54, 1.64) p=0.82 
0.73 (0.36, 1.47) p=0.38 
0.72 (0.47, 1.11) p=0.14 
0.55 (0.32, 1.27) p=0.12 
Gender 
Fem
ale 
1.66 (0.92, 3.01) p=0.09 
1.43 (0.77, 2.69) p=0.26 
1.68 (1.10, 2.57) p=0.02 
1.47 (0.93, 2.33) p=0.72 
Deprivation Status 
Low
 
0.67 (0.33, 1.38) p=0.28 
0.79 (0.38, 1.64) p=0.52 
0.67 (0.40, 1.12) p=0.13 
0.95 (0.64, 1.43) p=0.82 
M
id  
1.02 (0.61, 1.71) p=0.95 
1.01 (0.59, 1.73) p=0.97 
1.08 (0.74, 1.58) p=0.67 
0.95 (0.64, 1.43) p=0.82 
High 
1.34 (0.75, 2.41) p=0.32 
1.19 (0.65, 2.18) p=0.58 
1.25 (0.81, 1.93) p=0.31 
1.29 (0.81, 2.06) p=0.29 
Com
orbidities 
 
CVD 1 
0.92 (0.58, 1.47) p=0.72 
0.71 (0.42, 1.22) p=0.21 
0.79 (0.55, 1.13) p=0.20 
0.76 (0.26, 1.12) p=0.54 
HF 
1.78 (0.62, 5.10) p=0.28 
1.44 (0.48, 4.35) p=0.52 
1.87 (0.86, 4.03) p=0.11 
1.12 (0.44, 2.86) p=0.81 
DM
 
0.50 (0.18, 1.40) p=0.19 
0.44 (0.11, 1.58) p=0.33 
0.79 (0.43, 1.47) p=0.46 
0.68 (0.24, 1.67) p=0.52 
COPD 
1.08 (0.61, 1.90) p=0.80 
0.81 (0.44, 1.49) p=0.49 
1.47 (0.99, 2.18) p=0.06 
1.15 (0.57, 2.31) p=0.69 
Asthm
a
  
1.21 (0.64, 1.25) p=0.56 
0.78 (0.40, 1.53) p=0.47 
1.66 (1.09, 2.55) p=0.02 
1.09 (0.68, 1.75) p=0.72 
Cancer 
1.48 (0.79, 2.77) p=0.23 
1.58 (0.81, 3.06) p=0.18 
1.61 (1.02, 2.53) p=0.04 
1.75 (1.07, 2.87) p=0.03 
ш1 com
orbidities in addition to IRC 
1.18 (0.71, 1.98) p=0.52 
1.02 (0.51, 1.64) p=0.76 
1.31 (0.90, 1.91) p=0.16 
1.08 (0.57, 1.39) p=0.44 
Current Sm
oker 
1.07 (0.61, 1.90) p=0.81 
1.08 (0.79, 1.48) p=0.62 
1.35 (0.91, 2.01) p=0.14 
1.16 (0.75, 1.82) p=0.50 
O
besity  
1.69 (0.91, 3.11) p=0.10 
1.53 (0.81, 2.89) p=0.19 
1.67 (1.06, 2.62) p=0.03 
1.38 (0.84, 2.26) p=0.21 
Alcohol Dependence 
1.73 (0.40, 7.42) p=0.47 
1.76 (0.10, 5.99) p=0.47 
4.45 (1.93, 10.26) p<0.001 
4.82 (1.83, 12.73) p=0.02 
Num
ber of prim
ary 
care contacts 
0-5 
0.09 (0.01, 1.27) p=0.12 
0.42 (0.08, 1.34) p=0.18 
0.16 (0.02, 1.19) p=0.07 
0.33 (0.05, 2.47) p=0.28 
6-20 
0.28 (0.05, 1.15) p=0.06 
0.89 (0.12, 1.23) p=0.08 
0.33 (0.04 1.25) p=0.08 
0.87 (0.07, 3.75) p=0.35 
21-50 
3.03 (1.75, 5.24) p<0.001 
4.58 (2.47, 8.44) p<0.001 
2.60 (1.76, 3.84) p<0.001 
15.20 (5.93, 39.00) p<0.001 
>50 
6.58 (0.27, 18.27) p<0.001 
18.30 (5.85, 57.28) p<0.001 
7.34 (3.14, 17.17) p<0.001 
3.34 (2.21, 5.36) p<0.001 
 *Adjusted for significant unadjusted associations. Anxiety- adjusted for age 18-50 years and 66-75 years, num
ber of prim
ary care contacts 21-50 and 50+. Depression- adjusted for age 18-50 
years, 66-75 years, asthm
a, cancer, obesity, alcohol dependence and num
ber of prim
ary care contacts 21-50 and >50. 
1 CVD (Cardiovascular disease)  includes a history of stroke, IHD and PVD.
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The association between covariates and mood problems was also analysed for 
individual IRCs. There were too few individuals with AS, PsA or GCA who had mood 
problems to enable associations to be determined (number of individuals reported in 
table 7.3), so analysis focussed on RA and PMR, to see if there were any differences in 
covariates associated with mood problems in these two main conditions. As the results 
were very similar to overall IRCs, the tables reporting these associations are in appendix 
21.  
There was a statistically significant increase in the adjusted odds of anxiety (OR 
(95%CI) = 2.70 (1.15, 6.32)), in addition to anxiety and/ or depression (OR (95% CI) = 
2.07 (1.06, 4.04)), in people aged 18-50 years with RA, though no significant associations 
were found between age and mood problems in people with PMR. In people with RA 
and PMR, statistically significant adjusted associations were found between a high 
number of primary care contacts and mood problems, as was observed in overall IRCs. 
No significant unadjusted or adjusted associations were found between gender, 
deprivation status, smoking or obesity and mood problems, though analysis was limited 
by small sample sizes. 
 
7.4.2 Incidence of anxiety alone, and anxiety and/or depression (objective 2) 
 
In this section, characteristics of the cohorts used to assess the incidence of 
anxiety alone and incidence of anxiety and/ or depression will be described. 
Subsequently, I will assess and discuss the incidence of anxiety and median time to 
anxiety diagnosis, among those with and without IRCs, and make comparisons. This will 
be repeated for the outcome of anxiety and/ or depression. 
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I will further investigate the association between IRCs and anxiety, in addition to 
anxiety and/ or depression, at 0-1, 1-2, 2-5 and 5+ years post-index date.  
 
7.4.2.1 Incidence of anxiety- Cohort Characteristics 
As shown in table 7.5, the incidence of anxiety cohort comprised of 6879 
individuals; 1423 with IRCs and 5456 without IRCs. The majority with IRCs had RA 
(n=539) or PMR (n=660), whilst fewer had GCA (n=96), PsA (n=78) and AS (n=54).  
 
Table 7.5- Number of individuals with and without IRCs in the anxiety incidence cohort 
and the diagnoses of those individuals with IRCs 
 
Diagnoses of individuals in the anxiety incidence cohort 
Total number of individuals= 6879 
1423 with IRCs 
 
x Rheumatoid Arthritis (RA)= 539 
 
x Ankylosing Spondylitis (AS)= 54  
 
x Psoriatic Arthritis (PsA)= 78 
 
x Polymyalgia Rheumatica (PMR)= 660 
 
x Giant Cell Arteritis (GCA)= 96 
5456 without IRCs 
 
There was a ratio of 1:3.8 individuals with IRCs matched to individuals without 
IRCs by age, gender and GP practice. The ratio was less than 1:4 due to individuals with 
a diagnosis of anxiety pre-index date being excluded, as outlined in section 7.3.3.1. From 
the 1423 individuals with IRCs, 3 had Read codes for both PMR and GCA, whilst one had 
a combination of AS and PsA. 
Table 7.6 (p221-222), summarises the demographics, lifestyle factors, 
comorbidities and number of primary care contacts by individuals with and without 
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IRCs. The mean age of individuals with IRCs was 65.9 (SD=15.4), whilst approximately 
two thirds were female.  
Similar trends in age, gender, deprivation, comorbidities and lifestyle factors 
were observed in the anxiety incidence cohort, when compared to the prevalence 
cohort characteristics discussed in section 7.4.1.1. However, there were several 
differences. Although diabetes and asthma were more still more frequent in people with 
GCA, and smoking more frequent in people with RA, when compared to people without 
IRCs, these differences were not statistically significant. In contrast to the prevalence 
cohort, there was a statistically significant increase in both the number of current 
smokers with AS and the frequency of COPD in people with GCA, compared to those 
without IRCs. Although strokes remained less frequent in people with PsA and alcohol 
problems less frequent in people with AS, compared to those without IRCs, these 
differences were no longer statistically significant in the anxiety incidence cohort.  
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Table 7.6- Anxiety incidence cohort- Dem
ographics, com
orbidities, lifestyle characteristics and prim
ary care contacts by IRC status.  
 Covariate 
Condition
 a 
No IRC(n=5456) 
All IRCs(n=1423) 
RA (n=539) 
AS (n=54) 
PsA (n=78) 
PM
R (n=660) 
GCA (n=96) 
Age M
ean (SD) 
65.9 (15.4) 
65.9 (15.4) 
66.5 (15.3) 
44.7 (14.1) 
48.6 (13.5) 
74.3 (9.2) 
73.8 (10.6) 
Age Range 
(years) 
18-50 1 
953 (17.5) 
238 (16.7) 
133 (25.7) ** 
28 (66.7) ** 
34 (48.6) ** 
6 (0.9) ** 
0 (0) ** 
51-65 2 
1438 (26.4) 
367 (25.8) 
186 (35.9) ** 
12 (28.5) 
29 (41.1) ** 
111 (17.1) ** 
25 (25.8) 
66-75 3 
1439 (26.4) 
385 (27.1) 
120 (23.1) 
1 (2.4) ** 
7 (10.0) ** 
227 (35.0) ** 
28 (28.9) 
76-95 4 
1622 (29.7) 
433 (30.4) 
79 (15.3) ** 
1 (2.4) ** 
0 (0) ** 
305 (47.0) ** 
44 (45.3) ** 
Fem
ale (%
) 5 
4471 (65) 
925 (65) 
361 (67) 
14 (26) ** 
40 (51) * 
449 (68) 
70 (73) 
Deprivation 
Status   
Num
ber (%
) 
Least  
875 (16.2) 
287 (19.9) 
89 (16.5) 
11 (20.4) 
15 (19.3) 
153 (23.2) 
20 (20.9) 
M
id 
3359 (61.9) 
843 (59.2) 
333 (61.8) 
27 (50.0) 
43 (55.1) 
381 (57.7) 
61 (63.5) 
M
ost 6 
1189 (21.9) 
293 (20.6) 
117 (21.7) 
16 (29.6) 
20 (25.6) 
126 (19.1) 
15 (15.6) 
ш1 additional com
orbidities N(%
) 7 
2647 (48.5) 
768 (54.0) *** 
278 (51.6) 
14 (25.9) *** 
19 (24.4) *** 
395 (59.8) *** 
62 (64.6) ** 
Com
orbidity 
Num
ber (%
) 
HF 8 
170 (3.1) 
53 (3.7) 
16 (3.0) 
0 (0) 
0 (0) 
32 (4.8) * 
5 (5.2) 
IHD 9   
813 (14.9) 
235 (16.5) 
70 (13.0) 
2 (3.7) * 
4 (5.1) * 
137 (20.7) *** 
22 (22.9) * 
DM
 10 
633 (11.6) 
172 (12.1) 
62 (11.5) 
4 (7.4) 
4 (5.1) 
85 (12.9) 
17 (17.7) 
PVD 11 
296 (4.3) 
73 (5.1) 
25 (4.6) 
2 (3.7) 
3 (3.8) 
31 (4.7) 
8 (7.3) 
COPD 12 
1047 (19.2) 
370 (26.0) *** 
142 (26.3) *** 
7 (13.0) 
10 (12.8) 
175 (26.5) *** 
29 (30.2) * 
Asthm
a 13 
690 (12.7) 
257 (18.1) *** 
106 (19.7) *** 
5 (9.3) 
6 (7.7) 
115 (17.4) ** 
18 (18.8) 
Stroke 14 
446 (8.2) 
120 (8.4) 
25 (4.6) ** 
0 (0) * 
2 (2.6) 
76 (11.5) ** 
17 (17.7) ** 
Cancer 15 
836 (15.3) 
217 (15.3) 
67 (12.4) 
2 (3.7) * 
4 (5.1) ** 
128 (19.4) ** 
16 (16.7) 
Sm
oking Status  
Num
ber (%
) 
Current 16 
1289 (23.6) 
370 (26.0) 
174 (32.3) ** 
20 (37.0) * 
24 (30.8) 
131 (19.8) ** 
22 (22.9) 
Non-sm
oker 
2349 (43.1) 
595 (41.8) 
207 (38.4) 
20 (37.0) 
 26 (33.3) 
305 (46.1) 
38 (39.6) 
Ex-sm
oker 
1616 (29.6) 
447 (31.4) 
154 (28.6) 
13 (24.1) 
27 (34.6) 
220 (33.3) 
36 (37.5) 
Not know
n 
202 (3.7) 
11 (0.8) 
4 (0.7) 
1 (1.9) 
1 (1.3) 
5 (0.8) 
0 (0) 
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Table 7.6- ConƚinƵed͙
 
 Covariate 
Condition
 a 
No IRC(n=5456) 
All IRCs(n=1423) 
RA (n=539) 
AS (n=54) 
PsA (n=78) 
PM
R (n=660) 
GCA (n=96) 
O
besity
 Num
ber (%
) 17 
689 (12.6) 
210 (14.8) *** 
107 (19.9) 
*** 
5 (9.3) 
14 (17.9) 
75 (11.3) 
9 (9.4) 
Alcohol dependence
 N (%
) 18 
109 (1.9) 
27 (1.9) 
13 (2.4) 
1 (1.9) 
4 (5.1) * 
5 (0.8) * 
4 (4.2) 
Num
ber 
of 
prim
ary 
care 
contacts 
(12 
m
onths 
pre-index) 
M
ean (SD) 
31.1 (11.8) 
20.6 (12.3) 
20.4 (12.1) 
13.8 (8.8) 
16.0 (10.1) 
21.3 (12.1) 
23.6 (15.8) 
(n/10,000 
people, 
95%
 CI) 
0-5  
3070  
(3010, 3130)  
464  
(455, 473) 
464 
(455, 465) 
1667 
(1634, 1700) 
1410  
(1382, 1438) 
288  
(282, 294) 
208 
(204, 212) 
6-20 
4982  
(4891, 5079) 
5299  
(5195, 5303) 
5325 
(5221, 5429) 
6296 
(6173, 6419) 
5385 
(5279, 5491)  
5197  
(5097, 5299) 
5313 
(5209, 5417)  
21-50 
1822 
(1786, 1858) 
3893 
(3817, 3969) 
3915 
(3838, 3992) 
2037 
(1097, 2077) 
3077 
(3017, 3137) 
4152 
(4071, 4233) 
3646 
(3574, 3691) 
>50 19 
126 
(123, 129) 
344*** 
(337, 351) 
297* 
(291, 303) 
0 (0, 0) 
128 
(125, 131) 
364*** 
(357, 371) 
1833*** 
(1797, 1869) 
 Abbreviations; HF (heart failure), IHD (ischaem
ic heart disease), DM
 (diabetes m
ellitus), peripheral vascular disease (PVD), chronic obstructive pulm
onary disease (COPD), 
RA (rheum
atoid arthritis), AS (ankylosing spondylitis), PsA (psoriatic arthritis), PM
R (polym
yalgia rheum
atica), GCA (giant cell arteritis), SD (standard deviation), n (num
ber). 
a All IRCs and individual IRCs are com
pared to people w
ithout IRCs. P-values for the association betw
een different covariates and overall/ different IRCs are represented as 
*p<0.05, **p<0.01, ***p<0.001. W
here no asterix is given, associations are not statistically significant.  
b Reference categories for each covariate analysed are listed in footnotes 1-20 below
. 
 1 Aged 18-50 years Vs not aged 18-50 years,  2 Aged 51-65 years Vs not aged 51-65 years,  3 Aged 66-75 years Vs not aged 66-75 years,  4Aged 76-95 years Vs not aged 76-95 
years,  5  Fem
ale Vs m
ale gender,  6 M
ost Deprived Vs less deprived,  7 1 or m
ore com
orbidities in addition to IRC Vs no additional com
orbidities,  8 HF Vs no HF, 9 IHD Vs no IHD, 
10 DM
 Vs no DM
, 11 PVD Vs No PVD, 12 COPD Vs no COPD, 13 Asthm
a Vs no asthm
a, 14 Stroke Vs no stroke, 15 Cancer Vs no cancer, 16 Current Sm
oker Vs non-sm
oker, 17 Obese 
Vs not obese, 18 Alcohol dependence Vs no alcohol dependence, 19 Prim
ary Care Contacts >50 Vs Prim
ary Care Contacts ч50. 
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7.4.2.2 Incidence of anxiety and/or depression- cohort characteristics 
 
The incidence of anxiety and/or depression cohort comprised of 6417 
individuals; 1363 with and 5054 without IRCs. As detailed in table 7.7, the majority with 
IRCs had RA (n=516) or PMR (n=639), whilst fewer had GCA (n=89), PsA (n=73) and AS 
(n=50). Three individuals had Read codes for both PMR and GCA, whilst one individual 
had both AS and PsA. There was a ratio of 1:3.7 individuals with IRCs matched to 
individuals without IRCs by age, gender and GP practice. The ratio was less than 1:4 due 
to individuals with a diagnosis of anxiety and/or depression pre-index being excluded.  
Table 7.7- Number of people with and without IRCs in the anxiety and/or depression 
incidence cohort and the diagnoses of those individuals with IRCs 
 
Diagnoses of individuals in the anxiety and/or depression incidence cohort 
Total number of individuals in the cohort= 6417 
1363 with IRCs 
x Rheumatoid Arthritis (RA)= 516 
x Ankylosing Spondylitis (AS)= 50  
x Psoriatic Arthritis (PsA)= 73 
x Polymyalgia Rheumatica (PMR)= 639 
x Giant Cell Arteritis (GCA)= 89 
5054 without IRCs 
 
Table 7.8 summarises the the demographics, lifestyle factors, comorbidities and 
number of primary care contacts by individuals with and without IRCs (p224). Similar 
trends in age, gender, comorbidities and lifestyle factors were observed in the anxiety 
and/or depression incidence cohort, when compared to the anxiety incidence cohort 
(section 7.4.2.1). However, there was a statistically significant reduction in the number 
of smokers with PsA and the number of people with AS who were in the most deprived 
category, compared to those without IRCs. Although HF was more frequent in PMR, IHD 
more frequent in GCA and alcohol dependence less frequent in PsA, when compared to 
those without IRCs, these differences were no longer statistically significant. 
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Table 7.8- Anxiety and/or depression incidence cohort- Dem
ographics, com
orbidities, lifestyle characteristics and prim
ary care contacts by IRC status.  
 Covariate 
Condition
 a 
No IRC 
(n=5054) 
All IRCs 
(n=1363) 
RA (n=516) 
AS (n=50) 
PsA (n=73) 
PM
R (n=639) 
GCA (n=89) 
Age M
ean (SD) 
66.4 (15.2) 
66.4 (15.2) 
60.0 (14.4) 
45.4 (12.8) 
48.9 (13.8) 
74.1 (9.5) 
74.7 (10.3) 
Age Range 
(Years) 
18-50 1 
842 (16.7) 
221 (16.2) 
124 (25.0) ** 
24 (63.2) ** 
31 (47.0) ** 
7 (1.1) ** 
0 (0) ** 
51-65 2 
1306 (258) 
349 (25.6) 
177 (35.7) ** 
12 (31.6) 
28 (42.4) ** 
108 (17.1) ** 
20 (22.2) 
66-75 3 
1362 (26.9) 
372 (27.3) 
118 (23.8) 
1 (2.6) ** 
7 (10.6) ** 
219 (34.8) ** 
27 (30.0) 
76-95 4 
1540 (30.6) 
421 (30.9) 
77 (15.5) ** 
1 (2.6) ** 
0 (0) ** 
296 (47.0) ** 
43 (47.8) ** 
Fem
ale (%
) 5 
3285 (65) 
886 (65) 
341 (66) 
13 (26) *** 
36 (49) *** 
435 (68) ** 
57 (64) 
Deprivation 
Status   
Num
ber (%
) 
Least 
813 (16.2) 
278 (20.4) 
87 (16.9) 
9 (18.0) 
13 (20.5) 
149 (23.3) 
19 (21.3) 
M
id 
3110 (61.9) 
806 (59.1) 
318 (61.6) 
25 (50.0) 
40 (54.8) 
370 (57.9) 
55 (61.8) 
M
ost 6 
1099 (21.9) 
279 (20.5) 
111 (21.5) 
16 (32.0) * 
18 (24.7) 
120 (18.8) 
15 (16.9) 
ш1 additional com
orbidity N (%
) 7  
2459 (48.7) 
730 (53.6) ** 
263 (51.0) 
14 (28.0) *** 
17 (23.3) *** 
379 (59.3) *** 
57 (64.0) *** 
Com
orbidity 
Num
ber (%
) 
HF 8 
158 (3.1) 
49 (3.6) 
16 (3.1) 
0 (0) 
0 (0) 
29 (4.5) 
4 (4.5) 
IHD 9  
767 (15.2) 
227 (16.7) 
68 (13.2) 
2 (4.0) * 
4 (5.5) * 
113 (17.7) *** 
20 (22.5) 
DM
 10 
599 (11.6) 
164 (12.0) 
60 (11.6) 
4 (8.0) 
4 (5.5) 
80 (12.6) 
16 (18.0) 
PVD 11 
223 (4.4) 
71 (5.2) 
28 (5.4) 
2 (4.0) 
3 (4.1) 
30 (4.7) 
8 (9.0) 
COPD 12 
964 (19.1) 
346 (25.4) *** 
139 (26.9) *** 
7 (14.0) 
8 (11.0) * 
165 (25.8) *** 
27 (30.3) * 
Asthm
a
 13 
636 (12.6) 
238 (17.5) *** 
104 (20.2) *** 
5 (10.0) 
5 (6.8) 
107 (16.7) * 
17 (19.1) 
Stroke 14 
426 (8.4) 
118 (8.7) 
25 (4.8) ** 
0 (0) * 
2 (2.7) 
74 (11.6) ** 
17 (19.1) *** 
Cancer 15 
775 (15.3) 
203 (14.9) 
63 (12.2) 
2 (4.0) * 
4 (5.5) * 
121 (18.9) ** 
13 (14.6) 
Sm
oking 
Status  
Num
ber (%
) 
Current 16 
1170 (23.2) 
349 (23.6) 
165 (32.0) ** 
18 (36.0) * 
21 (28.8) 
127 (19.9) ** 
18 (20.2) 
Non-sm
oker 
2194 (43.4) 
575 (42.2) 
196 (38.0) 
19 (38.0) 
25 (34.2) 
298 (46.6) 
38 (42.7) 
Ex-sm
oker 
1493 (29.5) 
428 (31.4) 
151 (29.2) 
12 (24.0) 
26 (35.6) 
209 (32.7) 
33 (37.1) 
Not know
n 
197 (3.9) 
11 (0.8) 
4 (0.8) 
1 (2.0) 
1 (1.4) 
5 (0.8) 
0 (0) 
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Table 7.8- ConƚinƵed͙
 
 Covariate 
Condition
 a 
No IRC(n=5054) 
All IRCs(n=1363) 
RA (n=516) 
AS (n=50) 
PsA (n=73) 
PM
R (n=639) 
GCA (n=89) 
O
besity
 Num
ber (%
) 17 
617 (12.2) 
197 (14.5) * 
102 (19.8) 
*** 
4 (8.0) 
12 (16.4) 
73 (11.4) 
6 (6.7) 
Alcohol dependence
 N (%
) 18 
88 (1.7) 
21 (1.5) 
12 (2.3) 
1 (2.0) 
3 (4.1) 
3 (0.5) * 
2 (2.2) 
Num
ber 
of 
prim
ary 
care 
contacts 
(12 
m
onths 
pre-index) 
M
ean (SD) 
13.0 (11.5) 
20.2 (12.1) 
20.1 (12.1) 
13.2 (8.3) 
15.2 (9.4) 
21.1 (11.9) 
23.0 (15.0) 
(n/10,000 
people, 
95%
 CI) 
0-5  
3146 
(3048, 3208) 
477 
(465, 486) 
484 
(474, 494) 
1600 
(1669, 1631) 
1507 
(1477, 1537) 
297 
(291, 303) 
225 
(220, 230) 
6-20 
4982 
(4884, 5080) 
5360 
(5255, 5465) 
5426 
(5320, 5532) 
6600 
(6470, 6730) 
5616 
(5506, 5726) 
5258 
(5155, 5361) 
5506 
(5398, 5614) 
21-50 
1743 
(1709, 1777) 
3822 
(3747, 3897) 
3818 
(3743, 3893) 
1800 
(1765, 1835) 
2877 
(2821, 2933) 
4116 
(4034, 4198) 
3596 
(3525, 3667) 
>50 19 
129 
(126, 132) 
301 
(295, 307) *** 
271 
(266, 276) * 
0 (0, 0) 
0 (0, 0) 
329 
(323, 345) *** 
674 
(661, 687) *** 
 Abbreviations; HF (heart failure), IHD (ischaem
ic heart disease), DM
 (diabetes m
ellitus), peripheral vascular disease (PVD), chronic obstructive pulm
onary disease (COPD), 
RA (rheum
atoid arthritis), AS (ankylosing spondylitis), PsA (psoriatic arthritis), PM
R (polym
yalgia rheum
atica), GCA (giant cell arteritis), SD (standard deviation), n (num
ber). 
a All IRCs and individual IRCs are com
pared to people w
ithout IRCs. P-values for the association betw
een different covariates and overall/ different IRCs are represented as 
*p<0.05, **p<0.01, ***p<0.001. W
here no asterix is given, associations are not statistically significant.  
b Reference categories for each covariate analysed are listed in footnotes 1-20 below
. 
 1 Aged 18-50 years Vs not aged 18-50 years,  2 Aged 51-65 years Vs not aged 51-65 years,  3 Aged 66-75 years Vs not aged 66-75 years,  4Aged 76-95 years Vs not aged 76-95 
years,  5  Fem
ale Vs m
ale gender,  6 M
ost Deprived Vs less deprived,  7 1 or m
ore com
orbidities in addition to IRC Vs no additional com
orbidities,  8 HF Vs no HF, 9 IHD Vs no IHD, 
10 DM
 Vs no DM
, 11 PVD Vs No PVD, 12 COPD Vs no COPD, 13 Asthm
a Vs no asthm
a, 14 Stroke Vs no stroke, 15 Cancer Vs no cancer, 16 Current Sm
oker Vs non-sm
oker, 17 Obese 
Vs not obese, 18 Alcohol dependence Vs no alcohol dependence, 19 Prim
ary Care Contacts >50 Vs Prim
ary Care Contacts ч50.
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7.4.2.3 Association between IRCs and anxiety alone, in addition to anxiety and/ 
or depression 
In this section I will discuss the number of new mood consultations, then will 
report the median follow-up time to a mood consutation post-index date. Subsequently, 
for anxiety alone, then for anxiety and/ or depression, I will discuss the incidence rate 
(IR) and the risk of mood problems in people with IRCs compared to those without, 
expressed as a HR with an associated 95% CI. These results are summarised in table 7.9 
(p229).  
7.4.2.3.1 Number of new mood consultations  
The proportion of new anxiety diagnoses was slightly higher in overall IRCs 
compared to those without IRCs (9.0% Vs 8.8%). New anxiety diagnoses were lower in 
people with PsA (6.4%) and AS (3.7%), though considerably higher in people with GCA 
(14.6%), compared to people without IRCs (8.8%).  
The proportion of new anxiety and/ or depression diagnoses was higher in 
overall IRCs compared to those without IRCs (14.7% Vs 12.4%). Although the proportion 
of new anxiety and/ or depression diagnoses was lower in people with AS (10.0%), the 
proportion in all other IRCs was higher, particularly in people with RA (15.5%) and GCA 
(19.1%). 
 
7.4.2.3.2 Median follow-up time to mood consultation  
 
The median follow-up time to an anxiety consultation date post-index was 
longer in individuals with IRCs (5.6 years (interquartile range (IQR) 2.4-9.1)), compared 
to those without IRCs (5.1 years (IQR 2.6-9.6)). This suggests that overall, people with 
IRCs presented to their general practice later with symptoms of anxiety than those 
without IRCs. Considering individual IRCs, the follow-up time to an anxiety consultation 
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was shorter in individuals with GCA (4.5 years (IQR 2.3-7.6), but longer for people with 
RA, AS, PsA and PMR, when compared to those without IRCs. Individuals with AS and 
PsA had the longest median follow-up time to anxiety consultation of 6.6 years, 
compared to 5.1 years in people without IRCs. 
The median follow-up time to an anxiety and/or depression consultation post-
index was slightly longer in individuals with IRCs (4.9 years (IQR 2.2-9.1)), compared to 
those without IRCs (4.8 years (IQR 2.2-8.7)), suggesting that people with IRCs presented 
to their general practice marginally later with symptoms of anxiety and/or depression 
than those without IRCs. Considering different IRCs, the follow-up time to an anxiety 
and/or depression consultation was shorter in individuals with GCA (4.2 years (IQR 1.7-
7.6), but longer for people with RA, AS and PsA, when compared to those without IRCs.  
 
7.4.2.3.3 Incidence rate and risk of anxiety alone, in addition to anxiety and/or 
depression  
The incidence rate (IR) of new anxiety following diagnosis with an IRC per 1000 
person years was marginally lower in people with IRCs (IR= 14.21 (95% CI= 11.95, 16.91)) 
compared to those without IRCs (IR= 14.62 (95% CI= 13.37, 15.98)). However, the IR of 
anxiety did vary according to the type of IRC, being higher in individuals with GCA and 
PMR, though lower in individuals with RA, PsA, and AS, compared to those without IRCs. 
The IR of anxiety was notably high in people with GCA (IR=26.76 (95% CI=15.85, 45.18)). 
There was no significant difference between the risk of new anxiety in people 
with IRCs, compared to those without IRCs (adjusted HR= 0.95 (95% CI=0.80, 1.15)). 
Considering different IRCs, the risk of anxiety was reduced in RA, AS and PsA, but 
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increased in PMR and GCA. The increased risk of anxiety in GCA was significant (adjusted 
HR=1.76, 95% CI=1.05, 2.95)), though other associations were not significant.  
The IR of new anxiety and/or depression was higher in people with IRCs (IR= 
24.38 (95% CI=21.21, 28.04)) compared to those without IRCs (IR= 21.50 (95% CI=19.88, 
23.24)). The IR of anxiety and/or depression was particularly high in individuals with GCA 
(IR= 38.15 (95% CI=23.72, 61.37)), compared to other IRCs. However, the IR of anxiety 
and/or depression did vary, being much lower in individuals with AS (IR= 16.16 (95% 
CI=6.73, 38.82)) and PsA (IR= 17.16 (95% CI=8.93, 32.98)), compared to those without 
IRCs. 
The adjusted risk of new anxiety and/or depression in people with IRCs was 
increased compared to those without IRCs (HR= 1.10 (95% CI=0.93, 1.29)), though this 
difference was not statistically significant. Considering different IRCs, the risk of anxiety 
and/or depression was reduced in RA, AS and PSA, though increased in PMR and GCA. 
The increased risk of anxiety and/ or depression was statistically significant in people 
with PMR when unadjusted (1.29 (95% CI=1.02, 1.65)), though significance was lost on 
adjustment (1.24 (95% CI=0.97, 1.59)). The other associations were not significant.  
For anxiety, in addition to anxiety and/or depression, when the proportional 
hazards (PH) assumption was tested, all p values were >0.05, meaning the ratio of the 
hazards for any two individuals over time was constant.  
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Table 7.9- The association of anxiety alone, in addition to anxiety and/or depression, w
ith overall and different IRCs over tim
e. 
 Condition 
1 
Anxiety alone 2 
Anxiety and/ or depression 3 
New
 anxiety 
diagnoses 
N (%
) 
M
edian f/u 
tim
e to m
ood 
consultation 
(IQ
R) 
IR (95%
 CI) 
(per 1000 
person years) 
Risk of anxiety in people w
ith, 
com
pared to w
ithout IRCs 
New
 anxiety 
and/or 
depression 
diagnoses 
N (%
) 
M
edian f/u 
tim
e to m
ood 
consultation 
(IQ
R) 
IR (95%
 CI) 
(per 1000 
person years) 
Risk of anxiety and/or depression 
in people w
ith, com
pared to 
w
ithout IRCs 
Unadjusted 
HR (95%
 CI) 
Adjusted HR 
(95%
 CI) * 
Unadjusted HR 
(95%
 CI) 
Adjusted HR 
(95%
 CI) * 
No IRC
 
482 (8.8) 
5.1  
(2.6, 9.6) 
14.62 
(13.37,15.98) 
0.98  
(0.81, 1.19) 
p=0.84 
0.95  
(0.80, 1.15) 
p=0.59 
629 (12.4) 
4.8 
(2.2, 8.7) 
21.50 
(19.88,23.24) 
1.04 
(0.85, 1.27), 
p=0.73 
1.10 
(0.93, 1.29), 
p=0.26 
All IRCs  
128 (9.0) 
5.6  
(2.4, 9.1) 
14.21  
(11.95,16.91) 
200 (14.7) 
4.9 
(2.3, 9.1) 
24.38  
(21.21, 28.04) 
RA
 
47 (8.7) 
5.7  
(2.8, 10.0) 
13.32  
(10.01,17.73) 
0.84  
(0.61, 1.15) 
p=0.28 
0.81  
(0.59, 1.11) 
p=0.18 
80 (15.5)  
6.5  
(2.3, 9.4) 
25.12  
(20.15, 31.32) 
1.02  
(0.79, 1.31), 
p=0.88 
0.96  
(0.95, 1.24), 
p=0.78 
AS
 
2 (3.7) 
6.6  
(3.2, 10.1) 
5.39  
(1.35, 21.57) 
0.45  
(0.10, 1.94) 
p=0.28 
0.42  
(0.09, 1.96) 
p=0.27 
5 (10.0) 
6.5  
(2.9, 9.3) 
16.16  
(6.73, 38.82) 
0.86  
(0.33, 2.28), 
p=0.77 
0.78 
(0.28, 2.17), 
p=0.63 
PsA
 
5 (6.4) 
6.6  
(2.8, 12.0) 
6.97  
(2.62, 18.57) 
0.45  
(0.16, 1.27) 
p=0.13 
0.43  
(0.15, 1.22) 
p=0.11 
10 (13.7) 
6.5  
(2.5, 12.0) 
17.16  
(8.93, 32.98) 
0.84  
(0.41, 1.72), 
p=0.63 
0.74  
(0.35, 1.57), 
p=0.44 
PM
R
 
61 (9.2) 
5.4  
(2.6, 8.9) 
15.40  
(11.98,19.79) 
1.16  
(0.87, 1.55) 
p=0.31 
1.12  
(0.84, 1.50) 
p=0.43 
89 (13.9) 
4.8  
(2.3, 8.6) 
23.93  
(19.42, 29.50) 
1.29  
(1.01, 1.65), 
p=0.04 
1.24  
(0.97, 1.59), 
p=0.08 
GCA
 
14 (14.6) 
4.5  
(2.3, 7.6) 
26.76  
(15.85,45.18) 
1.91  
(1.01, 3.61) 
p=0.04 
1.76  
(1.05, 2.95) 
p=0.03 
17 (19.1) 
4.2  
(1.7, 7.6) 
38.15  
(23.72, 61.37) 
1.64  
(0.94, 2.90), 
p=0.08 
1.63  
(0.92, 2.89) 
p=0.10 
 HR= hazard ratio, IQ
R= Interquartile Range, IR= Incidence Rate, CI= confidence interval, N= num
ber of individuals. 
* Adjusted for age, gender, ethnicity, sm
oking status, obesity, alcohol problem
s and com
orbidities (HF, IHD, DM
, PVD, COPD, Asthm
a, Stroke, Cancer). 
1 For all associations, overall IRCs and individual IRCs have been com
pared to people w
ithout IRCs. 
2 Num
ber of individuals w
ith IRCs for anxiety alone calculations; No IRC (n=5456), IRC (n=1423), RA (n=539), AS (n=54), PsA (n=78), PM
R (n=660), GCA (n=96).  
3 Num
ber of individuals w
ith IRCs for anxiety and/ or depression calculations; No IRC (n=5054), IRC (n=1363), RA (n=516), AS (n=50), PsA (n=73), PM
R (n=639), GCA (n=89).
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7.4.2.3.4 Association between IRCs and anxiety alone at different follow-up 
time points 
 
 
Table 7.10 shows the association between IRCs and time to diagnosis of new 
anxiety over different time periods between 0-5+ years. Due to the small numbers of 
individuals with AS (n=2), PsA (n=5) and GCA (n=14) who developed anxiety post-index, 
analysis for these conditions was not possible. Therefore, analysis across different time 
periods was limited to RA (n=47) and PMR (n=61), for which there were a greater 
number of individuals who developed anxiety post-index.  
Table 7.10- Association between RA, PMR and time to diagnosis of anxiety over different 
time periods. 
 
Association between IRCs 
and time to anxiety 
diagnosis  
Condition 
Overall IRCs 
(n=128) 
RA 
(n=47) 
PMR 
(n=61) 
HR over 
different 
time periods 
0-1 years 1 1.07 (0.74, 1.54) 0.81 (0.44, 1.48) 1.45 (0.84, 2.51) 
1-2 years 2 0.75 (0.45, 1.25) 0.76 (0.34, 1.61) 0.91 (0.42, 1.98) 
2-5 years 3 1.00 (0.80, 1.42) 1.10 (0.64, 1.89) 1.02 (0.67, 2.17) 
5+ years 4 0.94 (0.61, 1.44) 0.49 (0.21, 1.15) 1.20 (0.67, 2.17) 
 
HR= hazard ratio, ʖ Ϯ(p)= chi-squared and p-value 
 
1 Number with; overall IRCs (n=39), RA (n=13), PMR (n=20) 
2 Number with; overall IRCs (n=28), RA (n=10), PMR (n=11) 
3 Number with; overall IRCs (n=34), RA (n=16), PMR (n=14) 
4 Number with; overall IRCs (n=27), RA (n=8), PMR (n=15) 
 
In individuals with RA, the risk of new anxiety was increased between 2-5 years, 
but reduced before 2 years and over 5 years after diagnosis of RA. However, in 
individuals with PMR, the risk of anxiety was increased across all time periods apart from 
1-2 years. However, none of these associations were statistically significant. The risk of 
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anxiety was highest between 0-1 years after diagnosis of PMR, suggesting individuals 
with PMR were at a greater risk of developing anxiety soon after being diagnosed with 
an IRC, compared to individuals with RA, whom had an increased risk of anxiety between 
2-5 years post-index. These results also suggest that the risk of developing new anxiety 
remains increased over a longer time period following a diagnosis of PMR, when 
compared to RA. 
7.4.2.3.4 Association between IRCs and anxiety and/ or depression at different 
follow-up time points 
 
Table 7.11 (p232) shows the association between IRCs and time to diagnosis of 
new anxiety and/or depression over different time periods between 0-5+ years. Due to 
the small numbers of individuals with AS (n=5), PsA (n=10) and GCA (n=17) who 
developed anxiety and/or depression post-index, analysis for these conditions was not 
possible. Therefore, analysis across different time periods was limited to RA (n=80) and 
PMR (n=89), for which there were a greater number of individuals who developed 
anxiety and/or depression post-index.  
In people with RA, the risk of new anxiety and/or depression was only increased 
between 1-2 years, whereas in people with PMR, the risk of anxiety and/or depression 
was increased across all time periods, being highest between 0-1 years after diagnosis. 
Although no associations were statistically significant, results suggest that people with 
PMR are at a higher risk of developing anxiety and/or depression at an earlier time point 
after being diagnosed with an IRC, compared to people with RA. These results also 
suggest that the risk of developing new anxiety and/or depression remains increased 
over a longer time period following a diagnosis of PMR, when compared to RA. 
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Table 7.11- Association between RA, PMR and time to diagnosis of anxiety and/or 
depression over different time periods. 
 
Association between IRCs 
and time to diagnosis of 
anxiety and/ or depression 
Condition 
Overall IRCs 
(n=200) 
RA 
(n=80) 
PMR 
(n=89) 
HR over 
different 
time 
periods 
0-1 years 1 1.26 (0.95, 1.66) 0.74 (0.40, 1.38) 1.51 (0.97, 2.35) 
1-2 years 2 1.89 (0.59, 1.33) 1.17 (0.75, 1.81) 1.24 (0.69, 2.24) 
2-5 years 3 1.19 (0.90, 1.56) 0.79 (0.40, 1.56) 1.18 (0.77, 1.81) 
5+ years 4 0.92 (0.60, 1.40) 0.98 (0.64, 1.51) 1.15 (0.63, 2.07) 
 
HR= hazard ratio, ʖ Ϯ(p)= chi-squared and p-value 
 
1 Number with; overall IRCs (n=57), RA (n=21), PMR (n=27) 
2 Number with; overall IRCs (n=67), RA (n=27), PMR (n=23) 
3 Number with; overall IRCs (n=42), RA (n=15), PMR (n=21) 
4 Number with; overall IRCs (n=34), RA (n=17), PMR (n=18) 
 
 
7.4.5 Summary of Results 
Overall, anxiety alone affected similar proportions with and without IRCs, whilst 
anxiety and/ or depression were more common in people with IRCs, compared to those 
without IRCs. Over time, people with IRCs were less likely to develop anxiety alone, 
though more likely to develop anxiety and/ or depression. People with IRCs had a longer 
median follow-up time to first anxiety consultation, and first anxiety and/ or depression 
consultation, compared to people without IRCs.  
Considering different IRCs, the prevalence of anxiety alone, in addition to anxiety 
and/ or depression, was higher in RA, AS, PsA and GCA, though lower in PMR, compared 
to people without IRCs. Whilst individuals with AS and PsA were less likely to develop 
anxiety alone, or anxiety and/or depression over time, people with PMR and GCA were 
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more likely to develop mood problems, when compared to people without IRCs. 
Meanwhile, people with RA were less likely to develop anxiety alone, though more likely 
to develop anxiety and/ or depression over time.  
When the association between RA, PMR and time to diagnosis with a mood 
problem was assessed over different time periods, individuals with PMR were noted to 
be at a greater risk of developing mood problems soon after being diagnosed with an 
IRC. Individuals with RA only had an increased risk of developing anxiety between 2-5 
years post-index, whilst their risk of developing anxiety and/ or depression was 
increased between 1-2 years post-index. Only individuals with GCA had a shorter 
median follow-up time to first mood consultation, compared to individuals without IRCs. 
 
7.5 Discussion                                                                                                  .    
 
7.5.1 Cohort characteristics  
The proportion of individuals with different IRCs, their ages and gender ratios, 
reflected patterns observed in other population epidemiological studies. Interestingly, 
individuals with IRCs were not significantly less deprived than those without IRCs, apart 
from in the incidence of anxiety and/ or depression cohort, where a significant 
association was found between AS and deprivation (table 7.8). This contrasts with the 
literature, which suggests individuals with long-term conditions (LTCs) are more likely 
to be socioeconomically deprived (Barnett et al., 2012, Elliot, 2016). Deprivation status 
was calculated using the IMD, which is linked to an individuals͛ postcode. It is possible 
that individuals͛ postcodes did not accurately reflect their living standards. Housing has 
become less affordable in the 21st century (HM Land Registry, 2019), hence younger 
people with AS could have been forced to rent accommodation, or buy housing in a less 
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affluent area, compared to someone earning an equivalent amount 20 years ago.  
Meanwhile, older people with PMR or GCA could have been living in the same home all 
their life, which may not reflect their ability to afford good living standards. 
Ethnicity was not reported, as a large proportion with IRCs (19%) and without 
IRCs (27%) had no recorded ethnicity. For those with a Read code for their ethnicity, the 
majority (98%) were white British. This could have been a reflection of local population 
demographics, though it is possible other ethnicities could have been under-
represented due to poor coding within general practice records. 
More people with IRCs were current smokers and obese, though there was no 
significant difference between the proportions with and without IRCs who had a Read 
code for alcohol misuse or dependence. The literature suggests individuals with LTCs, 
including IRCs, are more likely to smoke, be overweight and consume excess alcohol 
(Velten et al., 2018), though alcohol dependence was not more frequent in people with 
IRCs. Although more people with PsA had a Read code for alcohol dependence, 
significantly less people with AS and PMR had a history of alcohol dependence, 
compared to people without IRCs. It is possible that many individuals who consumed 
excess alcohol alcohol were not identified, due to Read codes for alcohol misuse and 
dependence being used to define excessive consumption of alcohol (as discussed in 
section 7.3.3.4 and listed in appendix 20), rather than the number of units consumed by 
individuals. However, the amount of alcohol consumed by individuals is often not 
explored or coded during primary care consultations, with the literature suggesting that 
alcohol disorders are under-recognised within general practice in the UK (Cheeta et al., 
2008). Evidence also suggests that people under-report the amount of alcohol they 
consume (Boniface & Shelton, 2013), potentially leading to under-recognition of alcohol 
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disorders. In addition, some individuals with IRCs could also have been counselled 
against consuming alcohol due to potential interactions with their medication. 
Furthermore, differences in smoking behaviour and obesity observed between people 
with and without IRCs, could have been due to surveillance bias, whereby individuals 
with IRCs had more primary care contacts, providing more opportunities for lifestyle 
factors to be discussed and recorded. It is also possible that some differences didn͛t 
meet statistical significance due to the small sample of individuals, particularly with AS 
and PsA.  
In common with existing literature (Naylor et al., 2012), individuals with IRCs had 
significantly more comorbidities than those without IRCs. An older mean age and 
glucocorticoid treatment side-effects could have contributed to the increased number 
of comorbidities, particularly cardiovascular disease (CVD), observed in people with GCA 
and PMR, compared to other IRCs. Meanwhile, the increased prevalence of cancer in 
PMR could have been due to overlapping symptoms of PMR and different malignancies 
(NICE, 2013b), leading to some individuals with early cancer being misdiagnosed with 
PMR. Meanwhile, the lower mean age of people with AS and PsA could explain the 
reduced prevalence of IHD, cancer and stroke in these IRCs, compared to those without 
IRCs. The increased prevalence of COPD in overall IRCs could have been contributed to 
by increased numbers of current smokers, compared to those without IRCs. 
The number of primary care contacts was higher in people with IRCs compared 
to those without IRCs. This could have been due to flares of the IRC requiring treatment 
or due to individuals with IRCs having more comorbidities requiring review in primary 
care. However, a limitation of this study was that primary care contacts included letters 
scanned onto a patients͛ record, or blood results (with several tests entered on one day 
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counting as a single contact), in addition to other entries such as telephone or face-to-
face consultations. Therefore, the higher contact rate in individuals with IRCs could have 
been due to rheumatology clinic letters and disease modifying anti-rheumatic drug 
(DMARD) monitoring blood tests being entered on the primary care records, rather than 
due to increased face-to-face contacts. A more accurate impression could have been 
gained by only recording telephone and face-to-face contacts with patients, though this 
would have required a manual review of thousands of peoples͛ records, which was not 
feasible. 
 
7.5.2 Prevalence of mood problems in people with IRCs  
The prevalence of anxiety alone, in addition to anxiety and/or depression, was 
higher in overall IRCs, RA, AS, PsA and GCA, when compared to those without IRCs. This 
would fit with the background literature, which suggests anxiety and depression are 
more prevalent in RA, as discussed in section 2.9.1 (Isik et al., 2006; Matcham et al., 
2013). These findings would also support the literature discussed in section 2.9.3 which 
reported an increased prevalence of anxiety and depression in AS (Hopkins & Moulton, 
2016; Shen et al., 2016) and PsA (McDonough et al., 2014). These findings would also 
support limited research showing a higher prevalence of depression in individuals with 
GCA (Li, Neogi & Jick, 2017), whilst providing new evidence of an increased prevalence 
of anxiety in GCA. 
However, the prevalence of anxiety alone, in addition to anxiety and/or 
depression, was lower in individuals with PMR, compared to individuals without IRCs. 
This contrasts with the limited background literature on mood problems in PMR, that 
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suggests 15-22% have self-reported symptoms of depression (Vivekanatham et al., 
2018; Muller et al., 2016) and 13% anxiety (Muller et al., 2016).  
It is unclear why anxiety or depression were less prevalent amongst individuals 
with PMR. As reported in table 7.2, primary care contacts were higher in individuals with 
PMR compared to those without IRCs, providing more potential opportunities for the 
recognition and coding of mood problems. However, compared to the other IRCs 
analysed, PMR is a condition that is more frequently managed within primary care. 
Therefore, primary care consultations could have been more focussed on medical 
management, including the prescription of glucocorticoids for treatment of the primary 
condition, leaving less time to discuss potential mood problems. In contrast, when 
consulting individuals with other IRCs largely managed by secondary care, such as RA, 
primary care practitioners may have had more opportunity to focus on comorbid 
problems during consultations. However, it could be argued that as PMR is more 
frequently managed in primary care, practitioners would have more opportunity to 
build rapport with affected patients over a series of consultations, facilitating disclosure 
and discussion of mood concerns.  
Prevalence rates were calculated over 12 months pre-index (12 months before 
the date of an IRC first being coded in the EMIS record). Therefore, glucocorticoid 
treatment could not have affected the prevalence of mood problems, as it would not 
have been started, unless the patient was prescribed glucocorticoid treatment for 
another condition. Alternatively, after developing symptoms, individuals with PMR 
could have presented earlier to primary care, or could have been diagnosed and 
managed more promptly than other IRCs, leaving less opportunity over the 12 months 
prior to diagnosis for mood problems to develop. 
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Following adjustment, the odds of anxiety alone became marginally reduced in 
individuals with IRCs, though the odds of anxiety and/or depression were increased, 
when compared to individuals without IRCs. However, these differences were not 
statistically significant. The reduced odds of anxiety alone in people with IRCs, contrasts 
with the prevalence results, which suggested that anxiety was more frequent in 
individuals with IRCs. 
When different IRCs were analysed, the odds of anxiety alone, in addition to 
anxiety and/ or depression, were increased in people with RA, AS, PsA and GCA, though 
reduced in people with PMR, compared to people without IRCs. However, the only 
statistically significant associations were found between PsA and GCA, and increased 
anxiety and/or depression. These associations remained significant after adjustment for 
covariates. As 46% of individuals with IRCs in the prevalence dataset had PMR, they 
heavily influenced the overall association between IRCs and anxiety. In addition, lower 
adjusted ORs between RA, AS, GCA and anxiety, when compared to anxiety and/or 
depression, could have contributed to the reduced overall odds of anxiety in IRCs. 
Of interest, the prevalence of anxiety, in addition to anxiety and/or depression, 
was highest in individuals with PsA and GCA, whilst the adjusted odds of anxiety and/or 
depression were also significantly increased in individuals with PsA and GCA. This is 
noteworthy, given that past research has largely focused on the association between RA 
and mood problems, as these findings suggest that comorbid mood problems are a 
potentially greater problem amongst individuals with PsA and GCA. 
When the association between covariates in people with IRCs and mood 
problems were analysed, the odds of having a Read coded mood problem were found 
to be reduced in people aged 66-75 years. The literature suggests that older people 
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frequently normalise mood problems, or can be more self-reliant, which can be barriers 
to them presenting to their GP or seeking help for mood problems (Wuthrich & Frei, 
2015). In addition, primary care practitioners may not recognise depression in older 
adults due to normalising it as an understandable aspect of ageing (Burroughs et al., 
2006), hence it is possible the odds of having a Read coded mood problem were reduced 
in older people due to under-recognition in this age group. In contrast, the odds of 
individuals with IRCs having anxiety alone, and anxiety and/ or depression were 
significantly increased in people aged 18-50 years. Recent research has shown a rise in 
mood disorders in younger general population cohorts, particularly females, potentially 
related to cultural trends, including an increase in electronic communication and digital 
media use, in addition to a reduction in sleep quality (Twenge et al., 2019).  
Prior to adjustment, female gender also had a significant association with anxiety 
and/ or depression. This reflects the literature on mood problems in the general 
population, which suggests women have a higher lifetime prevalence of depression and 
anxiety disorders, compared to men (Riecher-Rossler, 2016). In addition, a high number 
of primary care contacts were significantly associated with mood problems, likely due 
to these contacts providing a more opportunities for discussion of potential anxiety or 
depression. It is also possible that those with more primary care contacts had other 
comorbidities which could have increased their risk of developing a mood problem.  
No association was found between deprivation and anxiety and/ or depression, 
in contrast to the literature which suggests deprivation is associated with increased 
mood problems (Freeman et al., 2016). It is possible that the cohort of patients included 
in this study were less deprived than a general population cohort, though the CiPCA 
database does include people from a range of socioeconomic backgrounds.  Alcohol 
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dependence was associated with mood problems in people with IRCs, mirroring 
associations seen within the general population (Raimo & Schuckit, 1998).  
The odds of anxiety and depression were increased in people with IRCs who had 
one or more additional comorbidities, though this association was not statistically 
significant. This is surprising as the literature suggests that people with several LTCs are 
significantly more likely to develop mood problems (Read et al., 2017). Cancer was the 
only comorbidity analysed found to have a significant association with mood problems 
in people with IRCs after adjustment, despite other LTCs such as COPD (Naylor et al., 
2012), DM (Salinero-Fort et al., 2018) and coronary heart disease (CHD) (Bankier, Januzzi 
and Littman, 2004), having well established links with mood problems.  
An increased number of primary care contacts were significantly associated with 
mood problems in overall IRCs, in addition to RA and PMR, when they were analysed 
separately. Evidence suggests that mood problems can affect help-seeking behaviour, 
with anxious or depressed people potentially consulting more often (Fine et al., 2018). 
Whilst these individuals could have been consulting more for management of their 
anxiety or depression, they may also have been consulting due to increased pain or 
stiffness in relation to their IRC. Evidence suggests depression in people with IRCs is 
associated with increased disease activity (Matcham et al., 2016b), whilst my systematic 
review, discussed in chapter 6, also highlighted links between anxiety in people with 
IRCs and increased disease activity.  
 
7.5.3 Incidence of mood problems in people with IRCs  
The time to first mood consultation was longer in people with IRCs, compared to 
those without IRCs. However, the time to first mood consultation varied between 
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different IRCs, being shorter in people with GCA, though longer in people with RA, AS, 
PsA and PMR compared to those without IRCs. Overall, this suggests that people with 
IRCs presented later with symptoms of mood problems. It is possible that this trend was 
observed due to primary care consultations for people with IRCs focussing on the 
management of their inflammatory condition or other comorbidities, which are more 
frequent in people with IRCs. These competing priorities could have been a barrier to 
discussion of, or coding of mood problems. However, individuals with GCA were noted 
to present earlier with mood symptoms than people with other IRCs. A higher burden 
of multimorbidity could have led to individuals with GCA being more likely to be 
consulters, where they could have been asked about mood problems, contributing to 
earlier recognition of comorbid anxiety and depression. In particular, people with other 
LTCs, such as DM or COPD, could have attended a nurse-led annual review for this 
comorbid condition, where they could have been asked about potential mood 
problems. 
Overall, the incidence and adjusted HR of anxiety were reduced in people with 
IRCs, compared to those without IRCs. However, when different IRCs were analysed, the 
incidence and HR of anxiety were increased in individuals with PMR and GCA, though 
reduced in people with RA, AS and PsA, compared to those without IRCs. Of note, the 
adjusted HR of anxiety was significantly increased in GCA. These findings support limited 
literature showing an increased incidence of anxiety symptoms in people with PMR 
(Muller et al., 2016), whilst also adding to the literature by highlighting a particularly 
increased incidence and risk of anxiety in people with GCA. However, the findings for 
RA, contrasted with limited literature showing an increased incidence of anxiety in RA 
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(Marrie et al., 2018b, Qui et al., 2019) and AS (Shen et al., 2018), whilst providing 
evidence to suggest a reduced incidence of anxiety in PsA. 
Alternatively, it is possible that anxiety in individuals with RA, AS and PsA were 
not recognised or coded in the clinical records. As shown in table 7.2, primary care 
contact rates were lower in individuals with AS and PsA, than those without IRCs. The 
burden of comorbidities was also lower in people with AS and PsA compared to 
individuals with other IRCs, meaning people with these conditions would have had less 
opportunities to discuss potential mood problems. In addition, there were less 
individuals with AS (n=54) and PsA (n=78) in the anxiety incidence dataset compared to 
other IRCs, which could have limited the reliability of results.  
However, these reasons could not be used to explain the reduced incidence of 
anxiety in people with RA, as the sample size was comparatively larger for RA (n=539), 
whilst individuals with RA had higher primary care contact rates and a greater burden 
of comorbidities than people without IRCs, which would have provided further 
opportunities for the potential recognition of anxiety. However, ϵϱй CI͛s reported with 
the HR͛s for anxiety were particularly wide in RA, AS and PsA, suggesting a greater 
sample size still would have been required to accurately determine the association 
between these IRCs and anxiety. It is also possible that the burden of mood problems 
was not as high as expected due to this study using a primary care cohort. Individuals 
may have had less severe symptoms, compared to those managed in secondary care, 
where most of the prior prevalence studies were based.  
The incidence and adjusted HR of anxiety and/or depression was increased in 
people with IRCs, compared to those without IRCs. However, results again varied 
between different IRCs. Whilst the incidence of anxiety and/or depression was 
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increased in PMR and particularly GCA, it was reduced in people with AS, and PsA, 
compared to those without IRCs. Results were mixed for RA, with an increased incidence 
though a reduced adjusted HR of anxiety and/ or depression. Findings were supported 
by limited background literature, showing the incidence of anxiety and depression to be 
increased in PMR (Muller et al., 2016), GCA (Li, Neogi and Jick, 2017) and RA (Marrie et 
al., 2018b). However, findings for AS and PsA, contrasted with the literature, which 
suggests the incidence of anxiety and depression is increased in people with AS 
(Meesters et al., 2014; Wu et al., 2017, Shen et al., 2016), whilst the incidence of 
depression has also been found to be higher in people with PsA (Zusman et al., 2018). It 
is possible that the aforementioned reasons, including lower primary care contact rates 
and small sample sizes for AS and PsA contributed to the disparity in these results.  
When the risk of anxiety, in addition to anxiety and/or depression, in people with 
RA and PMR was examined over time, the risk of mood problems in PMR was raised 
over most time periods, particularly between 0-1 years after diagnosis. In contrast, the 
risk of mood problems in RA was only raised between 2-5 years after diagnosis for 
anxiety, and 1-2 years after diagnosis for anxiety and/or depression, suggesting that 
case-finding for comorbid anxiety and depression needs to be considered at an earlier 
time point after diagnosis in people with PMR, compared to those with RA. It is possible 
that the higher risk of mood problems after diagnosis of PMR could relate to the side-
effects of glucocorticoid treatments, which are known to potentially cause mood 
disturbances (Brown, 2009). 
7.5.4 Comparison of Prevalence and Incidence Results 
 
 The prevalence of anxiety was increased, though the adjusted odds of anxiety 
reduced in people with IRCs, compared to those without IRCs. The incidence and 
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adjusted HR of anxiety were also reduced in people with IRCs compared to those 
without IRCs. These contrasting non-significant results suggest further research is 
needed using a larger dataset to more accurately determine the association between 
IRCs and anxiety. 
Considering different IRCs, the prevalence and odds of anxiety were increased in 
RA, AS and PsA, though the incidence of anxiety reduced. Meanwhile, the prevalence of 
anxiety in PMR was reduced, though the incidence of anxiety was increased. The only 
IRC in which the incidence and prevalence of anxiety were increased was GCA. As 
prevalence rates were calculated over a 12-month period before the diagnosis of an IRC, 
whilst IR͛s were calculated from the date of diagnosis with an IRC, differences in 
prevalence and incidence rates could have related to variations in treatment response.  
For example, although the prevalence of anxiety was less in PMR, its͛ incidence was 
increased, suggesting treatment for PMR with glucocorticoids could have adversely 
affected mood. In addition, the increased prevalence, though reduced incidence of 
anxiety, in people with RA, AS and PsA, could have reflected an improvement in mood 
in response to better disease control following initiation of a DMARD.  
The incidence and prevalence of anxiety and/or depression were increased in 
people with IRCs, compared to those without IRCs. Considering different IRCs, although 
the incidence and prevalence of anxiety and/or depression were increased in people 
with RA and GCA, results varied for other IRCs. For example, the prevalence of anxiety 
and/or depression was reduced in PMR, though the incidence of mood problems was 
increased. The reverse was found in people with PsA and AS, who had an increased 
prevalence, though a reduced incidence of anxiety and/ or depression. Again, changes 
in mood in response to treatment could partially explain these contrasting results. 
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Whilst glucocorticoids could potentially provoke or worsen mood problems in 
individuals with PMR, leading to an increased incidence of anxiety and/or depression, 
treatments including anti-inflammatories or DMARDs could have led to reduced disease 
activity, hence a reduced incidence of anxiety and/or depression in individuals with AS 
and PsA. However, the incidence of mood problems remained high in RA, suggesting 
that despite treatment of the inflammatory condition, mood problems continued to 
effect people with this condition over time. The incidence and prevalence of anxiety 
and/or depression was highest in GCA, suggesting a particularly significant burden of 
mood problems in people with this IRC.  
 
7.5.5 Strengths and Limitations 
 
A strength of this study is that it utilised the CiPCA database, a well established 
database of anonymised medical record data from a subset of general practices in North 
Staffordshire, which have followed the Keele consultation data audit, training and 
validation programme, hence code clinical activity to a high standard (Porcheret et al., 
2004). Therefore, the quality of data is comparable to larger national databases (Jordan 
et al., 2007). However, a national database such as the CPRD would have provided more 
generalisable results due to data being derived from a larger number of more diverse 
individuals from across the UK. Due to the greater number of individuals in the CPRD 
database, statistical power would have been increased, enabling stronger conclusions 
to be made about the association between IRCs and mood problems, with less chance 
of type 1 errors, where a null hypothesis is incorrectly rejected. Having a larger number 
of individuals within the dataset would also have enabled analysis of the association 
between AS, PsA and GCA, and mood problems over time to be completed. 
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As discussed in section 7.3.3.1, the reliance on coded consultation data meant 
that depression alone could not be accurately analysed, due to it often being recorded 
using the Read code ͞anxiety with depression͟. A depression Read code list excluding 
the code ͞anxiety with depression͟ could have been used, though this could have led to 
a large number of people with mood problems being excluded from the analysis. 
Although depression alone was not examined, the depression and anxiety Read code 
lists were combined to enable analysis of individuals with anxiety and/ or depression. 
Although anxiety alone was analysed, it is possible some cases were missed that 
were only recorded in the clinical record in combination with depression. However, 
when an individual consults their GP with predominantly anxiety symptoms, a Read 
code for anxiety is usually recorded, not ͞anxiety with depression͟. In addition, 
analysing anxiety alone was felt to be important, due to the lack of literature reporting 
the prevalence of anxiety in different IRCs, in addition to the findings of the systematic 
review discussed in chapter 6, which suggested a significant association between 
anxiety in people with RA, and QoL and disease activity. 
Missing data on smoking, alcohol and obesity has been shown to not be missing 
at random in electronic health record datasets, hence multiple imputation techniques 
were not used. Instead, a more simplistic approach was used, where separate categories 
were created for those with missing data. A further potential limitation was unmeasured 
confounding. It is possible that some influential confounding factors could not be 
accounted for due to them being poorly recorded in the electronic health records, for 
example, a family history of mental illness.   
As this study relied on primary care consultation data, it is possible that some 
codes could have been misclassified. In addition, the use of consultation data could have 
  247 
led to the incidence and prevalence of mood problems being under-estimated, 
Individuals may not have presented to primary care, or disclosed symptoms of anxiety 
or depression, due to lacking candidacy for care of mood problems (Coventry et al., 
2011), or fearing of potential stigmatisation (Anderson et al., 2012). In addition, 
clinicians may not have recognised or recorded symptoms of potential mood problems. 
Evidence suggests that less than half of common mental disorders (CMDs), including 
anxiety and depression, are identified in primary care consultations (Goldberg & Huxley, 
1991). In particular, when people with psychological disorders normalise their 
symptoms, general practitioners are less likely to diagnose a mood disorder (Kessler, 
Lewis & Gray, 1999).  
 
7.6 Patient and Public Involvement and engagement                                   ..   
 
 The results of this study were discussed during a patient and public involvement 
and engagement (PPIE) meeting, attended by six individuals with different IRCs. 
Participants were interested to hear that the prevalence of anxiety, in addition to 
anxiety and/or depression was highest amongst individuals with PsA and GCA, rather 
than RA, as they had previously only heard about mood problems being linked to RA, 
not other IRCs. They were also interested to hear that individuals with PMR and GCA 
were more likely to develop mood problems over time, compared to other IRCs. 
Participants were surprised that mood problems were not more prevalent in people 
with PMR, like the other IRCs analysed, and queried whether mood problems were 
potentially not being recognised in people with IRCs within primary care. Therefore, 
they felt it would be important to share the results with patients to raise awareness of 
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the increased risk of comorbid mood problems in people with IRCs, whilst also informing 
primary care practitioners about the results.  
 Suggestions for dissemination included a presentation to the patient user group 
at the local rheumatology hospital and discussion with the members of the national 
rheumatoid arthritis society based in Stoke-on-Trent. Further ideas included to use 
social media to reach out to younger people with certain types of IRCs and to inform 
national organisations such as Versus Arthritis about research outcomes. Participants 
reflected that the wider multidisciplinary team in general practice may have more time 
than GPs to explore potential mood problems, hence they suggested a practice bulletin 
could be used to help inform healthcare assistants, nurses, pharmacists and physician 
associates. A dissemination plan was developed, taking account of these suggestions. 
Appendix 27 contains details of the presentations I have given to help disseminate my 
results, including those made to different lay audiences. 
 
7.7 Conclusion                                                                                                          .   
 
This study has provided new evidence of an increased prevalence of mood 
problems in people with GCA, whilst providing further evidence to support an increased 
prevalence of mood problems in people with RA, AS and PsA. Despite past research into 
mood problems in people with IRCs being focused on RA, this study found the 
prevalence of anxiety and/or depression to be highest in individuals with PsA and GCA. 
This study has also provided new evidence of an increased incidence of anxiety, in 
addition to anxiety and/or depression in people with PMR and GCA. As a consequence, 
future research needs to focus on the impact of comorbid mood problems in AS, PsA, 
PMR and GCA, to build on past research, which has focused on the impact of mood 
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problems in people with RA. Intervention studies could help to determine the most 
feasible and acceptable approach to improving the recognition and management of 
comorbid anxiety and depression in people with different IRCs. Guidelines also need to 
reflect evidence of an increased incidence and prevalence of mood problems in certain 
IRCs, particularly anxiety and/ or depression in people with PsA and GCA, to encourage 
improved recognition and management.  
This study has also shown the risk of anxiety alone, in addition to anxiety and/or 
depression to be highest at an earlier time point after diagnosis in individuals with PMR, 
compared to people with RA. This difference could potentially be related to the side-
effects of glucocorticoid treatment. However, it highlights the need for clinicians to 
consider case-finding for potential mood problems at an early stage after diagnosis in 
people with PMR. 
Overall, this study highlights the scale of mood problems in people with IRCs and 
the requirement to improve pathways to identify and manage comorbid mood 
problems, which could potentially reduce associated morbidity and mortality.  
 
7.8 Connection to the subsequent study                                                           .    
 
I conducted this study concurrently with my systematic review, which 
highlighted the burden of anxiety in people with RA, justifying the need for anxiety and 
depression to be given equal priority. Informed by the suggestions of my PPIE group in 
chapter 5 (section 5.8), and taken in response to a lack of literature on mood problems, 
particularly anxiety, in people with PMR and GCA, I conducted this cohort study to 
determine the incidence and prevalence of mood problems in different IRCs.  
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Through this cohort study, I have determined that mood problems are more 
common in different IRCs, particularly PsA and GCA. However, the incidence and 
prevalence rates of mood problems may have been under-estimated, as I have relied on 
Read codes from primary care data. Individuals with IRCs may not have recognised 
mood symptoms or sought help within primary care. In addition, practitioners may not 
have identified or recorded mood problems in the electronic health records of people 
with IRCs presenting with mood symptoms. My qualitative study in chapter 5, 
highlighted the many potential barriers to the recognition of mood problems in people 
with RA.  
Therefore, for my final study, I have used the case-finding questions to 
determine the proportion of people living with different IRCs who have anxiety or 
depression. This research has been conducted as part of the INCLUDE study, a pilot trial 
aiming to determine the feasibility and acceptability of a nurse-led review for people 
with IRCs. Drawing on my qualitative study outcomes, systematic review findings and 
cohort study results, in addition to the suggestions made by PPIE group members, this 
review has taken place within the context of a nurse-led review, based in primary care. 
I have aimed to determine the prevalence of mood problems in people with different 
IRCs participating in the INCLUDE study, through the analysis of responses to the case-
finding questions for anxiety and depression within baseline questionnaires. This has 
helped me to clarify the potential number of unrecognised mood problems in people 
with IRCs, by comparing differences between the proportion of mood problems which 
are recognised and recorded within primary care electronic records, to the number of 
mood problems identified following the use of the case-finding questions, within the 
INCLUDE baseline questionnaires.  
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8.0 INCLUDE STUDY 
 
8.1 Background                                                                                       .    
 
As described in section 2.9.1, people with RA are at an increased risk of common 
comorbidities, including anxiety and depression, which are often not recognised or 
treated, and can contribute to increased morbidity and mortality. 
Nurse-led care focussed on comorbidity management for individuals with 
rheumatoid arthritis (RA), has been found to increase the number of interventions taken 
to manage related comorbidities, such as initiation of lipid-lowering therapy and 
medication to treat osteoporosis (Dougados et al, 2015). However, this care is often 
delivered by specialist rheumatology services, rather than in primary care, where 
clinicians have more experience in providing care for individuals with multimorbidity 
(Smith et al., 2012).  
As discussed in section 2.9.1, the National Institute for Health and Care 
Excellence (NICE) quality standards for RA (QS33), recommend that clinicians should 
regularly reassess mood within the context of a holistic annual review (NICE, 2013c). 
Although the Quality and Outcomes Framework (QOF) provides an incentive for an RA 
annual review, the content of this is not specified, meaning important aspects could be 
missed. A national General Practitioner (GP) survey performed in 2015 found that 
primary care reviews frequently lack key elements, such as case-finding for depression 
(Hider et al., 2015), meaning potential opportunities for intervention are being missed. 
Evidence suggests that people with other inflammatory rheumatological 
conditions (RCs), including ankylosing spondylitis (AS), psoriatic arthritis (PsA), 
polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) can also be at an increased 
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risk of developing comorbidities such as cardiovascular disease (CVD) (Jamnitski et al., 
2013) (Hancock et al., 2012), osteoporosis (Gullick and Scott, 2011) and anxiety and 
depression (Meesters et al., 2014; McDonough et al., 2014; Vivekanatham et al., 2018; 
Li, Neogi & Jick, 2017). Literature reporting the prevalence of mood problems in IRCs is 
discussed within the background chapter (section 2.9.3), highlighting the lack of 
evidence available, particularly for PMR and GCA. Results from the cohort study (chapter 
7), have provided some evidence of the links between IRCs and mood problems. Despite 
the increased risk of comorbidities in AS, PsA, PMR and GCA, there are no incentives 
within the QOF for individuals with these conditions to have an annual review. In 
addition, NICE guidelines for these conditions do not suggest a similar annual review to 
improve the identification and management of potential comorbidities.  
To examine the feasibility and acceptability of a nurse led comorbidity review for 
these patients, a research study, INCLUDE (INtegrating and improving Care for patients 
with infLammatory rheUmatological DisordErs in the community: A pilot randomised 
controlled trial), (Hider et al., 2018) was conducted.  
Within the INCLUDE study, patients with RA, AS, PsA, PMR and GCA from 
intervention practices, were invited to attend a nurse-led review at their registered 
practice. These patients were compared to those from control practices who continued 
to receive usual care. Individuals from control and intervention practices were sent 
questionnaires at baseline, 3 and 6 months to help assess the impact of the review. 
Within the questionnaires, multiple domains were assessed, including mood, through 
use of the EuroQol 5-Dimension Scale (EQ-5D), Patient Health Questionnaire (PHQ)-8 
and Generalised Anxiety Disorder (GAD)-7 questions. 
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 The review was delivered by a rheumatology specialist nurse. During their 
review, patients were assessed for comorbidities linked to their long-term condition 
(LTC), including CVD, fracture risk, anxiety and depression. Patients were offered 
appropriate lifestyle advice, signposted to self-management resources or advised to 
attend a follow-up appointment with their practice nurse (PN) or GP, for additional 
comorbidity management (Hider et al., 2018). 
 
8.2 Aims and Objectives                                                                        .    
 Using data from the INCLUDE study, my aim was to determine the self-reported 
prevalence of anxiety and depression symptoms in people with different IRCs (RA, AS, 
PsA, PMR and GCA) and factors associated with self-reported mood problems. 
 
8.3 Methods                                                                                            .    
The INCLUDE study methods are described in detail within the published 
protocol (Hider et al., 2018), but brief context to the study design and methods is 
provided below. A flow chart for the INCLUDE study, sourced from the published 
protocol, is displayed in figure 8.1 (p255) (Hider et al., 2018).  
 
8.3.1 Design and setting 
The INCLUDE study is a pilot cluster feasibility study based in primary care in the 
United Kingdom (UK). Within this study, the units of randomisation were participating 
general practices and the units of observation, adults meeting the eligibility criteria 
outlined in section 8.3.2.2. 
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8.3.2 Participants 
8.3.2.1 General Practices 
General practices were recruited from the West Midlands North via the National 
Institute for Health Research (NIHR) Clinical Research Network (CRN). Practices were 
eligible for inclusion if they were willing to participate and provide clinical rooms, and if 
they used the clinical operating system, EMIS Web (EMIS Health, 2019).  
Figure 8.1- INCLUDE study flowchart (from Hider et al., 2018).  
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8.3.2.2 Eligibility criteria 
People were eligible to participate if they were adults aged 18 years or older, 
capable of giving written consent in English and registered with a participating practice, 
with a Read code in their electronic record for one of the 5 IRCs of interest (RA, AS, PsA, 
PMR and GCA). Prior to randomisation, the lead GP for each practice excluded any 
nursing home residents, palliative and/or vulnerable patients (eg. severe enduring 
mental illness or significant cognitive impairment). 
 
8.3.2.3 Randomisation 
Randomisation to the intervention or control group was performed at the GP 
practice level using stratified block randomisation. Stratification was by practice size 
(splitting by order of highest/lowest practice sizes) and using block sizes of 2 and/or 4 
within each stratum to ensure balanced clusters and individual patient numbers across 
study arms. All participants were sent baseline, 3 and 6 month questionaires. Patients 
within control practices continued to receive usual care from their GP practice, whilst 
eligible patients within intervention practices were invited to an INCLUDE review 
appointment. 
 
8.3.2.4 Study Procedures 
Eligible patients at control and intervention practices were posted a study 
baseline pack which included an invitation letter (appendix 22), patient information 
sheet (appendix 23), baseline questionnaire with consent form (appendix 24) and a 
prepaid return envelope. They were asked to complete and return the questionnaire 
and consent form. Reminder postcards were sent after 2 weeks and a reminder 
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invitation pack after 4 weeks. Patients who did not respond or consent at baseline were 
considered non-responders or decliners, and were not contacted again. In addition, 
patients who did not provide a date of birth to enable their age to be confirmed as 18 
or over were also deemed ineligible. Participants who consented and self-reported 
having one of the IRCs of interest remained in the study unless they requested to be 
withdrawn, whilst participants who did not report having one of the conditions of 
interest were deemed ineligible and excluded. All consenting responders were sent 
further postal questionnaires at 3 and 6 months.  
 
8.3.3 Data Collection 
 
8.3.3.1 Questionnaire data 
To retain patients͛ anonymity, all data was non-identifiable and stored in 
password-protected, encrypted files, separate from signed consent forms. Outcome 
measures used in the baseline questionnaire are summarised in table 8.1 (p258).  
Follow-up questionnaires were sent to participants at 3 and 6 months, when 
further questions were included to assess healthcare utilisation and the acceptability of 
treatment. However, for this thesis, only the baseline data has been used.  
Anxiety and depression were assessed using the GAD-7 and PHQ-8 questions 
(Spitzer et al., 2006; Kroenke et al., 2009). As discussed in section 2.7, the GAD-7 tool 
has been found to have acceptable pooled sensitivity and specificity for anxiety 
(Plummer et al., 2016). A meta-analysis of the PHQ-9 tool also found it to have a high 
negative predictive value ;Mitchell et al., ϮϬϭϲͿ, though its͛ positive predictive value was 
found to be 52% with a threshold score of ш10 (Levis et al., 2019).  
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Table 8.1- Assessments and outcome measures recorded in the INCLUDE baseline 
questionnaire. 
 
Assessment domain Assessments/ outcome measures 
IRC Checklist (RA/ AS/ PsA/ PMR/ GCA) 
General Health 
Comorbidities checklist (Diabetes Mellitus (DM), Angina, Depression/ 
Anxiety, Hypertension (HTN), Myocardial Infarction (MI), Stroke, 
Osteoporosis) 
Impact of your 
inflammatory 
condition 
Numerical Rating Scales (NRS) for pain, stiffness and fatigue  
Pharmacological treatments for the IRC 
General Health and 
Mood 
EuroQol 5-Dimension Scale (EQ-5D-5L) 
Physical function (modified health assessment questionnaire (MHAQ)) 
Fatigue (Functional Assessment of Chronic Illness Therapy (FACIT)) 
Generalised Anxiety Disorder (GAD)-7 
Patient Health Questionnaire (PHQ)-8 
Your understanding of 
your health condition 
Patient activation measure 
Multimorbidity Treatment Burden Questionnaire 
Self-efficacy measure 
Demographic/  
socioeconomic factors 
Demographics (date of birth, gender, ethnicity) 
Socioeconomic factors (living alone, employment, fitness to work) 
Lifestyle factors Alcohol consumption and smoking status 
Measurements Height and weight (for body mass index (BMI) calculation) 
 
Alternatively, the Hospital Anxiety and Depression Scale (HADS) questions could 
have been utilised, though these have also been found to lack specificity (Poole et al., 
2006), with some studies reporting a lower sensitivity for depression (Roberge et al., 
2013), compared to the reported sensitivity of the PHQ-9 tool. Meanwhile, a 
comparison of the accuracy of PHQ-9 and HADS for diagnosing major depression in 
cancer patients found the PHQ-9 had the best screening performance (Hartung et al., 
2017). As the PHQ tool is widely reported in the literature, use of this tool facilitated 
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comparison with prior research. In addition, as discussed in section 2.7, the PHQ-2 can 
be useful as an initial screening tool, hence this was utilised within the INCLUDE review 
to help identify individuals who would benefit from further exploration of mood, 
through use of the PHQ-9. Therefore, using the same tool within the INCLUDE 
questionnaires facilitated comparison of questionnaire findings with clinic outcomes. 
The 9th question of the PHQ tool, ͞thoughts that you would be better off dead, 
or thoughts of hurting yourself in some way͟ ;Kroenke, Spitzer Θ Williams, ϮϬϬϭͿ, was 
not included in the INCLUDE study questionnaires, due to the potential clinical risk 
posed by someone disclosing suicidal ideas, which would not necessarily be 
acknowledged until several days later after receipt of the questionnaire through the 
post. However, this question was included within the INCLUDE review, when the 
consulting nurse had the opportunity to assess suicidal risk if required. 
Other key outcome measures included health-related quality of life (EuroQol 5-
Dimension Scale (EQ-5D-5L)) (Herdman et al., 2011), pain intensity (Numerical Rating 
Scale (NRS) 0ʹ10), physical function (Modified Health Assessment Questionnaire 
(MHAQ)) (Pincus et al., 1983), fatigue (Functional Assessment of Chronic Illness Therapy 
(FACIT)) (Webster et al., 2003), the Patient Activation Measure (Hibbard et al., 2005), 
Multimorbidity Treatment Burden Questionnaire (Duncan et al., 2018) and the Self-
Efficacy for Managing Chronic Disease scale (Borkovec and Nau, 1972). Patients also 
reported demographic, socioeconomic and lifestyle characteristics. Self-reported height 
and weight measurements were used to calculate body mass index (BMI). 
Multimorbidity, the presence of two or more comorbidities, was considered as a further 
outcome measure due to reported links between multimorbidity in people with IRCs 
and mood problems (Vancampfort et al., 2017; Read et al., 2017). However, individuals 
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selected for this study already had at least one morbidity (an IRC). Therefore, the 
presence of one or more comorbidities in addition to an IRC was included as a covariate 
in the analysis. 
 
 
8.3.2.2 INCLUDE review data 
In addition to the questionnaires mailed to all participants, consenting patients 
from intervention practices were invited to attend an INCLUDE review appointment at 
their GP practice. At the INCLUDE review, a trained study nurse conducted a holistic 
consultation which included case-finding for anxiety and depression (GAD-2 and PHQ-
2), with full measures (GAD-7 and PHQ-9) used as appropriate. An individualised 
management plan was developed and a summary sheet provided to the patient at the 
end of the consultation. The review was recorded using an EMIS template specifically 
developed for the study.  
 
 
8.3.4 Data analysis 
For the purposes of this thesis, a descriptive analysis of the baseline 
questionnaire data was performed using SPSS (version 24). Patient characteristics and 
responses to outcome measures were summarised using means and standard 
deviations for continuous measures and frequencies and percentages for categorical 
measures. Logistic regression analysis was used to help determine factors associated 
with self-reporting of anxiety and depression symptoms; associations were expressed 
in terms of odds ratios (OR) and corresponding 95% confidence intervals (CI). 
Adjustments were made for covariates that had a significant unadjusted association. 
This was to avoid overadjustment, due to a lack of significant unadjusted associations 
found between covariates and mood problems. 
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8.3.5 Ethical Approval 
The INCLUDE study was approved by the Wales REC 5 Research Ethics 
Committee (REC reference 17/WA/0427). Health Research Authority approval for the 
study was obtained on 11 January 2018. The document confirming ethical approval for 
this study is in appendix 25. 
 
 
8.4 Results                                                                                               .   
 
8.4.1 Recruitment of individuals to the INCLUDE study 
Patient recruitment commenced in March 2018. As shown in figure 8.2, four GP 
practices were randomised to control and intervention arms. 384 individuals were 
invited to participate from the intervention arm, from whom there were 163 eligible 
responders. From 405 individuals invited to participate from the control arm there were 
170 eligible responders. 333 baseline questionnaires from eligible participants were 
returned for analysis. 
Figure 8.2- INCLUDE participants in the intervention and control arms. 
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8.4.2 Proportions with different IRCs 
As shown in table 8.2, the highest proportion of individuals reported having RA 
(51.7%), followed by PMR (26.4%), AS (15.9%), PsA (13.8%) and GCA (5.1%). This is 
similar to prevalence estimates reported for different IRCs in the general population, 
with the prevalence of RA being approximately 0.67% (Abhishek et al., 2017), compared 
to lower estimates of 0.13% for AS (Dean et al., 2016), 0.22% for PsA (Egeberg et al., 
2017) and 0.25% for GCA (Yates et al., 2016). Potentially more individuals with PMR 
would have been expected, as PMR has an estimated prevalence of 0.91-1.53% (Yates 
et al., 2016).  
Of note, whilst 298 (89.5%) participants reported having one IRC, 35 (10.5%) 
participants self-reported having more than one IRC, hence the number of individuals 
with different IRCs when summed exceeds the overall number of participants. The most 
commonly observed combinations of IRCs were RA and PMR, in addition to RA and PsA.  
 
Table 8.2- Proportions self-reporting different IRCs within the INCLUDE baseline 
questionnaire 
 
Proportion self-reporting different IRCs in the INCLUDE baseline questionnaires 
IRC N (%) * 
Rheumatoid Arthritis 172 (51.7) 
Ankylosing Spondylitis 53 (15.9) 
Psoriatic Arthritis 46 (13.8) 
Polymyalgia Rheumatica 88 (26.4) 
Giant Cell Arteritis 17 (5.1) 
 
N= number of individuals, IRC= inflammatory rheumatological condition 
 
* Some participants self-reported having more than one IRC, hence the total number of individuals with 
different IRCs does not add up to the total number of participants (333). 
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Considering the combination of RA and PsA observed, an epidemiological study 
has reported the prevalence of RA in people with PsA to be increased (Tsai et al., 2011). 
In addition, it is possible that individuals with psoriasis incorrectly self-reported having 
PsA, leading to the more frequent observation of PsA in combination with RA in this 
dataset. The literature also suggests that late-onset RA and PMR can be difficult to 
distinguish, as both can involve peripheral arthritis (Cutolo, Cimmino & Sulli, 2009). 
Furthermore, a prospective study evaluating the clinical features of people with PMR 
and late-onset RA with a PMR-like onset, found that 23% of individuals with PMR 
developed RA during the 1-year follow-up period (Caproali et al., 2001). This suggests 
that individuals with PMR could be more likely to develop RA over time, though it is 
possible that due to overlapping symptoms, individuals at an early disease stage could 
have been given the wrong diagnosis. To help to determine the impact of having more 
than one IRC, the association of one verus two or more self-reported IRCs with mood 
problems, has been explored by logistic regression in table 8.10 (section 8.4.7.5, p280). 
 
8.4.3 Demographic and socio-economic factors 
Table 8.3 (p265), contains a summary of population demographics and 
socioeconomic factors, self-reported by individuals completing the baseline 
questionnaire. These include the proportion living alone, the employment status of 
participants and their fitness to work. The age of individuals ranged from 21.8-91.9 
years, with a mean of 68.2 years. Overall, 58.3% of responders were female. Reflecting 
gender ratios reported for different IRCs in the population, more females had RA 
(Abhishek et al., 2017), PMR (Crowson et al., 2011) and GCA (Dasgupta et al., 2010), 
whilst AS affected more males (Sieper, 2009) and PsA affected almost equal proportions 
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of males and females (Gladman et al., 2005). Considering ethnicity, 95.8% were white 
British, with similar high proportions also observed among different IRCs, reflecting the 
predominantly white British population living in North Staffordshire. Due to the small 
numbers reporting other ethnicities (Asian, Black/ African/ Caribbean, Mixed/ multiple 
ethnic groups) these have been grouped together under ͞other ethnicities͟. 
Only 18.6% of participants reported living alone. This compares to 28% of the 
national UK population who live alone, almost half of whom are aged over 65 years 
(Knipe, 2017). The proportion living alone was similar in different IRCs, though a higher 
proportion of individuals with PMR and GCA did not give a response. These were older 
individuals who would have been more likely to be living alone, hence this missing data, 
in addition to the relative minority of younger adults living with IRCs, could have 
contributed to the proportion of individuals living alone being lower in this dataset than 
in the general population.   
The majority were retired (59.2%), reflecting the older mean age of the 
population. 4.8% reported not working due to ill health, whilst 20.4% described being 
employed and 2.7% reported being a housewife/ husband. From those who reported 
working, 74.7% were doing their usual job. However, over a quarter of those employed 
were doing lighter duties (3.4%), working fewer hours (16.1%) or on sick leave (5.7%).  
Considering individual IRCs, the highest proportion of employed people had PsA 
(41.3%), whilst the highest proportion of retired people had GCA (88.2%). These groups 
had the youngest and oldest mean ages respectively. The highest proportion not 
working due to ill health had AS (5.7%). From those working, more people with RA had 
lighter duties at work (6.7%), or were working fewer hours (24.4%), compared to other 
IRCs. 
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Table 8.3- Dem
ographic factors self-reported by individuals com
pleting the INCLUDE baseline questionnaire 
 Dem
ographic/ Socio-econom
ic factors 
Condition 
All IRCs (333) 
N (%
) 
RA (172) 
N (%
) 
AS (53) 
N (%
) 
PsA (47) 
N (%
) 
PM
R (88) 
N (%
) 
GCA (17) 
N (%
) 
Age (years) 
 
Range 
21.8-91.9 
25.0-91.9  
21.8-88.2 
25.2-89.3 
48.0-91.3 
64.3-86.1 
M
ean (SD) 
68.2 (13.4) 
67.6 (12.7) 
67.9 (13.1) 
59.2 (14.8) 
75.7 (8.6) 
77.9 (6.7) 
Age Groups 
(years) 
 
18-50 
39 (11.7) 
17 (9.9) 
6 (11.3) 
15 (31.9) 
1 (1.1) 
0 (0) 
51-65 
83 (24.9) 
49 (28.5) 
10 (18.9) 
13 (27.7) 
14 (15.9) 
2 (11.8) 
66-75 
109 (32.7) 
61 (35.5) 
24 (45.3) 
14 (29.8) 
25 (28.4) 
5 (29.4) 
76-95 
102 (30.7) 
45 (26.1) 
13 (24.5) 
5 (10.6) 
48 (54.6) 
10 (58.8) 
Gender  
N (%
) 
Fem
ale 
194 (58.3) 
111 (64.5) 
24 (45.3) 
24 (52.2) 
53 (60.2) 
10 (58.8) 
Unknow
n/ am
biguous 
8 (2.4) 
5 (2.9) 
1 (1.9) 
1 (2.1) 
2 (2.3) 
0 (0) 
Ethnicity 
N (%
) 
W
hite 
320 (95.8) 
163 (94.8) 
52 (98.1) 
46 (97.9) 
85 (96.6) 
16 (94. 1) 
Other ethnicities 
11 (3.3) 
6 (3.5) 
1 (1.9) 
0 (0) 
3 (3.4) 
1 (5.9) 
Unknow
n/ am
biguous 
3 (0.9) 
3 (1.7) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Living alone 
N (%
) 
Yes 
62 (18.6) 
30 (17.5) 
8 (15.1) 
8 (17.4) 
16 (18.2) 
3 (17.6) 
No   
212 (63.7) 
111 (64.5) 
39 (73.6) 
30 (65.2) 
46 (52.3) 
9 (52.9) 
Unknow
n/ am
biguous 
59 (17.7) 
31 (18.0) 
6 (11.3) 
8 (17.4) 
26 (29.5) 
5 (29.5) 
Em
ploym
ent 
Status  
N (%
) 
Em
ployed 
68 (20.4) 
36 (20.9) 
9 (17.0) 
19 (41.3) 
9 (6.8) 
0 (0) 
Retired 
197 (59.2) 
98 (57.0) 
34 (64.2) 
18 (39.1) 
67 (76.2) 
15 (88.2) 
Not w
orking due to ill health 
16 (4.8) 
9 (5.2) 
3 (5.7) 
2 (4.3) 
3 (3.4) 
0 (0) 
Housew
ife/ husband 
9 (2.7) 
6 (3.5) 
0 (0) 
0 (0) 
3 (3.4) 
0 (0) 
Unem
ployed/ seeking w
ork 
14 (4.2) 
6 (3.5) 
3 (5.7) 
2 (4.3) 
3 (3.4) 
0 (0) 
Unknow
n/ am
biguous 
29 (8.7) 
17 (9.9) 
4 (7.5) 
5 (10.9) 
6 (6.8) 
2 (11.8) 
Fitness to 
w
ork (if 
w
orking)  
N (%
) 
Doing usual job 
65 (74.7) 
28 (62.3) 
9 (75.0) 
20 (87.0) 
8 (88.9) 
0 (0) 
Lighter duties 
3 (3.4) 
3 (6.7) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Sick leave 
5 (5.7) 
3 (6.6) 
1 (8.3) 
0 (0) 
1 (11.1) 
0 (0) 
W
orking few
er hours 
14 (16.1) 
11 (24.4) 
2 (16.7) 
3 (13.0) 
0 (0) 
0 (0) 
 N= N
um
ber of individuals, SD= Standard deviation
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8.4.4 Lifestyle factors 
 Lifestyle factors, including smoking history, alcohol consumption and BMI are 
reported in table 8.4, (p268). Considering smoking history, the majority of individuals 
completing the INCLUDE baseline questionnaire had never smoked (46.5%), whilst 
42.3% were ex-smokers. Only 6.9% of individuals reported being a current smoker. The 
proportion of current smokers was highest in people with RA (12.2%) whilst the 
proportion of ex-smokers was highest in people with PMR (43.2%) and GCA (47.1%). 
These groups had the highest mean age, potentially indicating that they quit smoking 
after health campaigns highlighted the negative impact of smoking. 
47.7% of people with IRCs reported regularly consuming alcohol, whilst 12.3% 
had never consumed alcohol and 23.4% reported only consuming alcohol on special 
occasions. Compared to other IRCs, more people with AS (56.6%) and PsA (58.7%) 
reported that they regularly consumed alcohol (ш once per weekͿ, potentially reflecting 
their younger mean age. Alcohol consumption could have been comparatively lower in 
people with RA (43.6%) due to more individuals with this condition taking medication 
that would potentially be affected by alcohol consumption.  
  BMI was calculated using self-reported weight and height (weight in kilograms/ 
(height in centimetres)2) (NHS, 2018). BMI ranged between 17.4-47.6, with a mean of 
28.6, indicating that the average individual completing the INCLUDE baseline 
questionnaire was overweight. 27.3% of individuals with IRCs were obese (BMI шϯϬͿ. 
Considering different IRCs, obesity was least frequent in people with AS (15.1%), though 
more frequent in people with RA (31.4%), compared to other IRCs. 
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8.4.5 Comorbidities 
Self-reported comorbidities are summarised in table 8.4 (p269). More than two 
thirds of individuals who completed the baseline questionnaire (68.4%), reported having 
at least one comorbidity from a prespecified morbidity checklist, in addition to their IRC, 
indicating multimorbidity. Multimorbidity was most frequent in people with GCA 
(82.3%) and least frequent in people with PsA (56.5%), compared to other IRCs. It is 
likely that age contributed to these trends, as people with GCA had the highest mean 
age (77.9 years) and PsA the lowest (59.2 years), and multimorbidity is associated with 
ageing (Barnett et al., 2012). 
The commonest self-reported comorbidity was hypertension (46.4%), followed 
by anxiety or depression (21.3%), diabetes (15.6%) and osteoporosis (11.1%). The 
proportion with hypertension was highest in RA (50.6%), whilst anxiety or depression 
was most frequent amongst individuals with PsA (37%). Interestingly, no individuals with 
GCA self-reported a history of anxiety or depression, whilst fewer people with PMR 
(14.8%) reported a history of mood problems, compared to other IRCs. More individuals 
with AS had diabetes (28.3%) compared to other IRCs, whilst osteoporosis was most 
frequent in people with PMR (23.9%) and GCA (23.5%), potentially due to individuals 
with these conditions being older or due to these conditions being treated with 
glucocorticoids which can reduce bone density. It could be argued that the frequency of 
osteoporosis in people with PMR and GCA should be lower, as guidelines suggest that 
individuals with these conditions, who are at high risk of osteoporosis, should be on 
bone protection. However, is possible that individuals who self-reported having 
osteoporosis, did so due to being on treatment for this.
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Table 8.4- Lifestyle factors and com
orbidities self-reported by individuals com
pleting the INCLUDE baseline questionnaire 
 Lifestyle Factors 
Condition 
All IRCs (333) 
RA (172) 
AS (53) 
PsA (47) 
PM
R (88) 
GCA (17) 
Sm
oking 
Status  
N (%
) 
Current sm
oker 
23 (6.9) 
21 (12.2) 
6 (11.3) 
3 (6.5) 
5 (5.7) 
0 (0) 
Never sm
oked 
155 (46.5) 
71 (41.3) 
27 (50.9) 
21 (45.7) 
41 (46.6) 
9 (52.9) 
Previously sm
oked 
141 (42.3) 
27 (15.7) 
20 (37.8) 
19 (41.3) 
38 (43.2) 
8 (47.1) 
Unknow
n/ am
biguous 
14 (4.2) 
41 (23.8) 
0 (0) 
3 (6.5) 
4 (4.5) 
0 (0) 
Alcohol  
(How
 often 
do you drink 
alcohol?) 
N (%
) 
Regularly (ш once a w
eek)  
106 (47.7) 
75 (43.6) 
30 (56.6) 
27 (58.7) 
44 (50.0) 
8 (54.4) 
1 to 3 tim
es a m
onth 
41 (12.3) 
22 (12.8) 
4 (7.5) 
6 (13.0) 
10 (11.4) 
3 (17.6) 
Special occasions only 
78 (23.4) 
41 (23.8) 
12 (22.7) 
7 (15.2) 
19 (21.6) 
5 (29.4) 
Never 
41 (12.3) 
26 (15.1) 
6 (11.3) 
5 (10.9) 
11 (12.5) 
1 (5.9) 
Unknow
n/ am
biguous 
14 (4.2) 
8 (4.7) 
1 (1.9) 
1 (2.2) 
4 (4.5) 
0 (0) 
BM
I  
 
M
ean (SD) 
28.6 (5.0) 
29.2 (5.0) 
28.7 (5.0) 
28.5 (5.0) 
28.5 (4.9) 
28.9 (4.0) 
Range 
17.4-47.6 
19.0-42.6 
19.2-41.6 
19.2-41.6 
17.4-47.6 
21.7-37.7 
Proportion  
under/ over-
w
eight or obese  
N (%
) 
Underw
eight (<18.5) 
3 (0.9) 
0 (0) 
0 (0) 
0 (0) 
3 (3.4) 
0 (0) 
Norm
al (18.5-24.9) 
70 (21.0) 
23 (13.4) 
16 (30.2) 
10 (21.4) 
18 (20.5) 
3 (17.6) 
Overw
eight (25-29.9) 
108 (32.4) 
58 (33.7) 
18 (34.0) 
12 (25.5) 
22 (25.0) 
6 (35.3) 
Obese ш30 
91 (27.3) 
54 (31.4) 
8 (15.1) 
13 (27.7) 
24 (27.3) 
6 (17.6) 
Unknow
n/ am
biguous N (%
) 
68 (20.4) 
35 (20.3) 
11 (20.8) 
11 (23.9) 
19 (21.6) 
2 (11.8) 
Com
orbidities 
N (%
) 
Diabetes M
ellitus (DM
) 
52 (15.6) 
28 (16.3) 
15 (28.3) 
9 (19.6) 
12 (13.6) 
2 (11.8) 
Angina 
24 (7.2) 
12 (7.0) 
4 (7.5) 
4 (8.7) 
6 (6.8) 
4 (23.5) 
Depression/ anxiety 
70 (21.3) 
40 (23.3) 
13 (24.5) 
17 (37.0) 
13 (14.8) 
0 (0) 
Hypertension (HTN) 
154 (46.2) 
87 (50.6) 
24 (45.3) 
17 (37.0) 
42 (47.7) 
8 (47.1) 
M
yocardial infarction (M
I) 
25 (7.5) 
17 (9.8) 
4 (7.5) 
3 (6.5) 
7 (8.0) 
2 (11.8) 
Stroke 
18 (5.4) 
13 (7.6) 
3 (5.7) 
2 (4.3) 
3 (3.4) 
0 (0) 
Osteoporosis 
37 (11.1) 
25 (14.5) 
6 (11.3) 
5 (10.9) 
15 (17.0) 
4 (23.5) 
Unknow
n/ am
biguous 
94 (28.2) 
42 (24.4) 
11 (20.8) 
20 (43.5) 
21 (23.9) 
3 (17.6) 
One or m
ore com
orbidities in addition to an IRC* N (%
) 
228 (68.4) 
126 (73.3) 
39 (73.5) 
26 (56.5) 
61 (69.4) 
14 (82.3) 
 N= num
ber of individuals, BM
I= Body M
ass Index *Num
ber of com
orbidities (self-reported history of DM
, angina, depression/ anxiety, HTN
, M
I, stroke and osteoporosis). 
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8.4.6 Pain, stiffness and fatigue 
 
8.4.6.1 Pain, stiffness and fatigue reported using a numerical rating scale 
To help understand the daily burden of symptoms related to an individuals͛ IRC, 
participants were asked to report their current pain, stiffness and fatigue in relation to 
their condition. On a NRS of 0-10 where 0 is none and 10 is the worst, the mean reported 
pain score was 4.9, whilst the mean score for stiffness was 5.0 and for fatigue, 5.2. This 
would suggest that on average, participants had moderate pain, stiffness and in 
particular, fatigue. 
As shown in table 8.5 (p270), the highest mean pain (5.5) and fatigue (5.8) scores 
were in people with RA, whilst the highest mean scores for stiffness were amongst 
individuals with AS (5.7) and RA (5.6). All scores were lowest in people with GCA, 
suggesting treatments are potentially more effective for GCA, resulting in a lower 
symptom burden in prevalent cases. 
 
8.4.6.2 Fatigue reported using the FACIT questionnaire 
 
 The FACIT score is reported on a scale of 0-52, with higher scores indicating less 
fatigue. The mean FACIT score for individuals completing the INCLUDE baseline 
questionnaire was 33.2. Scores were lowest amongst individuals with RA (31.7 (standard 
deviation (SD) 11.6), AS (31.7, SD (12.2)) and PsA (31.3, SD (12.0)), indicating greater 
fatigue than in individuals with PMR (34.5, SD (11.4)) and GCA (34.7, SD (13.9)). The 
range of FACIT scores included lower values in people with RA (range 1-51) compared 
to other IRCs (range 6-52), suggesting this group included individuals with the worst 
fatigue. This would be consistent with results from the NRS for fatigue, which are 
reported with the FACIT scores in table 8.5 (p270). 
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Table 8.5- Pain, stiffness and fatigue reported by individuals with different IRCs 
completing the INCLUDE baseline questionnaire. 
 
Pain, Stiffness and Fatigue 
Scores  
Condition 
All IRCs (333) RA (172) AS (53) PsA (47) PMR (88) GCA (17) 
Numerical 
Rating 
Scale  1 
Pain 
Score 
Mean 
(SD) 4.9 (2.6) 5.5 (2.5) 5.1 (2.9) 4.9 (2.7) 4.4 (2.8) 3.2 (3.2) 
Range 0-10 0-10 0-10 0-9 0-10 0-9 
Stiffness 
Score 
Mean 
(SD) 5.0 (2.6) 5.6 (2.4) 5.7 (2.6) 5.1 (2.6) 4.3 (2.7) 3.3 (3.1) 
Range 0-10 0-10 0-10 0-9 0-10 0-8 
Fatigue 
Mean 
(SD) 5.2 (2.7) 5.8 (2.6) 5.5 (2.5) 5.6 (3.0) 4.6 (2.7) 3.8 (3.0) 
Range 0-10 0-10 0-10 0-9 0-10 0-8 
FACIT 
Score 2 
Mean (SD) 33.2 (11.6) 31.7 (11.6) 
31.7 
(12.2) 
31.3 
(12.0) 
34.5 
(11.4) 
34.7 
(13.9) 
Range 1-52 1-51 6-51 8-52 8-52 8-52 
 
SD= standard deviation 
1 The Numerical Rating Scale is a 0-ϭϬ Ɛcale ǁhere Ϭ iƐ ͞no pain͕ ƐƚiffneƐƐ or faƚigƵe͟ and ϭϬ iƐ ͞pain͕ 
stiffness or fatigue as bad as could be͟. 
2 The FACIT Score is a 0-52 scale where a higher score indicates less fatigue. 
 
 
8.4.7 Anxiety and Depression 
 
8.4.7.1 Responses to PHQ-8 score for depression  
 
Table 8.6 (p272), shows the overall responses to the PHQ-8 questions. The most 
frequently reported symptoms were ͞trouble falling or staying asleep, or sleeping too 
much͟ and ͞feeling tired or having little energy͟. These symptoms could reflect 
depression, but could also represent symptoms directly related to the underlying IRC, 
such as fatigue and pain related to the inflammatory process disrupting sleep. As shown 
in table 8.7 (p273), the mean score on PHQ-8 for depression, (where 5-9 indicates mild 
depression, 10-14 moderate, 15-19 moderately severe and 20-24 severe depression) 
(Kroenke et al., 2009), was 5.8. Mean scores were highest in GCA (6.5) and AS (6.3) and 
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lowest in RA (5.1). Median scores were lower, at 4 for all IRCs, implying that distribution 
of scores were skewed to the right.  
The literature suggests a cut off score of ш10 should be used to indicate 
depression, (Kroenke et al., 2009; Levis et al., 2019). The proportion of individuals 
meeting this threshold, who had moderate, moderately severe or severe symptoms of 
depression, was 21.5%. The highest proportions with moderate to severe depression 
had GCA (33.4%) and PMR (30.2%), whilst the proportion with depression was lowest in 
people with RA (18.3%). A notable proportion of people with AS (26.0%) and PsA (28.2%) 
also reported moderate to severe symptoms of depression. 
8.4.7.2 Responses to GAD-7 score for anxiety  
 
 Table 8.6 (p272), shows the overall responses to the GAD-7 questions. The most 
frequently reported symptoms were ͞worrying too much about different things͟, 
͞trouble relaxing͟ and ͞becoming easily annoyed or irritable͟. Table 8.7 (p273), shows 
the total and mean scores for GAD-7. The overall mean score for individuals completing 
the GAD-7 score for anxiety, (where 5-9 indicates mild symptoms, 10-14 moderate and 
>15 severe symptoms) (Spitzer et al., 2006) was 4.67. The highest mean GAD-7 scores 
were in individuals with PsA (5.63) and RA (5.44). Median scores were lower, between 
2-4, implying that the distribution of scores was skewed to the right.  
The literature suggests a cut off score of ш10 should be used to indicate anxiety 
(Spitzer et al., 2006; Plummer et al., 2016). The proportion of individuals meeting this 
threshold who had moderate or severe symptoms of anxiety was 17.4%. The highest 
proportion with moderate or severe anxiety scores had PsA (23.9%) whilst the lowest 
proportion had PMR (10.3%).  A notable proportion of people with RA (21.0%), AS 
(23.5%) and GCA (17.7%), also reported moderate or severe anxiety symptoms. 
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Table 8.6- Overall responses to the PHQ
-8 and GAD-7 questions. 
 M
ood 
problem
 
O
ver the past 2 w
eeks, how
 often have you been 
bothered by the follow
ing problem
s? 
Num
ber (%
) 
Not at all 
Several days 
> half the days 
Nearly every day 
M
issing/ am
biguous 
Depression 
(PHQ
-8 
questions)  1 
Little interest or pleasure in doing things 
178 (53.3) 
106 (31.7) 
28 (8.4) 
14 (4.2) 
8 (2.4) 
Feeling dow
n, depressed or hopeless 
191 (57.2) 
91 (27.2) 
31 (9.3) 
14 (4.2) 
7 (2.1) 
Trouble falling or staying asleep, or sleeping too m
uch 
113 (33.8) 
98 (29.3) 
56 (16.8) 
61 (18.3) 
6 (1.8) 
Feeling tired or having little energy 
69 (20.7) 
149 (44.6) 
52 (15.6) 
58 (17.4) 
6 (1.8) 
Poor appetite or overeating 
192 (57.5) 
70 (21.0) 
36 (10.8) 
29 (8.7) 
7 (2.1) 
Feeling bad about yourself or that you are a failure or 
have let yourself or your fam
ily dow
n 
214 (64.1) 
72 (21.6) 
16 (4.8) 
24 (7.2) 
8 (2.4) 
Trouble concentrating on things, such as reading the 
new
spaper or w
atching television 
223 (66.8) 
63 (18.9) 
26 (7.8) 
15 (4.5) 
7 (2.1) 
M
oving or speaking so slow
ly that other people could 
have noticed, or m
oving around a lot m
ore than usual 
249 (74.6) 
51 (15.3) 
22 (6.6) 
4 (1.2) 
8 (2.4) 
Anxiety 
(GAD-7 
questions)  2 
Feel nervous, anxious or on edge 
169 (50.8) 
110 (33.0) 
29 (8.7) 
16 (4.8) 
9 (2.7) 
Not being able to stop or control w
orrying 
177 (53.2) 
101 (30.3) 
23 (6.9) 
21 (6.3) 
11 (3.3) 
W
orrying too m
uch about different things 
143 (42.6) 
127 (38.1) 
36 (10.8) 
22 (6.6) 
6 (1.8) 
Trouble relaxing 
153 (45.9) 
112 (33.6) 
34 (10.2) 
26 (7.8) 
8 (2.4) 
Being so restless that its hard to sit still 
217 (65.2) 
74 (22.2) 
23 (6.9) 
10 (3.0) 
9 (2.7) 
Becom
ing easily annoyed or irritable 
136 (40.8) 
127 (38.1) 
37 (11.1) 
25 (7.5) 
8 (2.4) 
Feeling afraid as if som
ething aw
ful m
ight happen 
216 (64.9) 
64 (19.2) 
28 (8.4) 
17 (5.1) 
8 (2.4) 
 1 PHQ
-8 questions (Spitzer et al., 2006).  . 2 GAD-7 questions (Kroenke et al. 2009).  .  
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Table 8.7- Total, m
ean and m
edian PHQ
-8 and GAD-7 scores.  
 Depression and Anxiety Severity  
Condition 
All IRCs 
RA 
AS  
PsA 
PM
R 
GCA 
Depression 1 
(From
 317 
com
pleted 
PHQ
-8 Scores)  
Depression 
Severity 
 Num
ber 
(%
) 
M
inim
al Depression (0-4) 
167 (52.7) 
97 (59.1) 
23 (46.0) 
21 (45.7) 
42 (50.6) 
7 (46.6) 
M
ild Depression (5-9) 
82 (25.9) 
37 (22.6) 
14 (28.0) 
12 (26.1) 
25 (30.1) 
3 (20.0) 
M
oderate Depression (10-14) 
38 (12.0) 
16 (19.8) 
8 (16.0) 
10 (21.7) 
8 (15.1) 
4 (26.7) 
M
oderately Severe 
Depression (15-19) 
20 (6.3) 
9 (5.5) 
2 (4.0) 
3 (6.5) 
6 (11.3) 
1 (6.7) 
Severe Depression (20-24) 
10 (3.2) 
5 (3.0) 
3 (6.0) 
0 (0) 
2 (3.8) 
0 (0) 
M
ean PHQ
-8 Score (SD) 
5.8 (5.5) 
5.1 (5.4) 
6.3 (5.8) 
6.2 (4.7) 
5.8 (5.5) 
6.5 (6.8) 
M
edian PHQ
-8 Score (IQ
R) 
4 (6) 
4 (7) 
4 (7) 
4 (7) 
4 (8) 
4 (7) 
Anxiety 2 
(From
 315 
com
pleted 
GAD-7 scores) 
 
Anxiety 
Severity 
 Num
ber 
(%
) 
M
inim
al Anxiety (0-4) 
176 (55.7) 
77 (47.5) 
26 (51.0) 
21 (45.7) 
55 (62.5) 
10 (58.8) 
M
ild Anxiety (5-9) 
85 (26.9) 
51 (31.5) 
13 (25.5) 
14 (30.4) 
19 (21.6) 
4 (23.5) 
M
oderate Anxiety (10-14) 
39 (12.3) 
23 (14.2) 
9 (17.6) 
8 (17.4) 
7 (8.0) 
2 (11.8) 
Severe Anxiety (15-21) 
16 (5.1) 
11 (6.8) 
3 (5.9) 
3 (6.5) 
2 (2.3) 
1 (5.9) 
M
ean GAD-7 Score (SD) 
4.7 (4.8) 
5.4 (5.0) 
5.2 (5.2) 
5.6 (5.0) 
3.4 (3.9) 
4.3 (4.7) 
M
edian GAD-7 Score (IQ
R) 
3 (7) 
2 (6) 
3 (7) 
3 (7) 
4 (7) 
3 (7) 
 SD= standard deviation, IQ
R= interquartile range 
1 PHQ
-8 score (Spitzer et al., 2006). 2 GAD-7 score (Kroenke et al., 2009).
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8.7.3 Responses to EQ-5D-5L anxiety/ depression questions 
 
As reported in table 8.8 (p275), 17.1% of people with IRCs responding to the EQ-
5D-5L anxiety/ depression questions reported moderate symptoms, 2.1% severe and 
0.3% extreme symptoms of anxiety or depression. Meanwhile, 33.6% reported slight 
symptoms and 44.7% no symptoms of anxiety or depression. 2.1% gave no or more than 
one response. Considering individual IRCs, 23.3% of people with RA reported moderate, 
severe or extreme anxiety or depression, compared to 26.4% with AS, 30.4% with PsA, 
20.4% with PMR and 17.6% with GCA. Therefore, self-reported symptoms of anxiety 
and/or depression were highest amongst individuals with AS and PsA. These results are 
displayed graphically in figure 8.3 below. 
 
 
Figure 8.3- The proportions with IRCs who self-reported moderate, severe or extreme 
symptoms of anxiety or depression, according to the EQ-5D-5L questions.  
 
 
IRC= Inflammatory rheumatological condition, RA= rheumatoid arthritis, AS= ankylosing spondylitis, 
PsA= psoriatic arthritis, PMR= polymyalgia rheumatica, GCA= giant cell arteritis. 
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Table 8.8- Responses to the EQ
-5D-5L anxiety and depression questions in overall and different IRCs. 
Responses to the EQ
-5D-5L 
questions 1  
Condition 2 
All IRCs 
(n=333) 
RA 
(n=172) 
AS 
(n=53) 
PsA 
(n=46) 
PM
R 
(n=88) 
GCA 
(n=17) 
 Severity of 
m
ood 
sym
ptom
s 
 Num
ber of 
individuals (%
) 
I am
 not anxious or 
depressed  
149 (44.7) 
67 (38.7) 
22 (41.5) 
15 (32.6) 
48 (54.5) 
11 (64.7) 
I am
 slightly anxious or 
depressed 
112 (33.6) 
65 (37.8) 
17 (32.1) 
17 (36.9) 
20 (22.7) 
3 (17.6) 
I am
 m
oderately anxious or 
depressed  
57 (17.1) 
29 (16.9) 
13 (24.5) 
12 (26.1) 
18 (20.5) 
3 (17.6) 
I am
 severely anxious or 
depressed 
7 (2.1) 
6 (3.5) 
1 (1.9) 
0 (0) 
0 (0) 
0 (0) 
I am
 extrem
ely anxious or 
depressed  
1 (0.3) 
1 (0.6) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
No/ m
ore than one 
response 
7 (2.1) 
4 (2.3) 
0 (0) 
2 (4.3) 
2 (2.3) 
0 (0) 
Proportion w
ith m
oderate, severe or 
extrem
e anxiety or depression N (%
) 
60 (18.0) 
40 (23.3) 
14 (26.4) 
14 (30.4) 
20 (20.5) 
3 (17.6) 
  n= num
ber of individuals  
1 EQ
-5D-5L (Herdm
an et al., 2011).  
2 Som
e participants reported having m
ore than one IRC, hence the total num
ber of individuals w
ith different IRCs does not add up to the total num
ber of participants (333). 
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8.4.7.4 Comparison of PHQ-8, GAD-7 and EQ-5D-5L anxiety and depression responses 
 
 In table 8.9 the proportions with mild, moderate and severe mood problems 
according to the EQ-5D-5L, GAD-7 and PHQ-8 scores are compared, then displayed as a 
bar chart in figure 8.4 (p277). The comparison includes 295 individuals who completed 
responses to all three sets of questions.  
 
Table 8.9- Comparison of anxiety and depression severity according to the EQ-5D, GAD-
7 and PHQ-8 scores.  
 
Comparison of symptom severity according to different anxiety/  
depression scales 
 
(295 individuals who completed the EQ-5D-5L, GAD-7 and PHQ-8 questions) 
Anxiety and/or 
depression scale 
Symptom Severity  (number/ %)  
No/ minimal 
symptoms Mild symptoms 
Moderate 
symptoms 
Severe 
symptoms 
EQ-5D-5L 1 141 (47.8) 94 (31.9) 52 (17.6) 8 (2.7) 
GAD-7 2 168 (56.9) 77 (26.1) 34 (11.5) 16 (5.4) 
PHQ-8 3 155 (52.5) 78 (26.4) 36 (12.2) 26 (8.9) 
 
1 Noͬminimal symptomsс ͞I am not anxious or depressed͟, mild symptomsс ͞I am slightly anxious or 
depressed͟, moderate symptomsс ͞I am moderately anxious or depressed͟, severe symptomsс ͞I am 
severely anxious or depressed͟ or ͞I am extremely anxious or depressed͟. 
 
2 No/minimal symptoms=0-4, mild symptoms=5-9, moderate symptoms=10-14, severe symptoms=15-21. 
 
3 No/minimal symptoms=0-4, mild symptoms=5-9, moderate symptoms=10-14, severe symptoms=15-24. 
 
When comparing different anxiety/ depression scales, the proportion with 
moderate to severe mood symptoms was 20.3% for the EQ-5D-5L, 16.9% for GAD-7, and 
21.1% for the PHQ-8. This suggests that depression (PHQ-8) was more frequent than 
anxiety (GAD-7) in people with IRCs. As the EQ-5D-5L assesses for anxiety and 
depression, it is interesting that the proportion with moderate to severe symptoms was 
lower on comparison to the PHQ-8, which assesses for depression alone. However, more 
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individuals reported mild mood symptoms when assessed using the EQ-5D-5L, 
compared to GAD-7 or PHQ-8. This would suggest that the EQ-5D-5L potentially has a 
higher threshold for moderate to severe mood symptoms, compared to the GAD-7 and 
PHQ-8 questions. 
Within the INCLUDE baseline questionnaire, when participants were asked 
about their existing comorbidities, 21% self-reported a history of anxiety or depression 
(table 8.4). This is marginally higher than the proportion with moderate and severe 
symptoms of mood problems when assessed using EQ-5D-5L (20.3%) and GAD-7 (16.9%) 
scales, and similar to the proportion with moderate to severe depression when assessed 
using the the PHQ-8 (21.1%) questions. It is possible that individuals perceived milder 
symptoms to indicate a mood problem. If mild symptoms of anxiety and/ or depression 
are taken into account, the proportion with anxiety and depression is much higher; EQ-
5D-5L (52.7%), GAD-7 (44.3%) and PHQ-8 (47.3%). 
 
Figure 8.4- Severity of mood problems according to different scores. 
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8.4.7.5 Covariates associated with reporting of moderate or severe anxiety and 
depression 
 In table 8.10 (p280), the association between different covariates (demographic 
and lifestyle factors, comorbidities, IRC symptom severity, number of IRCs, number of 
comorbidities) and depression (PHQ-8 ш10) and anxiety (GAD-7 ш10) are reported.   
Significant associations were found between pain (adjusted OR (95% CI) = 1.17 
(10.4, 1.31)), stiffness (adjusted OR (95% CI) = 1.22 (1.08, 1.37)) and depression. One or 
more comorbidities in addition to an IRC, were associated with depression, though this 
association was not statistically significant (adjusted OR (95% CI) = 1.65 (0.96, 2.84)).  
The odds of anxiety were slightly increased in people with one or more 
comorbidities, in addition to their IRC (adjusted OR (95% CI) = 1.14 (0.27, 1.98)). 
Significant unadjusted associations were also found between obesity, a self-reported 
history of anxiety and/ or depression, increased IRC symptom severity (higher NRS 
scores for pain, stiffness and fatigue, and reduced FACIT scores) and anxiety. However, 
after adjustment, the only remaining significant associations were between increased 
fatigue and anxiety (NRS fatigue and anxiety, OR (95% CI) = 1.24 (1.03, 1.44)) (FACIT 
score and anxiety OR (95% CI) = 0.87 (0.81, 0.94)). 
No significant associations were noted between age, gender, living alone, 
smoking, regularly consuming alcohol, comorbidities and anxiety or depression. 
However, the odds of being aged 51-65 years and having depression, or being 18-65 
years old and having anxiety, were increased. Smoking was also associated with 
increased adjusted odds of anxiety or depression, whilst regular alcohol consumption 
was associated with anxiety, though these associations were not significant. Of note, in 
people with more than one IRC, the adjusted odds of mood problems, particularly 
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anxiety (OR (95% CI) = 1.81 (0.26, 3.87)) were increased, though this difference was not 
statistically significant.  
 Further analysis of the association between covariates and mood problems in RA 
was performed, to determine if there were any significant differences compared to the 
associations found between covariates and mood problems in overall IRCs. There were 
too few individuals with AS, PsA, PMR or GCA, to accurately determine statistical 
associations. The results have been reported in appendix 26, as they were similar to 
overall IRCs. A statistically significant adjusted association was found between increased 
NRS scores for pain (OR (95% CI) = 1.22 (1.02, 1.46)) and stiffness (OR (95% CI) = 1.42 
(1.15, 1.75)), and depression, as observed in overall IRCs. Significant unadjusted 
associations were found between pain, stiffness, fatigue and anxiety, though after 
adjustment, these associations all became non-significant. However, a significant 
adjusted association was found between lower FACIT scores, indicating worse fatigue, 
and anxiety in people with RA (OR (95% CI) = 0.89 (0.84, 0.94)), as observed in overall 
IRCs. 
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Table 8.10- Association betw
een covariates and m
oderate to severe anxiety and depression in individuals w
ith IRCs. 
 Covariate 
M
oderate to severe depression (PHQ
-8 scoreш10) 
M
oderate to severe anxiety (GAD-7 score ш10) 
Unadjusted O
R (95%
 CI) 
Adjusted O
R (95%
 CI)* 
Unadjusted O
R (95%
 CI) 
Adjusted O
R (95%
 CI) * 
Age Groups 
18-50 years 
0.95 (0.48, 1.86) p=0.88 
0.39 (0.23, 0.69) p<0.01 
1.85 (0.84, 4.07) p=0.62 
1.91 (0.13, 6.32) p=0.92 
51-65 years 
1.43 (0.86, 2.39) p=0.17 
1.70 (0.89, 3.26) p=0.11 
1.10 (0.57, 2.12) p=0.77 
1.98 (0.62, 6.38) p=0.25 
66-75 years 
0.96 (0.60, 1.55) p=0.87 
1.03 (0.58, 1.84) p=0.91 
1.08 (0.59, 2.00) p=0.81 
0.84 (0.29, 2.48) p=0.76 
76-95 years 
0.78 (0.48, 1.25) p=0.30 
0.75 (0.42, 1.32) p=0.32 
0.56 (0.28, 1.15) p=0.11 
0.60 (0.17, 2.20) p=0.45 
Fem
ale gender 
0.95 (0.60, 1.50) p=0.82 
1.09 (0.61, 1.93) p=0.78 
1.92 (1.01, 3.65) p=0.05 
2.46 (0.75, 8.12) p=0.14 
Living alone  
0.58 (0.32, 1.06) p=0.08 
0.93 (0.45, 1.94) p=0.85 
0.71 (0.31, 1.63) p=0.42 
0.79 (0.23, 2.76) p=0.71 
Current sm
oker  
1.28 (0.53, 3.10) p=0.60 
1.42 (0.48, 4.23) p=0.53 
1.98 (0.73, 5.32) p=0.18 
1.18 (0.01, 2.96) p=0.23 
Regular alcohol consum
ption ш w
eekly  
1.21 (0.77 1.90) p=0.41 
1.01 (0.57, 1.78) p=0.98 
0.65 (0.35, 1.19) p=0.16 
1.44 (0.41, 5.01) p=0.57 
Obesity (BM
I ш30) 
0.70 (0.41, 1.18) p=0.18 
1.28 (0.66, 2.51) p=0.47 
2.01 (1.03, 3.94) p=0.04 
1.91 (0.31, 2.70) p=0.08 
ш1 com
orbidities in addition to an IRC 
1.08 (0.67, 1.73) p=0.76 
1.65 (0.96, 2.84) p=0.06 
1.46 (0.76, 2.83), p=0.26 
1.14 (0.27, 1.98) p=0.36 
Diabetes  
0.78 (0.42, 1.43) p=0.41 
1.14 (0.56, 2.31) p=0.73 
1.64 (0.79, 3.39) p=0.18 
1.34 (0.09, 1.34) p=0.12 
Cardiovascular Disease 1  
0.81 (0.59, 1.10) p=0.17 
0.89 (0.57, 1.42) p=0.63 
1.10 (0.75, 1.62) p=0.62 
1.07 (0.38, 2.98) p-0.90 
Osteoporosis 
0.77 (0.38, 1.56) p=0.47 
0.92 (0.43, 1.95) p=0.83 
1.70 (0.75, 3.84) p=0.21 
1.37 (0.38, 4.87) p=0.63 
Anxiety/ depression 
0.71 (0.41, 1.21) p=0.21 
0.82 (0.44, 1.51) p=0.52 
3.63 (1.94, 6.83) p<0.01 
1.98 (0.67, 5.89) p=0.22 
ш2 IRCs 
0.87 (0.42, 1.77) p=0.69 
1.23 (0.55, 2.77) p=0.62 
2.10 (0.94, 4.67) p=0.07 
1.81 (0.26, 3.87) p=0.99 
Pain Score 
1.25 (1.02, 1.54) p<0.01 
1.17 (1.04, 1.31) p<0.01 
1.30 (1.14, 147) p<0.01 
1.19 (0.85, 1.66) p=0.32 
Stiffness Score 
1.26 (1.01, 1.56) p<0.01 
1.22 (1.08, 1.37) p<0.01 
1.25 (1.11, 1.42) p<0.01 
1.01 (0.73, 1.40) p=0.94 
Fatigue Score 
1.00 (0.92, 1.08) p=0.95 
1.07 (0.96, 1.20) p=0.22 
1.30 (1.14, 1.49) p<0.01 
1.24 (1.03, 1.44) p=0.02 
FACIT score 
1.01 (0.99, 1.03) p=0.48 
0.99 (0.97, 1.02) p=0.58 
0.89 (0.86, 0.92) p<0.01 
0.87 (0.81, 0.94) p<0.01 
 OR= odds ratio, CI=confidence interval, BM
I= Body M
ass Index. 1 Cardiovascular disease= stroke, angina, m
yocardial infarction and hypertension 
* Adjustm
ents m
ade for significant unadjusted associations. Bold entries statistically significant.
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8.5 Discussion                                                                                                  .    
8.5.1 Summary of findings 
Analysis of the INCLUDE baseline questionnaires revealed that the burden of 
comorbidity was high in people with IRCs. A history of anxiety and/ or depression was 
self-reported by 21.3% of individuals with IRCs, being most frequent in people with PsA 
(37.0%) and AS (24.5%), and least frequent in people with PMR (14.8%) and GCA (0.0%).   
On the EQ-5D-5L questions, 19.5% of individuals with IRCs reported moderate, 
severe or extreme symptoms of anxiety and/ or depression, which is slightly less than 
those self-reporting a history of comorbid mood problems (21.3%). However, 33.6% also 
reported mild anxiety and/ or depression symptoms on the EQ-5D-5L questions. 
Considering individual IRCs, the proportions reporting moderate, severe or extreme 
anxiety and/ or depression, were particularly high in people with AS (26.4%) and PsA 
(30.4%), though lower in people with PMR (20.5%) and GCA (17.6%), mirroring the 
proportions self-reporting a history of comorbid anxiety and/ or depression. 
Considering anxiety in particular, on assessment using the GAD-7 questions, 
17.4% of individuals with IRCs had moderate or severe anxiety. The highest proportions 
with moderate or severe anxiety had PsA (23.9%) and AS (23.5%), and the lowest 
proportions, GCA (17.7%) and PMR (10.3%), mirroring the trends observed with other 
mood assessments.   
This would fit with the background literature discussed in sections 2.8.1 and 
2.8.3, which reported anxiety to be more prevalent in people with RA (Covic et al., 2012), 
with limited studies also reporting an increased prevalence of anxiety in people with PsA 
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(Zusman et al., 2018), AS (Martindale et al., 2006) and PMR (Muller et al., 2016). This 
study provides new evidence of an increased prevalence of anxiety in people with GCA. 
An association between one or more comorbidities (in addition to an IRC), and 
anxiety was found, though this was not statistically significant. The literature supports 
an association between anxiety and multimorbidity. A cross sectional study examining 
the association between nine chronic physical conditions, multimorbidity and anxiety, 
used data from 181,845 adults participating in the World Health Survey (Vancampfort 
et al., 2017). After adjustment for confounders, one comorbidity was associated with an 
almost twofold increased odds of anxiety symptoms (OR (95% CI) = 1.94 (1.76,2.13)), 
whilst this figure rose in those with шϱ conditions ;OR ;ϵϱй CIͿ с 5.49 (3.73, 8.09)). 
A significant unadjusted association was also found between a self-reported 
history of mood problems, and anxiety. This association would be supported by the 
literature. For example, a study involving 429 participants with a history of at least one 
lifetime anxiety disorder, who were remitted at baseline, found that 23.5% developed a 
recurrent anxiety disorder over 2-years follow-up (Scholten et al., 2013).  
In addition, a significant unadjusted association between increased IRC symptom 
severity (pain, stiffness and fatigue) and anxiety was found. However, only the 
association between fatigue and anxiety remained significant after adjustment. I would 
have expected a significant association between pain and stiffness to have been 
maintained after adjustment, due to my systematic review (chapter 6), finding anxiety 
to be associated with increased disease activity. The literature supports the strong 
association found between anxiety and fatigue (Stebbings et al., 2010).  
Compared to anxiety, different trends were observed on assessment for 
depression using the PHQ-8 questions. Overall, 20.4 % of individuals with IRCs reported 
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moderate to severe depression symptoms. Unlike comorbid anxiety, the proportions 
with moderate to severe depression were highest in people with GCA (33.4%) and PMR 
(30.2%). A large proportion of people with AS (26.0%) and PsA (28.2%) also reported 
moderate to severe symptoms of depression, with the proportion being lowest in 
people with RA (18.3%). These findings would fit with the background literature, which 
suggests depression is more prevalent in people with RA, compared to people without 
IRCs, as discussed in section 2.9.1 (Matcham et al., 2013). These findings would also 
support the literature discussed in section 2.9.3, which reported an increased 
prevalence of depression in AS (Hopkins & Moulton, 2016) and PsA (Zusman et al., 
2018), in addition to limited evidence of a higher prevalence of depression in people 
with PMR (Vivekanatham et al., 2018; Muller et al., 2016) and GCA (Li, Neogi & Jick, 
2017). 
These findings suggest that depression is a more common comorbidity than 
anxiety in people with PMR and GCA. The most frequently reported depression 
symptoms, such as sleep problems and fatigue, were noted to potentially overlap 
between physical and mental health problems. Therefore, the increased symptoms of 
depression reported on the PHQ-8 questions, could have related to worse overall 
physical health. However, pain, stiffness and fatigue scores were actually lowest in 
people with PMR and GCA, suggesting that the higher depression scores were not 
necessarily attributable to a greater physical health burden. 
The odds of depression were increased in people with one or more comorbidities 
in addition to their IRC, compared to no comorbidities, though this difference was not 
statistically significant. Strong links between multimorbidity and depression have been 
reported in the literature (Read et al., 2017). It is possible that a statistically significant 
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difference was not found, due to some comorbidities not being asked about within the 
INCLUDE questionnaires, whilst recall bias could have contributed to the under-
reporting of comorbid conditions. 
Evidence suggests depression is a highly recurrent disorder (Burcusa & Iancono, 
2007), hence it is surprising that a self-reported history of anxiety or depression was not 
associated with depression, when determined using the PHQ-8 questions within the 
INCLUDE baseline questionnaires (PHQ-8 шϭϬͿ. This could suggest depression was 
under-recognised in this population, or through recall bias, it may not have been 
correctly recorded by participants.  
Pain and stiffness had a significant association with depression in people with 
IRCs. This association would be supported by previous studies which have reported 
depression to be associated with increased disease activity, including pain, in people 
with RA (Matcham et al., 2016b).  
However, fatigue and depression were not associated. This is surprising, as one 
of the PHQ-ϴ questions is about ͞feeling tired or having little energy͟ and a systematic 
review examining psychological correlates of fatigue in RA found a frequent association 
between low mood and fatigue (Matcham et al., 2015). It is possible that this association 
was not found in the INCLUDE cohort, due to individuals completing the questionnaire 
having milder disease than that seen in hospital-based cohorts, leading them to report 
less fatigue. Lower FACIT scores, indicating worse fatigue, have been reported in 
hospital-based cohorts of people with RA (Smolen et al., 2017). For example, in a study 
comparing treatment response to a placebo or biologic drug treatment in people with 
RA, the placebo cohort of 176, had a mean baseline FACIT score of 22.2 (SD 10.6) 
(Smolen et al., 2017), compared to 33.2 (SD 11.6), in the INCLUDE cohort. Study 
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participants had moderate to severe RA, hence their overall disease activity could have 
been worse than in the INCLUDE cohort, potentially contributing to increased fatigue. 
Fatigue, pain and stiffness were frequently worse in people with RA compared 
to people with GCA. People with GCA may have reported less pain and stiffness due to 
their predominant initial symptom being a headache, rather than joint pain or stiffness. 
Furthermore, once GCA is treated with glucocorticoids there is usually a more rapid 
relief of symptoms, whilst individuals with RA may have a more protracted diagnosis, 
take longer to respond to treatment, or could have underlying joint damage, leading to 
persistent symptoms. FACIT scores were consistent with NRS scores for fatigue, 
indicating worse fatigue in people with RA, AS and PsA, though less fatigue in people 
with GCA and PMR. 
 
8.5.2 Strengths and limitations 
This study is the first to determine the self-reported prevalence of anxiety and 
depression in five different IRCs. The use of validated questions to identify participants 
with mood problems helped to improve the sensitivity and specificity of the 
questionnaire for the identification of mood problems (Mitchell et al., 2016), and 
facilitated comparability with the literature. By obtaining data on demographic and 
socio-economic factors, in addition to comorbidities, potential associations between 
covariates and mood problems could be explored.  
Face-to-face interviews could have had higher specificity for diagnosing mood 
problems (Levis et al., 2019), though people with work or care commitments, or those 
from isolated areas, may have been less likely to participate. Alternatively, telephone 
interviews could have been more acceptable, though this would still have been time 
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consuming and would not have enabled data to be gathered over a short time period 
for over 300 participants. Questionnaires required less time to complete, potentially 
enabling a more diverse sample of individuals to participate.  
However, participants did need to ensure that the questionnaire was returned 
using the stamped, addressed envelope provided, hence those with poor mobility and 
no relatives or friends to seek assistance from, could have struggled to return the 
questionnaire by post. In addition, poor visual acuity or reduced literacy could have 
impacted on a participants͛ ability to complete the questionnaire. Furthermore, 
individuals with more severe depression, anxiety or joint pain could have struggled to 
complete the questionnaire, potentially meaning those with the most severe symptoms 
could have been missed. All of these factors could have contributed to response bias, 
meaning that those individuals who completed the questionnaire could have been 
systematically different from those who did not. However, as discussed in the study 
methods, considerable efforts were made to ensure a good response rate. In addition, 
involvement of patients in the development of patient facing documents, who advised 
on the content, layout, wording and length of the INCLUDE study questionnaires, helped 
to ensure that the questionnaire would be easy for patients to understand and 
complete, improving response rates and reducing potential response bias. Patient and 
public involvement and engagement (PPIE) is discussed further in section 8.6. 
Some participants may have felt more inclined to disclose mood symptoms on a 
questionnaire, due to feeling anonymous. In comparison, during a face-to-face 
interview, participants could have felt more concerned about potential stigmatisation. 
However, it could be argued that through the development of rapport during an 
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interview, people could have felt more encouraged to provide accurate and honest 
responses to questions about their mood. 
As data was derived from self-completed questionnaires, through recall bias, it 
is possible that some individuals did not self-report their IRCs or comorbidities correctly. 
Poor memory or concentration, a lack of knowledge about their health conditions or a 
lack of interest in the questionnaire could have contributed to recall bias. Medical 
record review would have enabled the comparison of self-reported and Read coded 
conditions. This is planned within the INCLUDE study, 12 months after participants 
consented to participate in the study. 
From 333 individuals completing the baseline questionnaires, 35 (10.5%) self-
reported having more than one IRC. The most frequent combinations of IRCs reported 
were RA and PMR, in addition to RA and PsA. Is is feasible that the combinations of IRCs 
reported were correct. As discussed in section 8.4.2, the prevalence of RA in people with 
PsA has been reported to be increased (Tsai et al., 2011), whilst the literature suggests 
that late-onset RA and PMR can be difficult to distinguish, (Cutolo, Cimmino & Sulli, 
2009), with some people who are diagnosed with PMR, later being diagnosed with RA 
(Caproali et al., 2001). The presence of more than one IRC could have confounded 
differences seen between the proportion with mood problems in different IRCs, though 
when analysed, the odds of developing anxiety or depression were not significantly 
increased in people with more than one IRC, when compared to those with a single IRC. 
Individuals reporting combinations of IRCs could have been analysed separately, though 
due to the small numbers involved in this pilot study, this would not have been feasible. 
Seven key comorbidities were asked about within the questionnaire, hence 
some conditions, including chronic obstructive pulmonary disease (COPD) and asthma, 
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were not accounted for, which potentially could have confounded the associations 
between IRCs and mood problems. Comorbidities on the questionnaire included 
osteoporosis, angina, MI, hypertension, stroke and anxiety or depression. These were 
chosen due to the INCLUDE review being focused on the identification of these 
comorbidities (Hider et al., 2018), which are known to be more frequent in people with 
IRCs (Gullick & Scott, 2011; Jamnitski et al., 2013; Maruotti, Corrado & Cantatore, 2014). 
Although I contributed to discussions about the questionnaire content, final decisions 
regarding its͛ content were made by the whole INCLUDE team. It is possible that 
associations between IRCs and mood problems calculated would have been more 
accurate if other comorbidities, such as common respiratory conditions, were 
accounted for. 
A further limitation was the relatively small number of individuals included in 
this study, all from the same demographic area. This was due to it being a pilot feasibility 
study rather than a full trial. In particular, the small sample size for rarer conditions such 
as GCA limited the generalisability and power of findings. However, a future full trial of 
the INCLUDE intervention would provide a larger dataset with more generalisable 
findings, within which different combinations of IRCs could be analysed separately. 
 
8.6 Patient and Public Involvement and engagement                           .    
The initial idea for the INCLUDE study arose from a PPIE group who met to 
discuss the qualitative study described in chapter 5. Patients had been recruited to this 
study after attending a nurse-led annual review at a community hospital, for a holistic 
review of their arthritis and associated comorbidities. When hearing the review was 
based at a community hospital, participants suggested that it should be performed in 
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primary care, where they already had reviews for other LTCs. They also queried why the 
review was limited to people with RA and did not include those with other IRCs. 
Following these suggestions, members of the Haywood User Group and the 
Keele University Research User Group (RUG) continued to contribute to the study. 
Haywood User Group members helped to review grant applications and documents for 
ethical approval, whilst a RUG member participated in the trial steering committee. 
After being recruited via a leaflet, shared through outpatient clinics and the RUG, six 
PPIE members with different IRCs met regularly throughout the study.  
At the first PPIE meeting, participants were enthusiastic about the proposed 
review, agreeing it would be important to prioritise comorbid mood problems, CVD, and 
bone health. Another key priority for patients was fatigue, which was incorporated into 
study questionnaires. Following this meeting, health professional stakeholders from 
primary care, rheumatology and nursing, also met to discuss the practicalities of 
implementing the review and to ensure that relevant QOF metrics (e.g. QRisk2) were 
captured. 
During subsequent PPIE meetings, participants suggested improvements to 
patient-facing documents, including questionnaires, study invitation letters and patient 
information leaflets. The group also suggested it would be useful for patients to have 
three key action points communicated via a summary sheet following their review, 
which they helped to develop.  
 
8.7 Conclusion                                                                                                 .    
 Analysis of baseline questionnaire data from the INCLUDE study has provided 
evidence of the burden of comorbid mood problems in RA, AS, PsA, PMR and GCA. 
  290 
Despite depression in RA being the main focus of past research into comorbid mood 
problems in people with IRCs, this data shows depression is even more frequent and 
severe in people with other IRCs, whilst also highlighting the burden of comorbid anxiety 
in people with IRCs. 
This study has shown the prevalence of anxiety to be particularly high in people 
with PsA, AS, and RA, though comparatively lower in people with GCA and particularly 
PMR. Therefore, results suggest a particular need to focus case-finding for anxiety on 
individuals with PsA, AS and RA. Meanwhile, the prevalence of depression was increased 
in all IRCs, particularly in GCA and PMR. This suggests a requirement for case-finding for 
depression in all IRCs, with a focus on people with GCA and PMR, in whom the burden 
of comorbid depression is the highest. 
 The evidence discussed supports the need for a review for people with IRCs, to 
enhance the recognition of and signposting for management of comorbid mood 
problems. Ultimately, through improved recognition and management of comorbidities, 
the quality of life (QoL) and potential life expectancy of people with IRCs could be 
improved.  
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9.0 DISCUSSION 
 
 Within this discussion chapter, I will provide an overview of the results from all 
studies, before contextualising them with the literature in section 9.2. I will summarise 
the strengths and limitations of my four studies, which are further detailed within each 
individual chapter. Subsequently, I will discuss the implications of my findings for clinical 
practice, education, training and research, before reflecting on how my clinical 
background has impacted on my research and vice versa.  
 
 
9.1 Summary of findings                                                                               .    
 
 
Through the use of mixed methods over 4 connected studies, I have explored 
the perspectives of people with rheumatoid arthritis (RA) of case-finding for anxiety and 
depression, determined the impact of comorbid anxiety in people with RA via a 
systematic review, and investigated the incidence and prevalence of comorbid mood 
disorders in people with different inflammatory rheumatological conditions (IRCs). 
Using qualitative methods, I have established that people with RA variably 
perceive an interaction between their arthritis and mood. Whilst most interview 
participants reported their RA to negatively impact on their mood, several perceived 
anxiety or depression to precipitate RA flares. Some only recognised a link between their 
RA and mood, when this was highlighted by a healthcare professional. 
There were multiple barriers to help-seeking for mood problems in people with 
RA, including fear of stigmatisation, lack of time in appointments and poor continuity of 
care. Some participants lacked candidacy for care, normalising their mood symptoms, 
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whilst others perceived their general practitioner (GP) to prioritise physical above 
mental health concerns, recursively affecting help-seeking. Meanwhile, participants 
perceived rheumatologists were only responsible for physical health care. However, 
establishment of rapport and continuity of care, either with a particular GP, or the 
annual review clinic nurse, were reported to facilitate disclosure of mood concerns. 
21% of people attending the RA annual review clinic scored ш ϯ on the Patient 
Health Questionnaire (PHQ)-2 questions, whilst 24% scored ш ϯ on the Generalised 
Anxiety Disorder (GAD)-2 questions, suggesting a requirement for further assessment 
to identify potential depression or anxiety. From those interviewed, the case-finding 
questions were perceived to be acceptable in the context of a nurse-led annual review 
clinic. Participants recognised the holistic focus of the review and appreciated the 
opportunity to learn about the wider impact of their RA. Disclosure of mood concerns 
was facilitated by the clinic nurse being perceived as approachable and having time to 
listen. 
A patient and public involvement and engagement (PPIE) group, acknowledging 
the need for patients with RA to be educated about comorbid mood problems, helped 
to collaboratively develop a patient information leaflet. The PPIE group also reflected 
on how often interview participants had discussed ways that their mood problems had 
prevented them from accessing care. In particular, those interviewed had described 
how anxiety had prevented them from seeing their GP or accessing psychological 
services, whilst several had also reported a perception that anxiety caused flares of their 
RA. However, a lack of literature was found reporting the impact of anxiety on quality 
of life (QoL) and disease activity in people with RA. 
  294 
A systematic review and meta-analysis were performed to determine the 
association between anxiety in people with RA, and quality of life (QoL) and disease 
activity. Anxiety was found to be cross-sectionally associated with a reduced QoL, 
though a lack of studies reported the prospective association between anxiety and QoL. 
On review of short form (SF)-36 subscale effect sizes, the largest impact of anxiety was 
seen on vitality, social functioning and mental health scores. Relatively larger effect sizes 
for reduced social functioning and mental health scores could have reflected symptoms 
of anxiety in addition to components of QoL, whilst the correlation between anxiety and 
vitality could have been confounded by known associations between mood and fatigue 
(Matcham et al., 2015).  
Anxiety in people with RA was also associated with increased disease activity, 
both cross-sectionally, and at 3, 6 and 12 months. The 2 larger studies reporting the 
association between anxiety and disease activity over time found the impact of baseline 
anxiety to reduce over time, potentially due to people with anxiety adapting to their RA 
diagnosis, leading to a reduction in subjective component scores within the Disease 
Activity Score in 28 joints (DAS28). The association found between anxiety and increased 
disease activity cross-sectionally in the systematic review may, in part, have been due 
to anxious people reporting higher patient global assessment of health (PtGA) scores 
and other subjective measures of disease activity, rather than their disease activity 
being objectively increased. 
The systematic review built on findings from the preceding qualitative study by 
providing further evidence of the negative impact of anxiety in people with RA, 
highlighting the need for a focus on the identification and management of comorbid 
anxiety in addition to depression. Further associated studies were guided by other 
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suggestions from the PPIE group, who queried why guidelines recommending an RA 
annual review did not extend to other IRCs. This led me to identify a lack of literature 
reporting the burden of anxiety in people with AS and PsA, in addition to anxiety and 
depression in people with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).  
Consequently, I performed a cohort study to determine the incidence and prevalence 
of anxiety and depression in different IRCs using a primary care dataset. 
Although the numbers of people reporting mood problems in GCA were small, 
and hence the results should be interpreted with caution, novel evidence of an 
increased prevalence of mood problems in people with GCA was identified, with further 
evidence being found to support an increased prevalence of anxiety alone, in addition 
to anxiety and/ or depression in people with RA, ankylosing spondylitis (AS), and 
psoriatic arthritis (PsA). Despite past research into mood problems in IRCs focusing on 
RA, the prevalence of anxiety and/ or depression was highest in people with PsA and 
GCA, whilst there was also a statistically significant increase in the adjusted odds of new 
anxiety and/or depression in these conditions.  
The incidence of anxiety alone was reduced in people with RA, AS and PsA, whilst 
the incidence of anxiety and/or depression was also reduced in people with AS and PsA, 
compared to those without IRCs. It is possible that mood problems were under-
recognised in these conditions. There were also less individuals with AS and PsA 
compared to the other IRCs analysed, which could have limited the reliability of results. 
Individuals with AS and PsA had fewer comorbidities and a lower number of primary 
care contacts, compared to people with other IRCs, hence had less opportunities for the 
potential recognition or discussion of mood problems. In addition, 95% CIs reported 
with the HR͛s for anxiety were particularly wide in people with RA, AS and PsA, 
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suggesting a greater sample size would have been required to accurately determine the 
association between these IRCs and anxiety. In contrast, the incidence of anxiety alone 
and anxiety and/ or depression, was increased in people with PMR and GCA. A 
statistically significant increase in the risk of new anxiety was found in people with PMR 
and GCA, which remained significant after adjustment in people with GCA.  
Through the use of primary care consultation data, it was recognised that mood 
problems could have been underestimated, due to patients not identifying symptoms 
or consulting, or due to clinicians not recognising or recording potential mood problems. 
For example, the literature suggests that older adults may normalise depression 
(Wuthrich & Frei, 2015), whilst primary care practitioners may not recognise depression 
in older adults due to normalising it as an understandable aspect of ageing, on a 
spectrum with loneliness and reduced functioning (Burroughs et al., 2006). 
Alternatively, through the use of questionnaires, data could have been obtained to 
compare the difference between self-reported mood symptoms and consultation for 
anxiety or depression. Otherwise, patients with IRCs could have been invited to a 
consultation where they could have been asked questions to identify potential mood 
problems. Supported by evidence from the cohort study and informed by the preceding 
qualitative study and systematic review findings, these alternative approaches, using 
both questionnaires and face-to-face consultations were utilised within the INCLUDE 
pilot trial (Hider et al., 2018).  
The INCLUDE study aimed to determine the feasibility and acceptability of a 
nurse-led review for people with IRCs, based in primary care, aiming to identify and 
facilitate the management of comorbidities. Due to mood problems in people with IRCs 
potentially not being recognised or coded in primary care records, I analysed responses 
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to the case-finding questions for mood problems from baseline questionnaires, 
completed by the INCLUDE study participants. This enabled me to compare differences 
between the proportion of mood problems recognised and recorded within primary 
care electronic health records, to the number of mood problems identified following the 
use of the case-finding questions within the INCLUDE study questionnaire.  
Analysis of the INCLUDE baseline data showed the burden of self-reported mood 
problems to be high, with anxiety (defined as GAD-7 шϭϬ) affecting 17.4% and 
depression (defined as PHQ-8 шϭϬͿ affecting 20.4% of study participants. The proportion 
with anxiety was particularly high in people with PsA and AS, though comparatively 
lower in people with PMR and GCA. In contrast, my cohort study, found the adjusted 
odds of anxiety to be particularly high in people with GCA, compared to other IRCs. 
Meanwhile, on further analysis of the INCLUDE data, depression was found to be most 
frequent in people with GCA and PMR, though a large proportion of people with AS and 
PsA also reported moderate to severe symptoms of depression. Although the 
prevalence of depression was lowest in people with RA, this was still much higher than 
the proportion reported to have depression in the general population (NatCen Social 
Research, 2016), as described in sections 2.5 and 2.8. 
The most frequently reported depression symptoms were sleep problems and 
fatigue, which could have related to worse physical health symptoms, rather than low 
mood. However, in people with GCA and PMR, for whom the prevalence of depression 
was highest, pain, stiffness and fatigue scores were actually lower, when compared to 
other IRCs, suggesting an underlying mood disorder as the cause of a high PHQ-8 score, 
rather than increased IRC symptoms. It is possible that steroid treatment could have 
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contributed to the increased prevalence of depression in people with PMR and GCA 
(Brown & Chandler, 2001). 
In overall IRCs, statistically significant associations were found between pain, 
stiffness, and current depression, whilst a significant association was also found 
between fatigue and anxiety. The presence of one of more comorbidities (in addition to 
an IRC) was associated with increased odds of anxiety and depression, though these 
associations were not statistically significant. Similar associations between covariates 
and mood problems were found in people with RA, when compared to overall IRCs. 
There were too few participants to enable analysis of the associations between 
covariates and mood problems in other IRCs. 
 
 
9.2 Comparison with existing literature                                            .    
 
My qualitative study (chapter 5), was the first to explore patients͛ perspectives 
of case-finding for comorbid mood problems in people with RA, during a nurse-led 
annual review. Reflecting findings for other long-term conditions (LTCs), this research 
suggested that patients may recognise an interaction between their RA and mood 
(DeJean et al., 2013; Dures et al., 2016b), though individuals who don͛t perceive their 
RA and mood to be connected may not understand why they are asked about their 
mood during LTC reviews (Anderson, Foy & House, 2015). 
Qualitative studies have been performed in other IRCs, in which participants 
have reflected on the interaction between their inflammatory condition and mood. In a 
qualitative study exploring the impact of AS, some participants perceived stress to 
trigger flares of pain ;Primholdt et al., ϮϬϭϳͿ, whilst in a study exploring patients͛ 
experiences of living with PMR (Twohig et al., 2015), participants reflected on the 
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negative impact of their disability on their mood. Within a qualitative study exploring 
patients͛ perspectives of GCA ;Liddle et al., ϮϬϭϳͿ, participants often connected anxiety 
symptoms to fear about their disease prognosis, including the risk of visual loss. 
Within my qualitative study, patients with RA, similarly to those with other LTCs 
(Coventry et al., 2011), were often found to lack candidacy for care, meaning they didn͛t 
seek help for anxiety or depression due to perceiving changes in their mood to be a 
normal response to living with a LTC. During interviews, people with RA discussed stigma 
as a barrier to help-seeking for mental health problems, echoing findings in other LTCs 
(Anderson et al., 2012).   
Considering further barriers to help-seeking, when a questionnaire was used to 
explore the preferences of people with inflammatory arthritis for psychological support, 
several participants described feeling unheard or struggling to ask for help for 
psychological problems (Dures et al., 2016b). This mirrored the perspectives of people 
with RA during my qualitative study, who perceived GPs to be dismissive of mood 
concerns. Further barriers to help-seeking for mood problems identified in my study 
included a perception of doctors prioritising physical above mental health concerns, a 
lack of time, anxiety-provoking appointments and poor continuity of care, all of which 
recursively affected help-seeking. However, several participants did describe being 
more receptive to discussing mood problems once they had been able to build a rapport 
with their GP, facilitated by continuity of care. Within the nurse-led RA annual review 
clinic, participants described the approachability of the nurse, who had time to listen, 
to facilitate disclose of mood concerns.  
My systematic review (chapter 6), was the first to examine the association 
between anxiety in people with RA, and QoL and disease activity. Anxiety in people with 
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RA was found to be cross-sectionally associated with reduced QoL. This complemented 
previous research examining the impact of depression in people with RA, which found 
depression to be associated with reduced physical and mental QoL (Bazzichi et al., 2005; 
Senra et al., 2017).  
My systematic review also demonstrated anxiety in people with RA to be 
associated with increased disease activity cross-sectionally, and at up to 12-months 
follow-up. This built on the findings of a study assessing the impact of combined anxiety 
and depression in people with RA. Both baseline and persistent mood problems, 
assessed using the EuroQol 5-Dimension Scale (EQ-5D), were associated with 
significantly increased DAS28 scores (Matcham et al., 2016b). Other studies have also 
found associations between depression in people with RA and increased disease 
activity. For instance, a systematic review found a temporal association between 
depression in people with RA and increased disease activity (Rathbun, Reed & Harrold, 
2013), whilst further studies have found baseline depressive symptoms to be associated 
with a reduced response to RA treatment over time (Matcham et al., 2018; Hider et al., 
2009; Hancock et al., 2012; Maruotti, Corrado & Cantatore, 2014) and a lower disease 
remission rate (Cook et al., 2016). 
My systematic review suggested that the association between anxiety and 
increased disease activity could, in part, have been due to people with anxiety reporting 
higher patient global assessment (PtGA) scores and other subjective measures of 
disease activity, rather than their disease activity having objectively increased. People 
with RA, particularly those with psychological comorbidities, have been found to rate 
their disease activity higher than their physicians (Liu, Bathon & Giles, 2015; Duarte et 
al., 2015). Patient-reported measures such as the Visual Analogue Scale (VAS), which 
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forms part of DAS28, have been found to be more strongly influenced by psychological 
variables (Cordingley et al., 2014).  
My cohort study (chapter 7), characterised the incidence and prevalence of 
anxiety, in addition to anxiety and/ or depression, in a range of different IRCs. The 
prevalence of anxiety alone, in addition to anxiety and/or depression was higher in 
overall IRCs, RA, AS, PsA and GCA, when compared to those without IRCs. This was 
consistent with the background literature, which suggested anxiety and depression 
were more prevalent in RA (Isik et al., 2006; Matcham et al., 2013), AS (Hopkins & 
Moulton, 2016; Shen et al., 2016) and PsA (McDonough et al., 2014), compared to the 
general population (NatCen Social Research, 2016). These findings also supported 
limited research showing a higher prevalence of depression in people with GCA (Li, 
Neogi & Jick, 2017), whilst providing new evidence of an increased prevalence of 
anxiety. 
However, the prevalence of mood problems was lower in people with PMR, 
compared to those without IRCs. This contrasts with the limited background literature, 
that suggests 15-22% of people with PMR have symptoms of depression (Vivekanatham 
et al., 2018; Muller et al., 2016) and approximately 13% have symptoms of anxiety 
(Muller et al., 2016). This also contrasts with data from the INCLUDE study 
questionnaires, which have found the prevalence of depression to 30.2%, and anxiety 
10.3%, in people with PMR.  
Compared to the other IRCs analysed, PMR is a condition that is more frequently 
managed exclusively within primary care. Therefore, primary care consultations could 
have been more focussed on medical management, including the prescription of 
glucocorticoids for treatment of the primary condition, leaving less time for discussion 
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of potential mood problems. Conversely, it could be argued that within primary care, if 
an individual with PMR had regularly attended follow-up with a clinician, they could 
have had more opportunity to develop a rapport, increasing their propensity to disclose 
mood concerns. 
In my cohort study, mood problems were most prevalent in people with PsA and 
GCA. This would reflect the findings of Freire et al. (2011), who estimated the prevalence 
of moderate anxiety and depression in people with PsA to be 17.6% and 29.7% 
respectively. Results would also be consistent with a study by Li, Neogi and Jick (2017), 
who estimated the prevalence of depression in people with GCA to be 17.6%. There was 
also a statistically significant increase in the adjusted odds of anxiety and/or depression 
in people with PsA and GCA. The adjusted odds of mood problems were increased in 
people with RA, though this increase was not statistically significant, despite the 
literature suggesting the prevalence of anxiety (Covic et al., 2012) and depression 
(Matcham et al., 2013) in people with RA to be high.  
Overall, the incidence of anxiety was reduced in people with IRCs, though 
increased in people with PMR and GCA, compared to those without IRCs. In addition, 
the risk of anxiety in people with overall IRCs, RA, AS and PsA was lower than in those 
without IRCs. However, the risk of anxiety in people with PMR and GCA was increased. 
This increase was statistically significant in people with GCA, compared to those without 
IRCs. These findings support limited literature showing an increased incidence of anxiety 
symptoms in people with PMR (Muller et al., 2016), whilst also adding to the literature 
by highlighting a particularly increased incidence of anxiety in people with GCA. 
However, the findings for RA and AS, contrast with literature showing an increased 
incidence of anxiety in these conditions (Marrie et al., 2018b, Qui et al., 2019; Shen et 
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al., 2018), whilst providing evidence to suggest a reduced incidence of anxiety in PsA. 
However, for the reasons discussed in section 7.5.3, including fewer comorbidities 
requiring nurse-led reviews, lower primary care contact rates and small sample sizes for 
AS and PsA, it is possible that the incidence of anxiety in some IRCs was under-
estimated. Also, as people were recruited for my cohort study from primary care, the 
burden of mood problems may not have been as high as in a secondary care cohort, in 
which people could have had more severe IRC symptoms, contributing to anxiety or 
depression. 
The incidence of anxiety and/ or depression was reduced in people with AS and 
PsA, though increased in people with RA, PMR and GCA, compared to those without 
IRCs. In addition, the risk of anxiety and/ or depression in people with RA, AS and PsA 
was lower than in those without IRCs. However, the risk of anxiety and/ or depression 
in people with PMR and particularly GCA was increased, compared to those without 
IRCs. Limited background literature supports the findings for PMR and GCA, reporting 
an increased incidence of anxiety and depression in people with PMR (Muller et al., 
2016), and an increased incidence of depression in people with GCA (Li, Neogi & Jick, 
2017). However, findings for AS and PsA, contrast with the literature, which suggests 
the incidence of mood problems is increased in people with AS (Meesters et al., 2014; 
Wu et al., 2017; Shen et al., 2016) and PsA (Zusman et al., 2018). Again, it is possible 
these differences were seen due to under-recognition of mood problems in some IRCs, 
a point I will discuss further, when comparing the cohort and INCLUDE study results. 
Within the INCLUDE study (Hider et al., 2018), validated tools such as the GAD-7 
and PHQ-8 questions were used to determine the prevalence of anxiety and depression 
in a range of different IRCs. Considering the GAD-7 assessment, the highest proportion 
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with moderate or severe anxiety had PsA (23.9%) and AS (23.5%), reflecting previously 
reported prevalence rates of moderate anxiety in people with PsA (29%) (Freire et al., 
2011) and AS (25%) (Martindale et al., 2006). The lowest proportions with moderate or 
severe anxiety had PMR (10.3%) and GCA (17.7%). This mirrored limited literature on 
the prevalence of anxiety in people with PMR (Muller et al., 2016), whilst providing new 
evidence of of moderate prevalence of anxiety in people with GCA.  
Unlike comorbid anxiety, the proportions with moderate to severe depression 
were highest in GCA (33.4%) and PMR (30.2%). Limited prior literature on comorbid 
depression in people with GCA, suggests the prevalence of depression to be much lower, 
at 17.6% (Li, Neogi & Jick, 2017), whilst the prevalence of depression in people with PMR 
has previously been estimated at 22% (Muller et al., 2016). Therefore, this new evidence 
suggests the burden of self-reported depression in GCA and PMR is higher than 
previously thought. 
A large proportion of people with AS (26.0%) and PsA (28.2%), also reported 
moderate to severe symptoms of depression, higher than previously reported in the 
literature, which estimates the prevalence of moderate to severe depression to be 8.2%-
18.0% in AS (Hopkins & Moulton, 2016; Zhao et al., 2018) and 17.6% in PsA (Freire et al., 
2011) respectively. This evidence suggests that the burden of depression in AS and PsA 
is also higher than previously thought. The proportion with depression was lowest in 
people with RA (18.3%), lower than the 38.8% previously reported to have depression 
in a meta-analysis of PHQ-9 scores (Matcham et al. 2013).  
A statistically significant adjusted association was found between fatigue and 
anxiety, which would be supported by the literature (Stebbings et al., 2010), whilst 
significant unadjusted associations were also found between pain, stiffness and anxiety. 
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Links between anxiety and increased disease activity, hence pain and stiffness, would 
be supported by my systematic review (chapter 6), whilst the literature also supports an 
association between mulitmorbidity and anxiety (Vancampfort, 2017).  
Although one or more comorbidities in addition to an IRC were associated with 
increased odds of depression, this association was not statistically significant. This is 
surprising, as strong links between multimorbidity and depression have been noted in 
the literature (Read et al., 2017). However, just seven key comorbidities were asked 
about within the questionnaire, hence some comorbid problems, such as asthma and 
chronic obstructive pulmonary disease (COPD), were not accounted for. Recall bias may 
also have contributed to the under-recording of comorbidities.  
Depression was significantly associated with increased pain and stiffness, 
supported by literature reporting strong links between low mood and increased disease 
activity (Rathbun, Reed & Harrold, 2013). However, no significant association between 
fatigue and depression was found. This contrasts with a systematic review examining 
psychological correlates of fatigue in RA, which found a frequent association between 
low mood and fatigue (Matcham et al., 2015). It is possible that no significant association 
was found due to individuals in the INCLUDE cohort having milder disease than that seen 
in hospital-based cohorts, leading them to report less fatigue. Lower FACIT scores, 
indicating worse fatigue, have been reported in hospital-based cohorts of people with 
RA (Smolen et al., 2017). 
Anxiety was more frequent, though moderate to severe depression less 
frequent, in people with two or more IRCs, compared to one IRC. There were no 
statistically significant associations found between having more than one IRC and 
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developing anxiety or depression, suggesting the presence of more than one IRC did not 
impact significantly on the development of mood problems.  
The prevalence of mood problems, when determined using primary care 
consultation data, was much lower than when determined using the case-finding 
questions within the INCLUDE study questionnaires. The prevalence of anxiety was 4.2% 
(range 2.8-9.4%) according to primary care data, compared to 17.4% (range 10.3-23.9%) 
when determined using the case-finding questions. Meanwhile, the prevalence of 
anxiety and/ or depression was 8.3% (range 6.0-14.4%) according to primary care data, 
whilst the prevalence of depression was 20.4% (range 18.3-33.4%) when determined 
using the case-finding questions. Similar trends were observed when individual IRCs 
were analysed.  
The proportion of people with IRCs found to have mood problems, when 
determined using the case-finding questions for anxiety and depression, was far in 
excess of the prevalence of mood problems found in the general population. For 
example, in 2014, a survey in England found approximately 5.9% of the general adult 
population to have self-reported symptoms of anxiety and 3.3%, symptoms of 
depression in the preceding week (NatCen Social Research, 2016). However, the 
prevalence of anxiety in people with IRCs was lower than that reported in the general 
population, when determined using primary care electronic health records, with anxiety 
and/ or depression affecting similar proportions with and without IRCs. 
As discussed in section 2.9, the literature suggests that the prevalence of mood 
disorders in people with RA is high, with approximately 20% having anxiety (VanDyke et 
al., 2004) and 38.8% depression (Matcham et al., 2013). The prevalence of depression 
in other IRCs has been reported as 18% in AS (Zhao et al., 2018), 20% in PsA (Zusman et 
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al., 2018) and 15% in PMR (Vivekanatham et al., 2018). Therefore, I would have expected 
the analysis of Read codes within primary care electronic health records to show a 
higher prevalence of mood problems, on comparison with general population. However, 
the prevalence of anxiety and depression was much lower when determined using 
primary care data, compared to when the case-finding questions were used wthin the 
INCLUDE questionnaires. This suggests that mood problems are under-recognised in 
people with IRCs, within primary care.  
The literature suggests that depression (Goldberg & Huxley, 1991) is under-
recognised in primary care, whilst recent research has also highlighted the under-
recognition of anxiety in people with LTCs (Barnes et al., 2019). A study involving 
adolescents, compared the prevalence of common mental disorders (CMDs) according 
to electronic primary care data, to the prevalence of CMDs determined by interviews. 
Many individuals who were found to have a CMD during interviews, had no record of a 
mental health problem in their electronic primary care record, suggesting that research 
using clinical databases could under-estimate the burden of mental health problems in 
a population (Cornish et al., 2016). 
It is possible that primary care consultations for people with IRCs focus on their 
inflammatory condition, leaving less time for discussion of mood concerns. The 
literature also suggests that there are barriers which can prevent people with mood 
problems from accessing care. People with LTCs have been reported to lack candidacy 
for care of mood problems (Coventry et al., 2011), whilst people with RA have discussed 
stigma as a barrier to help-seeking for anxiety or depression (Anderson et al., 2012). In 
chapter 5, my qualitative study revealed further potential barriers to people with RA 
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and mood problems from accessing care, which could have prevented potential anxiety 
or depression from being identified and recorded.  
Research suggests that when people with psychological disorders normalise 
their symptoms, general practitioners are less likely to diagnose anxiety or depression 
(Kessler, Lewis & Gray, 1999). In particular, older adults may normalise depression 
(Wuthrich & Frei, 2015), whilst primary care practitioners may not recognise depression 
in older adults due to normalising it as an understandable aspect of ageing (Burroughs 
et al., 2006). 
There were some consistencies between the cohort study and INCLUDE study 
data. For instance, the prevalence of anxiety was highest in people with PsA within both 
studies. In addition, the prevalence of anxiety and/ or depression was highest in people 
with GCA within the cohort study, whilst data from the INCLUDE study showed the 
prevalence of depression to be highest in people with GCA. Both studies also found the 
prevalence of anxiety in people with PMR to be lower, when compared to other IRCs. 
However, whereas the overall prevalence of mood problems in people with IRCs was 
high within the INCLUDE study, the cohort study did not find the prevalence of anxiety 
to be increased in people with IRCs, whilst the prevalence of anxiety and/or depression 
was only marginally increased in people with IRCs, compared to those without IRCs. This 
highlights the difference between prevalence rates when determined using the case-
finding questions within the INCLUDE study, compared to those determined using 
primary care electronic health records, within my cohort study. 
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9.3 Strengths and limitations                                                                       .    
 
The strengths and limitations of each study have been discussed in detail in each 
respective chapter (section 5.10.2, section 6.5.2, section 7.5.5 and section 8.5.2). Brief 
summaries of the strengths and limitations of each study are given below. 
 
9.3.1 Qualitative Study  
Use of exploratory methods, followed by further analysis using a framework, 
enabled deeper insights into the barriers and facilitators to patients with RA accessing 
care for psychological problems. As only patients with a high PHQ-2 or GAD-2 score were 
interviewed, different views could have been articulated by individuals without mood 
problems. In addition, participants were predominantly white British and female, hence 
a greater range of perspectives are likely to have been gained from a more diverse 
population, though a range of different socioeconomic statuses were represented 
within the sample interviewed, whilst attempts were made to purposively sample 
participants of different ages. 
 
9.3.2 Systematic Review 
A broad search strategy for the review helped to ensure all evidence on this topic 
was considered. However, several studies that did not report anxiety separately from 
depression had to be excluded. In addition, several conference abstracts that did not 
report sufficient data had to be excluded, after attempts made to contact the authors 
of all the abstracts to obtain relevant data were unsuccessful. The quality of studies 
varied, with several sources of potential heterogeneity identified. Meta-analysis was 
also limited by the small number of studies providing suitable data for statistical pooling 
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of results. Nonetheless, this review provided evidence supporting an overall association 
between anxiety in people with RA, and reduced QoL and disease activity. 
 
9.3.3 Cohort Study 
Although the data quality in the Consultations in Primary Care Archive (CiPCA) 
database is comparable to larger national databases, use of a national database such as 
the Clinical Practice Research Datalink (CPRD) would have provided a larger sample size, 
hence more generalisable results, enabling stronger conclusions to be made about the 
association between IRCs and mood problems.  
Results could have been biased by missing data and unmeasured confounding, 
though adjustments were made for a range of lifestyle factors and comorbidities known 
to be associated with mood problems. It is possible that some codes were misclassified. 
In addition, mood problems could have been underestimated due to patients not 
identifying symptoms or consulting for their mood concerns (Wuthrich & Frei, 2015), 
whilst clinicians may not have recognised or recorded potential mood problems 
(Burroughs et al., 2006). The reliance on coded consultation data meant that depression 
alone could not be accurately analysed, due to it often being recorded using the Read 
code ͞anxiety with depression͟. However, the anxiety and depression Read code lists 
were combined to enable analysis of individuals with anxiety and/ or depression. In 
addition, given the frequent focus of the thesis on anxiety, I analysed anxiety codes 
separately, though it is possible that these results were an underestimate, since some 
cases of anxiety could have been missed that were only recorded as ͞anxiety with 
depression͟ in the clinical record.  
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9.3.4 INCLUDE Study 
This feasibility study was strengthened by the use of validated measures (PHQ-8 
and GAD-7) to identify mood problems within a questionnaire developed with patients, 
to help ensure ease of completion. The use of face-to-face interviews could have 
facilitated a more accurate diagnosis of depression, though this would not have enabled 
data to be collected for over 300 people within a short period of time. As data was 
derived from self-completed questionnaires, it is possible there was some recall bias, 
though a medical record review is planned within the INCLUDE study, 12 months after 
participants consented to participate, to enable self-reported conditions to be 
compared to those recorded in patients͛ electronic health records using Read codes.  
Respiratory conditions, which could have confounded associations between IRCs 
and mood problems, were not asked about within the questionnaire, due to questions 
being focused on the comorbidities being explored within the INCLUDE review. 10.5% 
reported having more than one IRC, which also could have confounded differences seen 
between the proportion of mood problems in different IRCs, though the odds of having 
a mood problem were not significantly increased in people with more than one IRC 
compared to those with a single IRC.  
The number of participants was relatively small in the INCLUDE pilot study and 
they were all from the same demographic area, making it difficult to generalise findings. 
More than a third of invited people did not return the baseline questionnaire, hence it 
is possible that there was also a response bias, though efforts were made to ensure a 
good response rate. 
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9.4 Implications for clinical practice, education, training and research 
 
9.4.1 Implications for clinical practice 
Guidelines produced by the National Institute for Health and Care Excellence 
(NICE) outline how depression should be identified and treated in adults with chronic 
physical health problems (NICE, 2009b), though no similar guideline has been published 
to assist the recognition and management of anxiety in LTCs. This is surprising, given 
that both anxiety and depression in LTCs are under-recognised, under-treated (Cepoiu 
et al., 2007), and linked to increased morbidity and mortality (Ang et al., 2005). 
Therefore, guidelines are needed to inform clinicians about how to optimise the 
identification and treatment of anxiety in people with LTCs. 
Through use of case-finding questions, my research has highlighted an increased 
prevalence of comorbid mood problems in people with IRCs. However, the prevalence 
of mood problems in people with IRCs was higher when responses to the case-finding 
questions were analysed, compared to Read codes within electronic health records, 
suggesting a potential burden of undiagnosed mood problems in people with IRCs. This 
implies that annual reviews should be recommended for people with a range of 
different IRCs, including AS, PsA, PMR and GCA, in addition to people with RA.  
The requirement for an annual review to identify potential mood problems in 
people with IRCs would be supported by my qualitative study, during which I found 
several patients did not perceive a connection between their RA and mood until this link 
was highlighted by a healthcare professional. Quality and Outcomes Framework (QOF) 
incentives specifying an assessment of mood could also help to encourage GPs to 
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establish regular annual reviews for their patients with IRCs, to improve the recognition 
of comorbid anxiety and depression within general practice. 
Condition specific guidelines need to be updated to reflect the high proportions 
of people with IRCs who have comorbid mood problems. This would be supported by 
my research examining the self-reported prevalence of mood symptoms, in addition to 
my systematic review, which highlighted the potential impact of anxiety in people with 
RA.  
The impact of anxiety on disease activity suggests that rheumatologists and 
allied health care professionals should consider case-finding for mood problems in 
people who fail to respond to RA treatments, especially if subjective disease activity 
measures (PtGA, tender joint count (TJC)) are high relative to more objective scores 
(swollen joint count (SJC), erythrocyte sedimentation rate (ESR)). Managing mood 
alongside RA could lead to improved outcomes.  
 
9.4.2 Implications for education and training 
My research supports the requirement for all healthcare professionals to be 
aware of the burden of anxiety and depression in people with IRCs, and to be confident 
and competent to identify and respond to cues for mood problems, especially in those 
with multimorbidity. My qualitative study reveals that patients can find doctors to be 
dismissive of mood concerns, or perceive them to prioritise physical above mental 
health problems. However, development of rapport was reported to facilitate 
disclosure, hence improved continuity of care could help patients to disclose mood 
concerns. Furthermore, encouraging health care professionals to complete Improving 
Access to Psychological Therapies (IAPT) referrals on behalf of patients, particularly for 
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people who are anxious about self-referral, or older adults who are under-represented 
in IAPT services (Pettit et al., 2017), could help to facilitate access to psychological 
therapies, as highlighted within my qualitative study. 
A qualitative study exploring nurses͛ experiences of recognising depression in 
older people with multimorbidity, revealed that nurses can lack confidence discussing 
mood with their patients, often perceiving it to not be their responsibility (Waterworth 
et al., 2015). Practictioners have also reported struggling to incorporate the case-finding 
questions into reviews, finding them too mechanistic (Maxwell et al., 2013). However, 
my qualitative study found the case-finding questions to be acceptable, when delivered 
in the context of a nurse-led review. Therefore, there is a training requirement for 
practitioners, who need to be encouraged to case-find for potential mood problems and 
give equal priority to physical and mental health concerns. 
For a nurse-led review to improve the QoL and overall outcomes for people with 
IRCs, patients͛ health priorities will need to be taken account of, to facilitate shared 
treatment decisions. For example, when discussing the management of mood problems 
in IRCs, patients have often expressed a preference for psychological therapies to avoid 
the burden of further medication (Machin et al., 2017; Withers et al., 2015). 
Consequently, healthcare practitioners will need to be trained to optimise care for 
adults, whilst limiting treatment burden (Boyd et al., 2014) as much as possible, 
principles highlighted within NICE guidelines (NG 56) for the assessment and 
management of patients with multimorbidity (NICE, 2016). 
Some practitioners have been reported to favour an individualised approach to 
identifying potential mood problems, although it can take additional time to develop 
rapport (Maxwell et al., 2013). Due to increasing demands on GPs in primary care, 
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expanding the role of allied healthcare professionals is a key part of the GP five year 
forward view (NHS England, 2017a). Supporting other practitioners to be confident in 
the use of case-finding questions and managing mood problems, could improve the 
recognition of anxiety and depression. For instance, when practice nurses (PNs) were 
trained to deliver a psychosocial intervention within a collaborative care (CC) framework 
for people with depression and LTCs, patients valued a PN being able to listen to their 
mood concerns, though the need for more formal supervision to support PNs in 
undertaking the role of a case manager for people with depression and LTCs was 
emphasised (Webster et al., 2016). Provision of time and the approachability of the 
clinic nurse were integral factors in facilitating disclosure of mood concerns by patients 
with RA who participated in my qualitative study. Furthermore, a nurse-led review 
focused on comorbidity management for individuals with RA, has been found to 
increase the number of interventions taken to treat related comorbidities (Dougados et 
al, 2015). Therefore, educating and supporting nurses to deliver reviews for people with 
IRCs, that include case-finding for potential mood problems, could improve overall 
outcomes.  
Within my cohort study (chapter 7), the prevalence of mood problems recorded 
using Read codes in primary care electronic health records, was highest in people with 
GCA, whilst within the INCLUDE study baseline questionnaires, self-reported symptoms 
of depression were particularly high in people with PMR and GCA (chapter 8). 
Consequently, when primary care practitioners consult patients with these conditions, 
alongside assessments for steroid side-effects, they could consider opportunistic case-
finding for mood problems.  
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My research has also highlighted an educational need for patients around 
comorbid mood problems in IRCs, which I have promoted via dissemination activities, 
including the co-production of a patient information leaflet about mood problems in 
people with RA, which is available locally. 
 
9.4.3 Implications for research 
Evidence suggests there is an association between baseline anxiety and 
depression in people with RA, and increased disease activity, both from my systematic 
review and other reported literature (Matcham et al., 2016b; Rathbun, Reed and 
Harrold, 2013), in addition to a reduced treatment response (Matcham et al., 2018). 
Further research is required to determine whether treating mood problems leads to 
improved rheumatological outcomes. This could be addressed by the following research 
question. 
 
Does the identification and treatment of comorbid anxiety and/ or depression in 
people with IRCs lead to an improved QoL or reduced disease activity? 
 
A randomised controlled trial (RCT), similar to the INCLUDE study (Hider et al., 
2018), could be used to respond to this question. However, the INCLUDE intervention 
involved the assessment and management of cardiovascular risk and bone health 
alongside potential anxiety and/ or depression in people with IRCs. Therefore, to 
determine outcomes solely related to the identification and treatment of mood 
problems, adjustments for other comorbidities identified and treated would need to be 
made.  
Alternatively, people with different IRCs identified from electronic primary care 
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records, could be invited to participate in a new trial. All participants could be assessed 
for potential mood problems by questionnaire. People with symptoms of anxiety and/ 
or depression (GAD-7/ PHQ-9 шϭϬͿ could then be randomised to an intervention group 
or control group. The intervention could involve cognitive behavioural therapy (CBT), or 
alternatively, behavioural activation, a therapy that encourages people with depression 
to approach activities they may have been avoiding, and to define goals (Jacobson, 
Martell & Dimidjian, 2001). These therapies could be delivered by a psychological 
wellbeing practitioner over six to eight weekly sessions, as used in the COINCIDE trial 
(discussed in section 2.7), an RCT testing the effectiveness of an integrated collaborative 
care model for people with depression and long-term physical conditions (Coventry et 
al., 2015).  To integrate care, as in the COINCIDE trial, a short collaborative meeting 
between the patient, psychological wellbeing practitioner and PN from the patients͛ 
general practice, could take place during the middle and towards the end of the 
intervention, to review any progress made and to ensure that goals established during 
meetings with the psychological practitioner do not have any negative impact on 
physical comorbidities. The control group would continue to receive routine care. At 
baseline, 6 and 12 months, patients would be asked to complete questionnaires, 
including questions to assess mood (GAD-7/ PHQ-9), QoL (SF-36) and disease activity 
(VAS Pain). Outcomes between the intervention and control groups could then be 
compared, with adjustments made for potential confounding factors. 
This proposed trial would help to determine the effectiveness of a primary care 
intervention to identify and treat mood problems in people with IRCs. Alternatively, to 
help assess the impact of treating comorbid mood problems on treatment response, 
morbidity and mortality, people commencing biological drug treatments or disease 
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modifying anti-rheumatic drugs (DMARDs) could be recruited from secondary care. All 
participants at baseline could be assessed using questionnaires for mood problems, and 
if identified, could be randomised to a similar intervention, involving behavioural 
activation or CBT delivered by a psychological wellbeing practitioner. Follow-up 
questionnaires at six and twelve months could include questions to assess treatment 
response, in addition to QoL and mood. Alternatively, follow-up assessments could 
involve face-to-face clinic appointments, supported by blood tests, to enable DAS28 
scores to be calculated. Determining the impact of treating mood problems on 
rheumatological outcomes could support guideline changes to inform rheumatologists 
to routinely monitor mood, consider the impact of anxiety and depression on DAS28 
scores when making treatment decisions, and signpost patients for the treatment of 
mood problems. 
Despite literature reporting the negative impact of depression in people with RA, 
further research is required to determine the impact of comorbid mood problems in AS, 
PsA, PMR and GCA, on disease activity and treatment response. This could be addressed 
by the following research question. 
 
What is the impact of comorbid anxiety and/ or depression on disease activity and 
treatment response in people with AS, PsA, PMR and GCA? 
 
As all of these IRCs are managed differently, some more predominantly within 
primary care, separate studies could be performed for each condition. For example, a 
secondary care cohort of people with PsA starting on a DMARD or biological drug 
treatment could be identified. All of the cohort could be assessed for mood problems 
by questionnaire and have their baseline disease activity recorded. During follow-up 
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assessments at three, six and twelve months, mood problems and disease activity could 
be reassessed. The association between symptoms of anxiety and/ or depression and 
disease activity over time could then be determined.   
A cross-sectional study would enable the impact of mood problems on disease 
activity in several IRCs to be analysed within a single study. However, this would not 
enable causal associations over time to be determined. Participants could be identified 
using electronic primary care records. Questionnaires could be sent to people with AS, 
PsA, PMR and GCA, including questions to identify potential mood problems (PHQ-8 and 
GAD-7) and to assess disease activity, for example using VAS Pain, or a numerical rating 
scale (NRS) for pain and stiffness. The cross-sectional association between anxiety and/ 
or depression and VAS Pain or the NRS scores for pain and stiffness could then be 
analysed. These potential studies would help to inform clinicians about the impact of 
mood problems on treatment response, whilst also supporting guideline changes to 
reflect the need for regular case-finding for mood problems in a range of different IRCs.  
My systematic review meta-analysis was limited by lack of data for statistical 
pooling. As anxiety frequently exists in isolation from depression and can be associated 
with different help-seeking behaviour (Fine et al., 2008), future studies analysing 
comorbid mood problems should consider reporting anxiety and depression separately, 
to enable their individual effects to be analysed. The future availability of suitable data 
could then allow stronger conclusions to be drawn from a meta-analysis of the impact 
of anxiety on QoL and disease activity in people with RA.  
Future analysis of the incidence and prevalence of mood problems in people 
with IRCs could take advantage of a larger national database such as CPRD, which would 
help to increase statistical power, enabling stronger conclusions to be made, whilst also 
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providing more generalisable results.  
A full trial of the INCLUDE review would also provide more questionnaire data, 
to enable further analysis of the prevalence of mood problems in different IRCs. As some 
people have more than one IRC, this should be considered as a potential confounding 
factor, when examining associations between particular IRCs and outcome measures in 
future studies. A larger amount of data, derived from a national population would make 
results more generalisable and increase the strength of evidence, to ensure an effective, 
evidence-based annual review is developed for implementation nationally, to improve 
overall outcomes for people with IRCs.   
 
9.5 Reflections                                                                                         .    
 
 My research experiences have had wide-ranging impacts on my clinical practice, 
whilst my work as a GP has reciprocally influenced my academic work. Background 
reading in relation to my studies has led me to improve my knowledge of QOF targets, 
particularly in relation to RA. As a consequence, I have recommended a more robust 
system of annual reviews delivered by a nurse at my practice, to ensure that reviews 
include case-finding for potential mood problems, FRAX risk calculation and case-finding 
for potential anxiety and depression.  
Meanwhile, my knowledge of the features of IRCs has significantly improved. On 
seeing an individual with evidence of synovitis consistent with a potential IRC, I refer to 
rheumatology without waiting for the results of blood tests, to help avoid any 
unnecessary delays in diagnosis and treatment. 
The most significant impact my background reading and subsequent studies 
have had on my clinical practice, relates to the identification and management of mental 
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health problems in people with LTCs, which I will later reflect on further, as I discuss the 
impact my four studies have had on my work as a GP. Alongside each of these studies I 
will also reflect on my academic learning and progress.  
Considering my first qualitative study, I felt confident approaching patients who 
had attended local rheumatology clinics to interview them about their experiences, due 
to regularly meeting new people through my clinical work. However, through my early 
GP training, I had been required to develop communication skills that enabled me to 
complete consultations within 10 minutes. Therefore, I had to adapt my usual style of 
communication. Whereas in a GP consultation, I would begin with an open question, 
then used more closed questions to obtain details required to make a clinical decision, 
I had to keep my questioning open, to facilitate deeper insights and obtain richer data.  
The length of my interviews was varied, with the first being particularly short. At 
first I was concerned that this was due to me not effectively building rapport, though 
through subsequent interviews I came to recognise that the length was largely 
influenced by different peoples͛ personalities. In particular, more extroverted or lonely 
interview participants were inclined to diverge from the questions asked, hence longer 
interviews were not necessarily more insightful. 
During interviews, I had to closely interact with participants, during which time 
my role as an interviewer and a GP, potentially influenced patients͛ perspectives. 
Denscombe described the Ηinterviewer effectΗ, whereby an individuals͛ perception of 
their interviewer influences their response to questions (Sim & Wright, 2000, p109), 
with social differences such as nationality, race, class, age, gender and socioeconomic 
status all potentially affecting the establishment of rapport. When GPs participating in 
qualitative studies were interviewed by a peer, rather than a researcher from another 
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discipline, more personal accounts were obtained from interview participants. 
However, for several participants, the GP interviewer was identified as an expert and 
judge of clinical decision making, potentially making them afraid of saying something 
clinically inaccurate or reluctant to disclose negative views (Chew-Graham, May & Perry, 
2002). 
For my qualitative study, I intended to interview patients, to explore their 
perspectives of mood problems, including their interactions with GPs. If I had informed 
participants that I was a GP prior to interviewing them, they could have been more 
reluctant to disclose negative views of clinicians, or afraid of saying something clinically 
inaccurate. Therefore, to try and obtain more insights, I introduced myself as a 
researcher and not a GP when conducting interviews.  
As discussed in my methodology chapter, for my qualitative study, I undertook 
a ͞ value-bound͟ approach ;Sim & Wright, 2000), acknowledging that by interacting with 
patients during interviews, I would become an integral part of the research. However, I 
understood that I needed to be open about how my own preconceptions and 
experiences as a GP could have influenced the study. I also recognised that I needed to 
reflect on any changes to myself, precipitated by my involvement in the research. As 
described by Lincoln and Guba (1985), through a process of reflexivity, I tried to maintain 
my awareness of these processes by making diary entries after interviews to reflect on. 
I also regularly discussed interview extracts and my interpretation of these with 
colleagues. Had I just discussed extracts with one, more senior researcher, I may have 
struggled to challenge their views. In addition, if we had both held similar world 
viewpoints, we may have overlooked hidden meanings within interview extracts. 
Therefore, two supervisors with different clinical and research expertise contributed to 
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the interpretation of interview extracts. Having multiple investigators on a study has 
been shown to promote dialogue and potentially reveal hidden beliefs or perspectives 
from qualitative data (Barry et al., 1999). 
Interviewing patients in my qualitative study, conversely impacted on my clinical 
consulting style. Patients͛ perspectives of GPs as frequently dismissive or lacking time 
to discuss mood concerns, made me more aware of ensuring I responded to patient 
cues, particularly in relation to comorbid mental health problems. However, I 
recognised that it would not be practical to always give the time patients wanted within 
a ϭϬ minute GP consultation. Therefore, I drew on other patients͛ perspectives disclosed 
during interviews. For example, some participants had reported that rapport with their 
GP, encouragement to attend follow-up and continuity of care all facilitated disclosure 
of mood concerns. I tried to ensure that any further concerns were acknowledged and 
arranged a follow-up appointment with myself, to enable time to discuss these concerns 
further. 
Throughout these studies, I developed and applied a wide range of research 
skills. I helped to complete an application for ethical approval, developed and amended 
topic guides, performed semi-structured interviews, coded data and completed a 
thematic analysis. In addition, I lled my first PPIE group to discuss the interpretation of 
interview extracts and to seek advice regarding dissemination to patients. I also 
collaborated with patients to develop a patient information leaflet and presented my 
first research, orally and as a poster at several conferences (see appendix 27 for a list of 
conference presentations). Through these conferences, I learnt about the importance 
of networking and started to gain confidence with succinctly communicating my 
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research aims and outcomes. I also gained experience of preparing my first research 
article for publication. 
 During my second study, a systematic review, I learnt about how to perform a 
meta-analysis to pool data on the correlations between anxiety and different outcome 
measures, whilst building on my knowledge of quality assessment and the appraisal of 
research studies by attending a systematic review course, in addition to a course on the 
critical appraisal of research articles. This knowledge was applicable to my work as a GP, 
helping me to evaluate new research evidence and make informed decisions about 
whether to implement recommendations in my clinical practice. In particular, when 
patients approached me with newspaper articles regarding a ͞medical breakthrough͟, I 
felt more confident evaluating the research behind these statements and 
communicating findings in lay language. I further developed my skills in the appraisal of 
research evidence, by reviewing research articles using a variety of study methods, 
submitted to several journals. 
I anticipated that PPIE involvement in a systematic review would be difficult, but 
by avoiding the use of jargon when explaining the principles of a systematic review, I 
was able to ensure that participants understood the reasoning behind my study. Their 
understanding was demonstrated by their subsequent questions about the size of 
different studies included in the review, the comparability of different research articles 
and the quality of evidence found. 
 One main challenge of my systematic review was recruiting different researchers 
to help select relevant articles and extract data. I negotiated to help on a colleagues͛ 
systematic review in return for their assistance, whilst in exchange for another 
colleague͛s help, I agreed to co-author an article reporting on the extra-articular impacts 
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of RA (in list of publications, appendix 2). Competing demands on their time meant that 
the review took longer than anticipated. In addition, feedback on a draft article to 
submit for publication was delayed, and as further relevant literature was published, I 
had to update my search. However, I later found that by setting a target submission 
date, I was able to facilitate more timely responses from colleagues. 
 For my cohort study, my clinical knowledge was valuable when determining 
which covariates to include, that could have potentially confounded the association 
between anxiety and QoL or disease activity. I also used my clinical expertise to review 
Read code lists for different covariates, to help determine which were applicable. 
Through this process, I drew on training I had received completing a masters͛ module in 
statistics and epidemiology, interpreting the meaning of data obtained, whilst I also built 
my confidence in using different statistical software, including SPSS and Stata. One of 
the main challenges with this study were time delays in obtaining data for analysis, 
which meant I had to be flexible with my schedule and spend time on other projects. I 
reflected that on planning any future research project I would need to anticipate 
potential time delays, though this was not achievable within my fixed-term PhD. 
 As a co-applicant in the INCLUDE study, I learned about the procedures involved 
in a pilot trial. I helped to review grant applications and a research protocol, whilst by 
attending regular multidisciplinary team meetings, I was able to learn from the variety 
of professionals involved, from statisticians to health informatics, qualitative and mixed 
methods researchers. In particular, I learnt about the role of trial steering committees 
and the support offered by the Clinical Trials Unit. 
 Drawing on my primary care expertise, I co-facilitated a stakeholder group, 
attended by GPs, nurses and healthcare assistants, to obtain advice about the feasibility 
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and practical application of the INCLUDE review. I used my clinical knowledge to co-
develop and deliver the INCLUDE nurse training, which included slides, role play, use of 
simulated patients and in practice training using EMIS software. Through this process, I 
gained teaching experience and solidified my own confidence in the assessment and 
communication of risk to patients. In particular, I gained confidence in discussing QRisk2 
results in lay language, calculating FRAX risk scores and assessing suicide risk.  These 
experiences of teaching and mentoring will be applicable in the future when I become 
involved in training and supporting a wider primary care team. 
For the INCLUDE study, I also helped to design an EMIS template for the nurses 
to use to record the review. The skills I acquired through this process will enable me to 
develop clinical templates in practice, to ensure appropriate information is recorded 
within patients͛ records during consultations. In addition, I helped to develop the 
INCLUDE study questionnaire. Through this process, I learnt about the importance of 
clear, lay instructions. I also reflected on the challenges of determining what essential 
questions to include in a questionnaire, without allowing it to become too long, which 
could adversely affect completion rates. 
As a member of the qualitative team on INCLUDE, I also contributed to the 
development of a qualitative protocol and helped to formulate topic guides for the 
patient, GP and nurse interviews. I helped to complete fidelity checks of the INCLUDE 
consultations, gaining experience of developing a fidelity checklist and helping to 
evaluate the success of training and determine points for future improvement. 
Attending regular qualitative meetings, I was also able to contribute to the analysis of 
interview extracts, which frequently drew parallels with my original qualitative study, 
when patients͛ experiences of case-finding for mood problems were discussed. 
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 By leading PPIE involvement throughout the INCLUDE study, I was able to take 
account of patients͛ perspectives when determining priorities for the INCLUDE review, 
developing patient-facing study documents and writing topic guides for interviews. PPIE 
members also gave suggestions for how to disseminate the INCLUDE study findings and 
potential improvements that could be made prior to a full trial of the intervention. I was 
also able to use my own knowledge of the strengths and potential limitations of general 
practice when testing a new intervention, to evaluate suggestions made by participants. 
I have been able to share and present my experiences of PPIE involvement within the 
INCLUDE study at conferences and have wrote a blog for the SPCR highlighting the 
potential contributions of patients to a pilot trial (https://www.spcr.nihr.ac.uk/news/ 
blog/involvement-within-the-include-study). 
 Analysing the INCLUDE baseline questionnaire data after completing my cohort 
study, has prompted me to draw comparisons between data from different sources and 
question the appropriateness of different research techniques.  Statistical knowledge 
gained from my cohort study and through the analysis of data from the INCLUDE study, 
has further enhanced my abilities to evaluate and explain research to patients, as tested 
in the associated PPIE groups. When discussing these studies with a PPIE group, they 
were surprised by the disparity in prevalence rates between mood problems recorded 
using Read codes in primary care electronic health records, compared to anxiety and 
depression identified through the use of the case-finding questions within the INCLUDE 
study questionnaires. 
PPIE involvement across my studies has enhanced my understanding of the 
potential breadth and depth of contributions that patients and the public can make to 
research. Alongside the PPIE meetings I have led, I have attended local meetings of 
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patients and research users, where I have been able to present and further disseminate 
my research findings. I have worked with patients who are members of national arthritis 
societies, helping to lead meetings to inform local people about IRCs. In addition, I have 
met with members of trial steering committees, people who help to review grant 
applications, individuals who are co-investigators on research studies and members of 
the public who volunteer as journal reviewers or have co-written articles for publication. 
Rather than being consulted about research, patients and the public can be active 
collaborators in designing, implementing and evaluating research, roles highlighted by 
national standards for public involvement (Involve, 2019), which crucially help to ensure 
that research remains relevant to patients.  
 In the future, I hope to apply my experiences of working with patients in primary 
care by facilitating meetings of our practices͛ patient participation group. As well as 
influencing my consulting style and communication with patients, working as a 
researcher has developed my skills in communicating key points when making written 
referrals or seeking advice from specialists on the telephone. In particular, presenting 
my thesis in 3 minutes has developed my ability to communicate ideas and concepts 
succinctly.  
Furthermore, my exposure to academic general practice has enabled me to 
promote careers in academic primary care to medical students I have mentored, as a 
personal development tutor. I have also been able to educate and inform clinical 
colleagues about the amount of valuable work academic GPs do in advancing clinical 
practice, which I feel often requires greater appreciation. It has been rewarding to offer 
clinical insights to academic colleagues, struggling to comprehend medical concepts. 
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Within my academic position, I have also learned about further opportunities for 
involvement in research within primary care, for instance, as a research ready practice. 
At times, I have sacrificed my work/ life balance in order to grasp new 
opportunities or meet deadlines. Reflection on these experiences has taught me to be 
more confident in evaluating my ability to take on work, be aware of my personal limits 
and learn to decline extra work when appropriate. However, I have particularly enjoyed 
the opportunities to travel around the country, meet new and inspiring people and 
compete with other researchers when presenting my work, and I feel I have been 
resilient in responding to the demands of a portfolio career.  
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 Through 4 connected studies reported in this thesis, I have explored the 
perspectives of people with rheumatoid arthritis (RA) on comorbid mood problems, 
determined the impact of anxiety in people with RA on quality of life (QoL) and disease 
activity and investigated the incidence and prevalence of mood problems in different 
inflammatory rheumatological conditions (IRCs), using Read codes from primary care 
electronic health records, in addition to patients͛ responses to the case-finding 
questions. 
 I have determined that mood problems in people with IRCs are common, 
potentially under-recognised within primary care, and associated with increased disease 
activity and a reduced QoL. Through my qualitative study, I have established that the 
case-finding questions for anxiety and depression are acceptable for people with RA, 
when delivered in the context of a nurse-led annual review.  
 Through my extensive dissemination activities, I have shared my results with a 
broad range of primary and secondary care physicians, researchers and most 
importantly the public. I have raised awareness of the frequency and impact of 
comorbid mood problems, whilst also emphasising the positive impact that improved 
recognition of anxiety and depression could have on the lives of people living with IRCs. 
In addition, I have highlighted the need for clinicians to give mental and physical health 
problems equal priority and to build rapport with patients over time to facilitate 
disclosure of concerns. I have also worked to inform and empower patients with IRCs, 
to help them to identify and seek appropriate support to manage comorbid anxiety and 
depression. 
 The findings from my 4 studies, alongside the valuable contributions of patients 
involved in my research, have contributed to the development of a pilot nurse-led 
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review for people with different IRCs, based in primary care. If successful, the 
intervention will go to trial, potentially helping to improve the recognition of comorbid 
mood problems in people with IRCs nationally. In addition to this planned study, future 
research could aim to determine whether active assessment for and management of 
mood problems, could improve overall outcomes for people with IRCs. 
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Appendix 1- Research prizes 
 
Prizes from research completed as part of the thesis 
ͻ PhD student of the year nomination, Find a PhD, 2019. 
ͻ 3 minute thesis prize, ILAS Postgraduate Conference, Keele University, 2018. 
ͻ Systematic review prize, Postgraduate Symposium, Keele University, 2018. 
ͻ Highly commended poster prize, SPCR Research Showcase, 2018. 
ͻ Highly commended prize, ͞Best example of innovation in PPIE͟, SPCR, 2018. 
ͻ Oral presentation first prize, GPACF Conference, Sheffield, 2017. 
ͻ Oral presentation prize, West Midlands Annual Clinical Academic Training Event, 
Birmingham, 2017. 
ͻ Poster prize, RCGP Midland Faculty Annual Education, Research and Innovation 
Symposium, 2016. 
ͻ Research poster prize, RCGP Annual Conference, Harrogate, 2016. 
ͻ Best poster prize, Celebration of 10 years of PPIE at the Keele Research Institute, 
2016.  
 
Prizes from research completed alongside the thesis 
ͻ Best poster prize, A person-centred approach to physical-mental multimorbidity 
conference, Keele University, 2019.  
ͻ Audit poster prize- shortlisted, RCGP Annual Conference, Harrogate, 2016. 
ͻ Clinical case best poster prize, RCGP Midland Faculty Annual Education, Research 
and Innovation Symposium, Warwick University, 2016. 
 
  401 
Appendix 2- Publications 
 
Publications from thesis research 
 
Machin, A.R., Hider, S., Dale, N. & Chew-Graham, C.A. (2017). Improving recognition of 
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8(1). doi: 2235042X18792373. 
 
Other research published whilst completing the thesis 
Scott, I.C., Machin, A., Mallen C., Hider, S.L. (2018). The extra-articular impacts of 
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Appendix 3: BJGP Paper reporting qualitative study 
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Appendix 4- The 2010 ACR-EULAR Classification Criteria for Rheumatoid 
Arthritis (Aletaha et al., 2010). 
 
Target population includes people who: 
1. have at least 1 joint with definite clinical synovitis (swelling) 
2. with the synovitis not better explained by another disease 
Classification criteria for RA (score-based algorithm: add score of categories A - D; a score of 
6 or more out of 10 is needed for a patient to be classified as having definite RA) 
Classification Criteria Score 
A. Joint Involvement 
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint) 4 
B. Serology (at least one result is needed for classification) 
Negative rheumatoid factor (RF) or anti-citrullinated protein antibody 
(ACPA) 0 
Low-positive RF or low-positive ACPA 1 
High-positive RF or high-positive ACPA 2 
C. Acute Phase Reactants (at least 1 test result is needed for classification) 
Normal c-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR) 0 
Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms 
Less than 6 weeks 0 
6 weeks or more 1 
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Appendix 5- Patient invitation to RA annual review clinic  
 
Haywood Hospital 
High Lane 
Burslem 
Stoke on Trent ST6 7AG 
[Date] 
 
 
 
Dear [Patient Name] 
 
 
Invitation to attend the Rheumatoid Arthritis Annual Review Clinic  
 
 
We are writing to tell you about a new nurse led Rheumatoid Arthritis Annual 
Review clinic which we are starting at the Haywood hospital. When you come 
for your next appointment you will be offered the opportunity to attend this new 
clinic. To see how well this clinic works and whether patients find it useful we 
are also asking patients who come to the clinic to take part in a research study.  
 
We are writing to because you have been seen at our clinic and may be eligible 
to come to this new clinic if you would like to. We have included an information 
sheet about the research study and if you would like to take part this will be 
discussed with you when you come to the clinic.   
 
Your decision regarding whether to take part in the study will not affect any 
future care you have at this Trust.  
 
Thank you very much for reading this letter, 
 
Yours sincerely, 
 
 
 
 
Dr SL Hider & Dr SN Kamath 
Consultant Rheumatologists 
Haywood Hospital 
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Appendix 6- RA annual review clinic patient questionnaire 
 
 
  413 
 
 
 
  414 
 
 
 
  415 
 
 
 
 
  416 
Appendix 7- Ethical approval for qualitative study 
 
 
 
  417 
 
 
  418 
 
 
 
  419 
Appendix 8- Patient information leaflet on face-to-face interview 
 
Rheumatoid Arthritis (RA) Annual Review Interview Study 
 
You are invited to take part in a research study. Before you decide to take part 
or not, it is important for you to understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully 
and discuss it with others if you wish. Ask us if there is anything that is not 
clear, or if you would like more information.  Please take time to decide whether 
or not you wish to take part. 
 
What is the purpose of the study? 
The aim of this study is to understand the views of patients about a new clinic for 
Rheumatoid Arthritis (RA). This is a nurse-led clinic and aims to offer patients an 
opportunity to discuss with the nurse specialist any problems they have with their 
RA, but also problems in other areas of their life, in particular problems with mood. 
 
Why have I been chosen?  
You have been chosen because you attended the RA clinic and had a consultation 
with the specialist nurse. You also ticked one of the boxes in the initial patient 
questionnaire which suggested you might have problems with low mood or anxiety. 
 
Do I have to take part?  
No ± it is your decision entirely. If you decide to take part, you are still free to 
withdraw from the study at any time and without giving a reason. All information we 
have collected from you will be destroyed if you wish.   
 
What will happen if I take part?   
 If you choose to take part, you will be given a copy of this Information Sheet 
and a signed Consent Form to keep. 
 
 The researcher, Annabelle Machin, will contact you to invite you to participate in 
a one to one interview. The interview will take place at the Haywood hospital or 
your home ± whichever is you prefer. The interview will be audio-recorded with 
your consent and is likely to last between 30 and 45 minutes. 
 
 The audio-recordings of the interview will be typed up and anonymised so that 
an\ SeUVonal infoUmaWion (VXch aV SaWienWV¶ and docWoUV¶ nameV, addUeVVeV, oU 
places of work) will not be included in the research.  The information will be 
stored on secure computers at Keele University and accessible by password to 
the researchers.    
 
What about confidentiality?     
Although we will inform your GP that you have taken part in the study, we will not 
tell them details of what you have said. We will not tell anyone else what you have 
said, and we will not tell you anything that anyone else in the study has told us. 
However, should something be disclosed during the interview which gives cause 
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for concern, then there is a duty of care to report such disclosure to appropriate 
agencies. 
 
All information collected during this study will be kept confidential. Although names 
will be used during the interviews, they will not be included when the recordings are 
transcribed. The audio recordings will be marked with an identification number only 
and then stored securely. Once transcribed, all audio recording will be destroyed.   
 
Only authorised persons will have access to any information about you. You will 
not be named or identified in any reports of the study. We may include brief 
quotations from some focus groups in our reports, but we will always remove 
details such as names and places so nobody can be identified. 
 
What are the possible risks and benefits of taking part?         
We do not anticipate any risks. We hope this study will benefit the care of future 
patients with RA and the clinicians involved in their care. Some people find that 
taking part in studies of this sort is useful because they have a chance to air their 
views.    
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to 
the researchers who will do their best to answer your questions.   
 
If they are unable to resolve your concern or you wish to or you would like to 
receive free independent advice please contact PALS (Patient Advice and Liaison 
Service) on 0800 0851 067.  
 
How will the data collected about me be stored and used?  
All data collected for this study will be kept safely and securely on computer and on 
transcribed paper records. Professor Carolyn Chew-Graham will be the 
custodian of all study data. With your permission, transcripts of audio recordings of 
the interview will be archived and stored at Keele University for 5 years after the 
end of this study for possible use in future studies. Access to these by researchers 
not involved in the current study will be subject to further ethical review. If you do 
not wish this to happen, your transcript will not be made available in this way.  
 
After all identifying details have been removed from the transcribed records the 
interview will be analysed by the study team. The results will be published in 
reports and scientific journals, but it will not be possible to identify any individuals 
from these reports. We will send you a summary of the results at the end of the 
study if you would like one.  
 
Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by West 
of Scotland REC 3. 
 
What do I need to do next? 
 
If you are happy to take part, please complete the reply slip and return it to us in 
the stamped and addressed envelope.                        
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Appendix 9- Interview Consent Form 
              
 
 
Rheumatoid Arthritis (RA) Annual Review Study 
 
Interview Study Consent Form 
 
Identification Number:  
 
 
Name of researcher: Dr Annabelle Machin 
                            Please 
initial box 
1. I confirm that I have read and understand the information sheet dated 2/4/15 
(version 4.0) for the above study. I have had the opportunity to consider the 
information, ask questions and have these answered satisfactorily.  
 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
  
 
3. I understand that audio recordings will be made as part of this study, and that 
brief quotations from the interview may be included in study reports without 
giving my name or disclosing my identity. 
   
 
4. I agree to transcriptions (a written or electronic record) of the interview being 
stored at Keele University for up to 5 years after the end of this study.  I 
understand that these will be held securely and that access to these by 
researchers not involved in the current study will be subject to further ethical 
review. 
 
Yes No 
5. I agree to my GP being informed that I will be taking part in the study.  
 
 
6.   I understand that relevant sections of the data collected during the study may be                  
looked at by individuals from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission for 
these individuals to have access these notes.  
 
7. I would like to receive a summary of the findings at the end of the study.  
 
 
Yes
  
No 
8. I agree to take part in the study.  
 
 
 
 
Name of participant 
 
  
Date 
  
Signature 
Name of researcher 
  
 Date   Signature  
 
When completed, one copy for participant, one for researcher file. 
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Appendix 10- Topic Guides 
 
Topic Guide 20th August 2015 
 
Introductions, Express thanks for participating. 
Explanation of purpose of interview (answer any queries); reassure re confidentiality; 
and gain signed Consent (x2 copies- one for patient, one for us) 
Turn recorder on. 
 
Can you tell me a bit about your health condition(s)? 
(Allow patient to initially describe all health conditions before moving on. Check if 
they have any other annual reviews eg. for diabetes) 
x Could you tell me  
o How long you have had RA? 
o How your Rheumatoid Arthritis affects you? 
x Who do you see for support in managing your RA?  
o explore role of GP, PN, hospital, other 
o how often seen? 
o What do each do? 
o Any other support (family/friends/complementary therapies) 
 
 
Can you tell me what you expected before you came to the clinic? 
x Did you know who you were going to see and what they would do? 
x Can you tell me what was covered in the clinic? 
x How did you feel about completing the questionnaires? 
x Were you asked about your mood at the clinic? 
o Did you expect this? 
o Did you feel able to talk about your mood? 
o  If yes, how did this feel? 
o  If no, did you want to? (or did you not have any mood problems 
to discuss) 
x Do you think this clinic is the place to discuss problems with mood? 
o If so, why? 
o If not, why not? 
 
 
Was there anything else you would have wanted to discuss with the nurse?...explore 
 
Aƚ ƚhe clinic͕ did ǇoƵ feel inǀolǀed in making deciƐionƐ ƌegaƌding ǇoƵƌ caƌe͍ ͙eǆƉlore 
 
 
 
  423 
Topic Guide 11th September 2015 (New questions underlined and in italic) 
 
Can you tell me a bit about your health condition(s)? 
(Allow patient to initially describe all health conditions before moving on. Check if 
they have any other annual reviews eg. for diabetes) 
x Could you tell me  
o How long you have had RA? 
o How your Rheumatoid Arthritis affects you? 
x Who do you see for support in managing your RA?  
o explore role of GP, PN, hospital, other 
o how often seen? 
o What do each do? 
o Any other support (family/friends/complementary therapies) 
Can you tell me what you expected before you came to the clinic? 
x Did you know who you were going to see and what they would do? 
x Can you tell me what was covered in the clinic? 
x How did you feel about completing the questionnaires? 
x Were you asked about your mood at the clinic? 
o Did you expect this? 
o Did you feel able to talk about your mood? 
o  If yes, how did this feel? 
o  If no, did you want to? (or did you not have any problems to 
discuss) 
Would you have felt better discussing your mood with someone other than this clinic 
nurse? (like with your GP, practice nurse or hospital doctor, other)? 
x If yes, why was this? 
x If no, why did you prefer to discuss your mood at the clinic? 
x Do you think this clinic is the best place to discuss problems with mood? 
o If so, why? 
o If not, why not? 
Did the clinic nurse talk with you about treatments available for low mood/anxiety? 
x Did the nurse refer you onto another service for help with anxiety or 
depression? If so, which? 
x Would you have liked the nurse to do anything else? 
Was there anything else you would have wanted to discuss with the nurse?...explore 
 
Aƚ ƚhe clinic͕ did ǇoƵ feel inǀolǀed in making deciƐionƐ ƌegaƌding ǇoƵƌ caƌe͍ ͙eǆƉloƌe 
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Topic Guide 30th September 2015 (New questions underlined and in italic) 
 
Introductions, Express thanks for participating. 
Explanation of purpose of interview (answer any queries); reassure re confidentiality; 
and gain signed Consent (x2 copies- one for patient, one for us) 
Turn recorder on. 
 
Can you tell me a bit about your health condition(s)? 
 
(Allow patient to initially describe all health conditions before moving on. Check if 
they have any other annual reviews eg. for diabetes) 
 
x Could you tell me  
o How long you have had RA? How long have you been attending the 
Haywood? 
o How your Rheumatoid Arthritis affects you? (Social, family and work 
impact/ losses) 
o Who do you see for support in managing your RA? explore role of GP, 
PN, hospital, other 
o how often seen? 
o What do each do? Who co-ordinates your care? 
o What is your role? 
o Any other support (family/friends/complementary therapies) 
x Some people with RA get anxious or low in mood. Has this ever been a problem 
for you? 
How has it affected you? 
Do you feel your anxiety/ low mood is linked to your RA or separate? 
 
Can you tell me what you expected before you came to the clinic? 
x Did you know who you were going to see and what they would do? 
x Can you tell me what was covered in the clinic? How did this clinic appointment 
differ from your usual ones? 
x Do you recall completing a questionnaire by yourself or with the nurse?  
How did you find that? (would the patient have preferred to complete the 
questionnaire themselves/ for the nurse to complete it) 
x Were you asked about your mood at the clinic? 
o Did you expect this? 
o Did you feel able to talk about your mood? 
o  If yes, what was it about the nurse that enabled you to open up? 
How did it feel to talk about your mood?  
o  If no, did you want to? (or did you not have any mood problems 
to discuss) 
x Do you think this clinic is the place to discuss problems with mood? 
  425 
o If so, why? 
o If not, why not? 
Would you have felt better discussing your mood with someone other than this clinic 
nurse? (like with your GP, practice nurse or hospital doctor, other)? 
x If yes, why was this? 
x If no, why did you prefer to discuss your mood at the clinic? 
Did the clinic nurse talk with you about treatments available for low mood/anxiety? 
x Did the nurse refer you onto another service for help with anxiety or 
depression? If so, which? 
x Would you have liked the nurse to do anything else? 
Was there anything else you would have wanted to discuss with the nurse?...explore 
Aƚ ƚhe clinic͕ did ǇoƵ feel inǀolǀed in making deciƐionƐ ƌegaƌding ǇoƵƌ caƌe͍ ͙eǆƉloƌe 
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Topic Guide 22nd October 2015 (New questions underlined and in italic) 
 
 
Introductions, Express thanks for participating. 
Explanation of purpose of interview (answer any queries); reassure re confidentiality; 
and gain signed Consent (x2 copies- one for patient, one for us) 
Turn recorder on. 
 
Can you tell me a bit about your health condition(s)? 
(Allow patient to initially describe all health conditions before moving on. Check if 
they have any other annual reviews eg. for diabetes) 
x Could you tell me  
o How long you have had RA? How long have you been attending the 
Haywood? 
o How your Rheumatoid Arthritis affects you? (Social, family and work 
impact/ losses) 
o Who do you see for support in managing your RA? explore role of GP, 
PN, hospital, other 
o how often seen? 
o What do each do? Who co-ordinates your care? 
o What is your role? 
o Any other support (family/friends/complementary therapies) 
x Some people with RA get anxious or low in mood. Has this ever been a problem 
for you? 
How has it affected you? 
Do you feel your anxiety/ low mood is linked to your RA or separate? 
 
 
Can you tell me what you expected before you came to the clinic? 
x Did you know who you were going to see and what they would do? 
x Can you tell me what was covered in the clinic? How did this clinic appointment 
differ from your usual ones? 
x Do you recall completing a questionnaire by yourself or with the nurse?  
How did you find that? (would the patient have preferred to complete the 
questionnaire themselves/ for the nurse to complete it) 
x Were you asked about your mood at the clinic? 
o Did you expect this? 
o Did you feel able to talk about your mood? 
o  If yes, what was it about the nurse that enabled you to open up? 
How did it feel to talk about your mood?  
o  If no, did you want to? (or did you not have any mood problems 
to discuss) 
x Do you think this clinic is the place to discuss problems with mood? 
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o If so, why? 
o If not, why not? 
x What have been your previous experiences seeking help for mood-related 
problems? 
 
Would you have felt better discussing your mood with someone other than this clinic 
nurse? (like with your GP, practice nurse or hospital doctor, other)? 
x If yes, why was this? 
x If no, why did you prefer to discuss your mood at the clinic? 
 
Did the clinic nurse talk with you about treatments available for low mood/anxiety? 
x Did the nurse refer you onto another service for help with anxiety or 
depression? If so, which? 
x Would you have liked the nurse to do anything else? 
 
Was there anything else you would have wanted to discuss with the nurse?...explore 
 
At the clinic, did you feel involved in making deciƐionƐ ƌegaƌding ǇoƵƌ caƌe͍ ͙eǆƉloƌe 
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Topic Guide 28th December 2015 (New questions underlined and in italic) 
 
Introductions, Express thanks for participating. 
Explanation of purpose of interview (answer any queries); reassure re confidentiality; 
and gain signed Consent (x2 copies- one for patient, one for us) 
Turn recorder on. 
 
Can you tell me a bit about your health condition(s)? 
(Allow patient to initially describe all health conditions before moving on. Check if 
they have any other annual reviews eg. for diabetes) 
x Could you tell me  
o How long you have had RA? How long have you been attending the 
Haywood? 
o How your Rheumatoid Arthritis affects you? (Social, family and work 
impact/ losses) 
o Who do you see for support in managing your RA? explore role of GP, 
PN, hospital, other 
o how often seen? 
o What do each do? Who co-ordinates your care? 
o What is your role? 
o Any other support (family/friends/complementary therapies) 
x Some people with RA get anxious or low in mood. Has this ever been a problem 
for you? 
How has it affected you? 
Do you feel your anxiety/ low mood is linked to your RA or separate? 
Do you ever feel like your anxiety or low mood affect the care you receive for 
your arthritis? 
 
 
Can you tell me what you expected before you came to the clinic? 
x Did you know who you were going to see and what they would do? 
x Can you tell me what was covered in the clinic? How did this clinic appointment 
differ from your usual ones? 
x Do you recall completing a questionnaire by yourself or with the nurse?  
How did you find that? (would the patient have preferred to complete the 
questionnaire themselves/ for the nurse to complete it) 
x Were you asked about your mood at the clinic? 
o Did you expect this? 
o Did you feel able to talk about your mood? 
o  If yes, what was it about the nurse that enabled you to open up? 
How did it feel to talk about your mood?  
o  If no, did you want to? (or did you not have any mood problems 
to discuss) 
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x Do you think this clinic is the place to discuss problems with mood? 
o If so, why? 
o If not, why not? 
x What have been your previous experiences seeking help for mood-related 
problems? 
 
Would you have felt better discussing your mood with someone other than this clinic 
nurse? (like with your GP, practice nurse or hospital doctor, other)? 
x If yes, why was this? 
x If no, why did you prefer to discuss your mood at the clinic? 
 
Did the clinic nurse talk with you about treatments available for low mood/anxiety? 
x Did the nurse refer you onto another service for help with anxiety or 
depression? If so, which? 
x Would you have liked the nurse to do anything else? 
 
Was there anything else you would have wanted to discuss with the nurse?...explore 
 
Aƚ ƚhe clinic͕ did ǇoƵ feel inǀolǀed in making deciƐionƐ ƌegaƌding ǇoƵƌ caƌe͍ ͙eǆƉloƌe 
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Topic Guide 18th March 2016 (New questions underlined and in italic) 
 
Introductions, Express thanks for participating. 
Explanation of purpose of interview (answer any queries); reassure re confidentiality; 
and gain signed Consent (x2 copies- one for patient, one for us) 
Turn recorder on. 
 
Can you tell me a bit about your health condition(s)? 
(Allow patient to initially describe all health conditions before moving on. Check if 
they have any other annual reviews eg. for diabetes) 
x Could you tell me  
o How long you have had RA? How long have you been attending the 
Haywood? 
o How your Rheumatoid Arthritis affects you? (Social, family and work 
impact/ losses) 
o Who do you see for support in managing your RA? explore role of GP, 
PN, hospital, other 
o how often seen? 
o What do each do? Who co-ordinates your care? 
o What is your role? 
o Any other support (family/friends/complementary therapies) 
x Some people with RA get anxious or low in mood. Has this ever been a problem 
for you? 
How has it affected you? 
Do you feel your anxiety/ low mood is linked to your RA or separate? 
Do you ever feel like your anxiety or low mood affect the care you receive for 
your arthritis? 
 
 
Can you tell me what you expected before you came to the clinic? 
x Did you know who you were going to see and what they would do? 
x Can you tell me what was covered in the clinic? How did this clinic appointment 
differ from your usual ones? 
x Do you recall completing a questionnaire by yourself or with the nurse?  
How did you find that? (would the patient have preferred to complete the 
questionnaire themselves/ for the nurse to complete it) 
x Were you asked about your mood at the clinic? 
o Did you expect this? 
o Did you feel able to talk about your mood? 
o  If yes, what was it about the nurse that enabled you to open up? 
How did it feel to talk about your mood?  
o  If no, did you want to? (or did you not have any mood problems 
to discuss) 
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x Do you think this clinic is the place to discuss problems with mood? 
o If so, why? 
o If not, why not? 
x What have been your previous experiences seeking help for mood-related 
problems? 
 
Would you have felt better discussing your mood with someone other than this clinic 
nurse? (like with your GP, practice nurse or hospital doctor, other)? 
x If yes, why was this? 
x If no, why did you prefer to discuss your mood at the clinic? 
 
Did the clinic nurse talk with you about treatments available for low mood/anxiety? 
x Did the nurse refer you onto another service for help with anxiety or 
depression? If so, which? 
x Would you have any preferences for treatment of anxiety or depression 
(including complementary therapies)? 
x Would you have liked the nurse to do anything else? 
 
Was there anything else you would have wanted to discuss with the nurse?...explore 
 
Aƚ ƚhe clinic͕ did ǇoƵ feel inǀolǀed in making deciƐionƐ ƌegaƌding ǇoƵƌ caƌe͍ ͙eǆƉloƌe 
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Appendix 11: Excel document used to store patient contact details for interview 
participantsͬ record why some interviews didn͛t take place 
 
Name Patient ID  Interview date Address 
Phone 
number 
GP 
Surgery 
Reason if interview not 
performed 
 1 21/9/15    n/a 
 2 26/9/15    n/a 
 Not Interviewed n/a    No time 
 Not Interviewed n/a    Busy having an operation 
 3 5/10/15    n/a 
 4 5/10/15    n/a 
 5 29/10/15    n/a 
 Not Interviewed n/a    Didn͛t want to participate 
 Not Interviewed n/a    Didn͛t want to participate 
 Not Interviewed n/a    Didn͛t want to participate 
 6 30/11/15    n/a 
 7 30/11/15    n/a 
 Not Interviewed n/a    Didn͛t answer phone (x3) 
 Not Interviewed n/a    Didn͛t answer phone ;xϯͿ 
 8 30/11/15    n/a 
 Not Interviewed n/a    Meeting arranged but didn͛t open door when I attended 
 9 28/12/15    n/a 
 10 2/2/16    n/a 
 Not Interviewed n/a    Cancelled- too busy 
 Not Interviewed n/a    Didn͛t want to participate 
 Not Interviewed n/a    Too poorly to participate 
 Not Interviewed n/a    Didn͛t want to participate 
 Not Interviewed n/a    Didn͛t answer phone ;xϯͿ 
 Not Interviewed n/a    Didn͛t want to participate 
 11 25/4/16    n/a 
 12 31/5/16    n/a 
 13 7/6/16    n/a 
 Not Interviewed n/a    Number didn͛t exist 
 14 11/8/16    n/a 
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Appendix 12: Excel docum
ent used to store patient dem
ographics and GAD-2/ PHQ
-2 scores for interview
 participants 
Patient 
ID 
Gender 
Age 
Ethnicity 
Em
ploym
ent 
GAD-2 
PHQ
-2 
1st Part of 
Postcode 
Em
ployed 
Off Sick 
Retired 
Retired 
through ill 
health 
Unem
ployed 
1 
F 
54 
w
hite British 
NA 
ESA 
Benefits  
NA 
NA 
NA 
5 
6 
 
2 
F 
56 
w
hite British 
Part-tim
e 
radiographer 
NA 
NA 
NA 
NA 
3 
4 
 
3 
F 
64 
w
hite British 
NA 
NA 
NA 
Y 
NA 
5 
5 
 
4 
F 
58 
w
hite British 
NA 
NA 
NA 
Y 
NA 
5 
4 
 
5 
F 
78 
w
hite British 
NA 
NA 
Y 
NA 
NA 
6 
6 
 
6 
M
 
70 
w
hite British 
NA 
NA 
Y 
NA 
NA 
3 
3 
 
7 
F 
61 
w
hite British 
NA 
Seeking PIP 
NA 
Y 
NA 
6 
4 
 
8 
F 
62 
w
hite British 
NA 
ESA 
Benefits 
NA 
Y 
NA 
5 
5 
 
9 
F 
68 
w
hite British 
NA 
NA 
NA 
NA 
Y 
5 
4 
 
10 
M
 
61 
w
hite British 
NA 
NA 
NA 
Y 
NA 
3 
3 
 
11 
F 
53 
w
hite British 
Part-tim
e 
teacher 
NA 
NA 
NA 
NA 
6 
6 
 
12 
F 
70 
w
hite British 
NA 
NA 
Y 
NA 
NA 
5 
4 
 
13 
F 
45 
w
hite British 
Part-tim
e 
cleaner  
NA 
NA 
NA 
NA 
5 
5 
 
14 
F 
71 
w
hite British 
NA 
NA 
Y 
NA 
NA 
6 
6 
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Appendix 13: Rheumatoid Arthritis and Mood Leaflet  
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Appendix 14- Systematic Review Protocol (registered on PROSPERO) 
 
Title A systematic review to determine the impact of anxiety on quality 
of life and disease activity in patients with rheumatoid arthritis  
First reviewer Dr Annabelle Machin (AM) 
Other 
reviewers  
Dr Randula Haththotuwa (RH)- 2nd Reviewer  
Dr Ian Scott (IS)- 2nd Reviewer 
Opeyemi Babatunde (OB)- 3rd Reviewer to resolve disagreements 
Funding 
source 
 
18 months part-time funding from the school of primary care 
research (SPCR) and 6 months part-time funding from the 
Haywood Foundation. 
 
PROSPERO ID CRD= 42017062580 
 
 
   
1. Background to review   
          
         Rheumatoid Arthritis (RA) is a long-term condition characterised by synovial 
joint inflammation, affecting 1% of the adult population. Patients typically present 
with persistent joint pain, swelling and stiffness.  
          It is well established that patients with RA have higher rates of depression. This 
is often under-recognised (Cepoiu et al., 2007), which can result in increased pain, 
fatigue, morbidity and mortality (Ang et al., 2005). The prevalence of anxiety in 
patients with RA is also significantly higher than within the general population, 
affecting up to 20% (VanDyke et al., 2004), (Isik et al., 2006) (Covic et al., 2012). This 
is also under-recognised and under-treated, though the impact of anxiety in RA on 
quality of life and treatment outcomes is not as well researched.  
          This systematic review aims to determine the impact of anxiety in patients 
with RA on quality of life and disease activity. Improved understanding of the 
impact of anxiety will provide evidence to facilitate better identification and 
management of anxiety in patients with RA, contributing to improved overall 
outcomes. 
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2. Specific objectives/questions the review will address 
 
A systematic review to determine how anxiety impacts on quality of life and disease 
activity in adults with Rheumatoid Arthritis.  
(Quality of life will be assessed using the 36-Item Short-Form Health Survey (SF-36) 
and disease activity, using the Disease Activity Score in 28 joints (DAS28). Secondary 
outcome measures will be considered.) 
 
 
3. a) Eligibility Criteria for including studies in the review  
i. Population, or participants and 
conditions of interest People aged ш 18 years with Rheumatoid Arthritis 
ii. Interventions/Exposure/item of 
interest Anxiety 
iii. Comparisons or control groups, 
if any 
People aged ш 18 years with Rheumatoid Arthritis 
without anxiety 
iv. Outcomes of interest Quality of Life (SF-36) and Disease Activity  (DAS28) 
v. Setting Any setting 
vi. Study designs 
Any study design will be included, though it is 
anticipated that the majority of relevant papers 
will be cross-sectional or cohort studies. 
 
3. b) Criteria for excluding studies not covered in inclusion criteria  
 
x Patients <18 years 
x Data not specific to anxiety and rheumatoid arthritis 
x When efforts to retrieve a full text have not been successful or when a conference 
abstract lacks sufficient data and the authors do not respond to requests to 
provide additional data 
x When an interpreter can not be found for a paper not written in the English 
language 
 
 
 
  438 
4. Search methods 
Electronic databases & websites 
Please list all databases that are 
to be searched and include the 
interface (eg NHS HDAS, EBSCO, 
OVID etc) and date ranges 
searched for each. 
 
 
x Web of Science 
x PsycINFO 
x CINAHL 
x Embase 
x Medline 
Other methods used for 
identifying relevant research  
ie contacting experts and 
reference checking, citation 
tracking 
 
x Reference checking  
x Citation tracking of index papers 
x Search using ͞www.opengrey.eu͟  
 
 
 
5. Methods of review 
How will search results 
be managed & 
documented? 
Refworks will be used to import search results and 
remove duplicates. Title, abstract and full text 
screening will then be performed using covidence. 
Selection process 
Two reviewers (AM and RH/IS) will independently 
screen the titles and abstracts, followed by the 
remaining full-text articles. A third reviewer (OB) will 
resolve disagreements. 
Quality assessment Newcastle Ottawa Scale 
How is data to be 
extracted? 
Data extraction form in Microsoft excel. This will first 
be piloted by two reviewers (AM/ OB). 
Outcomes to be 
extracted & 
hierarchy/priority of 
measures 
Data on outcomes of interest (SF-36/DAS-28) will be 
recorded. Secondary outcome measures will be 
considered if there are a lack of studies reporting the 
above outcome scores. 
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Narrative synthesis 
 
Narrative synthesis will be carried out using a 
framework which consists of four elements; 
1. Developing a theory of how anxiety impacts on 
quality of life/ treatment response in RA 
(narrative/ diagrams) 
2. Developing a preliminary synthesis of findings of 
included studies (tabulation/ vote counting) 
3. Exploring relationships within and between 
studies (Idea webbing/mapping, subgroup 
analysis of quality of life and treatment 
response, graphical tools to bring together 
scores for SF-26/DAS-28/HAQ) 
4. Assessing the robustness of the synthesis 
(Critical reflection on synthesis process) 
Meta-analysis 
 
When we are able to carry out a meta-analysis of 
primary outcome measures (SF-36 and DAS28), we will 
seek to report pooled data and comment on any 
potential sources of heterogeneity.  
 
6. Presentation of results 
Outputs from review  
 
Plan to submit paper for publication and present at a 
national rheumatology conference. 
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Appendix 15- Search Strategies 
 
Ovid MEDLINE Search Strategy 
 
 
The following table is an explanation of the symbols used in this search strategy. 
 
Symbols used in this search strategy 
/ indicates an index term (MeSH heading) 
exp  before an index term indicates that all subheadings were selected 
.ti,ab.kw  indicates a search for a term in title/ abstract/ keyword 
$ at the end of a term indicates that this term has been truncated 
adjn  
indicates a search for two terms where they appear within n words of 
each another 
 
1. exp arthritis, rheumatoid/ 
2. (rheumat$ adj3 (arthrit$ or diseas$ or condition$ or nodule$)).ti,ab,kw 
3. (felty$ adj2 syndrome).ti,ab,kw 
4. (caplan$ adj2 syndrome).ti,ab,kw 
5. (sjogren$ adj2 syndrome).ti,ab,kw 
6. (sicca adj2 syndrome).ti,ab,kw 
7. (still$ adj2 disease).ti,ab,kw 
8. or/1-7 
 
9. exp anxiety disorders/ 
10. exp anti-anxiety agents/ 
11. (anxiet$ or anxious).ti,ab,kw 
12. exp panic/ 
13. (agoraphobi$ or phobi$ or panic) adj3 (disorder$ or attack$)).ti,ab,kw 
14. (obsess$ adj3 compuls$).ti,ab,kw 
15. exp stress disorders, post-traumatic/ 
16. ((posttraumatic OR post traumatic OR post-traumatic) adj1 stress$).ti,ab,kw 
17. (PTSD).ti,ab,kw 
18. (feel$ adj5 (apprehens$ or dread$ or disaster$ or fear$ or worr$ or terr$)).ti,ab,kw 
19. or/9-18 
 
20. 8 AND 19 
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Ovid EMBASE  
 
Symbols used in this search strategy 
/ indicates an index term (MeSH heading) 
exp  before an index term indicates that all subheadings were selected 
.ti,ab.kw  indicates a search for a term in title/ abstract/ keyword 
* at the end of a term indicates that this term has been truncated 
adjn  
indicates a search for two terms where they appear within n words of 
each another 
 
 
1. exp arthritis, rheumatoid/ 
2. (rheumat* adj3 (arthrit* or diseas* or condition* or nodule*)).ti,ab,kw 
3. (felty* adj2 syndrome).ti,ab,kw 
4. (caplan* adj2 syndrome).ti,ab,kw 
5. (sjogren* adj2 syndrome).ti,ab,kw 
6. (sicca adj2 syndrome).ti,ab,kw 
7. (still* adj2 disease).ti,ab,kw 
8. or/1-7 
 
9. exp anxiety/ 
10. exp anxiolytic agent/ 
11. (anxiet* or anxious).ti,ab,kw 
12. exp panic/ 
13. (agoraphobi* or phobi* or panic adj3 (disorder* or attack*)).ti,ab,kw 
14. (obsess* adj3 compuls*).ti,ab,kw 
15. exp post-traumatic stress disorder/ 
16. ((posttraumatic OR post traumatic OR post-traumatic) adj1 stress*).ti,ab,kw 
17. (ptsd).ti,ab,kw 
18. (feel* adj5 (apprehens* or dread* or disaster* or fear* or worr* or terr*)).ti,ab,kw 
19. or/9-18 
 
20. 8 AND 19 
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EBSCO-CINAHL 
 
Symbols used in this search strategy 
+ indicates a subject heading 
TI, AB, KW  indicates a search for a term in title/ abstract/ keyword 
* at the end of a term indicates that this term has been truncated 
Nn  
indicates a search for two terms where they appear within n words of 
each another 
 
 
1. arthritis, rheumatoid+ 
Ϯ. ;TI or AB or KWͿ ͞rheumatΎ Nϯ ;arthritΎ or diseasΎ or conditionΎ or noduleΎͿ͟ 
ϯ. ;TI or AB or KWͿ ͞feltyΎ NϮ syndrome͟ 
ϰ. ;TI or AB or KWͿ ͞caplanΎ NϮ syndrome͟ 
ϱ. ;TI or AB or KWͿ ͞sjogrenΎ NϮ syndrome͟ 
ϲ. ;TI or AB or KWͿ ͞sicca NϮ syndrome͟ 
ϳ. ;TI or AB or KWͿ ͞stillΎ NϮ disease͟ 
8. or/1-7 
 
9. anxiety+ 
11. antianxiety agents+ 
12. (TI or AB or KW) (anxiet* or anxious) 
13. panic disorder+ 
14. (TI or AB or KW) (agoraphobi* or phobi* or panic N3 (disorder* or attack*)) 
15. (TI or AB or KW) (obsess* N3 compuls*) 
16. stress disorders, post-traumatic+ 
17. (TI or AB or KW) (posttraumatic or post traumatic or post-traumatic N1 (stress*)) 
18. (TI or AB or KW) (ptsd) 
19. (TI or AB or KW) (feel* N5 (apprehens* or dread* or disaster* or fear* or worr* or 
terr*)) 
20. or/9-19 
 
21. 8 AND 20 
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EBSCO- PsycINFO 
 
Symbols used in this search strategy 
+ indicates a subject heading 
TI, AB, KW  indicates a search for a term in title/ abstract/ keyword 
* at the end of a term indicates that this term has been truncated 
Nn  
indicates a search for two terms where they appear within n words of 
each another 
 
 
1. rheumatoid arthritis/ 
2. (TI or AB or KW) (rheumat* N3 (arthrit* or diseas* or condition* or nodule*)) 
3. (TI or AB or KW) (felty* N2 syndrome) 
4. (TI or AB or KW) (caplan* N2 syndrome) 
5. (TI or AB or KW) (sjogren* N2 syndrome) 
6. (TI or AB or KW) (sicca N2 syndrome) 
7. (TI or AB or KW) (still* N2 disease) 
8. or/1-7 
 
9. anxiety/ 
10. tranquilizing drugs/ 
11. (TI or AB or KW) (anxiet* or anxious) 
12. panic/ 
13. (TI or AB or KW) (agoraphobi* or phobi* or panic N3 (disorder* or attack*) 
14. (TI or AB or KW) (obsess* N3 compuls*) 
15. posttraumatic stress disorder/ 
16. (TI or AB or KW) ((posttraumatic OR post traumatic OR post-traumatic) N1 stress$) 
17. (TI or AB or KW) (complex ptsd) 
18. (TI or AB or KW) (feel* N5 (apprehens* or dread* or disaster* or fear* or worr* or 
terr*) 
19. or/9-18 
 
20. 8 AND 19 
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Web of Science 
 
Symbols used in this search strategy 
ts Indicates a search for topic terms within the title, abstract or keywords 
$ 
at the end of a term indicates that this term has been truncated, and the 
symbol can be substituted for zero or one character 
* 
at the end of a term indicates that this term has been truncated, and the 
symbol can be substituted for zero or more characters 
NEAR/n 
indicates a search for two terms where they appear within n words of each 
another 
 
 
1. ts=(rheumat* NEAR/3 (arthrit* or diseas* or condition* or nodule*)) 
2. ts=(felty* NEAR/3 syndrome) 
3. ts=(caplan* NEAR/3 syndrome) 
4. ts=(sjogren* NEAR/3 syndrome) 
5. ts=(sicca NEAR/3 syndrome) 
6. ts=(still* NEAR/3 disease) 
7. or/1-6 
 
8. ts=(anxiet* or anxious) 
9. ts=((agoraphobi* or phobi* or panic) NEAR/3 (disorder*$ or attack*)). 
10. ts=(obsess$* NEAR/3 compuls*) 
11. ts=((posttraumatic or post traumatic or post-traumatic) NEAR/3 (stress*)). 
12. ts=(ptsd). 
13. ts=(feel* NEAR/5 (apprehens* or dread* or disaster* or fear* or worr* or terr*)). 
14. or/8-13 
 
15. 7 AND 14 
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Appendix 16- Q
uality Assessm
ent of Studies 
 Q
uality Assessm
ent of Cross-Sectional Studies  
 
Author/ Year 
Selection 
Com
parability 
O
utcom
e 
Total 
Score 0-9 
Representativeness of 
the sam
ple * 
Sam
ple size 
* 
Non-respondents 
* 
Ascertainm
ent of 
the exposure ** 
Control for 
confounding 
factors ** 
Assessm
ent of 
outcom
e * 
Statistical test * 
Al-Fadl et al., 
2014  
Recruited from
 outpatient 
clinic of the Rheum
atology 
and Rehabilitation 
Departm
ent, Sohag 
University. Sam
pling 
m
ethod not described. 
26 patients. 
Sm
all sam
ple 
size not 
justified. 
No description. 
Self-report using 
HAM
-A. 
22 Age and Sex 
M
atched Controls. 
Q
uestionnaire 
com
pleted. No 
description of 
w
hether this w
as 
w
ith trained staff 
or self-com
pleted. 
Students͛ T test and 
Pearson͛s correlation 
test. 
M
oderate 
quality 
0 
0 
0 
** 
** 
0 
* 
5 
Alpi et al., 
2016 
Non-random
 sam
ple of 
patients attending the 
foundation city of Botoga. 
62 patients. 
No description. 
Self-report using 
HADS. 
Unadjusted. 
Self-report via 
questionnaire. 
Pearson͛s correlation 
test and Linear 
regression. 
M
oderate 
quality 
* 
* 
0 
** 
0 
0 
* 
5 
Celiker and 
Borm
an, 
2001 
Recruited from
 Hacettepe 
University outpatient 
clinics. Sam
pling m
ethod 
not described. 
20 patients. 
Sm
all sam
ple 
size not 
justified. 
No description. 
Self-report using 
the Spielberger 
State and Trait 
Anxiety Inventory. 
20 healthy fem
ale 
controls. 
Self-report via 
questionnaire. 
Student͛s T test, X
2 test 
and Pearson͛s 
correlation test. 
Low
 quality 
0 
0 
0 
* 
* 
0 
* 
3 
Grosso et al., 
2015 
(abstract)   
No description. 
200 patients. 
46 w
ith 
anxiety. 
No description. 
Self-report using 
HADS. 
107 healthy 
controls. 
Self-report via 
questionnaire. 
Kruskall-W
allis test. 
M
oderate 
quality 
0 
* 
0 
** 
* 
0 
* 
5 
Ichikaw
a et 
al., 1995 
Patients regularly attending 
researchers͛ outpatient 
clinics. Sam
pling m
ethod 
not described. 
92 patients. 
No description. 
Self-report using 
Zung͛s self-rating 
anxiety scale. 
24 healthy controls. 
Self-report via 
questionnaire. 
X
2 test, W
ilcoxon͛s rank 
sum
 test, W
ilcoxon͛s 
signed rank test and 
Linear regression. 
M
oderate 
quality 
0 
* 
0 
** 
* 
0 
* 
5 
Karahan et 
al., 2016 
Recruited from
 
Rheum
atology outpatient 
clinics at Necm
ettin 
148 patients. 
No description. 
Self-report using 
BAI. 
100 healthy 
controls w
ithout 
Self-report via 
questionnaire. 
X
2 or Fisher͛s exact test. 
Pearson͛s correlation 
test, Linear regression. 
M
oderate 
quality 
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University. Sam
pling 
m
ethod not described. 
rheum
atological 
conditions. 
0 
* 
0 
** 
* 
0 
* 
5 
Kojim
a et al., 
2009 
Recruited from
 outpatient 
rheum
atology clinics at 
Nogoya University Hospital. 
Sam
pling m
ethod not 
described. 
120 patients. 
303/321 consented 
to participate. 57 
excluded for not 
attending blood 
tests. 120/246 
com
pleted all 
exam
inations and 
questionnaires. 
Com
parability 
betw
een those 
included and 
excluded not 
discussed. 
Self-report using 
HADS-A. 
Adjustm
ents m
ade 
for age, sex, m
arital 
status and 
educational level. 
Self-report via 
questionnaire. 
Pearson͛s correlation 
test, m
ultivariate 
logistic regression and 
principal factor 
analysis. 
M
oderate 
quality 
0 
* 
0 
** 
** 
0 
* 
6 
M
iw
a et al., 
2002 
Recruited from
 outpatient 
clinics at the Departm
ent of 
Internal M
edicine, Show
a 
University. Sam
pling 
m
ethod not described. 
82 patients. 
No description. 
Self-report using 
HADS. 
Unadjusted. 
Self-report via 
questionnaires and 
m
edical record 
review
. 
Pearson͛s correlation 
test and regression 
analysis. 
M
oderate 
quality 
0 
* 
0 
** 
0 
0 
* 
4 
M
ok et al., 
2012 
Recruited consecutively 
from
 outpatient 
rheum
atology clinics at Pok 
Oi Hospital. 
200 patients. 
No description. 
Psychiatrist 
interview
 using the 
Chinese Bilingual 
Studied interview
 
from
 DSM
-IV Axis 1 
disorders. 
Adjustm
ents m
ade 
for age, sex, 
incom
e, years of 
education, 
em
ploym
ent status, 
m
arital status, RA 
duration, m
edical 
com
orbidities, 
fatigue.  
Self-report via 
questionnaires, 
facilitated by a 
research assistant. 
Pearson͛s correlation 
test and Linear 
regression. 
M
oderate 
quality 
* 
* 
0 
* 
** 
0 
* 
6 
Nas et al., 
2011 
Recruited consecutively 
(October 2006 to M
arch 
2009) from
 joint database 
of rheum
atology clinics of 
26 patients. 
No description. 
Turkish version of 
HADS. 
Adjustm
ents m
ade 
for age, disease 
duration and 
education. 
Self-report via 
questionnaires and 
m
edical record 
review
. 
Pearson͛s correlation 
test and m
ultivariate 
logistic regression. 
M
oderate 
quality 
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five University hospitals 
located in Eastern Turkey.  
* 
0 
0 
** 
** 
0 
* 
6 
Ozcetin et 
al., 2007 
All patients attending the 
outpatient departm
ent of 
Physical m
edicine and 
Rehabilitation Unit of Duzce 
M
edical Faculty for the first 
tim
e betw
een October 
2001 and M
arch 2002 
recruited. 
34 patients. 
No description. 
Self-report using 
BAI 
Logistic regression 
analysis perform
ed 
to determ
ine the 
influence of age, 
gender, occupation, 
m
arital status, 
education and 
duration of disease 
on outcom
es. 
Self-report via 
questionnaires. 
Independent sam
ple t-
test, one-w
ay ANOVA, 
pearson͛s correlation 
test and logistic 
regression. 
M
oderate 
quality 
* 
0 
0 
** 
** 
0 
* 
6 
Ruhaila &
 
Cheng, 2018 
Convenience sam
ple from
 
rheum
atology outpatient 
unit in M
elaka hospital. 
192 patients. 
189/192 patients 
approached 
com
pleted 
questionnaires. 
Self-report using 
DASS(21). 
No adjustm
ents 
reported. 
Self-report via 
questionnaires. 
Pearson͛s correlation 
test. 
M
oderate 
quality. 
* 
* 
* 
* 
0 
0 
* 
5 
W
an et al., 
2015 
Convenience sam
pling from
 
rheum
atology clinic at a 
tertiary centre in 
Singapore. 
108 patients. 
108/124 patients 
approached 
com
pleted 
questionnaires 
(87.1%
 response 
rate).  
Self-report using 
HADS. 
Subgroup analysis 
according by m
arital 
status, educational 
level, incom
e, 
em
ploym
ent status 
and ethnicity. No 
statistical difference 
in outcom
e values 
betw
een 
subgroups. 
Self-report via 
questionnaires, 
facilitated by a 
research assistant. 
Pearson͛s correlation 
test and linear 
regression. 
High quality 
* 
* 
* 
** 
** 
0 
* 
8 
Zulgerel and 
Nandin 
Erdene, 2014 
(abstract) 
Patients recruited from
 
rheum
atology outpatient͛s 
clinic. 
51 patients. 
No description. 
Speilberg Chennai 
Test. No description 
of this 
m
easurem
ent tool. 
Unadjusted. 
Self-report via 
questionnaire. 
Statistical tests not 
described. 
Low
 quality 
0 
* 
0 
0 
0 
0 
0 
1 
 BAIс Beck͛s A
nxiety Inventory, DASS= Depression, anxiety and stress scale, HADS= Hospital Anxiety and Depression Scale, HAM
-A= Ham
ilton Anxiety Rating Scale, RA= 
Rheum
atoid arthritis
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Q
uality Assessm
ent of Cohort Studies 
 Author/ 
Year 
Selection 
Com
parability 
O
utcom
e 
Total 
Score 
(0-9) 
Representative of 
the exposed cohort 
* 
Selection of 
non-
exposed 
cohort * 
Ascertainm
ent of 
exposure * 
Dem
onstration 
that outcom
e of 
interest w
as not 
present at start 
of study * 
Com
parability of 
cohorts ** 
Assessm
ent 
of outcom
e * 
W
as follow
-
up long 
enough for 
outcom
es to 
occur * 
Adequacy of 
follow
-up cohorts 
* 
Dyball et 
al., 2018 
(abstract) 
Data from
 BRAGGSS 
cohort, a m
ulticenter, 
observational study of 
RA patients w
ith 
severe active disease 
undergoing biological 
therapy. 
Com
pared to 
patients 
w
ithout 
anxiety 
draw
n from
 
sam
e 
BRAGGSS 
cohort. 
HADS, though not 
clarified if patients self-
com
pleted the 
questionnaire or if it 
w
as com
pleted by 
clinician interview
. 
Baseline disease 
activity recorded 
using DAS28. 
Adjustm
ents for 
pre-treatm
ent 
DAS28, gender, 
body m
ass index 
and synthetic 
DM
ARD use. 
DAS28 using 
clinical, 
biochem
ical 
and patient 
self-reported 
data. 
6 m
onths. 
Not reported. 
M
oderate 
quality 
* 
* 
0 
* 
** 
0 
* 
0 
6 
Fragoulis 
et al., 
2018 
(abstract) 
Data from
 SERA 
inception cohort of 
new
ly diagnosed RA 
patients follow
ed up 
at 6 m
onth intervals.  
Com
pared to 
patients 
w
ithout 
anxiety from
 
sam
e cohort. 
HADS, though not 
clarified if patients self-
com
pleted the 
questionnaire or if it 
w
as com
pleted by 
clinician interview
. 
Baseline disease 
activity recorded 
using DAS28. 
No reported 
adjustm
ents. 
DAS28 using 
clinical, 
biochem
ical 
and patient 
self-reported 
data. 
12 m
onths. 
Not reported. 
M
oderate 
quality. 
* 
* 
0 
* 
0 
0 
* 
0 
4 
Kuijper et 
al., 2018 
Data from
 the tREACH 
cohort in w
hich 
patients w
ere 
ram
dom
ised to triple 
DM
ARD therapy or 
m
ethotrexate 
m
onotherapy. 
Participants had early 
RA w
ith a high risk of 
developing persistent 
arthritis. 
Com
pared to 
patients 
w
ithout 
anxiety 
draw
n from
 
the sam
e 
cohort. 
HADS, though not 
clarified if patients self-
com
pleted the 
questionnaire or if it 
w
as com
pleted by 
clinician interview
. 
Baseline disease 
activity recorded 
using DAS28. 
Adjustm
ents m
ade 
for baseline DAS28, 
age, gender, 
rheum
atoid factor 
positivity and anti-
citrullinated 
protein status. 
DAS28 using 
clinical, 
biochem
ical 
and patient 
self-reported 
data. 
15 m
onths. 
120/281 had 
m
issing data, 
though m
issing 
values com
pleted 
using m
ultiple 
im
putation. Patients 
w
ith com
plete and 
incom
plete follow
-
up w
ere sim
ilar w
ith 
respect to m
ost 
baseline 
characteristics. 
High 
quality 
* 
* 
0 
* 
** 
0 
* 
* 
7 
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M
atcham
 
et al, 2016 
Patients consecutively 
approached in the 
w
aiting room
 w
hen 
attending 
rheum
atology 
outpatient 
appointm
ents at 
King͛s College, 
London. 
Com
pared to 
patients 
w
ithout 
baseline 
anxiety from
 
the sam
e 
cohort. 
Self-report using HADS. 
Baseline and 1yr 
outcom
es 
com
pared. 
Adjustm
ents 
m
ade for baseline 
score of outcom
e 
variables. 
Adjusted for 
disease duration, 
age, baseline score 
of outcom
e 
variables. 
DAS28 results 
obtained from
 
patient m
edical 
records at 1 
year 
appointm
ents 
(+/- 3 m
onths). 
1 year. 
13/56 had m
issing 
data. No system
atic 
difference betw
een 
patients w
ith and 
w
ithout m
issing 
data. 
High 
quality 
* 
* 
0 
* 
** 
* 
* 
0 
7 
Overm
an 
et al., 
2011 
Patients recruited 
from
 6 outpatient 
clinics of the Utrecht 
Foundation for 
Research in the 
Netherlands. 
Com
pared to 
patients 
w
ithout 
baseline 
anxiety from
 
the sam
e 
cohort. 
Im
pact of rheum
atic 
diseases on general 
health and lifestyle 
questionnaire, derived 
from
 the Spielberger 
state-trait anxiety 
inventory, though not 
clarified if patients self-
com
pleted the 
questionnaire or if it 
w
as com
pleted by 
clinician interview
. 
Baseline disease 
activity recorded 
using ESR and 
Thom
pson 
articular index. 
Adjusted for 
rheum
atoid factor 
positivity, age and 
fem
ale sex. 
Biochem
ical 
results (ESR) 
and Thom
pson 
articular index. 
Not stated if 
this w
as self-
reported or 
com
pleted by 
clinician 
interview
. 
5 years. 
545 patients, w
ith 
436 com
pleting 
>60%
 of clinical and 
psychological 
assessm
ents. The 
119 w
ho com
pleted 
<60%
 of 
assessm
ents did not 
differ significantly 
from
 the other 
group.   
M
oderate 
quality 
* 
* 
0 
* 
** 
0 
* 
0 
6 
Sergeant 
et al., 
2018 
Patients recruited to 
the Rheum
atoid 
Arthritis M
edication 
Study (RAM
S), a UK 
m
ulti-centre study of 
patients w
ith RA or 
undifferentiated 
polyarthritis, 
com
m
encing 
m
ethotrexate for the 
first tim
e. 
Com
pared to 
patients 
w
ithout 
baseline 
anxiety from
 
the sam
e 
cohort. 
Self-report using HADS 
questionnaire. 
Baseline disease 
activity recorded 
using DAS28. 
All clinical, 
biochem
ical and 
psychosocial 
variables assessed 
for association w
ith 
non-response 
(change in DAS28) 
using logistic 
regression. 
DAS28 by 
patient 
interview
, 
supplem
ented 
by biochem
ical 
tests and 
inform
ation 
from
 m
edical 
records. 
6 m
onths. 
From
 1656 
consenting to 
participate, due to 
death, w
ithdraw
al 
or m
issing data, 304 
lost at 3M
 and 
further 302 at 6M
. 
Characteristics of 
those lost to follow
-
up not described. 
High 
quality 
* 
* 
0 
* 
** 
* 
* 
0 
7 
 RA= Rheum
atoid arthritis, DAS28= Disease activity score in 28 joints, DM
ARD= Disease m
odifying anti-rheum
atic drug, ESR= Erythrocyte sedim
entation rate, HADS= Hospital 
Anxiety and Depression Scale. 
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Appendix 17- M
eta-analysis data 
  
Disease Activity Data- DAS28 
Author/ Year 
Num
ber of participants 
Results 
Al-Fadl et al., 2014
  
26 
Anxiety (HAM
-A) and DAS-28, r= 0.47 (p<0.05) 
Karahan et al., 2016  
148 
Anxiety (BAI) and DAS-28, r=0.159 (not significant) 
M
atcham
 et al., 2016 
56 
Anxiety (HADS) and DAS-28, Baseline, r= 0.29 (p<0.05) 
Ruhaila &
 Cheng, 2018 
189 
Anxiety (DASS21) and DAS-28, r=0.233 (p=0.001) 
Zulgerel et al., 2014 
51 
Anxiety (Spielberg Chennai test) and DAS-28, r=0.126 (p=0.380) 
   
DAS28 M
eta-analysis 
Author/ Year 
r 
n 
ƌ ΀Z͛΁ 
SE ;ƌ΀Z͛΁Ϳ 
ϵϱй
 CI ;ƌ΀Z͛΁Ϳ 
95%
CI (r) 
Al fadl et al., 2014 
0.47 
26 
0.5101 
0.209 
0.101, 0.919 
0.101, 0.725 
Karahan et al., 2016 
0.159 
148 
0.1604 
0.083 
-0.002, 0.323 
-0.002, 0.312 
M
atcham
 et al., 2016 
0.29 
56 
0.2986 
0.137 
0.029, 0.568 
0.029, 0.514 
Ruhaila &
 Cheng, 2018  
0.233 
189 
0.2374 
0.074 
0.094, 0.381 
0.093, 0.364 
Zulgerel et al., 2014 
0.126 
51 
0.1267 
0.144 
-0.156, 0.410 
-0.155, 0.388 
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SF-36 M
eta-analysis- Physical Q
O
L 
Author/ Year 
r 
n 
ƌ ΀Z͛΁ 
SE ;ƌ΀Z͛΁Ϳ 
ϵϱй
 CI ;ƌ΀Z͛΁Ϳ 
95%
CI (r) 
Al-Fadl et al., 2014 
-0.38 
26 
-0.400 
0.209 
-0.809, 0.0086 
-0.669, 0.009 
Kojim
a et al., 2009 
-0.25 
120 
-0.255 
0.092 
-0.437, -0.074 
-0.411, -0.074 
Nas et al., 2011 
-0.28 
421 
-0.288 
0.049 
-0.384, -0.192 
-0.366, -0.190 
Ozcetin et al., 2007  
-0.672 
34 
-0.814 
0.180 
-1.166, -0.462 
-0.823, -0.432 
  
Q
uality of Life Data- SF-36 
Author/ Year 
Num
ber of 
participants 
Ascertainm
ent of 
outcom
e 
Results 
Al-Fadl et al., 2014 
26 
PCS and M
CS of SF-36 
Anxiety and PCS of SF-36:   r=-0.38 (p<0.05) 
Anxiety and M
CS of SF-36:   r=-0.34 (p<0.05) 
Kojim
a et al., 2009 
120 
PCS and M
CS of SF-36 
 
HADS-A and PCS of SF-36:   r=-0.25 (p=0.01) 
HADS-A and M
CS of SF-36:   r=-0.51 (p<0.001) 
Nas et al., 2011  
421  
SF-36 subscales 
Anxiety and SF-36 subscale score for physical functioning:  r=-0.28 (p<0.001) 
Anxiety and SF-36 subscale score for m
ental health:   r=-0.48 (p<0.001) 
Ozcetin et al., 2007 
34 
SF-36 subscales 
Anxiety and SF-36 subscale score for physical functioning:   r=-0.672 (p<0.001) 
Anxiety and SF-36 subscale score for m
ental health:   r=-0.655 (p<0.001) 
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SF-36 M
eta-analysis- M
ental Q
oL 
Author/ Year 
r 
n 
ƌ΀Z͛΁ 
SE ;ƌ΀Z͛΁Ϳ 
ϵϱй
CI ;ƌ΀Z͛΁Ϳ 
95%
CI (r) 
Al-Fadl et al., 2004 
-0.34 
26 
-0.3541 
0.209 
-0.763, 0.055 
-0.643, 0.055 
Kojim
a et al., 2009 
-0.51 
120 
-0.5627 
0.092 
-0.744, -0.382 
-0.631, -0.364 
Nas et al., 2011 
-0.48 
421 
-0.523 
0.049 
-0.619, -0.427 
-0.550, -0.403 
Ozcetin et al., 2007 
-0.655 
34 
-0.784 
0.180 
-1.136, -0.432 
-0.813, -0.407 
 CI= confidence interval, n= num
ber of individuals, r = pearsons correlation coefficient, r;z͛Ϳ = Fisher͛s z scores, SE= standard error. 
 BAIс Beck͛s A
nxiety Inventory, DAS28= Disease activity score 28, DASS (21)= Depression, anxiety and stress scale, HADS= Hospital Anxiety and Depression 
Score, HAM
-A= Ham
ilton͛s A
nxiety Rating Scale, M
CS= M
ental Com
ponent Sum
m
ary, NHP= Nottingham
 Health Profile, PCS= Physical Com
ponent Sum
m
ary, 
Q
oL= Q
uality of life, RA= Rheum
atoid arthritis, SF-36= Short-form
 36 
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Appendix 18- GRADE Assessm
ent 
 
O
utcom
e 
Risk of Bias 
Inconsistency 
Indirectness 
Im
precision 
Large Effect 
(Strength of 
Association) 
Dose-Response 
Gradient 
Disease 
Activity 
From
 14 studies reporting 
disease activity outcom
e 
m
easures, there w
ere several 
potential sources of bias; 
-5 lacked detail on their 
sam
pling m
ethod  
-9 did not describe non-
respondents  
 How
ever; 
-13 had a good sam
ple size 
im
proving generalizability  
-All used validated tools to 
determ
ine the exposure and 
outcom
e 
-10 controlled for confounding 
factors  
M
eta-analysis 
-Relatively narrow
 CI 
w
ith low
 
heterogeneity 
 Narrative synthesis 
-Som
e differences in 
source populations, 
sam
pling m
ethods 
and adjustm
ents 
m
ade for 
confounding factors 
could explain som
e 
heterogeneity in 
results 
Differences in population 
(applicability) 
-Populations from
 different 
global areas. All had 
validated diagnoses of 
rheum
atoid arthritis, w
ith 
m
ost recruited from
 
rheum
atology outpatient 
clinics, though som
e 
studies lacked detail on 
their sam
pling m
ethods. 
 Differences in outcom
e 
m
easures 
-Studies reporting DAS28, a 
validated outcom
e 
m
easure analysed together 
for consistency. Secondary 
validated outcom
e 
m
easures discussed in 
narrative synthesis. 
M
ajority of 
ϵϱй
 CI͛s w
ere 
relatively 
narrow
, not 
including ͚no 
effect͛. 
Just one study 
(31) had a 
sm
all sam
ple 
size, w
ith the 
m
ajority having 
m
oderate to 
large sam
ple 
sizes. 
 
M
ost results 
reported as 
correlations. 
Effect sizes 
sm
all/ m
oderate. 
Overall, 
increased 
anxiety 
correlated/ 
associated w
ith 
higher disease 
activity 
Not dow
ngraded 
Upgrade 1 level 
Not dow
ngraded 
Upgrade 1 level 
Not dow
ngraded 
Upgrade 1 level 
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Q
uality of 
life 
From
 9 studies reporting 
disease activity outcom
e 
m
easures, there w
ere several 
potential sources of bias; 
-5 lacked detail on sam
pling 
m
ethod  
-8 did not describe non-
respondents  
-4 had sm
all sam
ple sizes 
lim
iting generalisability 
How
ever; 
-All used validated tools to 
determ
ine the exposure and 
outcom
e 
-8 controlled for confounding 
factors  
M
eta-analysis 
-Relatively narrow
 CI 
w
ith low
 
heterogeneity for 
m
ental QoL (10.3%
) 
but high 
heterogeneity for 
physical QoL 
(78.5%
). Differences 
in the source 
populations, 
sam
pling m
ethods 
and adjustm
ents 
m
ade for 
confounding factors 
could account for 
heterogeneity. 
 Narrative synthesis 
-Findings largely 
consistent across 
studies. M
ost effect 
sizes m
ild/ 
m
oderate. Som
e 
heterogeneity could 
be explained by 
above reasons given. 
Differences in population 
(applicability) 
-Populations from
 different 
global areas. All had 
validated diagnoses of 
rheum
atoid arthritis, 
though som
e studies 
lacked detail on their 
sam
pling m
ethods or did 
not describe non-
respondents. 
 Differences in outcom
e 
m
easures 
-Studies reporting SF-36, a 
validated outcom
e 
m
easure analysed together 
for consistency. Secondary 
validated outcom
e 
m
easures discussed in 
narrative synthesis. 
M
ajority of 
ϵϱй
 CI͛s w
ere 
relatively 
narrow
, not 
including ͚no 
effect͛. 
How
ever, 4/9 
studies had a 
sm
all sam
ple 
size. 
 
All results 
reported as 
correlations. 
Effect sizes 
sm
all/ m
oderate. 
Overall, 
increased 
anxiety 
correlated/ 
associated w
ith 
higher disease 
activity 
Not dow
ngraded 
Not dow
ngraded 
Not dow
ngraded 
Not 
dow
ngraded 
Not dow
ngraded 
Upgrade 1 level 
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Appendix 19- CiPCA Data Application 
 
 
DESCRIPTION OF PROPOSED RESEARCH (Max 2000 words) 
 
TITLE  
 
The incidence and prevalence of anxiety and depression in rheumatoid arthritis, ankylosing 
spondylitis, psoriatic arthritis, polymyalgia rheumatica and giant cell arteritis: a matched 
retrospective cohort study. 
 
PLAIN ENGLISH SUMMARY (Max 300 words) 
 
          I aim to find out how many people with inflammatory arthritis suffer from anxiety and 
depression. I also want to understand how many people develop mood problems after they 
are diagnosed with inflammatory arthritis. People with mood problems may not respond as 
well to treatments for their arthritis. Showing how many people with inflammatory arthritis 
have or develop anxiety and depression could help to improve how mood problems are 
recognised and treated. This could lead to an improved quality of life for those affected. 
Types of inflammatory arthritis include rheumatoid arthritis, psoriatic arthritis, 
ankylosing spondylitis and polymyalgia rheumatica. These long-term conditions can cause 
pain, swelling and stiffness of the joints. Another type of inflammatory arthritis, giant cell 
arteritis, can cause headaches. 
One in five people with rheumatoid arthritis suffer from mood problems, though 
there has been a lack of research into mood problems in other types of inflammatory 
arthritis. In particular, we do not understand how many people develop mood problems 
after they are diagnosed with inflammatory arthritis. 
I plan to find out how common anxiety and depression are in patients with different 
types of inflammatory arthritis by reviewing GP records. I will also look at how many people 
with inflammatory arthritis develop anxiety or depression over time and compare this to 
people without inflammatory arthritis. To do this I will use data from nine GP practices in 
North Staffordshire from the year 2000-2015.  
I will lead a patient and public involvement group to discuss what the results mean, 
how they could be shared with patients and further research needed. 
I will share my results with researchers and doctors nationally through 
presentations and publications. I will present my results to arthritis patient groups, and 
produce posters for display in GP surgeries taking part. 
 
BACKGROUND AND RATIONALE (include brief summary of previous 
relevant research and explain potential clinical or policy impact) 
 
An estimated 15 million people in the United Kingdom (UK) suffer from long-term 
conditions (LTCs) (Naylor et al., 2012). These encompass a range of illnesses that can be 
managed, but not cured. Examples include diabetes, asthma and rheumatoid arthritis. 
 Depression and anxiety are more prevalent in LTCs. The 2014 Adult Psychiatric 
Morbidity Survey reported 3.3% of the general population to have depression and 5.9% 
anxiety (NatCen Social Research, 2016).  In contrast, up to 20% of patients with LTCs are 
estimated to suffer from depression. Patients with LTCs are also two to three times more 
likely to suffer from anxiety (Naylor et al., 2012). Unfortunately, mood problems can often 
be under-recognised and treated in people with LTCs (Cepoiu et al., 2007).  
Inflammatory rheumatic conditions are LTCs which can involve inflammation of the 
joints, bones, cartilage, ligaments, muscles and internal organs. Rheumatoid Arthritis is an 
inflammatory rheumatic condition characterised by synovial inflammation, that affects 1% 
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of the adult population (Silman and Pearson, 2002). In common with other LTCs, RA is 
linked to an increased incidence and prevalence of anxiety and depression. Studies have 
suggested the prevalence of anxiety in RA to be between 13-14% (Isik et al., 2006) (Covic 
et al., 2012), whilst a meta-analysis found the prevalence of depression in RA to be 38.8% 
(Matcham et al., 2013). 
Bidirectional interactions between RA and depression have been identified 
(Rathbun et al., 2012). These include biological, psychological and behavioural processes 
(Rathbun et al., 2012). In terms of biological processes, depression has been linked to a 
rise in pro-inflammatory cytokines (Maes et al., 1995). A small study has also suggested 
that anti-tumour necrosis factor could interact with serotonin transmission, potentially 
affecting mood, though the need for further research has been highlighted (Cavanagh et 
al., 2010). Cytokine dysregulation is pivotal in the pathogenesis of RA, hence, pro-
inflammatory cytokines produced in RA could potentially precipitate or exacerbate 
depression and vice-versa. 
In terms of psychological processes, negative thoughts in patients with depression 
could influence how symptoms of RA are perceived (Rathbun et al., 2012). Depression 
could also affect behaviour, potentially causing a decrease in exercise, deconditioning, 
reduced endorphin release and increased pain (Covic et al., 2003). Greater disability in 
relation to RA could lead to reduced participation in valued social activities, contributing to 
depression (Neugebauer, Katz and Pasch, 2003). 
The presence of comorbid mental illness in LTCs such as RA has been estimated 
to raise total healthcare costs by 45% (Naylor et al., 2012). Specific links have also been 
identified between depression in RA and disease progression (Rathbun et al., 2012).  
A recent secondary analysis of a RCT aimed to examine the impact of anxiety and 
depression on treatment response, disease activity and physical disability. Mood problems 
were linked to a reduction in treatment response, higher disease activity scores and poorer 
overall health outcomes (Matcham et al., 2015).  
The literature suggests that depression in RA is also a risk factor for increased 
mortality (Ang et al., 2005). A cohort of patients with RA were followed-up at clinic 
appointments over 18 years. The primary independent variable was the mean Arthritis 
Impact Measurement Scale (AIMS) depression scores during the first 4 years of entry into 
the clinic cohort. After adjusting for covariates, the hazard ratio (HR) for each unit increase 
in the average 4-year depression score on mortality was 1.14 (p < 0.0001), suggesting that 
depression in RA was linked to increased mortality. 
Despite it being well established that patients with RA have higher rates of 
depression, the literature suggests it is often under-recognised (Cepoiu et al., 2007), which 
can result in increased pain, fatigue, morbidity and mortality (Ang et al., 2005). In 
recognition of the links between anxiety and/ or depression in RA and increased morbidity 
and mortality, NICE have created Quality Standards for the management of RA (QS33), to 
facilitate early recognition of comorbid mood problems (NICE, 2013). Within this Quality 
Standard, NICE recommends that clinicians should regularly reassess mood within the 
context of an annual review clinic (NICE, 2013). However, there is no specific guidance 
advocating an annual review for patients with other inflammatory rheumatological 
conditions. 
Past research exploring mood problems in patients with inflammatory rheumatic 
conditions has mainly focused on the prevalence of depression in RA. As a consequence, 
the scale and burden of mood problems, particularly anxiety, has been under-researched 
in other inflammatory conditions, such as psoriatic arthritis (PsA), ankylosing spondylitis 
(AS), giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). In particular, there has 
been a lack of research to explore the incidence of mood problems in people with 
inflammatory rheumatic conditions. 
In AS, estimates of the prevalence of depression vary. A population-based cohort 
study found that 10% with AS had doctor-diagnosed depression (Meesters et al., 2014). 
However, other estimates vary between 15-30% (Martindale et al., 2006; Barlow et al, 
1993). There is a lack of literature on anxiety in AS. One study estimated a prevalence of 
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anxiety in AS of 25%, though the study involved less than 100 patients hence would have 
limited generalisability (Martindale et al., 2006). 
In PsA, a small study found the prevalence of anxiety and depression to be higher 
than in the general population (36.6% and 22.2%, respectively) (McDonough et al., 2014). 
In PMR, a recent study using a cross-sectional questionnaire found the prevalence of 
depressive symptoms to be 15% (Vivekanantham et al., 2017). There has been a lack of 
research exploring anxiety in PMR and mood problems in GCA. 
Given the known links between RA, comorbid anxiety and/ or depression and 
increased morbidity and mortality, further research is needed to determine the incidence 
and prevalence of mood problems in patients with other types of inflammatory rheumatic 
conditions. 
Therefore, I aim to perform a matched retrospective cohort study to investigate the 
incidence and prevalence of anxiety and depression in patients with RA, PsA, AS, PMR 
and GCA. In particular, this study will improve our understanding of the proportion of 
patients with inflammatory rheumatic conditions that will become affected by anxiety and 
depression. Highlighting the scale of mood problems will help to promote pathways to 
improve the recognition and management of comorbid anxiety and depression. Ultimately, 
this could help to reduce associated morbidity and mortality. 
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OBJECTIVES 
 
The objectives are: 
 
(1)  Assess whether there is a possible causal association between the diagnosis of 
inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, 
polymyalgia rheumatica and giant cell arteritis) and the subsequent consultation for anxiety 
and depression.  
 
(2) Investigate the prevalence of, and factors associated with, anxiety and depression 
among patients with inflammatory arthritis. 
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METHODS (include study population(s), exposure(s), outcome(s), confounder 
analysis) 
 
Design and study population 
This study will be a matched retrospective cohort study using CiPCA, a well-established 
local database of primary care electronic health records. The cohort will include men and 
Zomen aged 18 \eaUV ZiWh UecoUded Read code diagnoViV of inflammaWoU\ aUWhUiWiV (RA, 
AS, PsA, AS, GCA) between 1/1/2001 and 31/12/2015 (the date of the diagnosis defined 
as the index date). The cohort will be followed up until 31/08/2016 (latest available data in 
CiPCA). Individuals below the age of 18 are excluded as the incidence of inflammatory 
arthritis is expected to be low in this group. A comparison group without inflammatory 
arthritis will be drawn by assigning each individual with inflammatory arthritis at their index 
date to up to four age (within 3 years), gender and general practice concurrent matched 
individuals without a record of inflammaWoU\ aUWhUiWiV XS Wo Whe SoinW of WheiU maWched caVe¶V 
index date and who were alive and contributing data at the time. Comparison individuals 
will be assigned the same index date as their matched inflammatory arthritis individuals. 
All individuals will be followed up from index date until occurrence of the events (anxiety, 
depression) of interest, or end of study defined as the earliest of date of death, end of 
registration at the practice, or 31/08/2016. Individuals with a record of inflammatory arthritis 
before the index date will be excluded. All individuals are required to have at least 12 
months registration history before the index date. 
Details for objective 1 (incidence study) 
Study population 
As outlined above but with exclusion of any individuals that had a record of anxiety or 
depression 12 months before the index date. 
Exposure  
The exposure of interest will be inflammatory arthritis, as used to define the cohort for 
analysis. Inflammatory arthritis will be defined using Read codes for rheumatoid arthritis, 
psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatic and giant cell arteritis. All 
the relevant lists of Read codes are available at www.keele.ac.uk/mrr. 
Outcome  
Outcomes of interest will be the time from the index date to first diagnosis of anxiety OR 
depression. Anxiety and anxiety and/or depresion will be analysed as separate outcomes. 
Anxiety and depression will be defined using relevant Read codes (available at 
www.keele.ac.uk/mrr).  
Covariates 
Covariates believed to potentially confound the relationship between inflammatory arthritis 
and anxiety/depression will include age and gender (mostly accounted for through the 
matched study design), Index of Multiple Deprivation (IMD), select comorbidities (COPD, 
asthma, diabetes mellitus, congestive heart failure, ischaemic heart disease, peripheral 
vascular disease, stroke, malignancy), obesity, alcohol use and smoking status. These 
potential confounders will be identified via Read codes and will be required to be identified 
in the record at any time prior to the diagnosis of inflammatory arthritis to avoid them 
potentially occurring onto the causal pathway. Charlson comorbidity index1 will also be 
calculated on the day prior to index date via a technique by Khan et al2. For confounders 
that can change over time (e.g. obesity, alcohol use), the information recorded closest to 
the index date will be used. Categories for missing data will be defined for obesity, alcohol 
and smoking in order to preserve sample size. 
Analysis 
Characteristics of individuals at index date will be compared between those with and 
without inflammatory arthritis using frequencies and percentages; success of matching will 
be described. Cox proportional hazard regression models will be used to obtain 
associations between inflammatory arthritis and time to occurrence of anxiety and 
depression, in terms of hazard ratios (HRs). Corresponding 95% confidence intervals (CIs) 
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will be based on robust standard errors to account for clustering due to matching. Both 
crude and covariate-adjusted HRs will be estimated. Proportionality of hazards assumption 
will be tested graphically and via Schoenfeld residuals. if the assumption fails for any 
covariate, interaction of that covariate with appropriate function(s) of time will be included 
in the model. Right censoring will be assumed non-informative and will be taken as the 
earliest of date of death, end of registration at the practice, or 31/08/2016. We may also 
explore the association of inflammatory conditions and anxiety/depression at different 
times, with follow-up being truncated at one year, two years, five years and ten years. 
Data will be managed and analysed in SPSS and STATA.  
Subgroup/sensitivity analyses 
Subgroup analyses by gender (male/ female) and different age groups will be performed. 
Sensitivity analyses will concern assessment of results arising from complete case 
analyses which ignore missing data on obesity, alcohol and smoking. Multiple imputation 
will not be considered for these variables as previous studies using primary care electronic 
health records (such as CPRD) have indicated that missing data on these variables are 
not missing at random3. 
Details for objective 2 (prevalence study) 
Prevalence estimates for anxiety and depression (separately and combined) in the 12 
months prior to index date will be calculated among those with inflammatory arthritis (and 
among those without for comparison purposes). Among those with inflammatory 
conditions, logistic regression models will be used to obtain estimates of association, in 
terms of odds ratios and associated 95% CIs, between covariates (age, gender, IMD, 
COPD, asthma, diabetes mellitus, congestive heart failure, ischaemic heart disease, 
peripheral vascular disease, stroke, dementia, obesity, alcohol use, smoking status) and 
anxiety/depression. Estimates of unadjusted associations will be obtained first, followed by 
adjustment for other covariates. 
 
1 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chronic 
Dis 1987;40:373±83. 
2 Khan NF, Perera R, Harper S, et al. Adaptation and validation of the Charlson Index for 
Read/OXMIS coded databases. BMC Fam Pract 2010;11:1 
3 Clarson, L.E., et al., Increased risk of vascular disease associated with gout: a 
retrospective, matched cohort study in the UK clinical practice research datalink. Ann 
Rheum Dis, 2015. 74(4): p. 642-7. 
 
Is this a pilot study?  No 
 
Time period for download: 
 
1/1/2000-31/08/2016 (or whenever the 
end of available data is) 
Age and gender criteria: 
 
≥18 years 
 
Please detail the clinical advice/support available for the project: 
Dr Samantha Hider- Reader in rheumatology 
Dr Annabelle Machin- GP 
Please detail statistical advice / support available for the project:   
Dr Milisa Blagojevic-Bucknall 
 
Outline how you have identified Read codes, and prescription lists for the study to 
define the study population, exposures, outcomes, and covariates. Please note 
established Institute code lists are available at www.keele.ac.uk/mrr and through 
the CiPCA Data Manager. 
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For rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, 
depression, I will use established read code lists available at www.keele.ac.uk/mrr. For 
anxiety, I will use an established read code list from the SAIL-2 study based at Keele, which 
Kelvin Jordan has provided me with. For giant cell arteritis I will use an established read 
code list from a previous study lead by James Prior at the Keele Research Institute. 
 
Outline funding for the study 
 
School of Primary Care Research (18M funding) and Haywood Foundation (6M funding). 
 
In which of the Research Programmes / Groups is this study contained? Has it been 
discussed and agreed by the Research Programme / Group? 
 
This work is nested within the inflammatory research group and the ideas have followed 
on from the pilot study INCLUDE. The proposed study has been discussed with the 
inflammatory research group. 
Have you discussed the proposed project with the CiPCA Data Manager and/or 
another member of the CiPCA Academic Custodianship Committee? Please give 
brief details 
 
The proposal has been discussed with M. Blagojevic-Bucknall (who is one of the 
co-supervisors for the proposed work). 
Please indicate the format you would like the data to be provided (i.e. STATA, 
SPSS, Excel) 
STATA/ SPSS 
 
 
I agree to: 
 comply with the Institute¶s data security and confidentiality procedures 
 to retain the data on the Institute's password-protected server at all times 
 undertake all analysis within the Institute 
x use the data only for the purposes of the project detailed here 
 not to attempt to identify any people included in the data received 
x not to link, or attempt to link, to any other sources of patient data  
x not release any data to any third party 
x allow the CiPCA Academic Custodianship Committee to audit use of released data 
if requested 
x include appropriate funding and other acknowledgements in all publications 
x inform the CiPCA Data Manager of all publications and presentations resulting 
from this project 
 
NAME: Dr Annabelle Machin 
SIGNATURE:  
 
DATE: 02/08/2017 
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Appendix 20- Read Code lists 
 
Alcohol misuse/ dependence 
Acute alcoholic intoxication 
Admitted to alcohol detoxification centre 
Alcohol dependence syndrome 
Alcohol disorder monitoring 
Alcohol problem drinking 
Alcohol withdrawal syndrome 
Alcoholic psychoses 
Alcoholism 
Chronic alcoholism 
Chronic alcoholism in remission 
Delirium tremens 
Referral to community alcohol team 
Referral to specialist alcohol treatment centre 
Under care of community alcohol team 
Wernicke-Korsakov syndrome 
 
 
Obesity 
Attends obesity monitoring 
Body mass index 30+ - obesity 
Body mass index 40+ - severely obese 
Body mass index 25-29- overweight 
Central obesity 
Follow-up obesity assessment 
Has seen dietician- obesity 
Initial obesity assessment 
Intervention for risk to health associated with obesity 
Morbid obesity 
O/E- weight >10% over ideal 
Obesity 
Obesity due to excess calories 
Obesity monitoring 
Obesity monitoring 1st letter 
Obesity monitoring verbal inv. 
Overweight 
Refuses obesity monitoring 
Simple obesity NOS 
Treatment of obesity started 
Weight management plan started 
Weight management programme offered 
[V] Dietary surveillance and counselling 
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Current smoker 
Trivial smoker - < 1 cig/day 
Occasional smoker 
Light smoker - 1-9 cigs/day 
Moderate smoker - 10-19 cigs/d 
Heavy smoker - 20-39 cigs/day 
Pipe tobacco consumption 
Ready to stop smoking 
Thinking about stopping smoking 
Not interested in stopping smoking 
Thinking about stopping smoking 
Not interested in stopping smoking 
Cigarette smoker 
Smoker 
Smoking started 
Smoking restarted 
Current smoker 
Smoking reduced 
Chews tobacco 
Cigarette consumption 
Cigar consumption 
Tobacco dependence 
Tobacco dependence; unspecified 
Tobacco dependence; continuous 
Smoking cessation advice 
Tobacco dependence NOS 
Smoking cessation advice declined 
Current smoker annual review - enhanced services  
Current smoker annual review 
Tobacco dependence 
Tobacco dependence; unspecified 
Tobacco dependence; continuous 
Tobacco dependence NOS 
 [V]Tobacco use 
[V]Tobacco abuse counselling 
Failed attempt to stop smoking 
 
  
Non smoker 
Never smoked 
Never smoked tobacco 
Non-smoker 
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Ex-smoker 
Ex smoker 
Date ceased smoking 
Ex-smoker annual review - enhanced services  
Ex-smoker annual review 
Tobacco dependence in remission 
Nicotine replacement therapy provided  
Nicotine replacement therapy using nicotine patches 
Nicotine replacement therapy using nicotine gum 
Nicotine replacement therapy using nicotine inhalator 
Nicotine replacement therapy using nicotine lozenges 
Smoking cessation drug therapy 
Other specified smoking cessation therapy 
Smoking cessation therapy NOS 
Nicotine replacement therapy 
Nicotine replacement therapy provided free 
Over the counter nicotine replacement therapy 
Smoking free weeks 
Stopped smoking 
Recently stopped smoking 
Ex roll-up cigarette smoker 
Ex pipe smoker 
Ex pipe smoker 
Ex cigar smoker 
Ex-trivial smoker (<1/day) 
Ex-light smoker (1-9/day) 
Ex-moderate smoker (10-19/day) 
Ex-cigarette smoker 
Ex-smoker - amount unknown 
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Appendix 21- Association betw
een covariates and m
ood problem
s in people w
ith RA and PM
R 
 Association betw
een covariates and anxiety, in addition to anxiety and/or depression, in people w
ith RA 
 Covariates 
Anxiety 
Anxiety and/ or depression 
Unadjusted OR (95%
 CI) p value 
Adjusted OR * (95%
 CI) p value 
Unadjusted OR (95%
 CI) p 
value 
Adjusted OR * (95%
 CI) p value 
Age Group (years) 
18-50 
2.90 (0.85, 4.24) p=0.01 
2.70 (1.15, 6.32) p=0.02 
2.01 (1.12, 3.66) p=0.02 
2.07 (1.06, 4.04) p=0.03 
51-65 
0.83 (0.35, 1.94) p=0.67 
0.94 (0.39, 2.26) p=0.89 
1.10 (0.60, 2.03) p=0.75 
2.27 (0.78, 6.65) p=0.14 
66-75 
0.28 (0.06, 1.18) p=0.08 
0.26 (0.06, 1.13) p=0.07 
0.28 (0.10, 0.81) p=0.02 
0.35 (0.12, 1.06) p=0.06 
76-95 
1.45 (0.53, 3.96) p=0.47 
0.81 (0.26, 2.53) p=0.72 
0.82 (0.34, 1.99) p=0.66 
0.44 (0.15, 1.29) p=0.14 
Gender 
Fem
ale 
1.64 (0.65, 4.17) p=0.30 
1.26 (0.48, 3.29) p=0.64 
1.74 (0.87, 3.49) p=0.12 
1.13 (0.54, 2.36) p=0.74 
Deprivation Status 
Low
 
0.66 (0.19, 2.24) p=0.51 
0.85 (0.24, 2.97) p=0.78 
0.56 (0.22, 1.45) p=0.23 
0.70 (0.26, 1.88) p=0.48 
M
id  
1.17 (0.51, 2.67) p=0.71 
1.25 (0.52, 3.01) p=0.62 
1.17 (0.63, 2.17) p=0.61 
1.31 (0.68, 2.54) p=0.42 
High 
1.08 (0.43, 2.75) p=0.87 
0.83 (0.30, 2.28) p=0.72 
1.18 (0.80, 2.35) p=0.63 
0.88 (0.42, 1.86) p=0.74 
M
ultim
orbidity  
0.97 (0.41, 2.26) p=0.93 
0.60 (0.24, 1.53) p=0.29 
1.56 (0.86, 2.85) p=0.15 
1.22 (0.62, 2.38) p=0.57 
Current Sm
oker 
1.31 (0.58, 2.95) p=0.51 
1.46 (0.63, 3.39) p=0.38 
1.35 (0.74, 2.46) p=0.33 
1.17 (0.61, 2.26) p=0.63 
O
besity  
0.96 (0.35, 2.61) p=0.94 
0.94 (0.34, 2.64) p=0.91 
1.04 (0.50, 2.160 p=0.91 
0.84 (0.38, 1.86) p=0.66 
Num
ber of prim
ary 
care contacts 
21-50 
2.27 (1.00, 5.14) p=0.04 
3.17 (1.27, 7.90) p=0.01 
2.54 (1.38, 4.70) p<0.01 
3.72 (1.88, 7.36) p<0.01 
50+ 
10.19 (2.47, 42.07) p<0.01 
19.10 (4.07, 89.64) p<0.01 
7.78 (2.12, 28.64) p<0.01 
19.82 (4.65, 84.42) p<0.01 
 OR= Odds ratio, CI= confidence interval 
*Adjusted for significant unadjusted associations.  
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 Association betw
een covariates and anxiety, in addition to anxiety and/or depression, in people w
ith PM
R 
 Covariates 
Anxiety 
Anxiety and/ or depression 
Unadjusted OR (95%
 CI) p value 
Adjusted OR * (95%
 CI) p value 
Unadjusted OR (95%
 CI) p value 
Adjusted OR * (95%
 CI) p value 
Age Groups 1 
51-65 
2.17 (0.81, 5.82) p=0.13 
2.52 (0.90, 7.01) p=0.08 
1.12 (0.50, 2.48) p=0.79 
2.52 (0.90, 7.01) p=0.08 
66-75 
0.68 (0.24, 1.91) p=0.46 
0.58 (0.19, 1.81) p=0.35 
0.99 (0.51, 1.94) p=0.99 
0.58 (0.19, 1.81) p=0.35 
76-95 
0.83 (0.33, 2.90) p=0.70 
0.82 (0.31, 2.14) p=0.68 
0.99 (0.53, 1.87) p=0.99 
0.82 (0.31, 2.14) p=0.68 
Gender 
Fem
ale 
2.54 (0.74, 8.80) p=0.14 
3.58 (0.80, 15.90) p=0.09 
1.70 (0.80, 3.64) p=0.17 
3.58 (0.80, 15.90) p=0.09 
Deprivation Status 
Low
 
0.89 (0.29, 2.71) p=0.83 
0.89 (0.28, 2.84) p=0.85 
0.80 (0.36, 1.76) p=0.58 
0.89 (0.28, 2.84) p=0.85 
M
id  
1.25 (0.49, 3.22) p=0.64 
1.21 (0.45, 3.23) p=0.71 
1.03 (0.54, 1.95) p=0.94 
1.21 (0.45, 3.23) p=0.71 
High 
0.80 (0.23, 2.77) p=0.72 
0.85 (0.24, 3.01) p=0.80 
1.22 (0.57, 2.12) p=0.62 
0.85 (0.24, 3.01) p=0.80 
M
ultim
orbidity  
1.07 (0.42, 2.76) p=0.89 
0.48 (0.16, 1.45) p=0.20 
1.47 (0.78, 2.78) p=0.24 
0.48 (0.16, 1.45) p=0.20 
Current Sm
oker 
1.08 (0.35, 3.31) p=0.89 
0.92 (0.26, 3.30) p=0.90 
0.98 (0.44, 2.17) p=0.96 
0.92 (0.26, 3.25) p=0.90 
O
besity  
2.79 (0.98, 7.97) p=0.06 
2.46 (0.83, 7.31) p=0.11 
1.60 (0.68, 3.73) p=0.28 
2.46 (0.83, 7.31) p=0.11 
Num
ber of prim
ary 
care contacts 
21-50 
3.52 (1.24, 9.99) p=0.02 
5.74 (1.62, 20.34) p<0.01 
2.36 (1.20, 4.65) p=0.01 
5.74 (1.62, 20.34) p<0.01 
50+ 
9.95 (1.96, 30.65) p<0.01 
30.25 (4.43, 206.63) p<0.01 
7.57 (1.88, 30.53) p<0.01 
30.25 (4.43, 206,63) p<0.01 
 OR= Odds ratio, CI= confidence interval 
*Adjusted for significant unadjusted associations.  
1 No individuals w
ith PM
R and m
ood problem
s aged <50 years, so this age category has been excluded from
 the analysis.
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Appendix 22- INCLUDE study invitation letter 
 
«title» «Given Name» «surname» 
«Address Line 1» 
«Address Line 2» 
«Address Line 3» 
«Postcode» 
Our ref: «Study ID» 
Date: «Day» «Month» «Year» 
Dear «title» «surname», 
Invitation to take part in the INCLUDE study 
 
INCLUDE: INtegrating and improving Care for patients with infLammatory 
rheUmatological DisordErs in the community: A pilot randomised controlled trial. 
Our GP practice, together with researchers at Keele University, is carrying out a 
study called INCLUDE which aims to find out more about the impact of 
inflammatory rheumatological conditions on quality of life. 
You are being invited to take part in the INCLUDE study because you have been 
identified as a patient registered at our practice with one of the inflammatory 
conditions being studied (rheumatoid arthritis, psoriatic arthritis, ankylosing 
spondylitis, polymyalgia rheumatica or giant cell arteritis). Enclosed with this 
letter is an information sheet explaining the study in more detail and how you can 
take part. Please take time to read this carefully. 
We hope that you will be able to spare some time to complete and return the 
enclosed questionnaire. We think it should take you about 20 minutes to 
complete. This questionnaire asks about how your condition affects you and 
about any associated health problems that you have. Your responses will help 
us to understand how the care of people with inflammatory conditions might be 
improved in the local area. 
All the information you provide to Keele University will be treated in strict 
confidence and in accordance with the 1998 Data Protection Act. This means 
that any personal information you provide during the study (e.g. name and 
address) will be shared with your GP practice but not passed on to any other 
organisation and will only be used in connection with this study. 
Your participation is voluntary and it is up to you whether you take part or not. 
We can assure you that, whether or not you take part in the study, your healthcare 
will not be affected in any way, now or in the future. 
If you do not reply to this questionnaire, you will be sent two reminders about this 
VWXd\ in aSSUo[imaWel\ WZo and foXU ZeekV¶ Wime. We would be very grateful if you 
would complete and return the questionnaire in the pre-paid envelope provided 
as soon as you can. You do not need a stamp. 
If you would like to know more about this study, or have any questions, please 
contact the INCLUDE Study Coordinator at Keele Clinical Trials Unit on 01782 
732950. 
Thank you very much for your help with this research study. 
 
Yours sincerely, 
«GP Name» 
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Appendix 23- INCLUDE study patient information sheet 
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Appendix 24- INCLUDE baseline questionnaire 
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Appendix 25- Letter of ethical approval for the INCLUDE study 
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Appendix 26- The association betw
een covariates and m
oderate to severe anxiety (n=34) and depression (n=30) in people w
ith RA. 
 Exposure 
M
oderate to severe depression (PHQ
-8 scoreш10) 
M
oderate to severe anxiety (GAD-7 score ш10) 
Unadjusted O
R (95%
 CI) 
Adjusted OR (95%
 CI)* 
Unadjusted O
R (95%
 CI) 
Adjusted OR (95%
 CI) * 
Age 
0.99 (0.97, 1.02) p=0.51 
0.98 (0.94, 1.02) p=0.42 
0.98 (0.95, 1.00) p=0.09 
0.97 (0.92, 1.01) p=0.14 
Fem
ale gender 
1.22 (0.62, 2.39) p=0.57 
1.09 (0.47, 2.51) p=0.84 
1.60 (0.67, 3.85) p=0.29 
1.24 (0.41, 3.73) p=0.67 
Living alone  
0.66 (0.27, 1.59) p=0.35 
0.76 (0.25, 2.27) p=0.62 
0.88 (0.30, 2.59) p=0.82 
0.78 (0.21, 2.87) p=0.71 
Current sm
oker  
2.57 (0.80, 8.22) p=0.11 
3.24 (0.75, 14.05) p=0.12 
1.83 (0.52, 6.36) p=0.35 
2.03 (0.43, 9.56) p=0.37 
Regular alcohol ш w
eekly  
1.12 (0.59, 2.12) p=0.73 
1.03 (0.45, 2.37) p=0.95 
0.49 (0.21, 1.11) p=0.09 
0.62 (0.22, 1.71) p=0.36 
Obesity (BM
I ш30) 
0.47 (0.22, 0.99) p=0.05 
0.63 (0.24, 1.65) p=0.35 
1.61 (0.69, 3.79) p=0.27 
1.39 (0.46, 3.96) p=0.56 
ш1 com
orbidity in addition to RA 
1.09 (0.23, 1.89) p=0.84 
1.15 (0.54, 1.76) p=0.32 
1.34 (0.56, 3.21), p=0.52 
1.19 (0.49, 3.96) p=0.20 
ш2 IRCs 
1.27 (0.53, 3.03) p=0.59 
1.73 (0.62, 4.80) p=0.29 
2.01 (0.78, 5.16) p=0.15 
2.96 (0.96, 9.11) p=0.06 
Pain Score 
1.19 (1.04, 1.36) p=0.01 
1.22 (1.02, 1.46) p=0.03 
1.26 (1.06, 1.51) p=0.01 
1.13 (0.92, 1.40) p=0.25 
Stiffness Score 
1.26 (1.09, 1.45) p<0.01 
1.42 (1.15, 1.75) p<0.01 
1.21 (1.02, 1.44) p=0.03 
1.10 (0.89, 1.36) p=0.39 
Fatigue Score 
1.10 (0.97, 1.25) p=0.15 
1.09 (0.92, 1.30) p=0.33 
1.22 (1.03, 1.45) p=0.02 
0.99 (0.82, 1.22) p=0.99 
FACIT score 
1.00 (0.97, 1.03) p=0.82 
1.00 (0.96, 1.04) p=0.94 
0.88 (0.84, 0.92) p<0.01 
0.89 (0.84, 0.94) p<0.01 
 OR= odds ratio, CI=confidence interval, BM
I= Body M
ass Index.  
* Adjustm
ents m
ade for significant unadjusted associations. Significant associations are in bold. 
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Appendix 27- Conference and lay audience presentations 
 
Conference Presentations 
x Machin AR, Blagojevic-Bucknall M, Chew-Graham CA, Hider SL. The incidence of 
anxiety and depression in patients with inflammatory rheumatological 
conditions. Poster presentation, British Society of Rheumatology (BSR) 
conference, 2019. 
x Machin AR, Haththotuwa R, Opeyemi B, Scott I, Blagojevic-Bucknall M, Corp N, 
Chew-Graham CA, Hider SL. The impact of anxiety on quality of life and disease 
activity in rheumatoid arthritis: A systematic review. Oral presentation as part of 
the poster showcase and poster presentation, BSR conference, 2019. 
x Machin AR, Hider SL, Jinks C, Herron D, Paskins Z, Cooke K, Chew-Graham CA. 
Development of an integrated nurse-led review based in primary care to identify 
and manage comorbidities in inflammatory rheumatological conditions: The 
INCLUDE study. E-Poster presentation, BSR conference, 2019. 
x Machin AR, Herron D, DeSilva E, Jinks C, Hider SL, Paskins Z, Cooke K, Chew-
Graham CA. Evaluation of nurse training to deliver an integrated care review for 
patients with inflammatory rheumatological conditions in primary care: a mixed 
methods study. A person-centred approach to physical-mental multimorbidity 
conference. Poster presentation, Keele University, 2019. (Best Poster Prize). 
x Herron D, Machin AR, DeSilva E, Jinks C, Hider SL, Paskins Z, Cooke K, Chew-
Graham CA. Acceptability of a nurse-led integrated care review for patients with 
inflammatory rheumatological conditions. Preliminary findings from a 
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qualitative study in the INCLUDE trial. A person-centred approach to physical-
mental multimorbidity conference. Poster presentation, Keele University, 2019.  
x Machin AR, Haththotuwa R, Opeyemi B, Scott I, Blagojevic-Bucknall M, Corp N, 
Chew-Graham CA, Hider SL.  The impact of anxiety on quality of life and disease 
activity in rheumatoid arthritis: A systematic review. Poster presentation, School 
for Primary Care Research (SPCR) Research Showcase, 2018. (Highly commended 
poster prize). 
x Machin AR, Herron D, Jinks C, Hider S, Cooke K, Chew-Graham CA. Evaluation of 
nurse training to deliver an integrated care review for patients with inflammatory 
rheumatological conditions in primary care: a mixed methods study. Oral 
presentation, Society for Academic Primary Care (SAPC) North, 2018. 
x Machin AR, Herron D, Jinks C, Hider S, Cooke K, Chew-Graham CA. Evaluation of 
nurse training to deliver an integrated care review for patients with inflammatory 
rheumatological conditions in primary care: a mixed methods study. Oral 
presentation, SAPC North, 2018. 
x Machin AR, Hider SL, Chew-Graham CA, Blagojevic-Bucknall M. The prevalence of 
anxiety and depression in patients with and without inflammatory rheumatic 
conditions. Poster presentation, SAPC North, 2018. 
x Herron D, Machin AR, DeSilva E, Jinks C, Hider SL, Paskins Z, Cooke K, Chew-
Graham CA. Acceptability of a nurse-led integrated care review for patients with 
inflammatory rheumatological conditions: a qualitative study. Poster 
presentation, SAPC North, 2018.  
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x Machin AR. Anxiety and depression in people with inflammatory arthritis. Bob 
Beattie Student of the Year Awards Ceremony. 3 Minute Thesis Final, Keele 
University, 2018. 
x Machin AR. Anxiety and depression in people with inflammatory arthritis. 
Institute for Liberal Arts and Science (ILAS) Postgraduate Conference 2018. 3 
Minute Thesis, Keele University, 2018 (3 minute thesis prize). 
x Machin AR, Haththotuwa R, Babatunde O, Scott I, Corp N, Bucknall M, Chew-
Graham CA, Hider SL. A systematic review to determine the impact of anxiety on 
quality of life and treatment response in patients with rheumatoid arthritis. Keele 
Postgraduate Symposium, Poster Presentation, 2018 (Systematic Review Prize). 
x Grose-Hodge E, Scott I, Hider SL, Machin AR, Dale N, Ryan S. Prevalence of 
impaired health literacy in patients with Rheumatoid Arthritis and its association 
with medication understanding and patient outcomes. Poster Presentation, BSR 
conference, 2018. 
x Muller S, Hider SL, Machin A, Stack R, Hayward RA, Raza K, Mallen C. Searching 
for a prodrome for rheumatoid arthritis in the primary care record: A case-control 
study in the Clinical Practice Research Datalink. Poster Presentation, BSR 
conference, 2018. 
x Machin AR, Haththotuwa R, Babatunde O, Scott I, Corp N, Bucknall M, Chew-
Graham C, Hider S. A systematic review to determine the impact of anxiety on 
quality of life and treatment response in patients with rheumatoid arthritis. West 
Midlands RCGP Symposium, Oral Presentation, Keele University, 2018. 
x Machin AR, Chew-Graham C, Hider S. The role of PPIE in developing a research 
protocol. Oral Presentation, GP Academic Clinical Fellows (ACF) Conference, 2018. 
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x Machin AR, Haththotuwa R, Babatunde O, Scott I, Corp N, Bucknall M, Chew-
Graham C, Hider S. A systematic review to determine the impact of anxiety on 
quality of life and treatment response in patients with rheumatoid arthritis. 
Poster presentation, GPACF Conference, Oxford, 2018. 
x Machin AR, Haththotuwa R, Babatunde O, Scott I, Corp N, Bucknall M, Chew-
Graham C, Hider S. A systematic review to determine the impact of anxiety on 
quality of life and treatment response in patients with rheumatoid arthritis. 
British Journal of General Practice Conference, Poster Presentation, 2018. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Perceived barriers and facilitators 
to the uptake of treatments for anxiety and depression in rheumatoid arthritis. 
GPACF Conference Oral Presentation, Sheffield, 2017. (Best oral presentation 
prize). 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Perspectives of patients with 
rheumatoid arthritis on case-finding for anxiety and depression within a nurse-
led annual review clinic. BSR Conference 2017. Poster Presentation. 
x Higginbottom A, Blackburn S, Campbell L, Rhodes C, Taylor R, Machin A, Hider S, 
Roddy E, Chew-Graham CA. Celebrating ten years of patient involvement in 
research of inflammatory conditions. Poster presentation, Annual European 
Congress of Rheumatology, 2017. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient preferences for 
management of comorbid anxiety and depression in rheumatoid arthritis: a 
qualitative study. Elevator Pitch, SAPC, Warwick, 2017. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Poster presentation on improving 
the recognition of anxiety and depression in patients with rheumatoid arthritis. 
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Poster presentation at Annual Clinical Academic Training Event, Keele, 2017. 
(Best poster presentation prize). 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient perspectives on case-
finding for anxiety and depression in patients with rheumatoid arthritis: The 
impact of PPIE. Oral presentation at Primary Care Mental Health Conference, 
Keele, 2017. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient perspectives on case-
finding for anxiety and depression in patients with rheumatoid arthritis- the 
impact of patient and public involvement and engagement. Oral presentation, 
Keele Postgraduate Student Symposium, 2017.  
x Hider SL, Ryan S, Dale N, Stanyer N, Machin A, Chew-Graham CA. Assessing 
depression in patients with established rheumatoid arthritis- how do different 
approaches compare? Poster presentation, Annual European Congress of 
Rheumatology Conference, 2017. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient perspectives on case-
finding for anxiety and depression in patients with rheumatoid arthritis. Poster 
presentation at RCGP Conference, Harrogate, 2016. (Best poster presentation 
prize).  
x Machin AR, Hider S, Dale N, Chew-Graham CA. Disclosure of anxiety and 
depression in rheumatoid arthritis- the importance of candidacy and recursivity: 
a qualitative study. Oral presentation at West Midlands Annual Clinical Academic 
Training Event (Birmingham), 2016. (Best oral presentation prize). 
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x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient perspectives on case-
finding for anxiety and depression in patients with rheumatoid arthritis. Oral 
Presentation at SAPC North, Kendal, 2016. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient perspectives on case-
finding for anxiety and depression in patients with rheumatoid arthritis: a 
qualitative study. Oral presentation, GPACF annual conference, Brighton, 2016. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient perspectives on case-
finding for anxiety and depression in patients with rheumatoid arthritis. Poster 
presentation at Postgraduate Student Symposium, Keele University, 2016. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient perspectives on case-
finding for anxiety and depression in patients with rheumatoid arthritis- the 
impact of patient and public involvement. Poster presentation at Mental Health 
Research Group Symposium, Keele University, 2016. 
x L Varadhan, A Machin, T Humphreys, Nayak UA, Jose B, Walker AB, Varughese 
GI. The dynamic changes of Diabetic Maculopathy with intensification of 
glycaemic control with GLP-1 agonist therapy. Poster Presentation at European 
Association for the Study of Diabetes conference, 2013. 
 
Lay Audience Presentations 
x Investigating mood disorders in people with inflammatory rheumatological 
conditions: A mixed methods study. Oral Presentation, Haywood Foundation, 
2019. 
x Machin AR. Improving how mood problems are identified and treated in people 
with inflammatory arthritis. Oral presentation, Haywood User Group, 2018. 
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x Machin AR. Improving how mood problems are identified and treated in people 
with inflammatory arthritis. Oral presentation, Stoke NRAS Meeting, 2018. 
x Machin AR. Developing a patient information leaflet on mood problems in 
rheumatoid arthritis. Poster presentation, Annual Research User Group meeting, 
Keele University, 2018. 
x Machin AR, Hider S, Dale N, Chew-Graham CA. Patient perspectives on case-
finding for anxiety and depression in patients with rheumatoid arthritis: The 
impact of PPIE. Poster Presentation at event celebrating 10 years of PPIE at the 
Keele Research Institute, 2016. (Best poster presentation prize). 
x Machin A. Mood problems in rheumatoid arthritis. Oral presentation, Haywood 
User Group, 2016. 
 
Other Conference Presentations 
x Machin A. ͞Is there a different medication I could have doctor? These anxiety 
pills are useless!͟ Poster presentation, RCGP Midland Faculty Annual Education, 
Research and Innovation Symposium, 2016. (Best poster presentation prize 
winner). 
x Machin, A. Audit of antibiotic prescribing for acute otitis media in a semi-rural 
GP practice. Poster presentation, RCGP annual conference 2016. (Shortlisted for 
a prize). 
x Machin, A. Audit of rheumatoid arthritis annual reviews including mood 
exploration within an urban GP practice. Poster presentation at RCGP annual 
conference 2016. 
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x Machin, A. Audit of Primary Care Physical Health Monitoring in Patients with 
Severe Mental Illness. Poster Presentation, Improving physical health for 
patients with severe mental illness, South Staffordshire and Shropshire NHS 
Foundation trust, 2016. 
x Machin, A. Audit of Physical Health Monitoring in Psychosis and Schizophrenia. 
Poster presentation, RCGP annual conference, 2014. 
 
